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Introduction:	  PART	  I	  
	  
1.	  The	  genomic	  landscape	  of	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  
	  
Acute	   lymphoblastic	   leukemia	   (ALL)	   is	   an	   aggressive	   tumor	   entity	   of	   highly	   proliferative	  
malignant	   lymphoid	   cells.	   This	   leukemia	   subtype	   occurs	   most	   frequently	   in	   children	   with	  
incidence	   peaks	   between	   2-­‐5	   years	   of	   age	   and	   is	   one	   of	   the	   most	   common	   childhood	  
malignancies	   worldwide.	   Current	   overall	   cure	   rates	   in	   children	   are	   reaching	   more	   than	  
85%1,2.	   Age	   at	   diagnosis,	   leucocyte	   count,	   race,	   sex	   and	   immunophenotype	   are	   clinical	  
prognostic	   parameters	   utilized	   to	   classify	   the	   patients	   into	   different	   risk	   groups2.	   Current	  
treatment	   regimens	   encompass	   risk-­‐adapted	   chemotherapy	   (including	   glucocorticoids,	  
asparaginase,	   mercaptopurine,	   methotrexate	   and	   vincristine),	   hematopoietic	   stem-­‐cell	  
transplantation	   and	   supportive	   care.	   Currently,	   new	   treatment	   strategies	   are	   under	  
evaluation	   as	   novel	   options	   for	   ALL	   therapy,	   including	   molecular	   therapies	   like	   tyrosine	  
kinase	  inhibitors	  and	  immunotherapeutics	  like	  autologous	  or	  allogeneic	  T-­‐cell	  therapies1.	  
	  
T-­‐cell	  ALL	  (T-­‐ALL)	  comprises	  10-­‐15%	  of	  pediatric	  and	  25%	  of	  adult	  primary	  ALL	  patient	  cases3	  
and	   is	   classified	   as	   a	   high-­‐risk	   group	   in	   ALL1.	   Overall	   cure	   rates	   are	   reaching	   over	   75%	   in	  
children	  and	  ~50%	   in	   adult	   T-­‐ALL	   cases3.	  Unfortunately,	   T-­‐ALL	  patients	  often	   relapse	  quite	  
early	  during	  treatment	  resulting	  in	  only	  a	  7-­‐23%	  5-­‐year	  survival	  rate	  of	  relapsed	  childhood	  T-­‐
ALL1	  and	  a	  6.5%	  5-­‐year	   survival	   rate	   in	   relapsed	  adult	  T-­‐ALL4.	  Of	  particular	  notice,	  T-­‐ALL	   is	  
characterized	   by	   a	   disturbed	   gender	   distribution	   towards	   man	   and	   boys	   (~3:1)3.	   Possible	  
explanations	   for	   this	   unusual	   male/female	   imbalance	   are	   starting	   to	   emerge	   by	   X-­‐linked	  
genomic	  studies5,6	  (see	  paper	  1;	  and	  Van	  der	  Meulen	  et	  al.	  submitted,	  see	  paper	  2).	  	  
	  
During	  normal	  T-­‐cell	  development,	   the	  most	  early	  T-­‐cell	   lineage	  committed	  precursor	  cells	  
are	   the	   immature	   CD34+	   cells	   that	   have	   just	   entered	   the	   thymus	   and	   subsequently	  
differentiate	  through	  various	  intermediate	  subsets	  into	  mature	  T-­‐cells	  harboring	  a	  functional	  
T-­‐cell	   receptor	   (TCR)	   belonging	   to	   the	   TCRαβ	   or	   TCRγδ	   lineage	   (Figure	   1)7.	   Primary	   T-­‐ALL	  
patient	   samples	   are	   characterized	   by	   clonal	   expansion	   of	   malignant	   T-­‐cells	   arrested	   at	   a	  
specific	  stage	  during	  T-­‐cell	  differentiation3.	  
	  
	  
	  
Figure	  1.	  Schematic	  representation	  of	  the	  major	  T-­‐cell	  differentiation	  stages	  during	  normal	  
T-­‐cell	  maturation	   in	   the	   thymus	   (adapted	   from	  Taghon	   et	   al.	   Curr	   Top	  Microbiol	   Immunol	  
20127,	  graphics	  from	  www.somersault1824.com)	  
	  
	  	   6	  
1.1	  Molecular-­‐genetic	  T-­‐ALL	  subgroups	  
	  
Using	   karyotyping,	   fluorescence	   in-­‐situ	   hybridization	   (FISH),	   array	   comparative	   genomic	  
hybridization	   (array	   CGH)	   and	   microarray	   gene	   expression	   profiling,	   a	   set	   of	   well-­‐defined	  
genetic	   subgroups	   that	  are	  marked	  by	  an	  arrest	  at	  a	   specific	   stage	  of	  T-­‐cell	  differentiation	  
have	   been	   delineated	   in	   T-­‐ALL	   (Figure	   2)3,8-­‐10.	   Genomic	   translocations	   are	   recurrent	   in	  
leukemic	   samples	   resulting	   in	   the	   elevated	   expression	   of	   developmentally	   important	  
transcription	   factor	   oncogenes.	   Hereby,	   T-­‐cell	   oncogenes	   are	   placed	   under	   the	   control	   of	  
strong	  T-­‐cell	  specific	  enhancers	  of	  the	  TCRβ	  and	  TCRαδ	  or	  strong	  regulatory	  sequences	  of	  T-­‐
cell	   specific	   genes.	   For	   example,	   the	   most	   common	   translocation	   t(10;14)(q24;q11)	  
juxtaposes	  the	  homeobox	  (HOX)	  transcription	  factor	  TLX1	  to	  the	  T-­‐cell	  specific	  enhancer	  of	  
TCRαδ11,	  whereas	  t(5;14)(q35;q32)	  translocates	  the	  HOX	  transcription	  factor	  TLX3	  to	  specific	  
regulatory	   sequences	   of	   the	   T-­‐cell	   regulator	   BCL11B12.	   Both	   translocations	   lead	   to	   strong	  
transcriptional	  activation	  of	  the	  two	  HOX	  genes,	  TLX1	  and	  TLX38,11-­‐15.	  Interestingly,	  oncogenic	  
activation	  of	  TLX1	  in	  transgenic	  mouse	  gives	  rise	  to	  lymphoid	  tumors	  with	  long	  latency16.	  As	  
TLX1	   and	   TLX3	   are	   closely	   related	   oncogenes	   in	   T-­‐ALL	   sharing	   similar	   gene	   expression	  
profiles8-­‐10	   and	   interaction	   networks17,18,	   a	   similar	   oncogenic	   role	   for	   TLX3	   in	   T-­‐ALL	   is	  
presumed	  although	  no	  effective	  in	  vivo	  modeling	  of	  TLX3	  has	  been	  reported	  yet.	  
	  
Besides	   TLX1	   and	   TLX3,	   the	   following	   oncogenes	   have	   been	   implicated	   in	   chromosomal	  
translocations	   in	   T-­‐ALL	   and	   define	   different	   T-­‐ALL	   subgroups:	   the	   basic	   helix-­‐loop-­‐helix	  
(bHLH)	  transcription	  factors	  TAL119,	  TAL220,	  LYL121	  en	  BHLHB122;	  the	  LIM-­‐only	  domain	  (LMO)	  
transcription	   factors	   LMO123,	   LMO224	   and	   LMO39;	   the	   HOX	   genes	   NKX2.19,	   NKX2.29	   and	  
HOXA10	   and	   the	   transcription	   factor	   MYB25.	   Although	   the	   clinical	   relevance	   of	   genetic	  
subtypes	   in	   T-­‐ALL	   remains	   controversial,	   some	   studies	   proposed	   a	   good	   prognosis	   for	   the	  
TLX1-­‐13	   and	   TAL1-­‐26rearranged	   T-­‐ALL	   patient	   cases	   and	   a	   dismal	   prognosis	   for	   the	   TLX3-­‐
rearranged	  T-­‐ALL	  patient	  cases27,28.	  
	  
	  
Figure	  2.	  Genetic	  T-­‐ALL	  subgroups	  marked	  by	  transcription	  factor	  oncogenes,	  genetic	  defects	  
and	  specific	  T-­‐cell	  differentiation	  arrest3,9,29-­‐32	  (graphics	  from	  www.somersault1824.com)	  
	  
Alternatively,	   genetic	   defects	   including	   chromosomal	   deletions,	   fusion	   genes	   and	   somatic	  
mutations	  have	  been	   identified	  that	   further	  define	  the	  different	  T-­‐ALL	  subgroups	   including	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SIL-­‐TAL1	  deletions	   in	   the	  bHLH/LMO	  subgroup19,	   the	  CALM-­‐AF10	   fusion33,	   the	  SET-­‐NUP214	  
fusion34	  and	  MLL1	   fusions35	   in	   the	  HOXA	  subgroup	  and	  mutations	   in	  ETV6,	  FLT3,	  DNMT3A,	  
IDH1,	   IDH2,	   GATA3,	   RUNX1	   and	   EP300	   in	   the	   immature	   T-­‐ALL	   subgroup3,29-­‐31,36	   (Figure	   2).	  
Notably,	   the	   immature	   T-­‐ALL	   subgroup	   is	   characterized	   by	   a	   gene	   expression	   signature	  
associated	   with	   hematopoietic	   stem	   cells	   and	   myeloid	   progenitors	   and	   often	   shows	  
expression	  of	  the	  myeloid	  antigens	  CD13	  and	  CD338-­‐10,29,37	  and	  lack	  of	  biallelic	  TCRγ	  deletion	  
(noted	   here	   as	   TCRγ+)32.	   Finally,	   a	   recent	   study	   demonstrated	   that	   immature	   T-­‐ALLs	   often	  
display	  elevated	  expression	  of	  the	  MEF2C	  transcription	  factor	  oncogene9.	  
	  
	  
1.2	  Defects	  across	  the	  T-­‐ALL	  subgroups	  
	  
The	  introduction	  of	  targeted	  and	  next-­‐generation	  sequencing	  techniques	  further	  broadened	  
the	   genetic	   landscape	   of	   T-­‐ALL	   by	   the	   identification	   of	   many	   novel	   defects	   belonging	   to	  
different	  molecular	  pathways3,5,6,31	  (see	  also	  paper	  1,	  2).	  These	  genetic	  lesions	  target	  genes	  
with	  important	  roles	  in	  NOTCH1	  signaling,	  cell	  cycle,	  hematopoiesis,	  signal	  transduction	  and	  
ribosomal	   machinery	   (Figure	   3).	   Importantly,	   like	   in	   any	   other	   tumor	   entity,	   recent	  
sequencing	  efforts	  revealed	  the	  implication	  of	  several	  key	  regulators	  of	  epigenetic	  modifiers	  
(Figure	  3).	  These	  defects,	  together	  with	  the	  other	  mutations,	  define	  the	  genetic	  make-­‐up	  of	  
the	  malignant	  T-­‐cells	  and	  are	  present	  in	  all	  T-­‐ALL	  subgroups.	  
	  
	  
Figure	   3.	   Defects	   in	   different	   molecular	   pathways	   contributing	   to	   T-­‐ALL	  
pathogenesis3,6,30,31,36,38	  (graphics	  from	  www.somersault1824.com)	  
	  
In	  the	  following	  part,	  the	  NOTCH1	  and	  MYB	  signaling	  pathways	  and	  their	  involvement	  in	  T-­‐
ALL	  will	  be	  described	  in	  detail,	  since	  both	  oncoproteins	  will	  also	  be	  discussed	  further	  in	  the	  
thesis.	   The	   epigenetic	   defects	   will	   be	   discussed	   in-­‐depth	   in	   the	   second	   part	   of	   the	  
introduction	  (2.	  The	  epigenomic	  landscape	  of	  T-­‐cell	  acute	  lymphoblastic	   leukemia	  and	  links	  
with	  therapeutical	  options).	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Defects	  in	  the	  NOTCH1	  signaling	  pathway	  
	  
The	  NOTCH1	  signaling	  pathway	   is	  a	  strongly	  conserved	  pathway	  essential	   for	  normal	  T-­‐cell	  
development	   stimulated	   through	   interaction	   with	   different	   NOTCH1	   ligands	   on	   the	   cell	  
surface38	   (Figure	   4).	   After	   NOTCH1	   stimulation,	   the	   NOTCH1	   heterodimer	   receptor	   is	  
processed	   through	   3	   different	   proteolytic	   cleavages	   including	   the	   final	   cleavage	   by	   the	  
gamma-­‐secretase	   complex.	   The	   intracellular	   domain	   (ICN)	   of	   NOTCH1	   subsequently	  
translocates	  to	  the	  nucleus	  and	  associates	  with	  CSL,	  EP300,	  MAML	  and	  different	  coactivators	  
(CoA)	  resulting	  in	  transcriptional	  activation	  of	  NOTCH1	  target	  genes38,39	  (Figure	  4).	  Important	  
NOTCH1	   direct	   and	   indirect	   targets	   in	   T-­‐ALL	   are	  MYC40,41,	   HES142,	   CYLD43,	   PTEN44,	   IL7R45,	  
PTCRA46,	   IGF1R47,	   CCR748,	   CCND349,	   SKP250	   and	   the	   signaling	   pathways	   PI3K-­‐AKT-­‐mTOR44,51	  
and	  NF-­‐Kβ43,52.	  The	  E3	  ubiquitin	  ligase	  FBXW7	  subsequently	  targets	  NOTCH1	  for	  proteasomal	  
degradation	  as	  well	  as	  other	  important	  oncoproteins	  like	  MYC,	  cyclinE,	  JUN	  and	  MCL153,54.	  
	  
	  
	  
Figure	   4.	   The	   NOTCH1	   signaling	   pathway	   (adapted	   from	   Grabher	   et	   al.	   Nature	   Reviews	  
Cancer	  200639,	  graphics	  from	  www.somersault1824.com)	  
	  
NOTCH1	   is	   one	   of	   the	  major	   oncogenic	   drivers	   in	   T-­‐ALL	   and	   is	   highly	   activated	   by	   specific	  
NOTCH1	   mutations	   (>60%	   of	   T-­‐ALL	   cases)55,	   translocations	   of	   the	   strong	   T-­‐cell	   specific	  
enhancers	   of	   TCRβ	   with	   NOTCH1	   (<1%)56	   or	   inactivating	   FBXW7	   mutations	   (~15%)57,58.	  
Constitutive	   activation	   of	   NOTCH1	   in	   a	   bone-­‐marrow	   transplantation	  model	   provokes	   the	  
quick	  formation	  of	  T-­‐cell	  leukemias	  highlighting	  the	  oncogenic	  potential	  of	  NOTCH1	  in	  T-­‐ALL	  
pathogenesis59.	  As	  the	  majority	  of	  T-­‐ALL	  patient	  cases	  experience	  highly	  activated	  NOTCH1	  
signaling,	   therapeutic	   efforts	   have	   been	   exploited	   to	   target	   NOTCH1	   in	   T-­‐ALL	   including	  
gamma-­‐secretase	   inhibitors	   (GSIs)38,40,55,60,61,	   NOTCH1-­‐specific	   inhibitory	   antibodies62	   and	  
stapled	  peptides	  targeting	  the	  NOTCH1	  transcriptional	  complex63	  (Figure	  4).	  	  
	  
The	  first	  trials	  warned	  against	  the	  use	  of	  GSIs	  as	  single	  agent	  as	  GSI	  resistance	  may	  rapidly	  
occur.	   Also,	   major	   side	   effects	   including	   severe	   gastrointestinal	   toxicity	   were	   observed	   in	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early	   studies60,64.	   GSI	   resistance	   can	   result	   from	   PTEN	   or	   FBXW7	   mutations	   leading	   to	   a	  
hyperactivated	   PI3K-­‐AKT-­‐mTOR	   signaling	   pathway44,57,65.	   Notably,	   combined	   treatment	   of	  
GSI	  with	  the	  mTOR	  inhibitor	  rapamycin	  or	  a	  dual	  PI3K-­‐mTOR	  inhibitor	  in	  a	  panel	  of	  T-­‐ALL	  cell	  
lines	   resulted	   in	   highly	   synergistic	   inhibition	   of	   T-­‐ALL	   cell	   growth51,66.	   Most	   interestingly,	  
these	  PI3K-­‐AKT-­‐mTOR	  pathway	  inhibitors	  seem	  to	  be	  the	  most	  effective	  in	  GSI-­‐resistant	  cells	  
harboring	  PTEN	  mutations44,51.	  
	  
In	   parallel,	   administration	   of	   GSI	   together	   with	   glucocorticoids	   reduced	   GSI-­‐induced	   gut	  
toxicity	   in	   vivo	   and	   most	   interestingly	   provoked	   effective	   cell	   death	   in	   glucocorticoid-­‐
resistant	   T-­‐ALL61,67.	   In	   accordance	   with	   the	   successful	   combined	   treatment	   of	   GSIs	   with	  
glucocorticoids,	   delivery	   of	   an	   AKT	   inhibitor	   together	   with	   glucocorticoids	   restored	  
glucocorticoid-­‐induced	  apoptosis	  in	  glucocorticoid-­‐resistant	  T-­‐ALL	  both	  in	  vitro	  and	  in	  vivo68.	  
Furthermore,	  combination	  of	  the	  chemotherapeutic	  agent	  vincristine	  with	  a	  dual	  PI3K-­‐mTOR	  
inhibitor	  or	  dual	  PI3K-­‐AKT	  inhibitor	  acted	  synergistically	  mediating	  effective	  cell	  death	  in	  T-­‐
ALLs	  with	  constitutive	  activation	  of	  PI3K-­‐AKT-­‐mTOR	  signaling69,70.	  All	  together,	  these	  studies	  
underscore	  the	  importance	  of	  multi-­‐drug	  treatment	  studies	  in	  T-­‐ALL	  therapy.	  
	  
As	  MYC	  is	  one	  of	  the	  key	  targets	  of	  NOTCH1	  in	  T-­‐ALL40,41	  and	  secondly	  also	  directly	  involved	  
in	  T-­‐ALL	  pathogenesis	  through	  chromosomal	  translocations71,	  MYC	  represents	  an	  interesting	  
therapeutic	  target	  in	  T-­‐ALL.	  Effective	  MYC	  inhibition	  was	  recently	  demonstrated	  both	  in	  vitro	  
and	  in	  vivo	  in	  many	  cancer	  types	  using	  small	  molecule	  inhibitors	  including	  JQ1,	  I-­‐BET-­‐762,	  I-­‐
BET-­‐151	  and	  PFI-­‐1	  against	  the	  BET	  family	  of	  chromatin	  acetyl	  group	  readers72,73.	  First	  clinical	  
trials	  with	  the	  BET	  inhibitor	  I-­‐BET-­‐762	  have	  just	  been	  initiated	  in	  NUT-­‐midline	  carcinoma	  and	  
other	   solid	   tumors74.	   These	   BET	   inhibitors	   specifically	   target	   genes	  with	   a	   super-­‐enhancer	  
controlling	  it’s	  expression75.	  Also	  in	  T-­‐cell	  leukemia	  samples,	  MYC	  is	  one	  of	  the	  key	  targets	  of	  
these	   inhibitors75.	   Furthermore,	   treatment	  with	   JQ1	   in	   human	   and	  murine	   T-­‐ALL	   cell	   lines	  
enabled	  a	  strong	  block	   in	  cell	  growth	  and	  reduction	  of	  MYC	  expression	   levels76.	  Moreover,	  
JQ1	  delivery	  also	  inhibited	  the	  growth	  of	  diagnostic,	  relapsed	  and	  induction-­‐failure	  pediatric	  
T-­‐ALL	   patient	   samples	   in	   vitro,	  even	   in	   samples	   that	   failed	   to	   respond	   to	  GSI	   treatment76.	  
These	  observations	  underscore	   the	   therapeutic	  potential	  of	  BET	   inhibitors	   in	  T-­‐ALL,	  also	   in	  
GSI-­‐resistant	   T-­‐ALL	   patient	   samples.	   In	   addition	   to	  MYC,	   another	  NOTCH1	   target	   IL7R	  was	  
shown	  to	  be	  sensitive	  to	  treatment	  with	  BET	  inhibitors	  in	  B-­‐cell	  ALL	  (B-­‐ALL)	  cell	  lines77.	  
	  
Defects	  in	  the	  MYB	  signaling	  pathway	  
	  
The	  MYB	  protein	  is	  a	  leucine	  zipper	  transcription	  factor	  that	  mostly	  acts	  as	  a	  transcriptional	  
activator	   in	   concert	  with	   co-­‐activators	  CREB	  binding	  protein	   (CBP)	  and	  EP300,	   two	  histone	  
acetyltransferases78-­‐80.	  MYB	  expression	  levels	  are	  elevated	  during	  early	  hematopoietic	  stages	  
and	   thereafter	   decrease	   during	   maturation80.	   MYB	   is	   crucial	   for	   hematopoiesis	   including	  
thymopoiesis.	  Myb	  knockout	  mice	  die	  early	  in	  utero	  displaying	  severe	  anemia,	  likely	  due	  to	  a	  
defect	   in	  the	  erythropoiesis	   in	  the	  fetal	   liver81.	  Furthermore,	  Myb	   loss	  demonstrated	  a	  role	  
for	   MYB	   in	   adult	   hematopoietic	   stem	   cell	   renewal82	   and	   early	   T-­‐cell	   development83.	   In	  
addition,	  MYB	  also	  contributes	  to	  the	  β-­‐selection	  phase	  in	  T-­‐cell	  development	  and	  is	  critical	  
for	   the	   survival	  of	  CD4+CD8+	  T-­‐cells	   and	  development	  of	  CD4+CD8-­‐	  mature	   thymocytes84-­‐86.	  
Furthermore,	  MYB	  transcriptionally	  controls	  more	  than	  80	  target	  genes80	  including	  genes	  of	  
importance	   in	   T-­‐cell	   development	   including	   CD487,	  GATA388,	   RAG289,	  H2A.Z90,	   BCL-­‐291	   and	  
BCL-­‐XL85.	  
	  
A	  role	  for	  MYB	  in	  malignant	  T-­‐cell	  development	  was	  first	  demonstrated	  by	  the	  appearance	  of	  
high	   grade	   T-­‐cell	   lymphomas	  when	   v-­‐Myb,	   a	   truncated	   and	   rearranged	   form	  of	  MYB,	  was	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ectopically	   expressed	   in	   T-­‐cells	   in	   mice92,93.	   Also,	   mice	   developing	   T-­‐cell	   lymphomas	   after	  
retroviral	  infection	  commonly	  demonstrated	  retroviral	  insertion	  sites	  in	  the	  Myb	  locus94,95.	  In	  
T-­‐ALL	  pathogenesis,	  MYB	  was	  found	  to	  be	  highly	  expressed	  in	  a	  subset	  of	  T-­‐ALL	  patients	  due	  
to	  translocation	  of	  MYB	  to	  the	  T-­‐cell	  specific	  enhancer	  of	  TCRβ	  (t(6;7)(q23;q34)	  -­‐	  7%)	  or	  by	  
somatic	  MYB	  duplications	  (10-­‐15%)25,96	  (Figure	  5).	  Notably,	  MYB	  translocated	  cases	  define	  a	  
separate	  T-­‐ALL	  subgroup	  marked	  by	  very	  young	  age	  (median	  age	  2.2	  years)	  and	  an	  elevated	  
expression	   of	   genes	   linked	   to	   cell	   cycle,	   cell	   proliferation	   and	  mitosis25.	   In	   contrast,	  MYB	  
duplications	  are	  identified	  in	  cases	  belonging	  to	  all	  different	  T-­‐ALL	  subgroups25.	  The	  majority	  
of	   MYB	   duplications	   are	   mediated	   by	   homologous	   recombination	   between	   Alu	   repeats	  
resulting	  in	  tandem	  duplications	  of	  MYB97.	  Elevated	  MYB	  levels	  in	  T-­‐ALL	  can	  also	  be	  caused	  
directly	   by	   the	   oncogenic	   TAL1/GATA3/RUNX1	   complex98	   or	   indirectly	   through	   the	  
TAL1/miR-­‐223/FBXW7	   regulatory	   axis99.	   In	   leukemias	   harboring	   MLL1-­‐fusions,	   MYB	   was	  
shown	   to	   be	   an	   essential	   downstream	   target	   of	  MLL1-­‐ENL	   and	  MLL1-­‐AF9	   contributing	   to	  
leukemic	   transformation100,101.	   In	   addition,	   MYB	   also	   interacts	   with	   MENIN	   to	   form	   a	  
complex	  with	  MLL1	  itself	  and	  with	  MLL1-­‐fusions102.	  
	  
	  
Figure	   5.	   Schematic	   representation	   of	   a	   MYB	   translocation	   t(6;7)(q23;q34)	   detected	   by	  
karyotype	   and	   FISH,	   and	   an	   array	   CGH	   plot	   of	   a	   focal	  MYB	   duplication	   on	   chromosome	   6	  
(graphics	  from	  www.somersault1824.com)	  
	  
Knockdown	  of	  MYB	  alone	  has	  only	  small	  effect	  on	  viability,	  proliferation	  and	  cell	  cycle;	  but	  
combined	  knockdown	  of	  the	  T-­‐ALL	  oncogenes	  MYB	  and	  NOTCH1	  in	  T-­‐ALL	  cell	  lines	  showed	  a	  
strong	   synergistic	   inhibitory	  effect	  on	  proliferation	  and	  viability.	   Furthermore,	   loss	  of	  MYB	  
enabled	  irreversible	  T-­‐cell	  differentiation	  of	  T-­‐ALL	  cell	  lines96	  underscoring	  the	  importance	  of	  
MYB	  directed	  therapies	  in	  T-­‐ALL.	  Direct	  MYB	  targeting	  approaches	  include	  short	  hairpin	  (sh)	  
RNA	  mediated	  decay96,101	   and	  antisense	  MYB	  oligodeoxynucleotides103,	   the	   latter	   currently	  
being	  tested	  in	  clinical	  trials103.	  Since	  MYB	  functions	  in	  concert	  with	  the	  co-­‐activators	  EP300	  
and	   CBP,	   histone	   deacetylase	   inhibitors	   (HDACi)	   can	   be	   employed	   as	   indirect	   therapeutic	  
approaches	  targeting	  MYB104,105.	  Treatment	  of	  the	  MYB-­‐duplicated	  T-­‐ALL	  cell	  line	  CCRF-­‐CEM	  
with	  HDACi	  trichostatin	  A	  was	  able	  to	  profoundly	  downregulate	  MYB	  expression,	  indicating	  
that	   MYB	   is	   highly	   sensitive	   to	   histone	   hyper-­‐acetylation	   in	   T-­‐ALL105.	   Interestingly,	   recent	  
studies	   identified	   a	   super-­‐enhancer	   that	   regulates	  MYB	   expression75,	   suggesting	   that	  MYB	  
might	   also	   be	   sensitive	   to	   BET	   inhibitors.	   In	   contrast	   to	  MYC	   where	   his	   super-­‐enhancer	   is	  
found	   in	  many	   cancer	   types,	   the	   presence	   of	   the	  MYB	   super-­‐enhancer	   seems	   to	   be	  more	  
restricted	  to	  T-­‐cell	   leukemia	  samples75.	  Moreover,	  the	  BET	  family	   inhibitors	  were	  shown	  to	  
have	  an	  impact	  on	  the	  MYB	  pathway	  since	  many	  MYB	  target	  genes	  were	  affected	  after	  JQ1	  
treatment101.	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2.	   The	   epigenomic	   landscape	   of	   T-­‐cell	   acute	   lymphoblastic	   leukemia	  
and	  links	  with	  therapeutical	  options	  
	  
DNA	  is	  built	  up	  from	  four	  nucleotides	  (adenine,	  cytosine,	  guanine	  and	  thymine).	  A	  stretch	  of	  
147	  base	  pairs	  of	  DNA	  is	  wrapped	  around	  an	  octamer	  of	  4	  core	  histone	  (H)	  proteins	  (2	  units	  
of	   H2A,	   H2B,	   H3	   and	   H4)	   shaping	   a	   nucleosome,	   a	   structure	   that	   enables	   efficient	   highly	  
condensed	   DNA	   compaction	   in	   chromosomes	   during	   replication	   (Figure	   6)106.	   The	   linker	  
histone	  H1	   is	   located	   between	   2	   nucleosomes	   enabling	   further	   compact	   packaging	   of	   the	  
DNA107.	  The	  majority	  of	  our	  genome	  shows	  a	  closed	  compact	  conformation	  associated	  with	  
transcriptional	  repression,	  whereas	  only	  a	  minority	  of	  our	  genome	  is	  actively	  transcribed	  and	  
resides	   in	   an	   open	   transcriptional	   configuration106.	   Activation	   or	   repression	   of	   gene	  
expression	   is	   enabled	   by	   intimately	   linked	   epigenetic	   modifications	   including	   DNA	  
methylation,	   nucleosome	   remodeling,	   histone	   variants	   and	   histone	   modifications108.	  
Epigenetic	   alterations	   encompass	   all	   heritable	   changes	   in	   gene	   expression	   that	   are	   not	  
resulting	   from	   DNA	   changes108.	   Besides	   genetic	   defects,	   almost	   all	   human	   cancer	   types	  
contain	  malignant	  epigenetic	  alterations	  that	  contribute	  to	  cancer	  formation106.	  Disturbance	  
of	   correct	   epigenetic	   configuration	   is	   postulated	   to	   act	   as	   a	   first	   seminal	   event	   in	  
carcinogenesis	  leading	  to	  early	  abnormal	  clonal	  expansion	  of	  stem/progenitor	  cells106,109.	  
	  
	  
Figure	   6.	   Graphical	   representation	   of	   DNA	   compaction	   into	   chromatin	   encompassing	   four	  
nucleotides	   (adenine,	   cytosine,	   guanine	   and	   thymine)	   wrapped	   around	   histone	   proteins	  
forming	  nucleosomes	  highly	  condensed	  packed	  in	  chromosomes	  during	  replication	  (graphics	  
from	  www.somersault1824.com)	  
	  
	  
2.1	  DNA	  methylation	  
	  
DNA	  methylation	  encompasses	  the	  covalent	  addition	  of	  methyl	  groups	  to	  cytosines	  mainly	  in	  
the	  CpG	  dinucleotide	  context106.	  CpG	   islands	  are	  more	   than	  300bp	   in	   length,	   contain	  a	  CG	  
content	  of	  over	  50%	  and	  are	  present	  at	  more	  than	  half	  of	  the	  genes	  in	  vertebrates110.	  DNA	  
methylation	   is	  executed	  by	  different	  DNA	  methyltransferases	  (DNMT)	   including	  DNMT1	  for	  
maintenance	   of	   DNA	  methylation	   and	   DNMT3A	   and	   DNMT3B	   for	   de	   novo	   methylation106.	  
Moreover,	   DNMT3A	   and	   DNMT3B	   seem	   to	   cooperate	   with	   DNMT1	   to	   maintain	   DNA	  
methylation.	   Finally,	   DNMT3L	   is	   a	   catalytic	   inactive	   homologue	   of	   DNMT3A	   and	  DNMT3B,	  
which	  is	  able	  to	  stimulate	  DNMT3A	  activity110.	  
	  
In	   general,	   DNA	   methylation	   of	   CpG	   islands	   at	   transcription	   start	   sites	   of	   the	   promoter	  
regions	  results	  in	  gene	  silencing.	  In	  contrast,	  DNA	  methylation	  in	  gene	  bodies,	  largely	  devoid	  
of	  CpG	  islands,	  might	  enhance	  transcriptional	  elongation	  and	  play	  a	  role	  in	  splicing110	  (Figure	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7).	  During	  normal	  development,	  most	  CpG	  islands	  on	  autosomal	  genes	  remain	  unmethylated	  
although	   the	   CpG	   island	   shores	   (2kb	   of	   sequence	   on	   either	   side	   of	   a	   CpG	   island)	   seem	   to	  
become	   methylated111.	   Furthermore,	   large	   undermethylated	   regions	   over	   3.5kb	   in	   length	  
were	   recently	   identified	   in	   hematopoietic	   stem	   cells	   (HSCs),	   called	   methylation	   canyons.	  
These	   hypomethylated	   regions	   are	   enriched	   for	   highly	   conserved,	   developmentally	  
important	   genes;	   whereby	   active	   HSC	   canyons	   marked	   with	   H3K4	   trimethylation	   often	  
contain	  genes	  frequently	  deregulated	  in	  leukemia112.	  
	  
The	  cancer	  epigenome	  is	  marked	  by	  global	  hypomethylation	  and	  local	  hypermethylation	  at	  
CpG	   islands	  of	   thousands	  of	   genes73,108,109,113	   (Figure	   7).	   These	  hypermethylated	   genes	   can	  
complement	  a	  single	  gene	  mutation	  or	  can	  collectively	  disrupt	  specific	  signaling	  pathways109.	  
Global	   hypomethylation	   encompasses	   often	   megabase	   regions	   of	   multiple	   chromosomes,	  
most	  frequently	  CpG-­‐poor	  regions	  like	  repetitive	  and	  gene	  body	  sequences73,109.	  
	  
	  
Figure	   7.	   	  Graphical	   representation	  of	  DNA	  methylation.	  Methylated	  DNA	  contributes	   to	  a	  
closed	  chromatin	  formation,	  whereas	  unmethylated	  DNA	  adds	  to	  an	  open	  chromatin	  state.	  
In	  contrast	  to	  normal	  cells,	  cancer	  cells	  display	  in	  general	  local	  hypermethylation	  at	  CpG-­‐rich	  
promoter	  regions	  and	  global	  hypomethylation	  mainly	  at	  CpG-­‐poor	  regions	  like	  gene	  bodies.	  
(graphics	  from	  www.somersault1824.com)	  
	  
In	  T-­‐ALL,	  hypermethylation	  of	  tumor	  suppressor	  genes	  has	  been	  described	  at	  CpG	  islands	  in	  
the	  promoter	  regions	  or	  first	  exons	  of	  CDKN2B114,	  SYK115,	  C/EBPA116,	  	  PAX5117,	  ABCG2118	  and	  
CDKN1A119.	   A	   CpG	   island	   methylator	   phenotype	   (CIMP)	   was	   proposed	   in	   T-­‐ALL	   and	   this	  
hypermethylator	   profile	   (CIMP+)	   was	   linked	   to	   poor	   prognosis120,121.	   Interestingly,	   the	  
majority	   of	   genes	   prone	   to	   DNA	   hypermethylation	   in	   the	   CIMP+	   profile	   were	   lineage-­‐
commitment	   genes	   that	   are	   regulated	   by	   the	   Polycomb	   repressive	   complexes	   PRC1	   and	  
PRC273,109,120	   and	   are	   thought	   to	   undergo	   an	   epigenetic	   switch	   from	   transient	   repression	  
towards	  a	  tight	  silencing	  state109.	  	  
	  
Therapeutic	   opportunities	   targeting	   the	   DNA	   methylation	   machinery	   encompass	   DNMT	  
inhibitors	   (DNMTi)	   that	   consist	   of	   cytosine	   analogs	   like	   5-­‐azacitidine	   (vidaza)	   and	  5-­‐aza-­‐2’-­‐
deoxycytidine	   (decitabine),	   which	   have	   been	   approved	   by	   the	   US	   Food	   and	   Drug	  
Administration	   (FDA)	   for	   treatment	  of	  myelodysplastic	   syndrome	  (MDS)73,108.	  These	  DNMTi	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reverse	   DNMT	   mediated	   gene	   silencing	   which	   enables	   their	   anti-­‐tumor	   activity73.	  	  
Mechanistically,	   the	   cytosine	   analogs	   are	   integrated	   in	   the	   RNA	   and/or	   DNA	   during	  
replication	   locking	   the	   DNMT	   through	   covalent	   binding73.	   Since	   CIMP+	   T-­‐ALL	   cases	   are	  
marked	   by	   a	   hypermethylation	   profile	   compared	   to	   CIMP-­‐	   and	   normal	   T-­‐cells120,121,	  
exploration	   of	  DNMTi	   treatment	   strategies	   in	   CIMP+	   T-­‐ALLs	  would	   be	   of	   great	   therapeutic	  
interest.	  
	  
Very	   recently,	   DNMT3A	   mutations	   were	   identified	   in	   immature	   T-­‐ALL30,36,122.	   In	   addition,	  
mutations	  in	  TET1,	  a	  gene	  coding	  for	  an	  epigenetic	  regulator	  that	  converts	  5-­‐methylcytosine	  
to	  5-­‐hydroxymethylcytosine	  using	  cofactors	  α-­‐ketoglutarate	  and	  Fe(II)123,	  were	  discovered	  in	  
6%	   of	   T-­‐ALL	   cases6.	   Moreover,	   immature	   T-­‐ALLs	   also	   show	  mutations	   targeting	   IDH1	   and	  
IDH230.	   Wild-­‐type	   IDH	   proteins	   convert	   isocitrate	   and	   NADP+	   into	   α-­‐ketoglutarate	   and	  
NADPH.	   In	   contrast,	   mutant	   IDH	   proteins	   generate	   an	   overload	   of	   2-­‐hydroxyglutarate	  
consuming	   α-­‐ketoglutarate	   and	  NADPH,	  which	   in	   turn	   inhibits	   the	   TET	   proteins	   and	   JmjC-­‐
domain	  containing	  histone	  demethylases	  (HDM)73,124. Both	   IDH	  and	  TET	  mutations	  seem	  to	  
provoke	  DNA	  hypermethylation	  in	  cancer	  pathogenesis109.	  Further	  exploration	  of	  the	  effects	  
mediated	   by	   DNMT3A,	   TET1,	   IDH1	   and	   IDH2	   mutations	   are	   essential	   in	   the	   further	  
unraveling	  of	  T-­‐ALL	  pathogenesis.	  Notably,	  specific	  drugs	  targeting	  mutant	  IDH	  have	  shown	  
effective	  growth	  arrest	  in	  glioma125.	  
	  
	  
2.2	  Nucleosome	  remodeling	  
	  
Nucleosome	  remodeling	  is	  mediated	  by	  ATP-­‐dependent	  multi-­‐subunit	  chromatin	  remodeling	  
complexes	   that	   execute	   unwrapping	   of	   the	   DNA	   from	   the	   histones,	   repositioning	   of	  
nucleosomes,	  evicting	  histones	  of	  DNA,	  attracting	  transcription	  factors	  for	  DNA	  binding	  and	  
switching	   of	   histone	   variants73,126,127.	   Five	   types	   of	   chromatin	   remodeling	   complexes	   have	  
been	   identified	   including	   the	   SWI/SNF,	   the	   NuRD,	   the	   ISWI,	   the	   INO80	   and	   the	   SWR1	  
families73,127,128.	   Of	   interest,	   specific	   subunits	   of	   these	   nucleosome	   remodelers	   enable	   a	  
range	   of	   interactions	   depending	   on	   specific	   configurations	   of	   histones	   hereby	   granting	  
different	   functions	   to	   these	   remodeling	   complexes.	   For	   example,	   the	  ATPases	   of	   SWI/SNF	  
family	  consist	  of	  BRM	  and	  BRG1	  and	  harbor	  a	  bromodomain	  for	  interaction	  with	  acetylated	  
histone	   tails129,	   whereas	   the	   CHD1-­‐5	   of	   the	   NuRD	   family	   contain	   chromodomains	   for	  
interaction	  with	  methylated	  histone	  tails130.	  	  
	  
Importantly,	   ATPase	   remodelers	   can	   promote	   transcriptional	   activation	   by	   facilitating	  
transcriptional	   elongation	   of	   RNA	   polymerase	   II	   (RNAPII)	   (primary	   role	   of	   SWI/SNF	  
complexes)	   or	   induce	   transcriptional	   repression	   (primary	   role	   of	   NuRD	   complex)127.	   Of	  
interest,	   the	   SWI/SNF	   protein	   BRM	   was	   shown	   to	   interact	   with	   the	   NOTCH1	   signaling	  
pathway	   promoting	   activation	   of	   NOTCH1	   targets131.	   Besides	   their	   role	   in	   transcriptional	  
regulation,	   nucleosome	   remodeling	   is	   also	   implicated	   in	   other	   cellular	   processes	   including	  
DNA	  damage	  response,	  DNA	  replication	  and	  cellular	  identity	  determination127.	  For	  example,	  
the	   INO80	  and	   the	  NuRD	   family	  play	  a	   role	   in	  DNA	  damage	  repair	  upon	   the	  occurrence	  of	  
DNA	  double-­‐strand	  breaks	  (DSBs)132-­‐134.	  In	  T-­‐ALL,	  one	  ETV6-­‐INO80D	  fusion	  has	  been	  detected	  
in	   an	   immature	   T-­‐ALL	   case31,	   but,	   to	   date,	   no	   other	   recurrent	   genetic	   defects	   affecting	  
ATPase	  remodeling	  complexes	  have	  been	  described.	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2.3	  Histone	  variants	  
	  
Within	   a	   nucleosome,	   histones	   H2A,	   H2B	   and	  H3	   can	   be	   exchanged	  with	   histone	   variants	  
including	   H2A.X	   and	   H2A.Z111,135.	   These	   exchanges	   enable	   fast,	   replication-­‐independent	  
changes	   to	   the	   chromatin	   in	   contrast	   to	   deposition	   of	   the	   canonical	   histones73,136.	  
Chaperones	   escort	   the	   histone	   variants	   to	   enable	   exchange	   of	   histones136.	   H2A	   harbors	   6	  
histone	  variants	  of	  which	  H2A.X	  is	  present	  in	  10-­‐15%	  of	  nucleosomes.	  In	  particular,	  H2A.X	  is	  
incorporated	   in	   nucleosomes	   guided	  by	   the	   FACT	   complex	  upon	  DNA	  damage,	   acting	   as	   a	  
caretaker	  of	  our	  genome126,136	   (Figure	   8).	   The	  FACT	  complex	   is	  essential	   for	   transcriptional	  
elongation	   through	   nucleosomes	   by	   removing	   of	   core	   H2A/H2B	   dimers137.	   Then	   DSBs,	  
leading	   to	   DNA	   damage,	   induce	   rapid	   phosphorylation	   of	   serine	   139	   of	   H2A.X	   forming	  
γH2A.X	   in	   chromatin	   regions	   up	   to	   1-­‐2Mb	   around	   the	   DSBs136.	   The	   kinases	   ATM	   and	   ATR	  
perform	   the	   specific	   phosphorylation	   of	   H2A.X	   and	   enable	   the	   assembly	   of	   DNA	   repair	  
complexes	   like	   the	   INO80	  remodeler136,138.	  The	  histone	  variant	  H2A.Z	  has	  a	  broad	  range	  of	  
functions,	   is	   located	  mainly	   at	   transcription	   start	   sites	   but	   also	   in	   heterochromatin,	   and	   is	  
guided	   by	   INO80	   and	   SWR1	   remodelers136.	   No	   mutations	   in	   histone	   variants	   or	   histone	  
variant	   chaperones	   have	   been	   described	   in	   T-­‐ALL	   so	   far,	   but	   loss	   of	   the	   T-­‐ALL	   tumor	  
suppressor	  PHF6	  can	  exert	  an	   increase	   in	  global	   levels	  of	  γH2A.X	   indicating	  a	  putative	   role	  
for	  PHF6	  in	  DNA	  damage	  repair	  (see	  further)	  (paper	  1)5.	  
	  
	  
Figure	   8.	   Exchange	   of	   the	   core	   histone	   H2A	   by	   the	   histone	   variant	   H2A.X	   guided	   by	   the	  
chaperone	  FACT	  upon	  DNA	  damage	  caused	  by	  DSBs	   in	  the	  DNA.	  Subsequently,	   the	  kinases	  
ATM	   and	   ATR	   catalyze	   the	   phosphorylation	   of	   H2A.X	   forming	   γH2A.X	   resulting	   in	   the	  
attraction	  of	  the	  DNA	  repair	  machinery136	  (graphics	  from	  www.somersault1824.com)	  
	  
	  
2.4	  Histone	  modifications	  &	  their	  mediators	  
	  
Histone	   modifications	   on	   the	   globular	   domain	   and	   the	   histone	   tails	   include	   lysine	   (K)	  
acetylation,	   lysine	   and	   arginine	  methylation,	   serine	   and	   threonine	   phosphorylation,	   lysine	  
ubiquitynilation,	   lysine	   sumoylation,	   arginine	   deimination,	   proline	   isomerization	   and	  
glutamic	  acid	  ADP-­‐ribosylation106,139.	  These	  histone	  modifications	  are	  transferred	  by	  specific	  
chromatin	   writers	   and	   modified	   or	   reverted	   by	   chromatin	   erasers.	   An	   additional	   set	   of	  
chromatin	   regulators	   can	   read	   the	   histone	   modifications	   and	   subsequently	   mediate	  
interactions	   between	   a	   protein	   or	   protein	   complex	   and	   the	   respective	   histone	  
modification(s)73.	  	  
	  
Histone	   acetylation	   is	   linked	   to	   transcriptional	   active	   regions	   and	   is	   accomplished	   by	  
neutralization	  of	  basic	  charges	  of	   lysines	   leading	  to	  unfolding	  of	   the	  DNA138.	  Acetylation	  of	  
histones	  is	  applied	  by	  histone	  acetyltransferases	  (HAT)	  and	  removed	  by	  histone	  deacetylases	  
(HDAC).	   Histone	   acetyltransferases	   can	   be	   divided	   into	   3	   families;	   the	   GNAT	   family,	   the	  
MYST	   family	  and	   the	  CBP/EP300	   family138.	  The	  HATs	  can	  acetylate	  multiple	   lysines	  of	  both	  
core	  histone	  proteins	   and	  non-­‐histone	  proteins	   including	  TP53,	  RB1	  and	  E2F138.	   The	  HDAC	  
	  	   15	  
family	   consists	  of	  18	  HDACs	   that	   remove	  acetyl	   groups	   from	  histone	   tails	   and	  non-­‐histone	  
proteins	  like	  TP53,	  E2F	  and	  TFIIF138.	  	  
	  
In	  contrast,	  histone	  methylation	  can	  be	  associated	  with	  active	  or	  repressed	  gene	  expression	  
depending	   on	   the	   lysine	   residue	   that	   is	   methylated	   and	   the	   degree	   of	   methylation	   (un,	  
mono,	  di	  and	  trimethylated).	  For	  example,	  histone	  H3	  lysine	  27	  trimethylation	  (H3K27me3)	  
and	  H3K9me3	  are	  linked	  to	  heterochromatin-­‐associated	  gene	  silencing,	  whereas	  H3K4me3,	  
H3K36me3	  and	  H3K79me2	  are	   linked	  to	  active	  transcription	  enriched	   in	  euchromatin106,138.	  
H3K27me3	   is	   the	  prototypical	  mark	  of	   the	  Polycomb	  repressors	   linked	  to	  a	  more	   transient	  
repression	  of	  DNA	  called	  facultative	  heterochromatin,	  whereas	  H3K9me3	  is	  mainly	  present	  
in	  stable	  tightly	  packed	  DNA	  called	  constitutive	  heterochromatin111.	  In	  general,	  H3K4me3	  is	  
enriched	  at	  transcription	  start	  sites	  (TSS)	  in	  promoter	  regions	  of	  genes,	  whereas	  H3K36me3	  
and	  H3K79me2	  are	  mainly	  detected	  in	  gene	  bodies111.	  Specific	  enhancers	  that	  contribute	  to	  
gene	  expression	  are	  marked	  by	  histone	  3	  lysine	  27	  acetylation	  (H3K27ac)	  and	  H3K4me1-­‐2	  in	  
active	   chromatin	   and	   contain	   H3K9me2-­‐3	   in	   a	   repressed	   transcriptional	   state111.	   Methyl	  
groups	   on	   lysines	   are	   placed	   by	   histone	   methyltransferases	   (HMT)	   using	   the	   cofactor	   S-­‐
adenosyl	  methionine	  (SAM)	  and	  removed	  by	  histone	  demethylases	  (HDMs)111.	  
	  
In	  T-­‐ALL,	  recurrent	  genetic	  defects	  have	  been	  identified	  in	  the	  putative	  histone	  reader	  PHF65	  
(see	   paper	   1),	   the	   H3K27me3	   HMT	   PRC2	   (targeting	   the	   members	   EZH2,	   SUZ12,	   EED	   and	  
JARID2)31,140,141,	  the	  H2A	  ubiquitinylase	  PRC1	  (targeting	  the	  member	  BMI1)36,	  the	  H3K27me3	  
HDM	  UTX6	  (Van	  der	  Meulen	  et	  al.	  submitted)	  (see	  paper	  2),	  the	  H3K4me3	  HMTs	  MLL1	  and	  
MLL236,	  the	  HAT	  EP30031	  and	  the	  H3K36me3	  HMT	  SETD231.	  
	  
The	  putative	  histone	  reader	  PHF6	  
	  
The	   PHF6	   protein	   belongs	   to	   a	   large	   family	   of	   proteins	   containing	   a	   plant	   homeodomain	  
(PHD)	  finger,	  also	  found	  in	  nuclear	  proteins	  and	  chromatin-­‐associated	  factors142.	  A	  Cys4-­‐His-­‐
Cys3	  motif	  characterizes	  the	  PHD	  finger	  and	  mediates	  the	  binding	  of	  two	  zinc	   ions142.	  Until	  
now,	  about	  fifteen	  PHD	  finger-­‐containing	  proteins	  have	  been	  identified	  that	  are	  capable	  of	  
reading	   the	   H3K4me3	   mark142.	   These	   PHD-­‐containing	   proteins	   contain	   a	   specialized	  
structural	   cage	   consisting	   of	   crucial	   hydrophobic	   or	   aromatic	   residues	   to	   enclose	  
preferentially	   the	  H3K4me3	   side	   chain142.	   Furthermore,	   the	   recognition	  of	   3	   other	   histone	  
lysine	   modifications	   was	   demonstrated	   to	   be	   mediated	   by	   PHD-­‐containing	   proteins,	  
including	  unmodified	  H3K4143,	  methylated	  H3K36144	  and	  methylated	  H3K9145.	  Moreover,	  PHD	  
fingers	  can	  also	  bind	  acetylated	  lysines146	  and	  can	  interact	  with	  non-­‐histone	  proteins	  like	  the	  
third	  PHD	   finger	  of	  MLL1	   that	  binds	  both	  H3K4me3	  and	   the	  MLL1-­‐associated	   co-­‐repressor	  
Cyp33	   hereby	   switching	   between	   transcriptional	   activation	   and	   repression147.	   Regarding	  
PHF6,	  no	  interactions	  between	  its	  two	  imperfect	  PHD	  fingers	  (Cys4-­‐His-­‐Cys-­‐His)	  and	  specific	  
histone	  H3	  marks	  or	  non-­‐histone	  proteins	  have	  been	  elucidated	  yet.	  	  
	  
Next	  to	  two	  imperfect	  PHD	  fingers,	  four	  nuclear	  localization	  signals	  are	  present	  in	  the	  PHF6	  
protein	  targeting	  PHF6	  to	  the	  nucleus	  and	  nucleolus148.	  In	  HEK293T	  cells,	  PHF6	  protein	  levels	  
are	   most	   profound	   in	   the	   nucleoplasm	   compared	   to	   the	   nucleolus	   measured	   by	   western	  
blotting133.	  Mass	  spectrometry	  analysis	   in	  HEK293T	  cells	  enabled	  the	   identification	  of	  PHF6	  
interaction	  partners	  including	  CHD3,	  CHD4,	  RBBP4	  and	  RBBP7	  of	  the	  NuRD	  complex	  (Figure	  
9)	   next	   to	   histones,	   splicing	   factors,	   40S	   and	   60S	   ribosomal	   proteins,	   and	   other	   nucleolar	  
proteins133.	  The	  NuRD-­‐PHF6	  complex	  was	   shown	   to	  be	  mainly	  present	   in	   the	  nucleoplasm,	  
whereas	   PHF6	   interacts	   with	   other	   proteins	   in	   the	   nucleolus	   probably	   mediating	   distinct	  
functions133.	   Of	   interest,	   both	   RBBP4	   and	   RBBP7	   have	   been	   shown	   to	   interact	   with	   other	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chromatin	  complexes	  including	  the	  PRC2	  complex149	  (Figure	  9).	  The	  histone-­‐binding	  proteins	  
RBBP4	  and	  RBBP7	  provide	  structural	  support	  and	  promote	  protein-­‐protein	  interactions134.	  
	  
	  
Figure	  9.	  Graphical	  representation	  of	  the	  chromatin	  complexes	  NuRD-­‐PHF6133,134	  and	  PRC2150	  
with	  matched	  chromatin	  conformation	  (graphics	  from	  www.somersault1824.com)	  
	  
Post-­‐transcriptional	   regulation	   might	   further	   affect	   PHF6	   function	   as	   it	   becomes	  
phosphorylated	  during	  cell	  cycle	  progression151	  and	  after	  DNA	  damage	  by	  ATM	  and	  ATR152.	  In	  
addition,	   loss	   of	   PHF6	   significantly	   increases	   global	   levels	   of	   γH2A.X	   present	   in	   the	  
chromatin,	   which	   has	   also	   been	   observed	   in	   the	   context	   of	   T-­‐ALL	   cells5,152.	   The	   NuRD	  
complex	   is	  also	   involved	  in	  DNA	  damage	  repair133,134	  and,	   likewise	  PHF6,	  target	  of	  the	  ATM	  
and	  ATR	  DNA	  damage	  checkpoint	  kinases152.	  Therefore,	  besides	  a	  possible	  role	  of	  NuRD	  and	  
PHF6	  in	  transcriptional	  regulation,	  the	  NuRD-­‐PHF6	  complex	  might	  also	  be	  involved	  in	  active	  
DNA	  repair133.	  
	  
The	  nucleolar	  localization	  of	  PHF6	  has	  first	  been	  described	  by	  Lower	  et	  al.	  by	  co-­‐localization	  
studies	  with	  the	  nucleolar	  protein	  nucleolin148.	  The	  nucleolus	   is	  a	  subnuclear	  compartment	  
primarily	  occupied	  by	  ribosomal	  biogenesis.	  Ribosomal	  genes	  (rDNA)	  are	  actively	  transcribed	  
to	  generate	  mature	  rRNAs	  that	  subsequently	  assemble	  with	  ribosomal	  proteins	  to	  form	  the	  
ribosome	  subunits153.	  In	  the	  nucleolus,	  PHF6	  binds	  to	  rDNA	  promoter	  sequences	  resulting	  in	  
repression	  of	  rDNA	  transcription.	  Loss	  of	  PHF6	  establishes	  an	  arrest	  at	  the	  G2/M	  phase	  and	  
inhibited	  cell	  proliferation,	  leading	  to	  DNA	  damage	  marked	  with	  increased	  level	  of	  γH2A.X	  at	  
the	  rDNA	  promoter154.	  	  
	  
Recurrent	  inactivating	  mutations	  and	  deletions	  were	  identified	  in	  the	  X-­‐linked	  PHF6	  gene	  in	  
16%	   of	   pediatric	   and	   38%	   of	   adult	   T-­‐ALL	   patient	   samples	   (see	   paper	   1)5.	   Furthermore,	  
hypermethylation	  of	  the	  PHF6	  promoter	  region	  occurs	   in	  10%	  of	  T-­‐ALL	  cases	  and	  has	  been	  
proposed	   as	   an	   additional	   mechanism	   of	   PHF6	   inactivation121.	   The	   presence	   of	   PHF6	  
mutations	   in	   T-­‐ALL	   is	   significantly	   associated	   with	   TLX1	   and	   TLX3	   aberrations5,	   NOTCH1	  
mutations,	   SET-­‐NUP214	   rearrangements	   and	   JAK1	   mutations155.	   Frequent	   somatic	  
inactivating	   mutations	   affecting	   PHF6	   were	   also	   reported	   in	   acute	   myeloid	   leukemia	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(AML)156-­‐158,	   chronic	   myeloid	   leukemia	   (CML)	   in	   blast	   crisis159,	   bladder	   cancer160	   and	  
hepatocellular	  carcinoma157.	  In	  a	  large	  AML	  study,	  somatic	  PHF6	  mutations	  were	  linked	  to	  a	  
reduced	  overall	  survival158.	  Interestingly,	  PHF6	  mutations	  are	  more	  frequently	  found	  in	  male	  
T-­‐ALL	   and	   AML	   patients,	   two	   leukemia	   types	   that	   display	   a	   disturbed	   gender	   distribution	  
with	  a	  higher	  prevalence	  in	  males	  (T-­‐ALL:	  ~3/1;	  AML:	  ~1.3/1)5,156.	  The	  identified	  mutations	  in	  
this	  X-­‐linked	  gene	  might	  provide	  a	  possible	  explanation	  for	  the	  unbalanced	  male-­‐to-­‐female	  
ratio	  present	  in	  these	  cancer	  types.	  	  
	  
In	   developmental	   diseases,	   PHF6	   mutations	   were	   first	   reported	   in	   2002	   to	   be	   the	   causal	  
event	   leading	   to	   the	   Börjeson-­‐Forssman-­‐Lehmann	   syndrome	   (BFLS)148.	   BFLS	   patients	   are	  
characterized	  by	  large	  ears,	  small	  genitalia,	  epilepsy,	  obesity	  with	  gynaecomastia,	  shortened	  
abnormal	   toes,	   tapered	   fingers	   and	   intellectual	   disability161.	   In	   general,	   BFLS	   affects	  
predominantly	  males	  with	  milder	  or	  no	  symptoms	  in	  females161	  and	  PHF6	  defects	  have	  only	  
been	   reported	   in	   2	   female	   BFLS	   patients162.	  Of	   interest,	   a	   BFLS	   patient	  was	   reported	  who	  
developed	   T-­‐ALL	   at	   age	   7,	   suggesting	   that	   BFLS	   may	   represent	   a	   cancer	   predisposition	  
syndrome163.	  A	  recent	  report	  identified	  de	  novo	  PHF6	  defects	  in	  7	  females	  that	  contain	  BFLS	  
characteristics	  but	  are	  also	  marked	  with	  distinct	  features	  like	  linear	  skin	  hyperpigmentation,	  
hypoplastic	   nails,	   dental	   anomalies,	   sparse	   hair	   and	   brachyclinodactyly	   hereby	   broadening	  
this	  X-­‐linked	  disorder164.	  Using	  whole-­‐exome	  sequencing,	  two	  de	  novo	  PHF6	  mutations	  were	  
also	   identified	   in	   patients	   with	   the	   Coffin-­‐Siris	   syndrome,	   a	   syndrome	   caused	   mainly	   by	  
mutations	  in	  genes	  coding	  for	  members	  of	  the	  SWI/SNF	  remodeling	  complex165.	  
	  
Furthermore,	  an	  important	  role	  for	  PHF6	  in	  cortical	  neuronal	  migration	  was	  elucidated166.	  In	  
the	   developing	   cerebral	   cortex,	   PHF6	   interacts	   with	   the	   PAF1	   transcription	   elongation	  
complex	  promoting	  transcription	  of	  the	  neuronal	  gene	  NGC/CSPG5166.	  The	  disturbed	  PHF6-­‐
PAF1-­‐NGC/CSPG5	  pathway	  gave	  rise	  to	  heterotopias	  in	  the	  cerebral	  cortex	  in	  which	  neurons	  
are	   hyperexcitable166,	   which	   can	   contribute	   to	   the	   pathogenesis	   of	   the	   developmental	  
disorders	  described	  above.	  
	  
The	  Polycomb	  repressor	  complexes	  PRC1	  &	  PRC2	  
	  
The	  Polycomb	  repressor	  complexes	  encompass	  2	  multi-­‐protein	  complexes,	  PRC1	  and	  PRC2.	  
PRC2	  consist	  of	  the	  core	  members	  EZH1/2,	  SUZ12,	  EED	  and	  RBBP4/7,	   interacts	  with	  HDACs	  
and	  DNMTs,	  and	  enables	  mainly	  di-­‐	   and	   trimethylation	  of	  H3K27	  provoking	   transcriptional	  
repression126,138,150	  (Figure	  9).	  PRC1	  is	  built	  up	  with	  core	  components	  from	  4	  protein	  families	  
including	   the	   RING1	   family	   (RING1A/B),	   the	   CBX	   family	   (CBX2/4/6/7/8),	   the	   PCGF	   family	  
(PCGF1/2/3/5/6	  and	  BMI1)	  and	   the	  HPH	   family	   (HPH1/2/3)107.	  PRC1	   recognizes	  H3K27me3	  
by	   a	   CBX	  member	   and	  mono-­‐ubiquitinylates	   H2A	   by	   a	   RING	   family	  member.	   In	   this	   way,	  
PRC1	  maintains	  the	  silenced	  state	  by	  restraining	  RNAPII	  and	  preventing	  eviction	  of	  H2A-­‐H2B	  
dimers107,150.	  	  
	  
The	   PRC2	   complex	   is	   mainly	   present	   at	   CpG-­‐rich	   promoter	   regions,	   whereas	   the	   PRC1	  
complex	   binds	   to	   parts	   of	   the	   gene	   bodies	   as	   well107.	   The	   DNA-­‐binding	   proteins	   AEBP2,	  
JARID2	  and	  the	  3	  PCL	  proteins	  PHF1,	  MTF2	  and	  PHF19	  were	  shown	  to	  co-­‐localize	  with	  PRC2	  
and	  its	  H3K27me3	  mark	  in	  CpG-­‐rich	  promoters	  of	  PRC2	  targets143,204	  (Figure	  9).	  Furthermore,	  
PRC2	  acts	  in	  concert	  with	  the	  long	  intergenic	  non-­‐coding	  RNAs	  (lincRNAs)	  XIST	  at	  the	  inactive	  
X-­‐chromosome	  and	  HOTAIR	  at	  the	  HOXC	  locus	  hereby	  possibly	  guiding	  PRC2	  to	  these	  specific	  
DNA	   sequences	   in	   the	   genome111,150	   (Figure	   9).	   Besides	   CpG-­‐rich	   promoters,	   the	   silencing	  
mark	   H3K27me3	   can	   also	   be	   found	   at	   intergenic	   regions,	   subtelomeric	   regions	   and	   long-­‐
terminal	  repeat	  retrotransposons150.	  Of	  interest,	  the	  Polycomb	  complexes	  are	  crucial	  during	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normal	  embryonic	  development	  since	  deletion	  of	  Ezh2,	  Suz12,	  Eed	  or	  Ring1B	   leads	  to	  early	  
embryonic	  lethality150.	  
	  
The	   Polycomb	   repressors	   are	   important	   for	   the	   maintenance	   of	   tissue-­‐specific	   gene	  
expression	  of	   several	   thousands	  of	   genes111.	   In	  particular,	   Polycomb	  proteins	   are	  essential	  
for	   correct	   homeotic	   gene	   expression	   during	   animal	   development150.	   Furthermore,	   a	  
dedicated	   role	   for	   Polycomb	   repressors	   is	   set	   in	   gene	   expression	   regulation	   in	   embryonic	  
stem	  cells	   (ESCs).	   In	  ESCs,	  about	  a	   fifth	  of	  CpG-­‐rich	  promoters	  are	  enriched	   for	  H3K27me3	  
but	   also	   contain	   H3K4me3	   defining	   them	   as	   bivalent	   promoters	   that	   are	   transcriptionally	  
silent111,150.	  Next	  to	  H3K27me3	  and	  H3K4me3,	  bivalent	  promoters	  are	  also	  marked	  with	  the	  
histone	   variant	   H2A.Z,	   paused	   RNAPII	   and	   lack	   of	   DNA	   methylation107,150	   (Figure	   10).	  
Interestingly,	   these	  poised	  bivalent	  promoters	  are	  mainly	  associated	  with	  developmentally	  
important	  genes	  that	  can	  be	  rapidly	  switched	  on	  during	  differentiation109,111.	  In	  cancer,	  these	  
gene	   promoters	   can	   become	   de	   novo	   methylated	   by	   interacting	   with	   DNMTs	   leading	   to	  
constitutive	  silencing109.	  Of	  note,	  PRC1	  localizes	  together	  with	  PRC2	  to	  a	  smaller	  set	  of	  PRC2	  
targets	  including	  key	  developmental	  regulators111,	  but	  PRC1	  can	  also	  bind	  in	  the	  absence	  of	  
PRC2167.	  
	  
	  
Figure	   10.	   Active,	   poised	   and	   inactive	   promoters	   marked	   by	   presence	   or	   absence	   of	  
H3K27me3,	   H3K4me3	   and	   the	   histone	   variant	   H2A.Z	   in	   ESC	   respectively	   (graphics	   from	  
www.somersault1824.com)	  
	  
Intriguingly,	  PRC2	  can	  act	  both	  as	  an	  oncogene	  or	  show	  tumor	  suppressor	  activity	  depending	  
on	  its	  cellular	  context.	  Namely,	  heterozygous	  mutations	  at	  hotspot	  Tyr641	  in	  EZH2	  were	  first	  
identified	   in	   2	   lymphoma	   subtypes	   arising	   from	   germinal	   center	   B-­‐cells	   including	   diffuse	  
large	  B-­‐cell	   lymphoma	  and	   follicular	   lymphoma.	  Co-­‐occurrence	  of	  wild-­‐type	  EZH2	  with	   the	  
Tyr641	  mutant	   establishes	   an	   increase	   of	   H3K27me3	   at	   Polycomb	   target	   genes168,169.	   The	  
first	  inhibitor	  affecting	  H3K27me3	  and	  EZH2	  protein	  levels	  was	  the	  S-­‐adenosylhomocysteine	  
hydrolase	  inhibitor	  3-­‐deazaneplanocin	  A	  (DZNep)	  inducing	  reactivation	  of	  PRC2	  target	  genes	  
and	   apoptosis	   of	   cancer	   cell	   lines170.	   Next,	   specific	   EZH2	   inhibitors	   like	   GSK-­‐126	   were	  
discovered	   that	   provoke	   global	   H3K27me3	   loss	   reactivating	   PRC2	   target	   genes,	   which	   is	  
observed	   most	   profoundly	   in	   lymphoma	   samples	   with	   activating	   EZH2	   mutations171.	   One	  
EZH2	  specific	  inhibitor,	  EPZ-­‐6438,	  has	  already	  entered	  phase	  I/II	  clinical	  trials	  in	  solid	  tumors	  
and	  B-­‐cell	  lymphomas74.	  
In	  contrast,	  inactivating	  deletions	  and	  mutations	  in	  EZH2	  and	  cofactors	  have	  been	  identified	  
in	  malignant	  myeloid	  diseases172,173	  and	  T-­‐ALL31,140,141.	  The	  tumor	  suppressor	  activity	  of	  PRC2	  
in	  the	  T-­‐cell	  lineage	  was	  further	  confirmed	  using	  a	  conditional	  Ezh2	  knockout	  mouse	  model	  
that	  spontaneously	  developed	  T-­‐cell	  leukemia140	  and	  xenografts	  of	  human	  T-­‐ALL	  cell	  lines141.	  
Of	  note,	  NOTCH1	  activation	   in	  T-­‐ALL	   leads	   to	  a	   loss	  of	  H3K27me3	  by	  eviction	  of	   the	  PRC2	  
complex	   of	   NOTCH1	   target	   genes.	   Interestingly,	   NOTCH1	   target	   genes	   are	   enriched	   for	  
known	  PRC2	  target	  genes141.	  
	  
	  	   19	  
The	  PRC1	  member	  BMI1	  was	  first	  linked	  to	  leukemogenesis	  through	  its	  interaction	  with	  the	  
oncoprotein	   MYC	   in	   B-­‐cell	   lymphomas174,	   inhibiting	   CDKN2A-­‐B	   expression	   and	   escaping	  
cellular	   senescence167,175.	   Leukemias	   harboring	   MLL1	   fusions	   cooperate	   with	   BMI1	   to	  
maintain	   leukemia	   initiating	   cells,	  whereas	  BMI1	  drives	  progression	   to	   acute	  blast	   crisis	   in	  
BCR-­‐ABL1	  rearranged	  CML	  cases176.	  Very	  recently,	   the	  first	  BMI1	  mutation	  was	  detected	   in	  
immature	  T-­‐ALL36,	  but	  research	  is	  needed	  to	  further	  explore	  the	  prevalence	  of	  BMI1	  defects	  
and	  their	  role	  in	  T-­‐ALL	  pathogenesis.	  
	  
The	  H3K27me3	  demethylase	  UTX	  
	  
Loss-­‐of-­‐function	   defects	   in	   the	   X-­‐linked	   UTX	   gene	   are	   identified	   in	   a	   broad	   range	   of	  
cancers177	  including	  T-­‐ALL6	  (see	  paper	  2)	  and	  can	  cause	  a	  specific	  hereditary	  disorder	  called	  
the	  Kabuki	  syndrome178.	  The	  role	  of	  UTX	  in	  normal	  development	  and	  disease	  is	  discussed	  in	  
detail	   in	  chapter	  2	   (review)	  of	   this	  doctoral	   thesis179.	  Briefly,	   the	  UTX	   family	  members	  UTX	  
and	  JMJD3	  were	  recently	  identified	  as	  histone	  H3K27me2/3	  demethylases180-­‐183.	  In	  contrast,	  
no	   enzymatic	   activity	   was	   detected	   for	   the	   third	   family	   member	   UTY180,184.	   The	   catalytic	  
activity	  of	  UTX	  is	  linked	  to	  HOX181,182	  and	  RB185	  network	  regulation	  in	  agreement	  with	  the	  co-­‐
operation	   of	   UTX	   with	   the	   MLL2-­‐3	   H3K4	   methyltransferase	   complex186,187	   (Figure	   11).	   In	  
addition,	   an	   H3K27me2/3	   demethylase	   independent	   function	   for	   the	   UTX	   family	   was	  
uncovered	  in	  promoting	  general	  chromatin	  remodeling	  in	  concert	  with	  the	  BRG1-­‐containing	  
SWI/SNF	   remodeling	   complex189.	   Notably,	   UTX	   is	   essential	   for	   cellular	   reprogramming190,	  
embryonic	   development	   and	   tissue-­‐specific	   differentiation,	   whereby	   UTY	   can	   surprisingly	  
partly	  compensate	  a	  set	  of	  UTX	  functions191-­‐195.	  	  
	  
	  
Figure	  11.	  Graphical	  representation	  of	  the	  MLL1	  complex188	  and	  the	  MLL2-­‐UTX	  complex186-­‐188	  
with	  matched	  chromatin	  conformation	  (graphics	  from	  www.somersault1824.com)	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The	  H3K4me3	  histone	  methyltransferases	  MLL1	  &	  MLL2	  
	  
The	  MLL1	  complex	  mediates	  active	  gene	   transcription	  and	  encompasses	   the	  core	  complex	  
members	  WDR5,	  RBBP5	  and	  ASH2L	  as	  well	  as	  the	  complex	  protein	  associate	  MENIN	  that	  can	  
guide	  MLL1	  to	  specific	  target	  genes142,167	  (Figure	  11).	  The	  MLL1	  protein	  has	  a	  SET	  domain	  to	  
write	   the	  activation	  mark	  H3K4me3,	  a	  PHD	   finger	  domain	   to	   read	  H3K4me2/3	  or	  Cyp33,	  a	  
CXXC	   domain	   to	   recognize	   unmethylated	   CpG	   islands	   and	   a	   transactivation	   domain	   to	  
interact	  with	   the	  HAT	  CBP126,142,147,167,188.	  The	  best-­‐characterized	  MLL1	   target	  genes	  are	   the	  
HOX	   gene	   family	   members,	   involved	   in	   hematopoietic	   differentiation,	   animal	   body	  
patterning	   and	   leukemogenesis126.	   The	   lincRNA	  HOTTIP	   can	   interact	   with	   WDR5	   to	   guide	  
WDR5-­‐MLL1	   complexes	   to	   HOXA	   loci	   inducing	   transcriptional	   activation196.	   Furthermore,	  
MLL1	   plays	   a	   role	   in	   cell	   cycle	   by	   directly	   regulating	   key	   targets	   involved	   in	   cell	   cycle	   like	  
cyclinA,	  cyclinB,	  cyclinE,	  CDKN2A	   and	  E2F197	  and	  by	  controlled	  expression	  of	  MLL1	   itself	  by	  
SCF	   and	   APC/C188	   during	   different	   cell	   cycle	   transition	   phases198.	   In	   ESCs,	   MLL	   proteins	  
contribute	  to	  stem	  cell	  gene	  activation	  through	  interaction	  of	  WDR5	  with	  OCT4	  to	  maintain	  
high	  H3K4me3	  levels	  at	  OCT4	  target	  genes	  including	  self-­‐renewal	  genes199.	  
	  
MLL1-­‐rearranged	   leukemias	   display	   elevated	   HOXA7,	   HOXA9,	   HOXA10	   and	   MEIS1	   levels	  
essential	   for	   leukemic	   transformation74,109.	   In	   T-­‐ALL,	   MLL1	   fusions	   encompass	   most	  
frequently	  MLL1-­‐AF4	   and	  MLL1-­‐ENL	   present	   in	   approximately	  5%	  of	   cases3.	  MLL1-­‐AF4	  and	  
MLL1-­‐ENL	  leukemias	  have	  elevated	  H3K79	  methylation	  levels	  through	  abnormal	  recruitment	  
of	   the	   H3K79me3	   HMT	   DOT1L73,200,201.	   Of	   interest,	   increased	   H3K79	  methylation	   levels	   by	  
enhanced	   DOT1L	   activity	   are	   also	   observed	   in	   CALM-­‐AF10	   fusion	   leukemias	   resulting	   in	  
upregulation	  of	  HOXA5202,203.	  	  Notably,	  ENL	  is	  a	  subunit	  of	  the	  SWI/SNF	  remodeling	  complex	  
whereby	  the	  MLL1-­‐ENL	  fusion	  also	  cooperates	  with	  the	  SWI/SNF	  complex	  to	  activate	  HOXA7	  
transcription126,204.	  	  
	  
Interestingly,	   DOT1L	   inhibitors	   have	   been	   generated	   that	   inhibit	   H3K79	   methylation	   at	  
MLL1-­‐fusion	   target	   genes	   and	   specifically	   inhibit	  MLL1-­‐rearranged	   leukemic	   cells	   both	   in	  
vitro	  and	   in	  vivo205.	  Mechanistically,	   the	  DOT1L	   inhibitor	  competes	  with	  the	  SAM	  substrate	  
that	  is	  essential	  for	  the	  HMT	  function	  of	  DOT1L.	  A	  phase	  I	  clinical	  trial	  has	  been	  initiated	  in	  
acute	   leukemia	   patients73.	   Another	   player	   in	   normal	  MLL1	   function	   and	  MLL1-­‐rearranged	  
leukemia	  is	  MENIN,	  which	  can	  be	  inhibited	  by	  the	  MI-­‐2	  inhibitor	  targeting	  the	  MLL1-­‐MENIN	  
interaction	   leading	   to	   effective	   apoptosis	   in	   MLL1-­‐rearranged	   cells206.	   As	   MENIN	   is	   also	  
important	   for	  normal	  MLL1	  function,	  more	  research	   is	  needed	  to	  explore	  the	  possible	  side	  
effects	  on	  normal	  hematopoiesis.	  
	  
In	  addition,	  MLL2	  mutations	  were	  recently	  identified	  in	  10%	  of	  adult	  immature	  T-­‐ALL	  cases36.	  
Of	   interest,	   an	   MLL2-­‐3	   complex	   was	   purified	   with	   main	   members	   WDR5,	   RBBP5,	   ASH2L,	  
DPY30,	  PTIP,	  ASC-­‐2,	  PA1	  and	  the	  histone	  H3K27me2/3	  eraser	  UTX186,187	  (Figure	  10).	  So	  H3K4	  
methylation	  can	  possibly	  cooperate	  with	  removing	  of	  the	  H3K27me2/3	  mark	  leading	  to	  gene	  
activation.	  The	  oncogenic	  effect	  mediated	  by	  these	  MLL2	  mutations	  will	  need	  to	  be	  further	  
explored	  in	  the	  pathogenesis	  of	  T-­‐ALL.	  
	  
The	  histone	  acetyltransferase	  EP300	  
	  
EP300	  belongs	  to	  the	  CBP/EP300	  family	  of	  HATs	  and	  shares	  63%	  of	  amino	  acids	  with	  CBP207.	  
The	   2	   family	  members	   share	   common	   functional	   roles	   such	   as	   acting	   as	   a	   transcriptional	  
cofactor	  for	  oncoproteins	  including	  MYB78,79,	  but	  also	  serve	  specific	  non-­‐overlapping	  roles	  in	  
different	   cellular	   processes	   like	   the	   role	   of	   EP300	   in	   the	   TGFβ	   signaling	   pathway207,208.	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Mechanistically,	   both	   EP300	   and	   CBP	   can	   acetylate	   all	   core	   histone	   proteins	   resulting	   in	  
active	  gene	  transcription207	  and	  acetylate	  non-­‐histone	  proteins	  including	  MYB,	  TP53,	  E2F	  and	  
RB1	  contributing	  to	  enhanced	  transcriptional	  activation	  and	  protein-­‐protein	  interactions207.	  
	  
In	  T-­‐ALL,	  inactivating	  EP300	  mutations	  were	  identified	  in	  immature	  T-­‐ALL	  cases31.	  Of	  interest,	  
chimeras	   with	   loss	   of	   EP300	   develop	   hematological	   malignancies	   including	   thymic	  
lymphomas	   defining	   EP300	   as	   a	   tumor	   suppressor	   gene	   in	   leukemia207.	   HDAC	   inhibitors	  
(HDACi)	  provoke	  a	  strong	  anti-­‐tumor	  activity	  by	  reversing	  gene	  silencing73.	  Vorinostat	  (SAHA)	  
and	   romidepsin	   are	   the	   first	   HDACi	   that	   are	   approved	   by	   the	   FDA	   for	   treatment	   of	   T-­‐cell	  
cutaneous	  lymphoma108,109.	  At	  present,	  clinical	  trials	  are	  initiated	  in	  a	  broad	  range	  of	  cancer	  
types	  with	  the	  FDA	  approved	  as	  well	  as	  novel	  HDACi73.	  These	  HDACi	  might	  be	  also	  beneficial	  
in	  treating	  T-­‐ALL	  patient	  samples	  harboring	  inactivating	  EP300	  mutations.	  
	  
The	  H3K36me3	  histone	  methyltransferase	  SETD2	  
	  
The	  SETD2	  protein	  acts	  as	  a	  H3K36	  methyltransferase	  enabling	  active	  gene	  transcription209.	  
Unlike	  NSD1	  and	  MMSET	  that	  are	  mono	  and	  dimethyltransferases	  of	  H3K36,	  SETD2	  mainly	  
trimethylates	  H3K36	  and	   couples	  H3K36me3	   to	   transcriptional	   elongation209.	   Furthermore,	  
SETD2	  has	  a	  role	   in	  splicing210,211,	   interacts	  with	  hnRNPL212	  and	  TP53213,	  and	  facilitates	  DNA	  
mismatch	   repair	   during	   cell	   cycle214.	   Importantly,	   SETD2	   plays	   a	   crucial	   role	   in	   embryonic	  
development	   since	   homozygous	   knockout	  mice	   die	   at	   embryonic	   day	   E10.5-­‐E11.5	  marked	  
with	  a	  loss	  of	  H3K36	  trimethylation215.	  Mutations	  in	  SETD2	  were	  first	  reported	  in	  3%	  of	  renal	  
cell	  carcinoma	  samples216	  and	  were	  recently	  described	  in	  8%	  of	  immature	  T-­‐ALL	  cases31.	  
	  
	  
2.5	  Intimately	  linked	  epigenetic	  modifications	  
	  
Aberrant	   DNA	   methylation	   is	   linked	   to	   altered	   histone	   modification	   patterns73.	   Silenced	  
genes	   marked	   by	   hypermethylation	   of	   the	   CpG	   islands	   in	   their	   promoter	   regions	   are	  
characterized	  by	  loss	  of	  H3-­‐H4	  acetylation,	  H2A.Z	  and	  H3K4	  trimethylation;	  and	  gain	  of	  H3K9	  
di-­‐	   and	   trimethylation109,217.	   DNA	   methylation	   is	   recognized	   by	   methyl-­‐binding	   proteins	  
(MBD)	  which	   are	   able	   to	   associate	  with	   complexes	   containing	  HDAC,	   HMT	   and	   chromatin	  
remodeling	   activities126.	   In	   contrast,	   accessible	   H3K4me3-­‐enriched	   regions	   at	   CpG-­‐rich	  
promoters	   are	  marked	  by	   hypomethylation,	   histone	   acetylation,	   RNAPII,	   occupancy	   of	   the	  
histone	  H2A.Z	  variant	  and	  nucleosome-­‐depleted	  regions	  upstream	  of	  their	  TSS109,111.	  Actively	  
transcribed	   genes	   have	   elevated	   H3K36	   methylation	   and	   are	   also	   marked	   by	   cytosine	  
methylation	   and	   deacetylated	   lysines	   in	   their	   gene	   bodies,	   which	   might	   promote	  
transcriptional	  elongation109,218.	  	  
	  
A	   direct	   interaction	   is	   also	   seen	   between	   different	   chromatin	   players,	   for	   example	   the	  
H3K27me2/3	  eraser	  UTX	  and	  H3K4me3	  methyltransferase	  MLL2	  reside	  in	  the	  same	  complex,	  
erase	   the	   H3K27me3	   mark	   and	   add	   the	   H3K4me3	   mark,	   leading	   to	   transcriptional	  
activation142,186,187.	   Furthermore,	  MLL1	   has	   been	   co-­‐purified	  with	   the	   HATs	   CBP	   and	  MYST	  
hereby	  directly	  linking	  histone	  methylation	  and	  acetylation	  to	  gene	  activation167.	  	  
	  
Combination	   therapies	   between	   DNMTi	   and	   HDACi	   have	   shown	   synergistic	   activities	  
probably	  due	  to	  the	  interrelationships	  between	  epigenetic	  silencing	  processes108,109.	  Clinical	  
trials	  with	  this	  dual	  therapeutic	  epigenetic	  approach	  are	  ongoing	  in	  many	  cancer	  types108,109.	  
Hence,	  a	  tight	  controlled	  interaction	  between	  histone	  modifiers,	  DNA	  methylation	  and	  ATP-­‐
dependent	  chromatin	  remodeling	  complexes	  is	  present	  and	  can	  be	  targeted	  simultaneously.	  
	  	   22	  
3.	  The	  microRNAome	  of	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  
	  
3.1	  MicroRNA	  biogenesis	  &	  function	  
	  
Next	   to	   genetic	   and	   epigenetic	   regulation	   of	   gene	   expression,	   another	   layer	   of	  
transcriptional	  regulation	  is	  executed	  by	  small	  non-­‐coding	  RNAs	  called	  microRNAs	  (miRNAs)	  
that	   repress	   (mainly	   in	   animals)	  or	   cleave	   (mainly	   in	  plants)	   their	   target	   genes	   resulting	   in	  
negative	   transcriptional	  or	   translational	   regulation219.	  MiRNA	  genes	  are	   located	   intronic	  or	  
exonic	   in	   coding	   regions	   or	   in	   intergenic	   regions	   in	   our	   genome220.	   The	   biogenesis	   of	   a	  
miRNA	   starts	   with	   the	   transcription	   of	   the	   miRNA	   gene	   by	   mostly	   RNAPII	   (or	   sometimes	  
RNAPIII)	   in	   the	   nucleus	   creating	   a	   long	   RNA	   precursor	   named	   pri-­‐miRNA	   (Figure	   12).	  
Subsequently,	  the	  pri-­‐miRNA	  is	  cleaved	  into	  a	  ~70	  nucleotide	  (nt)	  long	  pre-­‐miRNA	  by	  RNAse	  
III	  enzyme	  Drosha	  with	  support	  of	  the	  double-­‐stranded	  RNA-­‐binding	  protein	  Pasha.	  Next,	  the	  
pre-­‐miRNA	  is	  transported	  by	  the	  nuclear	  transport	  receptor	  Exportin-­‐5	  to	  the	  cytoplasm	  and	  
cleaved	  by	  the	  second	  RNAse	  III	  enzyme	  Dicer	  resulting	  in	  the	  formation	  of	  a	  ds	  ~22	  nt	  long	  
miRNA-­‐miRNA*	   duplex.	   After	   unwinding	   of	   the	   miRNA-­‐miRNA*	   duplex	   by	   helicases,	   the	  
mature	  miRNA	  is	  incorporated	  in	  the	  miRNA-­‐associated	  multiprotein	  RNA-­‐induced-­‐silencing	  
complex	   (miRISC).	   The	   miRNA	   target	   genes	   are	   subsequently	   cleaved	   by	   ribonucleases	  
present	   in	   the	   miRISC	   in	   case	   of	   perfect	   complementarity	   or	   translationally	   repressed	  
through	  binding	  of	  the	  miRNA	  within	  the	  3’	  untranslated	  region	  (UTR)	  of	  the	  mRNA	  in	  case	  
of	  imperfect	  complementarity219,220.	  An	  unexpected	  role	  in	  translational	  activation	  of	  target	  
genes	   by	   miRNAs	   was	   recently	   demonstrated,	   but	   more	   research	   is	   needed	   to	   further	  
explore	  this	  surprising	  mechanism	  of	  action221.	  
	  
	  
Figure	   12.	   MicroRNA	   biogenesis	   pathway	   and	   miRNA	   therapeutic	   agents	   (adapted	   from	  
Esquela-­‐Kerscher	   &	   Slack	   Nature	   Reviews	   Cancer	   2006219,	   graphics	   from	  
www.somersault1824.com)	  
	  
To	  identify	  possible	  miRNA	  target	  genes,	  most	  bioinformatic	  algorithms	  base	  their	  search	  on	  
the	   complementarity	   between	   the	   miRNA	   seed	   region	   (first	   2-­‐8	   bases	   at	   5’end)	   and	   the	  
3’UTR	  region	  of	  an	  mRNA.	  Each	  miRNA	  might	  target	  more	  than	  200	  mRNAs	  placing	  one	  third	  
of	   mRNAs	   under	   the	   control	   of	   these	   non-­‐coding	   RNA	   molecules219.	   MiRNAs	   play	   an	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important	   role	   in	   many	   tissue-­‐specific	   developmental	   processes	   like	   for	   example	   ESC	  
differentiation	  by	  miR-­‐134222	  and	  T-­‐cell	  differentiation	  by	  miR-­‐150223	  and	  miR-­‐181a224,225.	  	  
	  
Abnormal	   miRNA	   expression	   can	   be	   caused	   by	   deletion,	   amplification,	   translocation,	  
mutation	   or	   aberrant	  methylation	   provoking	   downregulation	   or	   overexpression	   of	   specific	  
miRNAs	  contributing	  to	  disease	  and	  cancer219.	  In	  agreement,	  more	  than	  50%	  of	  miRNAs	  are	  
located	   in	   cancer-­‐associated	   genomic	   regions	   that	   are	   prone	   to	   genomic	   alterations226.	  Of	  
note,	   miRNA	   expression	   was	   found	   to	   be	   globally	   lower	   in	   cancer	   samples	   than	   in	  
corresponding	   normal	   tissue227.	   Furthermore,	   miRNAs	   were	   shown	   to	   be	   able	   to	   classify	  
human	   tumors	   according	   to	   their	   embryonic	   lineage	   whereby	   for	   example	   hematopoietic	  
tumors	  cluster	  separately	   from	  the	  endothelial	   tumors228.	  Also,	  miRNA	  signatures	  or	   single	  
miRNAs	   can	   harbor	   a	   diagnostic	   or	   prognostic	   value	   useful	   in	   the	   clinical	  management	   of	  
cancer	   therapy227.	   For	   example,	   by	   use	   of	   a	  miRNA	   classifier	   the	   tissue	   of	   origin	   could	   be	  
determined	   of	  metastatic	   tumors	   of	   unknown	   primary	   site,	   and	   is	  more	   efficient	   than	   an	  
mRNA	   classifier229.	   So	   miRNAs	   can	   reflect	   the	   developmental	   history	   of	   the	   cancer	   types	  
underscoring	  the	  role	  of	  miRNAs	  in	  tissue-­‐specific	  developmental	  functions219.	  
	  
	  
3.2	  MicroRNAs	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  
	  
A	   classical	   mechanism	   of	   gene	   deregulation	   in	   T-­‐ALL	   through	   TCR	   rearrangement	   driven	  
formation	   of	   translocations	   was	   reported	   for	   the	   miR-­‐17-­‐92	   cluster	   (juxtaposition	   to	   the	  
TCRA/D	  promoter)230.	  Secondly,	   the	  miR-­‐17-­‐92	  cluster	   resides	   in	  a	   region	  of	   recurrent	  gain	  
on	  chromosome	  band	  13q31.2-­‐q31.3	  in	  a	  subset	  of	  T-­‐ALLs	  contributing	  to	  overexpression	  of	  
the	  members	  miR-­‐17,	  miR-­‐20a	  and	  miR-­‐19231.	  By	  use	  of	  the	  well-­‐established	  NOTCH1	  driven	  
T-­‐ALL	   inducing	   mouse	   model59,	   ectopic	   expression	   of	   miR-­‐19	   and	   NOTCH1	   resulted	   in	   a	  
strong	  acceleration	  in	  T-­‐ALL	  onset	  compared	  to	  NOTCH1	  only	  murine	  T-­‐ALLs230.	  	  Hence,	  miR-­‐
19	  acts	  as	  a	  novel	  oncogenic	  miRNA	  (oncomiR)	  and	  can	  cooperate	  with	  NOTCH1	  in	  T-­‐ALL230.	  
	  
Subsequent	   to	   this	   observation,	   an	   unbiased	   shRNA	   screen	   was	   performed	   to	   identify	  
protein-­‐coding	   genes	   that	   would	   phenocopy	   miR-­‐19	   overexpression	   and	   thus	   could	   be	  
further	  screened	  as	  bona	  fide	  miR-­‐19	  target	  genes230.	  Mechanistically,	  the	  shRNA	  encoding	  
plasmids	   are	   integrated	   in	   the	   genome	   after	   efficient	   transduction	   of	   the	   leukemic	   cells.	  
Next,	   the	   shRNAs	   are	   generated	   using	   the	   miRNA	   processing	   machinery	   mimicking	   pri-­‐
miRNAs232.	  The	  shRNA	  screen	  yielded	  a	  series	  of	  hits	  with	  the	  top	  candidates	  including	  Bim,	  
Pten,	  Prkaa1	  and	  Ppp2r5e230.	  Loss	  of	  Pten	  and	  Bim	  provided	  a	  strong	  acceleration	  of	  T-­‐ALL	  
onset	  in	  the	  NOTCH1	  T-­‐ALL	  mouse	  model	  in	  accordance	  with	  the	  introduction	  of	  miR-­‐19230.	  
In	  a	   collaborative	  effort	  with	   the	  Wendel	   lab	   (MSKCC,	  NY,	  USA),	  we	   further	  expanded	   this	  
regulation	   to	  a	  network	  of	   interacting	  oncomiRs	  miR-­‐20a,	  miR-­‐92,	  miR-­‐223,	  miR-­‐26a,	  miR-­‐
27a	   and	  miR148a/152	  with	   additional	   T-­‐ALL	   tumor	   suppressor	   genes	   Phf6,	   Ikzf1,	   Nf1	   and	  
Fbxw7	  (see	  paper	  3)233.	  Finally,	  CYLD	  was	  discovered	  as	  yet	  another	  direct	  miR-­‐19	  target	  in	  T-­‐
ALL	  hereby	  negatively	  regulating	  the	  NF-­‐κβ	  pathway234.	  
	  
Of	  interest,	  miR-­‐223	  overexpression	  also	  contributes	  to	  T-­‐ALL,	  which	  is	  directly	  activated	  by	  
the	   TAL1	   oncoprotein	   subsequently	   leading	   to	   downregulation	   of	   the	   miR-­‐223	   target	  
FBXW799,235.	   In	   accordance,	   TAL1-­‐positive	   T-­‐ALL	   patient	   cases	   harbor	   a	   higher	   miR-­‐223	  
expression	   than	   TAL1-­‐negative	   cases99.	   Furthermore,	   miR-­‐223	   resembles	   TAL1	   expression	  
during	   T-­‐cell	   development	   with	   highest	   expression	   in	   very	   immature	   T-­‐cell	   stages99.	   In	  
addition,	   another	   group	   reported	   that	   T-­‐ALL	   cases	  with	   a	  myeloid	   gene	   expression	   profile	  
have	  an	  elevated	  miR-­‐223	  expression	  compared	  to	  other	  T-­‐ALL	  cases236.	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Together	   with	   miR-­‐223,	   the	   miRNAs	   miR-­‐142	   and	   miR-­‐181	   were	   among	   the	   first	   miRNAs	  
found	   to	   be	   specifically	   expressed	   in	   hematopoietic	   cells237.	   MiR-­‐142-­‐3p	   is	   significantly	  
higher	   expressed	   in	   T-­‐ALL	   patient	   samples	   compared	   to	   healthy	   T-­‐cell	   controls238.	  
Furthermore,	  miR-­‐142-­‐3p	   targets	   the	   adenylyl	   cyclase	   9	   and	   the	   glucocorticoid	   receptor	  α	  
contributing	  to	  the	  promotion	  of	  glucocorticoid	  resistance	   in	  T-­‐ALL238,239.	  So	   inhibiting	  miR-­‐
142-­‐3p	   activity	   might	   be	   of	   therapeutic	   interest	   in	   glucocorticoid	   resistant	   T-­‐ALL	   patient	  
samples.	   Next,	   miR-­‐181a	   family	   members	   display	   elevated	   levels	   in	   T-­‐ALL	   cells	   and	   these	  
levels	  decline	  at	  remission240.	  Loss	  of	  the	  oncogenic	  miR-­‐181a-­‐1/b-­‐1	  delayed	  T-­‐ALL	  onset	  in	  
the	  NOTCH1	  T-­‐ALL	  mouse	  model	   and	   importantly,	   secondary	   transplants	  were	  not	  able	   to	  
induce	  leukemia.	  MiR-­‐181a-­‐1/b-­‐1	  mediates	  this	  inhibitory	  effect	  on	  NOTCH1-­‐driven	  T-­‐ALL	  by	  
dampening	   genes	   involved	   in	   NOTCH1	   signaling,	   pre-­‐TCR	   signaling	   and	   cytokine	   and	  
apoptosis	  pathways241.	  
	  
Interestingly,	  two	  additional	  miRNAs	  miR-­‐451	  and	  miR-­‐709	  were	   identified	  that	  are	  able	  of	  
blocking	   or	   slowing	   down	   NOTCH1-­‐induced	   T-­‐ALL	   growth	   when	   overexpressed	   in	   the	  
NOTCH1	   T-­‐ALL	  mouse	  model242,	   next	   to	   loss	   of	  miR-­‐181a-­‐1/b-­‐1241.	   Both	   tumor	   suppressor	  
miRNAs	   are	   direct	   transcriptional	   targets	   of	   the	   transcription	   factor	   E2A	   that	   itself	   is	  
downregulated	  by	  NOTCH1242.	  MiR-­‐451,	  but	  not	  miR-­‐709,	   is	   conserved	   in	  humans	  and	  can	  
negatively	   regulate	   MYC	   expression	   levels	   in	   human	   T-­‐ALL	   cell	   lines	   and	   in	   murine	   T-­‐ALL	  
lymphoblasts242.	  Meanwhile	  miR-­‐709	  was	  shown	  to	  silence	  Myc,	  Akt	  and	  Rasgrf1	  expression	  
in	  malignant	  murine	  T-­‐cells242.	  	  
	  
Finally,	  some	  T-­‐ALL	  subgroup	  specific	  miRNAs	  have	  been	  identified.	  In	  the	  early	  immature	  T-­‐
ALL	   subgroup,	   miR-­‐221	   and	   miR-­‐222	   are	   upregulated	   and	   miR-­‐19a	   and	   miR-­‐363	   are	  
downregulated	   in	   comparison	  with	   non-­‐immature	   T-­‐ALLs243.	   In	   the	   HOXA	   T-­‐ALL	   subgroup,	  
the	   expression	   level	   of	   miR-­‐196b	   is	   elevated	   together	   with	   HOXA9	   and	   HOXA10244,245	   in	  
agreement	  with	  its	  location	  within	  the	  HOXA	  locus244,245.	  	  
	  
	  
3.3	  MicroRNA	  biomarkers	  &	  therapeutics	  
	  
Circulating	  miRNAs	  present	  in	  the	  body	  fluid,	  including	  serum	  or	  plasma,	  can	  be	  used	  as	  non-­‐
invasive	  biomarkers	   in	  cancer221.	  These	  miRNAs	  are	  exported	  from	  the	  donor	  cells	   through	  
passive	   leakage,	   packed	   in	   exosomes	  or	  microvesicles,	   or	   in	   conjunction	  with	  RNA-­‐binding	  
proteins	  or	  lipoproteins221.	  In	  cancer,	  the	  origin	  of	  the	  donor	  cells	  is	  not	  totally	  clarified	  yet.	  
A	  study	  demonstrated	  that	   these	  circulating	  miRNAs	  are	   likely	  derived	   from	  tumor	  cells	  or	  
tissues	  associated	  with	  neoplastic	  transformation246,	  but	  others	  demonstrate	  that	  blood	  cells	  
themselves	   can	   contribute	   to	   the	   pool	   of	   circulating	   miRNAs	   in	   plasma	   and	   serum247.	  
Circulating	  miRNAs	  present	  in	  exosomes	  can	  be	  taken	  up	  by	  recipient	  cells,	  here	  surrounding	  
immune	  cells	  of	  the	  tumor	  microenvironment221,248,249.	  In	  cancer	  therapy,	  expression	  profiles	  
of	  circulating	  miRNAs	  can	  harbor	  a	  prognostic	  value	  or	  an	  indication	  for	  drug	  response221.	  
	  
The	   main	   advantage	   of	   miRNA	   therapeutics	   is	   the	   capacity	   of	   miRNAs	   to	   regulate	  
simultaneously	   a	   set	   of	   coding	   genes	   from	   the	   same	   pathway	   and/or	   interacting	  
pathways221.	   But	   caution	   is	   warranted	   in	  miRNA	   therapy	   as	   miRNAs	   direct	   transcriptional	  
control	  in	  a	  tissue-­‐specific	  manner,	  hereby	  miRNA	  delivery	  can	  be	  beneficial	  in	  one	  cell	  type	  
but	  harmful	   in	   another	   cell	   type.	   Furthermore,	   delivery	  of	   precursor	  miRNAs	  using	  miRNA	  
expression	  vectors	  should	  take	  into	  account	  that	  both	  strands	  of	  a	  miRNA	  (called	  3p	  and	  5p)	  
can	  have	  a	  different	  function	  and	  different	  target	  genes	  in	  the	  same	  cell221.	  In	  the	  latter	  case,	  
delivery	   of	   a	   mature	   miRNA	   using	   miRNA	   mimics	   can	   be	   employed	   to	   avoid	   unwanted	  
phenotypic	  effects221.	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Two	   therapeutic	   strategies	   are	   used	   to	   restore	   tumor	   suppressor	  miRNAs	   back	   to	   normal	  
expression	   levels,	  which	   encompass	  miRNA	  mimics	   and	  miRNA	   expression	   vectors	   (Figure	  
12).	  The	  miRNA	  mimic	  molecules	  are	  synthetic	  double-­‐stranded	  miRNA	  oligonucleotides	  that	  
are	   coupled	   with	   nanoparticles	   or	   packed	   into	   liposome	   or	   atelocollagen	   formulations221.	  
The	  first	  liposome-­‐based	  miRNA	  mimic	  MRX34	  has	  gone	  into	  Phase	  I	  clinical	  trial,	  which	  can	  
restore	   miR-­‐34	   levels	   in	   patients	   with	   advanced	   or	   metastatic	   liver	   cancer	   expectantly	  
leading	  to	  a	  reduction	  of	  tumor	  growth250.	  Secondly,	  miRNA	  levels	  can	  be	  restored	  to	  normal	  
tissue-­‐specific	  levels	  by	  use	  of	  the	  miRNA	  expression	  vectors	  in	  which	  miRNAs	  are	  under	  the	  
control	  of	  a	  specific	  promoter	  and	  can	  be	  delivered	  through	  viral	  particles221.	  
	  
To	   therapeutically	   target	   oncomiRs	   in	   cancer,	   several	   antisense	   oligonucleotides	   (ASO)	  
approaches	  are	  used	  including	  antagomiRs,	  locked	  nucleic	  acids	  (LNA)	  antimiRs	  and	  tiny	  LNA	  
antimiRs	  as	  well	  as	  the	  use	  of	  miRNA	  sponges221	  (Figure	  12).	  The	  first	  ASO	  approach	  consist	  
of	   synthetic	   RNAs	   that	   are	   conjugated	   with	   cholesterol	   for	   optimal	   cellular	   uptake	   and	  
modified	   with	   2’-­‐O-­‐methyl	   and	   phosphorothioate	   to	   improve	   binding	   affinity	   and	   inhibit	  
nuclease	   action251.	   These	   antagomirs	  were	   first	   tested	   and	   proved	   efficacy	   in	   vivo	   against	  
miR-­‐122,	   an	   abundant	   liver-­‐specific	   miRNA251.	   Unfortunately,	   the	   main	   disadvantage	   of	  
these	   antagomiRs	   is	   the	   necessity	   of	   high	   dosages	   for	   effective	   miRNA	   targeting221.	   This	  
shortcoming	   can	   be	   circumvented	   with	   the	   use	   of	   LNA-­‐based	   ASOs,	   which	   are	   synthetic	  
oligonucleotides	  in	  which	  some	  nucleotides	  are	  exchanged	  with	  bicyclic	  RNA	  analogues	  in	  a	  
‘locked’	   conformation221.	   LNA	   antimiRs	   are	   13-­‐22	   nucleotides	   long	   whereas	   tiny	   LNA	  
antimiRs	   only	   consist	   of	   8	   nucleotides	   specific	   to	   the	   seed	   region	   of	   the	   miRNA	   hereby	  
enabling	  silencing	  of	  multiple	  miRNAs	  from	  the	  same	  miRNA	  family221.	  A	  first	  LNA	  antimiR	  in	  
Phase	   I	   and	   IIa	   clinical	   trials	   is	   the	   antiviral	   agent	   miravirsen	   targeting	   miR-­‐122	   in	   the	  
treatment	  against	  hepatitis	  C	  virus252.	  Advantages	  of	  LNA	  based	  miRNA	  therapy	  are	  the	  lack	  
of	   toxicities	   and	   the	   efficient	   cellular	   uptake	  without	   the	   requirement	   of	   specific	   delivery	  
formulations221.	  Finally,	  miRNA	  sponges	  have	  shown	  efficacy	  to	  block	  an	  entire	  miRNA	  seed	  
family.	   These	   synthetic	   RNA	   molecules	   contain	   several	   heptamer	   sequences	   that	   are	  
complementary	  to	  the	  seed	  region	  of	  the	  miRNA	  seed	  family	  of	  interest,	  hereby	  preventing	  
translational	  inhibition	  of	  the	  miRNA	  target	  genes.	  As	  high	  concentrations	  of	  miRNA	  sponges	  
are	  again	  needed	  for	  efficient	  miRNA	  targeting,	  miRNA	  sponges	  are	  frequently	  incorporated	  
in	  plasmids	  or	  viral	  vectors221.	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Introduction
A decade ago, the identification of the first histone demethylase 
Lysine (K)-Specific Demethylase 1 (LSD1) served as a landmark 
discovery that triggered research on dynamic regulation of 
histone methylation.1 In the following years, numerous additional 
histone demethylases, that execute the removal of methyl groups 
on specific lysine residues of the histone tails and of non-histone 
substrates, were characterized in more detail (reviewed in ref. 
2). In 2007, several groups identified Ubiquitously Transcribed 
Tetratricopeptide Repeat on chromosome X (UTX) and Jumonji D3 
(JMJD3) as novel histone demethylases that catalyze the removal 
of di- and trimethyl groups on histone H3 lysine 27, thereby 
promoting target gene activation.3-6 Notably, Ubiquitously 
Transcribed Tetratricopeptide Repeat on chromosome Y (UTY) is 
a closely related homolog of UTX on the Y-chromosome but, up 
until now, no enzymatic H3K27me2/3 demethylase activity has 
been reported for UTY.3,7
The X-linked H3K27me2/3 eraser UTX is a member of 
the MLL2 histone H3K4 methyltransferase complex8,9 and 
contributes to animal body patterning by regulation of homeobox 
(HOX) genes.4,5 In contrast, a histone demethylation-independent 
role for UTX and JMJD3 has been demonstrated in normal and 
malignant T-cells through interaction with the BRG1-containing 
SWI/SNF remodeling complex.10 UTX knockout (KO) studies 
have unraveled important roles for UTX in many developmental 
processes, including cardiac development and hematopoiesis, 
but also suggested that UTX and UTY might have redundant 
functions during embryonic development.11-17
Upon the establishment of UTX as a histone eraser in the 
context of normal development, a number of studies started to 
report genetic defects targeting UTX as the underlying cause of 
specific diseases. In 2009, a role for the histone H3K27me2/3 
demethylase UTX as tumor suppressor was initially postulated in 
several human tumors including multiple myeloma, esophageal 
and renal cancer.18 In 2012, specific loss-of-function defects in 
UTX were identified in patients with a specific hereditary disorder 
named the Kabuki syndrome.19 In this review, we summarize 
the current knowledge on UTX in normal development and 
highlight recent findings on its implication in cancer and 
hereditary disease.
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In 2007, the Ubiquitously Transcribed Tetratricopeptide 
Repeat on chromosome X (UTX) was identified as a histone 
demethylase that specifically targets di- and tri-methyl groups 
on lysine 27 of histone H3 (H3K27me2/3). Since then, UTX 
has been proven essential during normal development, as it 
is critically required for correct reprogramming, embryonic 
development and tissue-specific differentiation. UTX is a 
member of the MLL2 H3K4 methyltransferase complex and 
its catalytic activity has been linked to regulation of HOX 
and RB transcriptional networks. In addition, an H3K27me2/3 
demethylase independent function for UTX was uncovered in 
promoting general chromatin remodeling in concert with the 
BRG1-containing SWI/SNF remodeling complex. Constitutional 
inactivation of UTX causes a specific hereditary disorder called 
the Kabuki syndrome, whereas somatic loss of UTX has been 
reported in a variety of human cancers. Here, we compile the 
breakthrough discoveries made from the first disclosure of 
UTX as a histone demethylase till the identification of disease-
related UTX mutations and specific UTX inhibitors.
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UTX Drives Context Dependent 
Transcriptional Regulation Mainly 
Through its H3K27  
Demethylase Activity
H3K27me2/3 demethylation
Methylation of H3K27 is a critical mediator 
of transcriptional gene repression and contributes 
to important biological processes including 
X-inactivation, genomic imprinting, stem cell 
maintenance, animal body patterning, circadian 
rhythms and cancer.5,20 Regulation of cellular 
H3K27me3 levels is mainly mediated by the 
H3K27 methyltransferase Polycomb Repressor 
Complex 2 (PRC2) and the H3K27me2/3 
demethylases UTX and JMJD3 (Fig. 1).3-6,21-24 
Two main classes of histone demethylases have 
been discovered until now including the flavin-
dependent amine oxidases, such as LSD1,1 
and the iron and α-ketoglutarate-dependent 
dioxygenases with a Jumonji C (JmjC) catalytic 
domain, such as UTX and JMJD3.3-7
The H3K27me2/3 demethylases UTX and JMJD3 
preferentially demethylate H3K27me3 followed by H3K27me2 
in vitro and in vivo. This demethylase activity is dependent on 
the catalytic JmjC domain, which contains conserved residues 
for binding with the co-factors iron and α-ketoglutarate.3-7 
Moreover, a newly identified zinc-binding domain within these 
H3K27me2/3 erasers provides specificity toward the histone 
lysine H3K27 and excludes interaction with the near-cognate 
histone lysine H3K9.25,26 Notably, the family member UTY 
lacks H3K27me2/3 erasing activity in vitro and in vivo despite 
a conserved JmjC domain and 88% sequence homology with 
the UTX protein.3,7,14 Finally, UTX and UTY proteins contain 
tetratricopeptide repeats (TPRs) at their N-terminal regions that 
are important for protein-protein interactions. These TPRs are 
lacking in the JMJD3 protein,3-7 which might suggest lack of 
redundant functions between the H3K27me2/3 demethylases 
UTX and JMJD3.
UTX, UTY and JMJD3 are evolutionary conserved from 
Caenorhabditis elegans (C. elegans) to human.3-7 The mouse 
genome contains the three H3K27me2/3 demethylase family 
members Utx, Uty and Jmjd3, whereas the genome of Drosophila 
melanogaster harbors only one ortholog of the mammalian 
H3K27me2/3 demethylases called dUTX.27 The C. elegans 
genome possesses 4 orthologs whereby UTX-1 resembles the 
mammalian UTX and the three other orthologs are more related 
to JMJD3.28
UTX is a member of the MLL2 H3K4 methyltransferase 
complex
In 2007, an MLL2 (also called ALR and formerly called 
MLL4) complex was identified in different mammalian cell types 
containing 12 protein members including MLL2, PTIP, UTX, 
ASC-2, ASH2L, RBBP5, WDR5, DPY30, matrin3, MGC4606, 
α- and β-tubulin.8 Furthermore, the 3 complex members 
MLL2, PTIP and UTX were shown to co-localize at promoter 
regions and first exons of MLL2 target genes marked with the 
transcriptional activation mark H3K4me3.8 Another group 
confirmed the identification of a similar H3K4 methyltransferase 
complex in which MLL2, MLL3, PTIP, UTX, ASC-2, ASH2L, 
RBBP5, WDR5, DPY30 and PA1 were also linked to H3K4 
methylation activity (Fig. 2).9 Interestingly, the composition of 
the MLL2 complex was confirmed in the Drosophila ortholog 
Trithorax related (Trr) complex29 and the C. elegans ortholog 
SET-16 complex.28 Hence, this conserved MLL2 complex acts 
like a classical H3K4 methyltransferase complex,8 which suggests 
a dynamic interplay between H3K27me2/3 demethylation and 
H3K4 methylation during transcriptional gene activation.
In flies, dUTX mutant tissues are marked by an increase in 
global H3K27me3 levels and surprisingly also a reduction in global 
H3K4me1 levels.20,30 The effect on H3K4me1, a mark enriched 
at enhancer regions and at gene bodies of actively transcribed 
genes, seems to be independent of the demethylation capacity 
of dUTX.20,30 Similarly, loss of the Trr H3K4 methyltransferase 
complex results in a global profound reduction of H3K4me1 
levels in many tissues.30,31 Notably, Trr and dUTX are enriched 
genome-wide near transcriptional start sites (TSSs) (enriched for 
H3K4me3 and RNAP II) but also on active enhancers (enriched 
for H3K4me1) indicating a promoter-proximal role as well as a 
promoter-distal role for the Trr-dUtx complex in transcriptional 
regulation.30 Importantly, loss of Trr provoked the most profound 
reduction in H3K4me1 levels at the enhancer regions compared 
with dUTX loss30 indicating that the Trr complex itself is the 
main driver of H3K4 monomethylation with support of dUTX.
UTX interacts with the SWI/SNF remodeling complex and 
the histone acetyltransferase CBP
Besides regulation of histone modifications like H3K27me3, 
ATPase-dependent remodeling complexes including the SWI/
SNF family contribute to regulation of chromatin accessibility 
hereby enabling transcriptional activation and repression.32 The 
SWI/SNF family is mainly linked to transcriptional activation 
whereby the ATPase complex members BRG1 and BRM interact 
Figure  1. The UTX family mediates H3K27me2/3 demethylation. Graphical illustration of 
open and closed chromatin states that are mediated by the histone demethylases UTX and 
JMJD3 and the histone methyltransferase PRC2 hereby erasing or writing methyl groups on 
H3K27 enabling activation or blockage of gene transcription, respectively (graphics from 
www.somersault1824.com).
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with acetylated histone tails through their bromodomain 
(Fig. 2).33,34 An interaction between the Brg1-containing SWI/
SNF remodeling complex and the histone H3K27me2/3 erasers 
Utx and Jmjd3 was demonstrated promoting general chromatin 
remodeling that was independent of their H3K27me2/3 
demethylase potential. Furthermore, UTX and JMJD3 were 
shown to be functionally required for transcriptional activation 
of lineage-defining T-box transcription factors (including T-bet, 
Eomes and Tbx5),10 which represent essential transcriptional 
regulators in early cell-fate decisions, differentiation and 
organogenesis.35
An interaction between the histone acetyltransferase Creb-
binding protein (CBP) and the SWI/SNF remodeling complex 
is observed in mammals10,36 and Drosophila.37 In flies, CBP 
and the PRC2 complex act antagonistically in the regulation of 
active and repressed chromatin states at Polycomb target genes 
by acetylation and methylation of H3K27, respectively (Fig. 2).37 
H3K27 acetylation is mainly detected at enhancers, promoters 
and gene bodies of actively transcribed genes.30 To enable efficient 
H3K27 acetylation, CBP was shown to associate with dUTX and 
the ATPase Brm of the SWI/SNF complex.37 The ATPase Brm 
in flies resembles the 2 mammalian orthologs BRM and BRG1 
of the SWI/SNF complexes.32,37 Genome-wide binding studies 
showed that the chromatin components dUTX, Brm and CBP 
co-occurred at Polycomb target genes enriched for H3K27ac, 
suggesting a collaborative effort antagonizing Polycomb 
mediated gene silencing.37 Of note, loss of dUTX or Trr results 
in a reduction of global H3K27ac levels in various tissues,30,37 so 
dUTX might be capable of promoting H3K27 acetylation and 
H3K4 monomethylation in concert with Trr, Brm and CBP.
UTX regulates dynamic HOX expression
The HOX genes are highly conserved transcriptional regulators 
essential during development of the anterior-posterior axis (head-
tail).38 The HOX family in humans consists of 39 HOX genes 
that encode 4 clusters of HOX proteins, i.e., HOXA to HOXD.39 
Aberrant expression of HOX genes leads to developmental defects 
and disease.39 Polycomb and Trithorax proteins are implicated 
in the complex regulation of spatio-temporal expression of 
HOX genes thereby regulating animal body patterning and 
cell differentiation.40 Evidence for direct involvement of UTX 
in regulation of HOX gene activity was demonstrated through 
UTX knockdown experiments in HEK293T cells in which loss 
of UTX induced transcriptional repression of HOXA and HOXC 
clusters.5 Furthermore, UTX loss also resulted in an increase of 
H3K27me2/3 levels at the promoter regions of HOXA13 and 
HOXC4, whereas no changes in MLL2 and PRC2 occupancy 
were observed.5
Chromatin immunoprecipitation (ChIP) of UTX followed by 
HOX-specific ultra-dense tiling microarrays (ChIP-chip) showed 
a strong UTX binding to narrow windows within 500 base 
pairs downstream of the TSSs of many HOX genes in human 
fibroblasts, but not in mouse embryonic stem cells (ESCs) where 
HOX genes are silenced. Importantly, H3K27 trimethylation 
was concomitantly diminished at UTX binding sites.3 Hence, 
HOX expression is tightly regulated by opposing activities of the 
Figure 2. The chromatin complexes MLL2-UTX, SWI/SNF and PRC2 contribute to open and closed chromatin conformations. Schematic representa-
tion of the H3K4 methyltransferase complex MLL2-UTX, the SWI/SNF ATPase remodeling complex and the H3K27 methyltransferase complex PRC2 
composed out of different protein-coding and non-protein-coding members. The histone eraser UTX is part of the MLL2 complex leading to a dynamic 
interplay between H3K4 methylation and H3K27me2/3 demethylation. Furthermore, UTX can cooperate with the BRG1-containing SWI/SNF complex 
where it plays a role in general chromatin remodeling independent of its H3K27 demethylase function. The MLL2-UTX and SWI/SNF complexes both 
contribute to an open chromatin formation. The PRC2 complex enables efficient methylation of H3K27 thereby promoting gene silencing and chroma-
tin compaction (graphics from www.somersault1824.com).
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H3K27me3 writer PRC2 and the H3K27me2/3 eraser UTX in 
order to enable context dependent transcriptional regulation.
UTX regulates a retinoblastoma gene network
Genome-wide ChIP-chip analysis of UTX, H3K4me2 and 
H3K27me3 in human fibroblasts identified UTX binding at 
1945 promoters mostly upstream of TSS.41 Out of these, the 
majority of UTX targets were enriched for H3K4me2 (62%) and 
showed transcriptional activity. This observation is consistent 
with UTX being a member of the H3K4 methyltransferase MLL2 
complex.8,9,41 Using Ingenuity Pathway analysis (IPA), a RB 
gene network including RB1, HBP1 and RBBP4, 5, 6 and 9 was 
discovered as the most significant network of UTX-bound genes 
enriched for H3K4me2.41 Loss of UTX in human fibroblasts 
and mouse embryonic fibroblasts (MEFs) confirmed increased 
levels of H3K27me3 at promoters of genes from the identified 
RB-network thereby contributing to deregulated RB-dependent 
cell cycle arrest leading to ectopic cell proliferation.41,42
UTX Escapes X-Inactivation
The female genome harbors 2 X-chromosomes of which 
one X-chromosome is silenced to compensate the difference 
in gene dosage with males.43 X-inactivation is mediated by the 
long intergenic non-coding RNA (lincRNA) XIST, which 
coats the inactive X-chromosome. Next, the PRC2 complex is 
guided by XIST to the inactive X-chromosome hereby enabling 
H3K27 methylation leading to the formation of facultative 
heterochromatin and gene silencing (Fig. 2).44
Utx is one of the few genes that can escape X-inactivation 
in female mice and human.45 In agreement, Utx shows higher 
expression in female tissue of brain, liver, neurons and sexual 
organs.46,47 In line with this observation, a female-specific 
function was reported for Utx in the regulation of the X-linked 
homeobox genes Rhox6 and Rhox9.46 It was shown that Utx is 
expressed at higher levels in undifferentiated female ESCs as 
compared with male ESCs, which resulted in a stronger Utx 
binding in the promoter regions of Rhox6 and Rhox9 in females. 
Subsequently, Utx mediates a more profound H3K27me3 
removal and transcriptional activation of these homeobox genes 
in female cells.46
The Role of UTX in Cellular Reprogramming
Pluripotency is the unique characteristic of ESCs and the 
early developmental stage embryo to induce the generation 
of the three germ layers endoderm, ectoderm and mesoderm 
finally constituting all tissues of the adult organism.48 Through 
in vitro reprogramming of somatic cells via induction of the 
four transcription factors OCT4, SOX2, KLF4 and MYC; 
pluripotency can be re-established hereby generating induced 
pluripotent stem cells (iPSC).48,49 During reprogramming, 
genome-wide changes in the transcriptome and the chromatin 
structure are induced to achieve the switch to the pluripotent 
state.48
The histone H3K27me3 demethylase Utx has a critical 
role in efficient induction or re-establishment of pluripotency 
during the generation of iPSCs in vitro, but is dispensable for 
maintenance of pluripotency.50 The requirement for UTX to 
ensure correct reprogramming depends on its H3K27me3 
demethylase activity.50 During iPSC induction, Utx target 
genes that are enriched with H3K4me3 in Utx wild-type MEFs 
aberrantly accumulate H3K27me3 in Utx mutant MEFs. These 
loci, including the stem-cell maintenance genes Sall1, Sall4, 
and Utf1 as well as validated Klf4 and Oct4 target genes, fail 
to reactivate during reprogramming due to loss of Utx.50 Hence, 
Utx seems to play a crucial role during reprogramming through 
its H3K27me2/3 demethylation activity in correct re-activation 
of essential pluripotency genes.
A Critical Role for UTX in Embryonic Stem Cells  
and Embryonic Development
Embryonic stem cells
H3K27 methylation is important in the maintenance of 
self-renewing ESCs by repressing tissue-specific developmental 
genes.51-53 During ESC differentiation, the re-activation of 
developmental genes is associated with loss of H3K27me3.51 Loss 
of Utx does not influence ESC self-renewal and proliferation, 
but seems to provoke an effect on the differentiation capacity 
of ESCs.11,12,50,54 This differentiation defect is reflected by loss 
of induction of a set of developmental genes including some 
ectoderm markers (Otx2, Msi1, Sox1, and Pax6 ),54 endoderm 
markers (Gata4, Gata6, Foxa2, Sox17, Gsc, and Ncad)12,55 and 
mesoderm markers (Vegfr2, Wnt3, and Brachyury),12,13,54,55 
presumably due to loss of Utx binding to the promoter regions 
of these genes.54
Contradicting studies report on whether the effect of UTX loss 
on ESC differentiation depends on its H3K27me3 demethylase 
activity.12,13,54,55 Namely, male UTX KO ESCs that express a 
catalytic inactive or wild-type Utx protein both could rescue 
the induction of expression of the mesoderm genes Wnt3 and 
Brachyury supporting an H3K27me3-demethylase-independent 
role of Utx during ESC differentiation.54 Furthermore, Utx binds 
directly to the promoters of the ectoderm genes Msi1 and Sox1 
and the mesoderm gene Brachyury marked with an increase in 
H3K4me3 levels but without a change in H3K27me3 levels.54 
In contrast, a decrease in H3K27me3 levels and an increase 
in H3K4me3 levels was seen at the promoter of the Utx target 
Hoxb1 during differentiation of Utx wild-type ESCs confirming 
that Utx still plays an H3K27me3 demethylase-dependent role 
in transcriptional regulation of homeotic and developmental 
genes.54 Therefore, UTX regulates transcriptional activation of 
UTX target genes during ESC differentiation in different ways 
dependent or independent of its H3K27me2/3 demethylation 
activity.
Embryonic development in mice
Several groups have shown that complete loss of Utx in UtxΔ/Δ 
female mice leads to embryonic lethality between embryonic day 
(E) 10.5 and E12.5, whereas UtxΔ/+ heterozygous female mice are 
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viable and fertile.11-15 Surprisingly, UtxΔ/Y male mice are marked 
by a diverse outcome ranging from embryonic lethality to tumor 
formation in adults.11-15 The viable adult UtxΔ/Y male mice are 
smaller in size compared with their littermates12,14 and remain 
fertile indicating that Utx is not required for male fertility.12 
Interestingly, UtxΔ/UtyΔ male mice, in which both Utx and Uty are 
eliminated, phenocopy the UtxΔ/Δ female mice,14 suggesting that 
the Y-linked Uty gene can partially rescue the effect of complete 
loss of Utx.11 In addition, Utx and Uty can both interact with 
Rbbp5 (member of the Mll2 complex) regulating H3K4 
methylation rather than H3K27me2/3 demethylation at Utx and 
Uty target genes.14
Embryonic development in Drosophila melanogaster
Homozygous dUTX Drosophila mutants are lethal, with only 
5% of the animals that survive the pupal stage although not 
reaching adulthood.20 More specifically, dUTXΔ homozygotes 
that lack both maternal and zygotic dUTX protein (dUTXΔmat-
zyg-) die as larvae, whereas dUTXΔ homozygotes that lack only 
zygotic dUTX protein (dUTXΔmat+zyg-) can develop further but die 
quickly after the pupal stage.56 dUTX was shown to be necessary 
for the controlled expression of 2 specific homeotic genes Ubx 
and Abd-B in very early fly development.56 Furthermore, sex 
combs malformation, rough eyes, wrinkled wings and wing vein 
defects are observed in the dUTX mutants which resembles some 
characteristics of Trithorax mutants and is in concordance with 
the effect of these proteins on Hox gene regulation.20,56
Embryonic development in Caenorhabditis elegans
In agreement with Drosophila, UTX-1 mutant worms lacking 
both maternal and zygotic UTX-1 protein (UTX-1m-z-) die as 
late stage embryos or malformed L1 larvae. Mutants with loss of 
only the zygotic UTX-1 (UTX-1m+z-) protein are viable and reach 
adulthood, but a reduction in fertility is observed due to defects 
in gonad migration and oocyte organization. The UTX-1m-z- 
mutants show an increase in global H3K27me2/3 levels at the 
embryonic stage, but introduction of a catalytic inactive mutant 
of UTX-1 in UTX-1m+z- mutant animals rescued the fertility 
indicating that the UTX-1 demethylase activity is not necessary 
for this developmental process. Interestingly, loss of UTX-1 
complex members SET-16 (MLL2–3), PIS-1 (PTIP), WDR-5.1 
(WDR5) and F21H12.1 (RBBP5) also resulted in posterior and 
gonadal defects further confirming that these genes are acting in 
the same genetic complex.28
A Critical Role for UTX in Tissue-Specific and 
Developmental Processes
UTX contributes to a variety of tissue-specific and 
developmental processes including cardiac development,11-15 
hematopoiesis,13,15,57,58 myogenesis,16,17,27,59 osteogenic 
differentiation,60 wound healing,61 and aging.62,63 Cardiac 
development and hematopoiesis will be discussed in further 
detail.
Cardiac development
The histone eraser Utx seems to play an important role in 
cardiac development. UtxΔ/Y ESCs that in vitro differentiate into 
mature cardiac cells show absence of effective heart-like rhythmic 
contractions due to a failure of inducing cardiac-specific gene 
expression.11 Furthermore, UtxΔ/Δ female mice and UtxΔ/UtyΔ male 
mice exhibited strong cardiac developmental and neural tube 
closure defects (cranioschisis) at day E9-E10.5.11-15 This cardiac 
malformation is presumably caused by 2 mechanisms. First, loss 
of Utx disables the induction of transcriptional activation of 
cardiac-specific genes mediated by H3K27me2/3 demethylation, 
whereby the core cardiac transcription factors Nkx2-5, Tbx5, 
Gata4 and Srf specifically guide Utx to the promoter regions of 
cardiac-specific genes (Fig. 3).11 Second, loss of Utx disturbs the 
interaction between the Brg1-containing SWI/SNF chromatin 
remodeling complex and the core cardiac transcription factor 
Tbx5, an effect that is thought to be independent from the 
H3K27me2/3 demethylase activity of UTX (Fig. 3).10,11 This 
dual role of UTX is further supported by an independent study 
showing that UTX and UTY can physically interact with BRG1, 
NKX2-5, SRF and TBX5 hereby inducing expression of cardiac-
specific genes.14 Hence UTX enables transcriptional activation 
of cardiac-specific genes through H3K27me3 demethylase 
dependent and independent mechanisms during cardiac 
development.
Hematopoiesis
Utx expression levels peak in hematopoietic stem and progenitor 
cells and drop during hematopoietic differentiation.58 In UtxΔ/Δ 
female mice embryos (E10.5), a lack of red bloods cells (anemia) 
was observed indicating a critical role for Utx in hematopoiesis.13 
Furthermore, female adult mice in which Utx was homozygously 
eliminated at 11–14 wk of age showed an enlarged spleen, 
reduced hemoglobin levels, anemia, thrombocytopenia and mild 
leukocytopenia compared with normal controls. In addition, 
hematopoietic transcription factors Tal1, Gata1 and Lyl1 were 
downregulated in the bone marrow of Utx KO female mice.15 
Furthermore, Utx was identified as an essential regulator of stem 
cell migration since loss of Utx blocked the migration potential 
of hematopoietic progenitor cells in vitro and of primordial germ 
cells in vivo.15
Constitutional UTX Defects Cause  
the Kabuki Syndrome
Constitutional loss-of-function defects in UTX cause the 
so-called Kabuki syndrome. This rare congenital anomaly 
syndrome, also called the Kabuki make-up syndrome, was first 
described by Niikawa and Kuroki in 1981.64,65 The Kabuki 
syndrome is characterized by moderate-to-severe mental 
retardation, visceral and skeletal abnormalities, postnatal growth 
impairment (short stature) and facial abnormalities including 
large protruding ears.64-66 The Kabuki syndrome has a prevalence 
of about 1 in 32 000 live births.65 Using whole-exome sequencing, 
nonsense and frameshift mutations in the MLL2 gene were first 
identified as a cause of the Kabuki syndrome67 in 74% of these 
patients.68 Two years later, 3 focal deletions targeting the histone 
demethylase UTX were identified in 1 male and 2 female Kabuki 
patients.69 Subsequently, 2 nonsense mutations and a small 
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indel mutation were discovered in 1 female and 2 male Kabuki 
patients.19
As discussed in the next part, both the MLL2 and the UTX 
gene have been reported as important histone modifier genes 
involved in cancer pathogenesis. Until now, 6 Kabuki patients 
have been described that developed different types of cancer 
including pre-B-ALL,70 hepatoblastoma,71 neuroblastoma,71,72 
Burkitt lymphoma,73 and fibromyxoid sarcoma74 marking the 
Kabuki syndrome as a cancer predisposition syndrome.
UTX as a Bona Fide Tumor Suppressor Gene in 
Cancer Biology
Over the last years, deregulated histone methylation became a 
major theme in cancer biology research including the balance of 
H3K27 methylation. In 2009, somatic loss-of-function mutations 
and deletions targeting the UTX gene were identified in multiple 
cancer types including multiple myeloma, esophageal and renal 
cancer.18 This notion was further supported by subsequent 
identification of recurrent inactivating UTX mutations and 
deletions in several leukemia as well as solid tumor types (Fig. 4; 
Fig. S1; Tables S1 and 2), mainly through exome- or genome-
wide sequencing strategies.75-84 Furthermore, a recent study 
of The Cancer Genome Atlas (TCGA) in which whole-exome 
sequencing was performed on 3281 tumors derived from 12 
tumor types identified 127 significantly mutated genes including 
the tumor suppressor gene UTX.85
Bladder cancer has one of the highest frequencies of UTX 
mutations (Fig. 4) typically consisting of truncating mutations 
in the region coding for the functional JmjC domain of UTX. 
Interestingly, more than 50% of bladder cancer patients harbor 
genetic aberrations in a bigger set of chromatin remodeling 
genes including UTX, CREBBP, EP300, ARID1A, CHD6, 
Figure 3. The involvement of UTX in genetic regulation of cardiac development. During cardiac development UTX, guided by the core cardiac transcrip-
tion factors NKX2–5, TBX5, GATA4 and SRF, promotes specific gene activation of cardiac-specific genes through demethylation of H3K27me2/3 at their 
promoter regions. In addition, UTX and UTY can interact with the BRG1-containing SWI/SNF chromatin remodeling complex enabling general chroma-
tin remodeling at these cardiac-specific gene loci (graphics from www.somersault1824.com).
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MLL1, MLL3, and NCOR1.77 Furthermore, multiple myeloma 
cases harboring mutations in UTX or in the Trithorax complex 
members MLL1, MLL2, and MLL3 were linked with high 
expression of HOXA976 confirming the role of UTX in HOX 
gene regulation.3
Interestingly, a study in chronic myelomonocytic leukemia 
(CMML) identified loss-of-function mutations in both UTX and 
EZH2 despite their opposing roles on H3K27me3 regulation. 
Notably, these mutations occurred in a mutually exclusive 
manner in CMML patient samples.86 UTX and EZH2 defects 
in CMML were associated with ASXL187 and TET288 loss-of-
function mutations, two genes also implicated in epigenetic 
regulation of gene expression.86 These studies indicate that the 
chromatin regulatory machinery is a recurrent mutational target 
in a broad range of cancer types highlighting the importance of 
correct regulation of chromatin remodeling in the homeostasis of 
normal tissues.32
Whole-exome and whole-genome next-generation sequencing 
studies in medulloblastoma identified mutations in different 
chromatin regulators including UTX, MLL2, MLL3, SMARCA4 
(BRG1), ZMYM3, and CREBBP.78-80 In general, four prognostically 
relevant subgroups (SHH-subgroup, WNT-subgroup, subgroup 
3 and subgroup 4) are defined in this malignant childhood brain 
tumor.80 Of particular interest, medulloblastoma is marked by a 
disturbed gender distribution toward males in subgroups 3 and 489 
and mutations targeting the X-linked UTX gene were exclusively 
identified in these 2 subgroups.79,80,90 In line with the fact that 
UTX escapes X-inactivation,45 female medulloblastoma patients 
harboring UTX defects showed bi-allelic UTX inactivation 
(splice-site UTX mutation and deletion80 or missense mutation 
and loss of chromosome X79), suggesting that complete loss of 
UTX is required for malignant transformation. In addition, 
more than 50% of UTX mutant male medulloblastoma patients 
had a deletion of the Y-chromosome (including the UTX family 
member UTY ) compared with less than 10% of UTX wild-type 
males.80 Furthermore, gain or overexpression of the H3K27 
methyltransferase EZH2 as well as inactivating mutations in 
H3K4me3 regulators CHD7 and ZMYM3 were also present in 
subgroups 3 and 4 of medulloblastoma. All together, these data 
indicate that deregulation of H3K27 and H3K4 methylation is 
a core oncogenic component of medulloblastoma. Importantly, 
mutations targeting the X-linked gene UTX might partially 
explain the higher male prevalence in medulloblastoma subgroups 
3 and 4.80
So far, the functional consequences of cancer related UTX 
mutations have been poorly characterized. Western blot analyses 
show lack of UTX protein expression in UTX mutant cancer 
cell lines.18 Furthermore, re-expression of UTX in UTX mutant 
cancer cell lines was associated with lower H3K27me3 levels 
at the promoters of Polycomb target genes and concomitant 
inhibition of cell proliferation.18 In adenoid cystic carcinomas, the 
impact of the identified UTX missense mutations was evaluated 
by introduction of these UTX mutants in HEK293T cells, which 
led to an increase in cell growth and a decrease in H3K27me3 
levels.84 Finally, a Sleeping Beauty based insertional mutagenesis 
screen using a Kras driven pancreatic mouse model identified 543 
candidate cancer driver genes with 10% of the genes involved 
in chromatin regulation including the Utx gene. This un-biased 
screening approach provides an independent in vivo confirmation 
of the potential role of Utx as a bona fide tumor suppressor gene 
in cancer biology.91
Figure 4. UTX defects in primary cancer samples. Schematic representation of the presence of UTX defects (%) in primary cancer samples of a broad 
range of leukemic and solid cancer types investigated in multiple genomic studies.
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against some or all JmjC enzymes but are unable to target one 
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Conclusions
In this review, we have summarized and discussed the 
identification of the histone H3K27me2/3 erasers UTX and 
JMJD3, and the role of UTX in normal development and disease. 
UTX cooperates with a set of chromatin players, including 
the histone methyltransferase complex MLL2, the histone 
acetyltransferase CBP and the BRG1-containing SWI/SNF 
remodeling complex,8-10,37 to trigger active gene transcription by 
H3K27me2/3 demethylation or H3K4 methylation.3-6,8-10,30,37 Up 
until now, the main direct target genes of UTX encompass a broad 
set of HOX genes important in animal body patterning3,5 and a 
RB gene network implicated in cell fate control.41 Furthermore, 
UTX loss can lead to the development of the Kabuki syndrome69 
and can contribute to cancer pathogenesis.18
The third UTX family member UTY has no clear enzymatic 
demethylase activity despite the presence of a conserved JmjC 
domain and high amino acid conservation.3,7,14 Surprisingly, 
UTY can partly compensate UTX functions including the 
cooperation with the MLL2 and BRG1-containing SWI/SNF 
complexes.14 Also, UTY can partially rescue embryonic lethality 
in UTX KO male mice.11-15 Furthermore, UTX mutations are 
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gene locus in male cancer patients.18,80 Hence, a set of overlapping 
functions between UTX and UTY in transcriptional regulation 
seems present despite the lack of H3K27me2/3 demethylase 
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All together, the complexity of biological functions assigned 
to UTX is just starting to emerge and will trigger additional 
research in a broad range of developmental processes. Multiple 
studies have highlighted UTX as an important player in cancer 
biology, but its role as a bona fide tumor suppressor still needs 
further confirmation using genetically engineered in vivo 
models. Ultimately, these biological insights will clarify to 
what extend loss of UTX provides therapeutic opportunities for 
human disease.
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  Figure	  1.	  UTX	  defects	  in	  cancer	  cell	  lines	  
Schematic	   representation	   of	   the	   presence	   of	  UTX	   defects	   (%)	   in	   cancer	   cell	   lines	   derived	  
from	  a	  broad	  range	  of	  leukemic	  and	  solid	  cancer	  types	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Supplemental	  Table	  1.	  UTX	  defects	  in	  primary	  cancer	  samples	  
Cancer	  type	   Defects	  (%)	   Paper	  
Multiple	  myeloma	   2/49	  (4.1%)	  
van	  Haaften	  et	  al.	  
Nature	  Genetics	  2009	  
Esophageal	  squamous	  cell	  carcinoma	   1/54	  (1.85%)	  
Renal	  cell	  carcinoma	   4/401	  (1%)	  
Glioblastoma	   0/96	  (0%)	  
T-­‐cell	  acute	  lymphoblastic	  leukemia	   3/67	  (4.48%)	   De	  Keersmaecker	  et	  al.	  Nature	  Genetics	  2013	  
B-­‐cell	  acute	  lymphoblastic	  leukemia	   5/138	  (3.62%)	   Mar	  et	  al.	  Leukemia	  
2012	  Acute	  myeloid	  leukemia	   0/50	  (0%)	  
Myelodysplastic	  syndrome	  /	  Acute	  
myeloid	  leukemia	   1/40	  (2.5%)	  
Gelsi-­‐Boyer	  et	  al.	  BJH	  
2009	  
Acute	  myeloid	  leukemia	   1/150	  (0.67%)	   Wartman	  et	  al.	  JCI	  2011	  
Chronic	  myelomonocytic	  leukemia	   4/52	  (7.69%)	   Jankowska	  et	  al.	  Blood	  
2011	  CMML-­‐derived	  acute	  myeloid	  leukemia	   2/20	  (10%)	  
Multiple	  myeloma	   1/38	  (2.63%)	   Chapman	  et	  al.	  Nature	  2011	  
Bladder	  cancer	   22/97	  (22.68%)	   Gui	  et	  al.	  Nature	  Genetics	  2011	  
Bladder	  cancer	   10/35	  (29%)	   Ross	  et	  al.	  Modern	  Pathology	  2013	  
Medulloblastoma	   5/125	  (4%)	   Jones	  et	  al.	  Nature	  2012	  
Medulloblastoma	   3/92	  (3.26%)	   Pugh	  et	  al.	  Nature	  2012	  
Medulloblastoma	   8/93	  (8.6%)	   Robinson	  et	  al.	  Nature	  2012	  
Medulloblastoma	   7/175	  (4%)	   Dubuc	  et	  al.	  Acta	  Neuropathol	  2013	  
Renal	  Cell	  Carcinoma	   12/412	  (2.91%)	   Dalgliesh	  et	  al.	  Nature	  2010	  
Renal	  Cell	  Carcinoma	   4/132	  (3.3%)	  
Gossage	  et	  al.	  Genes,	  
chromosomes	  &	  
cancer	  2013	  
Adenoid	  cystic	  carcinoma	   4/60	  (6.67%)	   Ho	  et	  al.	  Nature	  Genetics	  2013	  
Prostate	  cancer	   6/50	  (12%)	   Grasso	  et	  al.	  Nature	  2012	  
Prostate	  cancer	   4/63	  (6.35%)	  
Lindberg	  et	  al.	  
European	  Urology	  
2013	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Supplemental	  Table	  2.	  UTX	  defects	  in	  cancer	  cell	  lines	  
Cancer	  type	   Defects	  (%)	   Paper	  
Multiple	  myeloma	   4/9	  (44.4%)	  
van	  Haaften	  et	  al.	  
Nature	  Genetics	  2009	  
Esophageal	  squamous	  cell	  carcinoma	   5/23	  (21.7%)	  
Renal	  cell	  carcinoma	   2/18	  (11.1%)	  
Glioblastoma	   2/29	  (6.9%)	  
Acute	  myeloid	  leukemia	   2/22	  (9.1%)	  
Bladder	  cancer	   2/18	  (11.1%)	  
Breast	  cancer	   2/45	  (4.4%)	  
Chronic	  myeloid	  leukemia	   3/3	  (100%)	  
Colorectal	  adenocarcinoma	   3/40	  (7.5%)	  
Endometrial	  adenocarcinoma	   1/10	  (10%)	  
Hodgkin	  lymphoma	   1/6	  (16.7%)	  
Non-­‐small	  cell	  lung	  cancer	   1/85	  (1.2%)	  
Pancreatic	  adenocarcinoma	   1/17	  (5.9%)	  
Small	  cell	  lung	  cancer	   2/66	  (3.0%)	  
T-­‐cell	  acute	  lymphoblastic	  leukemia	   1/15	  (6.7%)	  
Lung	  cancer	   10/19	  (52.6%)	   Liu	  et	  al.	  Genome	  Research	  2012	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Research	  Objectives	  
	  
T-­‐ALL	  is	  an	  aggressive	  hematological	  cancer	  with	  cure	  rates	  ranging	  from	  50-­‐75%	  depending	  
on	  the	  age.	  Regrettably,	  in	  a	  significant	  number	  of	  adult	  and	  pediatric	  T-­‐ALL	  patients	  relapse	  
occurs	  early	  during	  therapy	  whereby	  only	  a	  fifteenth	  till	  a	  quarter	  survives	  the	  next	  5	  years,	  
respectively.	   The	   exploration	   of	   the	   genetic	   make-­‐up	   of	   T-­‐ALL	   by	   karyotyping,	   FISH,	  
arrayCGH,	   sequencing	   and	   gene	  expression	  profiling	  has	   lead	   to	   the	   classification	  of	   T-­‐ALL	  
patient	  cases	  in	  a	  set	  of	  well-­‐defined	  T-­‐ALL	  subgroups	  of	  which	  some	  are	  linked	  to	  good	  or	  
dismal	   prognosis.	   Moreover,	   the	   advances	   in	   identifying	   and	   characterizing	   the	   multiple	  
genetic	   events	   occurring	   in	   T-­‐ALL	   is	   paving	   the	   way	   towards	   individualized	   treatment	  
regimes,	  also	  coined	  precision	  medicine,	  as	  novel	  drugs	  targeting	  cancer	  cells	  with	  particular	  
genetic	  alterations	  are	  rapidly	  emerging	  and	  being	  tested.	  	  
	  
AIM	   1.	   Identification	   of	   X-­‐linked	   epigenetic	   drivers	   in	   T-­‐ALL	   and	   their	   role	   in	  
sensitivity	  to	  epigenetic	  therapy	  
	  
T-­‐ALL	  is	  one	  of	  the	  few	  cancers	  characterized	  by	  a	  gender	  bias,	  with	  a	  threefold	  higher	  T-­‐ALL	  
occurrence	  in	  males.	  A	  possible	  reason	  for	  this	  skewed	  gender	  distribution	  towards	  males	  in	  
T-­‐ALL	  could	  be	  the	  presence	  of	  tumor	  suppressor	  genes	  on	  the	  X-­‐chromosome.	  To	  test	  this	  
hypothesis,	   we	   investigated	   the	   possible	   presence	   of	   recurrent	   genetic	   defects	   on	   the	   X-­‐
chromosome	   in	   primary	   T-­‐ALL	   patient	   samples	   (paper	   1).	   By	   sequencing	   of	   the	   entire	   X-­‐
chromosome	   exome	   followed	   by	   targeted	   sequencing	   of	   the	   identified	   candidates,	   we	  
detected	   recurrent	   loss-­‐of-­‐function	  mutations	   in	   the	   putative	   chromatin	   reader	   PHF6	   in	   a	  
large	  proportion	  of	  pediatric	  and	  adult	  T-­‐ALL	  patient	  samples,	  marking	  PHF6	  as	  one	  of	   the	  
major	  novel	  tumor	  suppressor	  genes	  in	  T-­‐ALL	  (paper	  1,	  Nature	  Genetics,	  2010).	  	  
	  
In	   view	  of	   the	   rapidly	   emerging	   importance	   of	   epigenetic	   regulators	   in	   cancer,	  we	   further	  
sought	  for	  additional	  candidate	  tumor	  suppressor	  genes.	  One	  of	  the	  possible	  candidates,	  the	  
Ubiquitously	  Transcribed	  tetratricopeptide	  repeat	  on	  chromosome	  X	  or	  UTX,	  was	  also	  located	  
on	   the	  X-­‐chromosome	  and	  was	   already	   found	   to	   be	  mutated	   in	   other	   cancer	   entities.	  We	  
therefore	  hypothesized	  that	  a	  second	  X-­‐linked	  tumor	  suppressor	  gene	  could	  be	  implicated	  in	  
T-­‐ALL.	  Subsequent	  mutation	  analysis	   indeed	  revealed	   inactivating	  mutations	   in	  this	  histone	  
H3K27me2/3	  demethylase	  (paper	  2,	  submitted)	  with	  further	  in	  vivo	  experiments	  supporting	  
an	  important	  role	  for	  UTX	  in	  T-­‐ALL	  pathogenesis	  (paper	  2).	  In	  a	  next	  step,	  we	  took	  advantage	  
of	  the	  rapid	  development	  of	  novel	  epigenetic	  drugs	  and	  explored	  their	  effects	  on	  malignant	  
T-­‐cell	   lymphoblasts	   harboring	   different	   epigenetic	   defects.	   The	   results	   of	   this	   translational	  
component	  are	  also	  presented	  in	  paper	  2.	  
	  
AIM	  2.	  Search	  for	  deregulated	  microRNA	  networks	  in	  T-­‐ALL	  
	  
Next	   to	  defects	   in	  protein-­‐coding	  genes	   that	   contribute	   to	  T-­‐ALL	   formation,	  we	  wanted	   to	  
explore	   the	   possible	   involvement	   of	   miRNAs	   in	   T-­‐ALL.	  MiRNAs	   are	   small	   non-­‐coding	   RNA	  
molecules	  that	  negatively	  regulate	  mRNA	  target	  gene	  expression.	  Therefore	  deregulation	  of	  
miRNAs	  might	   execute	   another	  mechanism	  of	  malignant	   activation	   of	   T-­‐ALL	   oncogenes	   or	  
tumor	  suppressor	  genes.	  First,	  we	  wanted	  to	  identify	  oncogenic	  miRNAs	  (oncomiRs)	  in	  T-­‐cell	  
leukemia	   formation.	   To	   this	   end,	   we	   profiled	   the	   miRNAome	   of	   a	   set	   of	   T-­‐ALL	   patient	  
samples	   and	   normal	   thymocytes	   at	   different	   stages	   of	   differentiation	   and	   evaluated	   the	  
oncogenicity	  of	  the	  top	  candidate	  oncomiRs	  in	  a	  NOTCH1	  T-­‐ALL	  mouse	  model.	  This	  work,	  for	  
the	   first	   time,	   uncovered	   an	   extensive	   miRNA-­‐tumor	   suppressor	   gene	   network	   in	   T-­‐ALL	  
(paper	  3,	  Nature	  Genetics,	  2011).	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Following	   the	   discovery	   of	   these	   oncomiRs,	   we	   also	   explored	   a	   possible	   role	   for	   tumor	  
suppressive	   miRNAs	   in	   T-­‐ALL	   development.	   First,	   we	   took	   advantage	   of	   an	   in	   house	  
optimized	   3’UTR	   library	   screen	   allowing	   the	   unbiased	   identification	   of	   miRNAs	   targeting	  
selected	   T-­‐ALL	   oncogenes.	   Following	   this	   approach,	  we	   identified	  miR-­‐193b-­‐3p	   as	   a	   novel	  
tumor	  suppressor	  miRNA	  targeting	  the	  MYB	  proto-­‐oncogene,	  the	  latter	  playing	  a	  crucial	  role	  
in	   normal	   T-­‐cell	  maturation	   and	   T-­‐ALL	   oncogenesis.	   Further	   in	   vitro	   and	   in	   vivo	   functional	  
studies	  confirmed	  the	  presumed	  tumor	  suppressor	  role	  of	  miR-­‐193b-­‐3p.	  The	  results	  of	   the	  
latter	  work	  are	  presented	  in	  paper	  4	  (in	  preparation).	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  T-­‐cell	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Tumor suppressor genes on the X chromosome may skew the 
gender distribution of specific types of cancer1,2. T-cell acute 
lymphoblastic leukemia (T-ALL) is an aggressive hematological 
malignancy with an increased incidence in males3. In this study, 
we report the identification of inactivating mutations and 
deletions in the X-linked plant homeodomain finger 6 (PHF6) 
gene in 16% of pediatric and 38% of adult primary T-ALL 
samples. Notably, PHF6 mutations are almost exclusively found 
in T-ALL samples from male subjects. Mutational loss of PHF6 
is importantly associated with leukemias driven by aberrant 
expression of the homeobox transcription factor oncogenes 
TLX1 and TLX3. Overall, these results identify PHF6 as a new 
X-linked tumor suppressor in T-ALL and point to a strong 
genetic interaction between PHF6 loss and aberrant expression 
of TLX transcription factors in the pathogenesis of this disease.
T-ALL is an aggressive malignancy in which multiple genetic defects 
collaborate in the transformation of T-cell progenitors4,5. Notably, 
T-ALL has a threefold higher incidence in males3, whereas other 
immature hematological tumors such as precursor B-lineage ALL 
are equally frequent in males and females3.
To identify a possible X-linked tumor suppressor in T-ALL, we 
performed an X-chromosome-targeted mutational analysis in tumor 
DNA samples from 12 males with T-ALL. For each sample, we per-
formed in-solution DNA capture of 7,674 regions encompassing 
3,045,708 nucleotides corresponding to 5,215 X-chromosome exons 
using the Agilent Sure Select oligonucleotide capture system6. DNA 
samples enriched for X-chromosome exons were then analyzed 
by next-generation sequencing using the SOLiD 3 platform from 
Applied Biosystems. This analysis identified 66 candidate previously 
uncharacterized nonsynonymous single-nucleotide variants and 
7 positions with high confidence calls for containing complex variants 
such as insertions or deletions (Fig. 1a). Dideoxynucleotide DNA 
sequencing of PCR products encompassing affected exons confirmed 
the presence of 92% (61/66) of these single-nucleotide variants and 
57% (4/7) of the more complex variants, including 2 insertions and 
2 deletions (Supplementary Tables 1 and 2). Sequence analysis of 
paired DNA samples obtained at the time of clinical remission showed 
that most of these variants corresponded to previously unreported 
germline polymorphisms. However, and most notably, we also identi-
fied three somatically acquired changes corresponding to two non-
synonymous single-nucleotide substitutions (A902G T300A and 
A990G H330R) and a frameshift-creating insertion of five nucleotides 
(124_125insAGGCA, H43fs) in the PHF6 gene (Fig. 1a).
In a complementary approach we analyzed X-chromosome array 
comparative genome hybridization (array-CGH) data from 246 
primary T-ALL samples (179 male and 67 female) in a multicenter 
setting. These analyses revealed the presence of recurrent deletions 
in chromosomal band Xq26 in 8 out of 246 (~3%) T-ALL samples 
(Table 1). For three del(X)(q26)-positive T-ALL samples, we per-
formed array-CGH analysis against the corresponding remission 
material, which showed that these Xq26 deletions were somatically 
acquired leukemia-associated genetic events (Table 1). Reanalysis 
of all eight del(X)(q26)-positive T-ALL samples on a custom 
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high-resolution X-chromosome oligo-
nucleotide array (Fig. 1b,c)  narrowed down 
the common minimally deleted region to 
an area of 80 kb containing the PHF6 gene. 
Consistently, quantitative PCR analysis confirmed loss of the PHF6 
locus in the del(X)(q26)-positive cases (Fig. 1d). The convergent find-
ings of our X-chromosome exon mutation analysis and analysis of 
copy number alterations by array-CGH thus identified PHF6 as a new 
tumor suppressor gene mutated and deleted in T-ALL.
PHF6 encodes a plant homeodomain (PHD) factor containing 
four nuclear localization signals and two imperfect PHD zinc-finger 
domains7 with a proposed role in controlling gene expression7. 
Notably, inactivating mutations in PHF6 cause Börjeson-Forssman-
Lehmann syndrome (MIM301900), a relatively uncommon type of 
X-linked familial syndromic mental retardation that has not been 
associated with increased incidence of T-ALL7–9. Quantitative 
RT-PCR analysis demonstrated ubiquitous expression of PHF6 tran-
scripts in human tissues, with highest levels of expression in thy-
mus, ovary and thyroid, and moderate levels of expression in spleen, 
testes and adipose tissue (Supplementary Fig. 1). Consistent with 
these results, PHF6 was readily detected by immunohistochemis-
try in mouse thymus (Supplementary Fig. 1). Finally, quantitative 
RT-PCR analysis of human thymocyte populations at different 
stages of development showed variable levels of PHF6 expression, 
with marked upregulation of PHF6 transcripts in CD4/CD8 double-
 positive cells (Supplementary Fig. 1).
Mutational analysis of PHF6 in an extended panel of pediatric and 
adult T-ALL primary samples identified truncating or missense muta-
tions in PHF6 in 38% (16/42) of adult and ~16% (14/89) of pediatric 
T-ALL samples (Fig. 2a and Table 1). In all available cases (7/30), anal-
ysis of matched buccal and/or bone marrow remission genomic DNA 
confirmed the somatic origin of PHF6 mutations (4/21 frameshift 
mutations and 3/9 missense mutations) (Fig. 2b and Table 1). Finally, 
no mutations in PHF6 were identified in DNA samples from B-lineage 
ALL (n = 62), suggesting that mutational loss of PHF6 in lymphoid 
tumors could be restricted to T-ALL.
Nonsense and frameshift mutations accounted for 70% (21/30) 
of all PHF6 mutations identified in our series and were evenly 
distributed throughout the gene. Missense mutations accounted for 
the remaining 30% (9/30) of PHF6 lesions and recurrently involved 
codon C215 and the second zinc-finger domain of the protein (Fig. 2a). 
DNA sequence analysis of PHF6 in a panel of 15 well-characterized 
T-ALL cell lines (Supplementary Table 3) showed the presence of 
truncating mutations in PHF6 in the DND41, HPB-ALL and T-ALL1 
cell lines. Protein blot analysis and immunohistochemical staining 
demonstrated robust expression and nuclear localization of PHF6 in 
PHF6 wild-type tumors and complete loss of PHF6 protein in T-ALL 
cell lines harboring mutations in PHF6 (Fig. 2c,d).
PHD finger-containing proteins have been implicated in numerous 
cellular functions, including transcriptional regulation and in some 
instances as specialized reader modules that recognize the methylation 
status of histone lysine residues10. In addition, PHF6 has been reported 
to be phosphorylated during mitosis11 and by the ATM and ATR kinases 
upon DNA damage12, which suggests a dynamic regulation of PHF6 dur-
ing cell cycle and DNA repair. Consistent with this notion, short hairpin 
RNA (shRNA) knockdown of PHF6 resulted in increased levels of phos-
phorylated H2AX (G-H2AX), a post-translational modification associated 
with the presence of DNA double-strand breaks13 (Fig. 2e).
Sex determination in humans is controlled by differential 
 representation of the X and Y chromosomes, with the presence of 
an XY pair in males and two copies of the X chromosome in females. 
The presence of numerous genes in the nonautosomal region of the 
X chromosome could result in a genetic imbalance between male and 
female cells, which is compensated for by random chromosomal inac-
tivation of one copy of the X chromosome in female cells14. However, 
allelic-expression analysis has shown that some genes can escape 
X-chromosome inactivation in certain tissues1,2,15. To test the pos-
sibility that PHF6 could escape X-chromosome inactivation in 
T-ALL cells, we performed allelic-expression analysis of a silent SNP 
(rs17317724) located in the 3` UTR of PHF6 in lymphoblasts from 
three informative samples from females with T-ALL. In each of these 
samples, PHF6 was monoallelically expressed, suggesting that biallelic 
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Figure 1 Next-generation sequencing and 
microarray-based comparative genomic  
hybridization (array-CGH) analysis of the  
X chromosome identifies PHF6 mutations in  
human T-cell acute lymphoblastic leukemia (T-ALL).  
(a) Overview of mutation screening approach of 
the human X-chromosome exome in a panel of 
tumor DNA samples from 12 males with T-ALL 
using oligonucleotide sequence capture and next-
generation sequencing with SOLiD 3. After filtering 
and confirmation of high-throughput sequencing 
data, analysis of corresponding remission DNA 
samples led to the identification of three somatically 
acquired changes in PHF6. (b) Schematic overview 
of the recurrent genomic deletions involving 
chromosomal band Xq26.3 in eight human  
T-ALL samples. Specific genes located in Xq26.3 
are shown. (c) Detailed view of a representative 
oligonucleotide array-CGH plot of leukemia DNA/
control DNA ratios (blue trace) versus the dye-swap 
experiment (red trace) in an individual harboring an 
Xq26.3 deletion. (d) DNA quantitative PCR analysis 
of PHF6 copy number dose in female and male 
reference genomic DNAs and two primary samples 
from males with T-ALL harboring Xq26.3 deletions.
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 expression of PHF6 is not commonly found in T-ALL (Fig. 3a). Most 
notably, we found that PHF6 mutations are almost exclusively found 
in samples from males with T-ALL. PHF6 mutations were present in 
32% (29/92) of males and in only ~2.5% (1/39) of females (P < 0.001; 
Fig. 3b and Supplementary Table 4). Moreover, all eight PHF6 
 deletions identified by array-CGH analysis were found in samples 
from males with T-ALL, and each of the three cell lines with mutations 
in PHF6 were derived from males with T-ALL.
Table 1 Characteristics of 38 primary T-ALL samples showing PHF6 inactivation
ID Sex Age WBC (× 109 l–1) Immuno-phenotype Genetic subtype NOTCH1 Type of alteration
Deletion size or predicted 
PHF6 protein lesion
Germline or 
somatic
1 M Ped 77 Cortical TLX3 Mut Deletion 0.55 Mb NA
2 M Ped 46 Pre-T TLX3 WT Deletion 0.23 Mb NA
3 M Ped 31 Pre-T TLX3 NA Deletion 1.50 Mb NA
4 M Ped 2 Pre-T Unknown NA Deletion 0.27 Mb NA
5 M Ped NA Cortical HOXA NA Deletion 1.90 Mb Somatic
6 M Ped NA Cortical Unknown NA Deletion 0.20 Mb Somatic
7 M Ped NA Cortical TLX1 NA Deletion 0.08 Mb Somatic
8 M Adult NA Pre-T Unknown NA Deletion 0.11 Mb NA
9 M Ped 185 Cortical TLX3 WT Nonsense G122X NA
10 M Ped 417 Pre-T TLX3 Mut Nonsense R116X NA
11 F Ped 280 Pre-T TLX1 Mut Frameshift F172fs NA
12 M Ped 405 Pre-T TLX3 Mut Frameshift Y303fs NA
13 M Ped 159 Pre-T TLX1 Mut Nonsense K235X NA
14 M Ped 500 Pre-T TLX3 Mut Frameshift A41fs NA
15 M Ped 347 Cortical HOXA Mut Nonsense K274X NA
16 M Ped 129 Cortical Unknown Mut Frameshift D333fs NA
17 M Ped 174 Cortical TLX3 Mut Nonsense R225X NA
18 M Ped 27 Cortical TLX1 WT Nonsense R116X NA
19 M Ped 310 Cortical TAL1 Mut Missense C283R NA
20 M Ped 189 Cortical TAL1 Mut Frameshift C28fs NA
21 M Adult 170 Cortical TLX3 WT Frameshift H44fs NA
22 M Adult 21 Cortical TLX1 Mut Frameshift H43fs Somatic
23 M Adult NA Pre-T TLX3 Mut Frameshift T98fs Somatic
24 M Adult 14 Pre-T TLX3 WT Frameshift Y105fs NA
25 M Adult 28 Mature TLX3 WT Frameshift S158fs NA
26 M Adult NA Cortical TLX3 Mut Missense C215Y NA
27 M Adult NA Pre-T Unknown Mut Missense C215F NA
28 M Adult 31 Cortical Unknown Mut Missense C215Y NA
29 M Adult NA Mature TLX3 Mut Missense T300A Somatic
30 M Adult 21 Cortical TLX1 WT Missense A311P NA
31 M Adult 30 Mature Unknown WT Missense C280Y NA
32 M Adult 23 Cortical Unknown WT Missense H329R Somatic
33 M Ped NA NA TAL1 NA Nonsense R257X Somatic
34 M Ped NA NA TLX1 NA Frameshift S191fs Somatic
35 M Adult NA NA TLX1 NA Missense C215F Somatic
36 M Adult NA NA TLX1 NA Nonsense Y303X NA
37 M Adult NA NA Unknown NA Nonsense R274X NA
38 M Adult NA NA Unknown NA Frameshift H135fs NA
Mb, megabases; Mut, mutated; NA, not available; Ped, pediatric; WT, wild-type; X, stop codon.
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Figure 2 PHF6 mutations and expression in 
T-cell acute lymphoblastic leukemia (T-ALL) 
lymphoblasts. (a) Structure of the PHF6 
protein, including four nuclear localization 
signals (NLSs) and two imperfect plant 
homeodomain (PHD) zinc-finger domains. 
Overview of all PHF6 mutations identified 
in primary T-ALL samples and T-ALL cell 
lines. Filled circles represent nonsense and 
frameshift mutations, whereas missense 
mutations are depicted as open circles. The 
circle filled in gray indicates the mutation 
identified in a sample from a female with  
T-ALL. aa, amino acids. (b) Representative 
DNA sequencing chromatograms of paired 
diagnosis and remission genomic T-ALL DNA 
samples showing a somatic mutation in exon 7 
of PHF6. (c) Protein blot analysis of T-ALL cell lines revealed complete loss of PHF6 protein expression in the PHF6-mutated T-ALL cell lines.  
(d) PHF6 immunostaining in the Jurkat and HPB-ALL, wild-type and mutant T-ALL cell lines, respectively. (e) Protein blot analysis of PHF6 and  
G-H2AX expression in HEK293T cells upon PHF6 short hairpin RNA knockdown. Actin concentrations are shown as a loading control.
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Immunohistochemical analysis of PHF6 
expression in wild-type primary T-ALL sam-
ples showed positive PHF6 immunostaining 
(n = 5; three males and two females), whereas 
cases with PHF6-truncating mutations 
(n = 4) (Fig. 3c) or a point mutation in C215 
(C215F) were negative for PHF6 protein 
expression (Fig. 3c). In contrast, primary 
T-ALL cells harboring a PHF6 point muta-
tion in the PHD2 domain (T300A) were posi-
tive for PHF6 protein expression (Fig. 3c). 
Overall, these results suggest that truncat-
ing mutations and point mutations in C215 
impair PHF6 expression, whereas amino acid 
substitutions in the PHD2 domain of PHF6 
may selectively impair the tumor suppressor 
function of this protein.
Leukemic transformation of immature 
thymocytes is the result of a multistep pro-
cess involving numerous genetic abnormali-
ties, which can be associated with different clinical features, including 
age and prognosis. Notably, PHF6 mutations were significantly more 
prevalent in adult T-ALL patients (16/42; 38%) than in pediatric 
patients (14/89; 16%) (P = 0.005; Fig. 4a). Detailed genetic infor-
mation was available for T-ALL cases treated in Dutch Childhood 
Oncology Group (DCOG) clinical trials (n = 65) (Supplementary 
Table 5). In this cohort, PHF6 mutations were significantly associ-
ated with the aberrant expression of TLX1 and TLX3 (P < 0.005; 
Fig. 4b and Supplementary Table 5), two related oncogenes activated 
by chromosomal translocations in T-ALL16–18. No significant associa-
tions were observed between PHF6 mutations and NOTCH1, FBXW7 
or PTEN mutations in either pediatric (n = 65) or adult (n = 34) 
T-ALL cohorts (Supplementary Tables 5 and 6). Overall survival in 
PHF6 wild-type children with T-ALL treated on DCOG protocols19 
was 65% (33/51) vs. 71% (10/14) for PHF6-mutated cases (log-rank 
P = 0.71) (Fig. 4c). Overall survival in PHF6 wild-type adults with 
T-ALL treated in the Eastern Cooperative Oncology Group ECOG-2993 
clinical trial was 36% (7/12) vs. 58% (8/22) for PHF6-mutated 
samples (log-rank P = 0.24) (Fig. 4d).
Overall, these results identify PHF6 as a new X-linked tumor sup-
pressor gene and imply a specific interaction between the oncogenic 
programs activated by aberrant expression of TLX transcription 
factors and mutational loss of PHF6 in the pathogenesis of T-ALL.
METHODS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Clinical samples and cell lines. Leukemic DNA and cryopreserved lympho-
blast samples were provided by collaborating institutions in the United States 
(ECOG), The Netherlands (DCOG), France (Hôpital Saint-Louis, Paris), 
Austria (Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, 
Vienna) and Belgium (Department of Pediatric Hemato-Oncology, Ghent 
University Hospital, Ghent; Department of Hematology, Hospital St.-Jan, 
Bruges). All samples were collected in clinical trials with informed consent 
and under the supervision of local institutional review board committees. 
The subjects’ parents or their legal guardians provided informed consent to 
use leftover material for research purposes according to the Declaration of 
Helsinki. T-cell phenotype was confirmed by flow cytometry. Survival analysis 
was performed in pediatric T-ALL samples from DCOG trials ALL7, ALL8 
and ALL9 (ref. 19) and from adults with T-ALL treated in the ECOG2993 
clinical trial20.
Jurkat and PF382 cells were obtained from the American Type Culture 
Collection. The ALL-SIL, HPB-ALL and T-ALL-1 cell lines were from the 
DSMZ repository (the German national resource center for biological mate-
rial). The DND41 cell line was a gift from A.T. Look (Dana-Farber Cancer 
Institute). T-ALL cell lines were cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin G and 100 Mg/ml strepto-
mycin at 37 °C in a humidified atmosphere under 5% CO2.
X chromosome exome capture and next-generation sequencing. Libraries of 
synthetic biotinylated RNA oligonucleotides (baits) targeting the X-chromosome 
exons were obtained from Agilent Technologies. The targeted region includes 
5,217 exons for a total of 3 megabases and is designed to capture 85% of 
the exons on the human X chromosome. Fragment libraries using 2–4 Mg of 
genomic DNA as starting material were prepared following the SOLiD stand-
ard library preparation protocol with some modifications, including the use 
of shortened adaptors and a precapture amplification for six cycles. A total of 
500 ng of captured library were hybridized with the baits for 42 h, washed and 
eluted using the protocol provided by Agilent. The resulting captured DNA was 
amplified using Herculase II Fusion DNA polymerase (Agilent) for 18 cycles. 
Enrichment in the targeted regions was calculated by real-time PCR quantifi-
cation of single exons within four X-chromosome loci (ARSF, OTC, NAP1L3 
and SOX3), which showed an average enrichment of 400- to 1,200-fold for 
the different loci across the 12 different samples. After library quantification 
by real-time PCR, the amplified captured libraries were subjected to emulsion 
PCR and sequenced following standard SOLiD 3 protocols by depositing 10–15 
million beads per sample using an eight-region mask.
Data analysis SOLiD3 ultradeep sequencing. A reference genome of the cap-
tured regions was created based on the March 2006 human reference sequence 
(hg18). To map the sequence data into this reference genome, we used the 
SHRiMP algorithm with its default parameters21. SOLiD platform employs a 
two-base encoding system, where a single variation in the color space solely 
indicates a sequencing error and two consecutive variations in the color space 
point to a base change in the nucleotide-space. In our analysis we included 
only the reads with a maximum number of two color-space mismatches that 
are also uniquely mapped to the reference genome. An average 90.1% of 
the reference genome is covered in the 12 samples, where the mean depth is 
42 per base. Less restrictive filtering increases the false-positive rate of can-
didate genomic variants without improving the coverage to any great extent. 
We found 66 candidates of exonic nonsynonymous single-nucleotide varia-
tion by requiring each variation to be reported in a minimum 75% of at least 
three reads mapping to its position. These candidates exclude the previously 
reported SNPs in the human genome. Using ParMap, an algorithm specifi-
cally developed to identify small deletions and insertions (along with their 
nucleotide sequence) through statistical analysis of partially mapped reads22, 
we identified seven candidates of such complex variations. Validation of the 
next-generation sequencing results was done by Sanger sequencing of PCR 
amplified exons. Overall, 89% of all previously uncharacterized candidate 
variants were confirmed.
Microarray-based comparative genomic hybridization. Analysis of 
X-chromosome array-CGH data was performed in a multicenter setting. 
Depending on the institution of origin, array-CGH analysis was performed 
using an oligonucleotide array-CGH platform18,23 (Agilent) or a tiling path 
BAC array-CGH platform24. To determine the exact size of the recurrent Xq26 
deletions, we reanalyzed all eight del(X)(q26)-positive T-ALL cases using a 
custom high-resolution X-chromosome oligonucleotide array with an average 
resolution of 3 kb according to the manufacturer’s instructions (Agilent). Slides 
were scanned in a 2565AA DNA microarray scanner (Agilent). Microarray 
images were analyzed using Feature Extraction software (Agilent), and the data 
were subsequently imported into array-CGH Analytics software (Agilent).
Real-time quantification of DNA copy number. Chromosome Xq26.3 dele-
tions were confirmed with real-time quantitative DNA PCR using the Fast 
SYBR Green Master Mix (Applied Biosystems) and the LightCycler 480 Real-
Time PCR System (Roche Diagnostics) as described25 using TIE2 as control 
gene. Data were analyzed using the comparative $$CT method (Applied 
Biosystems). The primers used for the quantitative PCR analysis of the PHF6 
locus are shown in Supplementary Table 7.
PHF6 mutation analysis. PHF6 mutations were analyzed by PCR amplification of 
PHF6 exons 2–10 followed by direct bidirectional DNA sequencing. The primers 
used for PHF6 mutation detection are summarized in Supplementary Table 7.
Protein blot and immunohistochemistry. Protein blot analysis was per-
formed using a rabbit polyclonal antibody specific to PHF6 (1:10,000; Novus 
Biologicals) recognizing a C-terminal (amino acids 315–365) epitope in PHF6; 
a mouse monoclonal antibody (1:1,000) recognizing an N-terminal (amino 
acids 120–140) PHF6 epitope26; an antibody specific to G-H2AX (1:1,000; Cell 
Signaling Technologies) and a mouse monoclonal antibody specific to GAPD 
(1:1000; Santa Cruz Biotechnology) using standard procedures.
Immunohistochemistry analysis was performed as described following 
the standard avidin-biotin immunoperoxidase staining procedure using an 
N-terminal antibody to PHF6. Briefly, PHF6 immunostaining of formalin-
fixed paraffin-embedded tissue sections was performed after heat-induced 
epitope retrieval in a microwave in citrate buffer, pH 6.0. Subsequently, 
sections were incubated in 10% normal goat serum for 30 min, followed 
by primary antibody incubation (amino acids 1–94 of rabbit polyclonal 
 antibody to PHF6; Sigma Prestige Antibodies, dilution 1:100) overnight at 
4 °C. Next, slides were incubated with biotinylated immunoglobulins specific 
to rabbit at a 1:1000 dilution (Vector Laboratories) for 30 min, followed by 
avidin-biotin peroxidase complexes at a 1:25 dilution (Vector Laboratories) 
for 30 min. Diaminobenzidine was used as the chromogen and hematoxylin 
as a nuclear counterstain.
Quantitative real-time PCR. Thymocyte populations were isolated from 
human thymi as described before27. Total RNA was extracted using the Trizol 
method (Invitrogen) following the manufacturer’s instructions. Total RNA 
from 20 different normal human tissues was obtained from the FirstChoice 
Human Total RNA Survey Panel (Applied Biosystems). Complementary DNA 
(cDNA) was generated with the ThermoScript RT-PCR system (Invitrogen) 
and analyzed by quantitative real-time PCR using the SYBR Green RT-PCR 
Core Reagents kit (Applied Biosystems) and the 7300 Real-Time PCR System 
(Applied Biosystems). PHF6 expression levels were calculated using GAPDH 
as a reference gene. Primers used for PHF6 expression analysis are shown in 
Supplementary Table 7.
SNP genotyping. Genotyping of SNP rs17317724 located in the 3` UTR region 
of PHF6 was performed using a TaqMan SNP Genotyping Assay (Assay ID 
C__34812972_10, Applied Biosystems) according to manufacturer’s instruc-
tions in DNA samples from females with wild-type PHF6 T-ALL. Genotyping 
was confirmed by direct DNA sequencing of PCR products encompassing 
the 3` UTR of PHF6. Allelic expression analysis was performed in cDNA 
samples from heterozygous females with T-ALL so as to evaluate mono-
allelic and biallelic PHF6 expression. Before cDNA synthesis, RNA samples 
were treated with DNase I using the DNA-free DNase Treatment kit (Applied 
Biosystems) to remove any traces of genomic DNA. The PHF6 3` UTR-specific 
primers used for amplification of SNP rs17317724 are also summarized in 
Supplementary Table 7.
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PHF6 shRNA knockdown. We produced lentiviral particles driving 
the expression of a shRNA directed against PHF6 (target sequence 
CAGAATTTGGAGACTTTGA) using the pGIPZ Lentiviral shRNAmir vector 
system (V2LHS_138602, Open Biosystems) as described28. We infected 
HEK293T cells with viral supernatants generated with pGIPZ PHF6 or an empty 
pGIPZ control using spinoculation in the presence of polybrene. PHF6 knock-
down was evaluated by protein blot analysis at 72 h as described above.
Statistical analysis. Fisher’s exact test was used to compare the frequency of 
PHF6 mutations between clinical and genetic groups of T-ALL. Bar graphs 
represent mean values o s.e.m. Therapeutic outcome was analyzed in leukemia 
patients treated in DCOG trials ALL7, ALL8 and ALL9 and in ECOG trial 2993 
according to overall survival. Kaplan-Meier curves were used to assess survival, 
and differences between groups were compared by the log-rank test.
21. Rumble, S.M. et al. SHRiMP: accurate mapping of short color-space reads. PLOS 
Comput. Biol. 5, e1000386 (2009).
22. Khiabanian, H., Van Vlierberghe, P., Palomero, T., Ferrando, A.A. & Rabadan, R. 
ParMap, an algorithm for the identification of complex genomic variations in nextgen 
sequencing data. Nature Precedings published online, <http://hdl.handle.net/10101/
npre.2010.4145.1> (12 January 2010).
23. Clappier, E. et al. The C-MYB locus is involved in chromosomal translocation and 
genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining 
a new T-ALL subtype in very young children. Blood 110, 1251–1261 (2007).
24. Erdogan, F. et al. Impact of low copy repeats on the generation of balanced and 
unbalanced chromosomal aberrations in mental retardation. Cytogenet. Genome 
Res. 115, 247–253 (2006).
25. Lahortiga, I. et al. Duplication of the MYB oncogene in T cell acute lymphoblastic 
leukemia. Nat. Genet. 39, 593–595 (2007).
26. Voss, A.K. et al. Protein and gene expression analysis of Phf6, the gene mutated 
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Gene Expr. Patterns 7, 858–871 (2007).
27. González-García, S. et al. CSL-MAML-dependent Notch1 signaling controls 
T lineage-specific IL-7RA gene expression in early human thymopoiesis and 
leukemia. J. Exp. Med. 206, 779–791 (2009).
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Figure S1. PHF6 expression in normal tissues and lymphoid progenitors.  
(a) Quantitative RT-PCR analysis of PHF6 transcripts in human tissues. (b) PHF6 
immunostaining in mouse thymus. (c) Quantitative RT-PCR analysis of PHF6 expression 
normalized to GAPDH in lymphoid populations isolated from human thymus. Error bars indicate 
s.d. 
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Table S3. PHF6 mutations in T-ALL cell lines 
    
T-ALL cell line Gender 
Translocation-
associated T-ALL 
oncogene  
PHF6 mutation 
    
DND41 M TLX3 Frameshift     p.G10fs 
    
HPB-ALL M TLX3 Nonsense     p.S320X 
    
T-ALL1 M Unknown Frameshift     p.G263fs 
    
JURKAT M TAL1 Wildtype 
    
LOUCY F SET-NUP214 Wildtype 
    
MOLT16 F MYC Wildtype 
    
PEER F NKX2.5 Wildtype 
    
PF382 F Unknown Wildtype 
    
SKW3 M Unknown Wildtype 
    
RPMI8402 F LMO1 Wildtype 
    
P12-ICHIKAWA M Unknown Wildtype 
    
CUTLL1 M NOTCH1 Wildtype 
    
KOPTK1 M TAL1 Wildtype 
    
HSB2 M LCK Wildtype 
    
ALL-SIL M TLX1 Wildtype 
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Table S4. Gender distribution of PHF6 mutations in T-ALL 
     
 PHF6 mutation PHF6 wild-type Total P-Valuea 
     
Male 29 63 92 0.0001 
     
Female 1 38 39  
     
Total 30 101 131  
     
aFisher’s exact test 
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Table S5. Molecular characterization of pediatric T-ALL cases treated in DCOG studies 
ALL7, ALL8 and ALL9 (n=65). 
     
     
 All patients PHF6 mutation PHF6 wild-type P-valuea 
     
Number 65 14 (21.5%) 51 (78.5%)  
     
     
Genetic 
subgroup  
   
     
TLX1 6 (9%) 3 (50%) 3 (50%) 0.108 
     
TLX3 17 (26%) 7 (41%) 10 (59%) 0.037 
     
TLX1/TLX3  23 (35%) 10 (43%) 13 (57%) 0.0032 
     
HOXA 5 (8%) 1 (20%) 4 (80%) 0.708 
     
TAL1/2 or 
LMO1/2 26 (40%) 
2 (8%) 24 (92%) 0.033 
     
     
     
Mutations     
     
NOTCH1 40 (61%) 11 (27%) 29 (73%) 0.216 
     
FBXW7 11 (17%) 2 (18%) 9 (82%) 1.00 
     
PTEN 8 (12%) 0 (0%) 8 (100%) 0.185 
     
a Fisher’s exact test 
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Table S6. Molecular characterization of adult T-ALL cases from ECOG study 2993 
(n=34). 
     
     
 All patients PHF6 mutation PHF6 wild-type P-valuea 
     
Number 34 13 (38%) 21 (62%)  
     
     
     
NOTCH1 20 (62%) 8 (40%) 12 (60%) 1.00 
     
FBXW7 6 (18%) 2 (33%) 4 (67%) 1.00 
     
PTEN 4 (12%) 0  4 (100%) 0.14 
     
     
a Fisher’s exact test 
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Table S7. List of primer sequences      
       Forward primer  Reverse primer Genomic DNA 
quantitative PCR    
     PHF6  CTCGGCGAACAAGTGCAA  GGGGCAGGATCAGAGGAGA HPRT1  TACCACCGTGTGTTAGAAAA  ATTCCAGGACAGAACAAAAC miR-424/503  AGGAGCGACTTGACATCA  ACACCCCAGCTGAGTTAT miR-450/542  TTTTTGCGATGTGTTCCTA  CCCTCCATCTTTTCATCTG TIE  CGAGATCCAGCTGACATGGAA  CTCCACAACGTACTTGGATATTGG 
      
     PHF6 mutation analysis    
     PHF6 Exon 2 TTTCTTGGGGCTTAGAGTG  AAATGGCATAGCATTAGTGA PHF6 Exon 3 GCTATGCCATTTTTACTAGAAA  GCTGGCTCAGAGAAAAAAAA PHF6 Exon 4 CCCCAGAAGAATTTTATTCC  AAACGTGGCTAAATGATGTA PHF6 Exon 5 AAAGGGTGTTTTTGATAAGA  AAACGTGGCTAAATGATGTA PHF6 Exon 6 GGGTGGCTTTATTGAACAT  GCTATCGGTATTTCAAGCTTA PHF6 Exon 7 TTGGATTCTTACTTTTGTTGC  GGGGAAATTTTTTGGTTACTA PHF6 Exon 8 TTTTCCTGCATTTTTCTTCT  GCAAATGCCTTGAAATGTAT PHF6 Exon 9 GAGGGCTTATCAAAGTATGG  AGGAAAATGCCAATTGTAGT PHF6 Exon 10 AGCCTCATCCACTAATGTTG  GAGTTGGGCAGTAAAAAGTT 
     PHF6 mono/bi-allelic expression analysis   
     
PHF6 Exon 11 (3’UTR) AGGCTGAGTTTGACATGTT  CAAGCCCTACAAGAAGAAA 
     PHF6 quantitative RT-PCR analysis   
     PHF6 
 
AAAAGGGCCTACAAGACAG 
 
ACAATGGCACAAAGAACAC 
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ABSTRACT	  
	  
T-­‐cell	  acute	  lymphoblastic	  leukemia	  (T-­‐ALL)	  is	  an	  aggressive	  form	  of	  human	  leukemia	  that	  is	  
mainly	  diagnosed	  in	  children	  and	  shows	  a	  skewed	  gender	  distribution	  towards	  males.	  Here,	  
we	   report	   somatic	   loss-­‐of-­‐function	   mutations	   in	   the	   X-­‐linked	   histone	   H3K27me3	  
demethylase	  UTX	   in	  human	  T-­‐ALL.	   Interestingly,	  UTX	  mutations	  were	  exclusively	  present	   in	  
male	  T-­‐ALL	  patients	  and	  allelic	  expression	  analysis	  revealed	  that	  UTX	  escapes	  X	  inactivation	  
in	   female	   T-­‐ALL	   lymphoblasts.	   The	   Polycomb	   repressive	   complex	   2	   (PRC2)	   regulates	   gene	  
repression	   through	  methylation	  of	  H3K27	  and	   therefore	  counteracts	  UTX	  activity.	  Notably,	  
we	   demonstrate	   in	   vivo	   that	   -­‐	   despite	   encoding	   opposing	   activities	   -­‐	   the	   H3K27me3	  
demethylase	  Utx	  and	  the	  PRC2	  H3K27me3	  methyltransferase	  complex	  both	  function	  as	  bona	  
fide	   tumor	   suppressors	   in	   T-­‐ALL.	   Moreover,	   T-­‐ALL	   driven	   by	   UTX	   inactivation	   exhibits	  
collateral	  sensitivity	  to	  pharmacological	  H3K27me3	  inhibition.	  All	  together,	  our	  results	  show	  
how	  a	   gender-­‐specific	   and	   therapeutically	   relevant	   defect	   in	   balancing	  H3K27	  methylation	  
contributes	  to	  T-­‐cell	  leukemogenesis.	  
	  
	  
STATEMENT	  OF	  SIGNIFICANCE	  
	  
The	  H3K27me3	  demethylase	  UTX	   is	   recurrently	  mutated	   in	  primary	  T-­‐ALL	  patient	   samples,	  
most	  exclusively	  in	  males.	  Loss	  of	  UTX	  contributes	  to	  T-­‐ALL	  formation	  and	  confers	  sensitivity	  
to	  H3K27me3	  inhibition.	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INTRODUCTION	  
	  
T-­‐cell	  acute	   lymphoblastic	   leukemia	   (T-­‐ALL)	   is	  an	  aggressive	  hematological	  malignancy	   that	  
occurs	  in	  children	  and	  adolescents	  and	  is	  diagnosed	  more	  frequently	  in	  males	  than	  females.	  
Current	   treatment	  schedules	  consist	  of	   intensified	  chemotherapy	  and	  are	  often	  associated	  
with	   considerable	   side	   effects	   (1,	   2).	   T-­‐ALL	   arises	   from	   a	   multistep	   oncogenic	   process	   in	  
which	   different	   genetic	   alterations	   drive	   malignant	   transformation	   of	   immature	   T-­‐cell	  
progenitors.	   Several	   key	  oncogenic	  drivers	  mark	  particular	  molecular-­‐genetic	   subgroups	  as	  
demonstrated	   by	   genome-­‐wide	   transcriptome	   studies	   on	   large	   cohorts	   of	   primary	   T-­‐ALL	  
samples	  (3-­‐5).	  Activation	  of	  NOTCH	  signaling	  has	  been	  recognized	  as	  an	  oncogenic	  hallmark	  
of	  T-­‐ALL	  driven	  by	  activating	  NOTCH1	  mutations	  (6)	  and	  loss-­‐of-­‐function	  mutations	  targeting	  
the	  E3-­‐ubiquitin	  ligase	  FBXW7	  (7,	  8).	  Furthermore,	  a	  plethora	  of	  additional	  mechanisms	  of	  T-­‐
cell	  transformation	  have	  been	  elucidated	  involving	  an	  increasing	  number	  of	  T-­‐ALL	  oncogenes	  
and	  tumor	  suppressors	  (9).	  
	  
Recent	  sequencing	  studies	  have	  identified	  the	  core	  components	  EZH2,	  EED	  and	  SUZ12	  of	  the	  
PRC2	   complex,	   which	   mediates	   gene	   silencing	   through	   tri-­‐methylation	   of	   H3K27	   (10),	   as	  
tumor	  suppressors	   in	  the	  pathogenesis	  of	  T-­‐ALL	  (9,	  11,	  12).	  Moreover,	  conditional	  ablation	  
of	   Ezh2	   in	   mouse	   hematopoietic	   stem	   cells	   was	   shown	   to	   be	   sufficient	   for	   murine	   T-­‐ALL	  
development	   (12).	   The	   histone	   demethylase	   Ubiquitously	   Transcribed	   X	   Chromosome	  
Tetratricopeptide	  Repeat	  Protein	  (UTX)	  counters	  the	  enzymatic	  activity	  of	  PRC2	  by	  removing	  
di-­‐	   and	   trimethyl	   groups	   from	  H3K27	   (13,	   14).	   In	  2009,	   somatic	   loss-­‐of-­‐function	  mutations	  
targeting	   the	   UTX	   gene	   were	   identified	   in	   a	   variety	   of	   human	   tumors	   including	   multiple	  
myeloma,	   esophageal	   and	   renal	   cancer	   (15).	   In	   that	   study,	   re-­‐expression	   of	   UTX	   in	   UTX	  
mutant	   cancer	   cell	   lines	  was	   associated	  with	   lower	   H3K27me3	   levels	   at	   the	   promoters	   of	  
Polycomb	  target	  genes	  and	  concomitant	   inhibition	  of	  cell	  proliferation.	  Recently,	  a	  general	  
role	   for	   UTX	   as	   tumor	   suppressor	   in	   human	   cancer	   was	   further	   supported	   by	   the	  
identification	  of	   recurrent	   inactivating	  UTX	  mutations	   in	   several	   leukemia	   and	   solid	   tumor	  
cancer	  types	  (15-­‐17).	  
	  
In	   this	   report,	  we	   report	   the	   identification	   of	   somatic	   loss-­‐of-­‐function	  mutations	   targeting	  
the	  histone	  demethylase	  UTX	  in	  human	  T-­‐ALL	  and	  provide	  in	  vitro	  and	  in	  vivo	  evidence	  for	  its	  
tumor	  suppressor	  function.	  Notably,	  our	  study	  unravels	  that,	  despite	  their	  putative	  opposite	  
effects	  on	  H3K27me3	  levels,	  both	  the	  PRC2	  complex	  as	  well	  as	  the	  histone	  demethylase	  UTX	  
can	  serve	  as	  bona	  fide	  tumor	  suppressors	  in	  the	  molecular	  pathogenesis	  of	  T-­‐ALL.	  Finally,	  we	  
show	   that	   UTX	   mutant	   leukemias	   are	   more	   sensitive	   to	   treatment	   with	   an	   H3K27me3	  
inhibitor	  providing	  new	  opportunities	  for	  epigenetically	  targeted	  therapy	  in	  T-­‐ALL.	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RESULTS	  
	  
Mutations	  recurrently	  target	  the	  H3K27me3	  demethylase	  UTX	  in	  male	  T-­‐ALL	  patients	  
	  
To	   identify	   a	   potential	   role	   for	   the	   H3K27me3	   demethylase	   UTX	   in	   the	   molecular	  
pathogenesis	  of	  T-­‐ALL,	  we	  performed	  sequencing	  and	  copy	  number	  analysis	  in	  a	  series	  of	  35	  
primary	  leukemia	  samples	  (10	  female	  versus	  25	  male),	  including	  25	  pediatric	  and	  10	  adult	  T-­‐
ALL	  cases.	  We	  identified	  loss-­‐of-­‐function	  mutations	  in	  UTX	  in	  5	  out	  of	  35	  (14.3%)	  primary	  T-­‐
ALL	  patient	  samples	  (Fig.	  1A,	  Supplementary	  Table	  S1)	  including	  3	  frameshift	  and	  2	  in-­‐frame	  
insertion/deletion	  mutations.	  UTX	  mutations	  were	   localized	   in	  a	  hotspot	   region	  within	   the	  
catalytic	   Jumonji	   C	   (JmjC)	   domain	   of	   the	   protein	   (Fig.	   1B)	   and	   sequencing	   of	   available	  
remission	  material	   confirmed	   the	   somatic	  origin	  of	   these	  mutations	   (Fig.	   1A).	   The	   somatic	  
UTX	  mutations	   in	  our	  patient	  population	  were	  exclusively	   identified	   in	   samples	   from	  male	  
origin.	  
	  
Equal	   dosage	   of	   chromosome	   X	   genes	   between	   male	   and	   female	   cells	   is	   regulated	   by	  
random	   inactivation	  of	  one	   copy	  of	   the	  X	   chromosome	   in	   female	   cells.	  However,	  previous	  
studies	   have	   shown	   that	   some	   genes,	   including	   UTX	   (18),	   can	   escape	   chromosome	   X	  
inactivation	  in	  certain	  tissues.	  Notably,	  we	  analyzed	  two	  silent	  SNPs,	  rs181547731	  situated	  in	  
the	   3’	  UTR	   and	   rs20539	   situated	   in	   exon	   20	   of	  UTX,	   in	   lymphoblasts	   from	  3	   female	   T-­‐ALL	  
patients	  and	  confirmed	  bi-­‐allelic	  expression	  of	  UTX	  in	  female	  T-­‐ALL	  lymphoblasts	  (Fig.	  1C).	  
	  
In	  T-­‐ALL,	  a	  wide	  variety	  of	  oncogenic	   lesions	  cooperate	  to	   induce	  T-­‐cell	   transformation.	  To	  
identify	  genetic	  lesions	  that	  co-­‐occur	  with	  loss	  of	  UTX	  in	  T-­‐ALL,	  we	  classified	  our	  cohort	  into	  
the	  known	  molecular	  genetic	  subgroups	  based	  upon	  the	  aberrant	  expression	  of	  transcription	  
factor	   oncogenes	   (3-­‐5)	   (Fig.	   1D).	   Furthermore,	   we	   screened	   our	   patient	   population	   for	  
alterations	   targeting	   T-­‐ALL	   specific	   oncogenes	   and	   tumor	   suppressors	   (Fig.	   1D,	  
Supplementary	   Fig.	   S1).	   This	   analysis	   showed	   that	  UTX	   mutations	   co-­‐occur	   with	   aberrant	  
expression	  of	  the	  TLX3	  oncogene,	  activating	  NOTCH1	  mutations,	  and	  mutations	  or	  deletions	  
targeting	  the	  putative	  chromatin	  remodeling	  factors	  PHF6	  or	  SUZ12	  (Fig.	  1D).	  
	  
Oncogenic	  advantage	  for	  Utx	  knockdown	  in	  murine	  T-­‐ALL	  
	  
To	   functionally	   validate	   the	   role	   of	   Utx	   as	   a	   putative	   tumor	   suppressor	   in	   the	   context	   of	  
malignant	  T-­‐cell	   transformation,	  we	  used	   the	   interleukin	   (IL2/IL7)	  dependent	  murine	  T-­‐ALL	  
cell	   line	   MOHITO	   (19).	   We	   transduced	   MOHITO	   cells	   with	   Utx	   and	   Suz12	   shRNAs	  
(Supplementary	   Fig.	   S2A-­‐B)	   and	   an	   empty	   vector	   control	   and	   examined	   GFP	   enrichment	  
after	  successive	  rounds	  of	  interleukin	  depletion	  as	  an	  indicator	  of	  tumor	  promoting	  activity	  
(Supplementary	  Fig.	  S2C).	  Notably,	  murine	  tumor	  cells	  infected	  with	  functional	  Utx	  shRNA#1,	  
Utx	   shRNA#3	   and	   Suz12	   shRNA#3	   showed	   significant	   GFP	   enrichment	   over	  MOHITO	   cells	  
infected	  with	   the	  non-­‐functional	  Utx	   shRNA#2	  or	  an	  empty	  vector	   control	   (Supplementary	  
Fig.	  S2D-­‐E).	  
	  
Next,	  we	  used	  a	  bone	  marrow	  transplant	  mouse	  model	  of	  NOTCH1-­‐induced	  T-­‐ALL	  (20)	  (Fig.	  
2A)	  to	  study	  the	   in	  vivo	   role	  of	  Utx	   in	  the	  pathogenesis	  of	  T-­‐ALL.	  Leukemic	  onset	   in	  mouse	  
recipients	   receiving	   fetal	   liver	   cells	  with	   enforced	  NOTCH1	  expression	   occurred	   around	   55	  
days	   (n=14,	   mean	   latency	   =	   54	   days)	   (Fig.	   2B).	   Co-­‐introduction	   of	   Utx	   shRNA#1	   caused	   a	  
strong	   acceleration	   in	   leukemic	   onset	   (n=7,	   p<0.0001,	   mean	   latency	   =	   29	   days),	   whereas	  
introduction	  of	  Utx	  shRNA#3	  provided	  a	  milder	  effect	  on	  T-­‐ALL	   latency	  (n=4,	  p=0.02,	  mean	  
latency	   =	   43.5	   days;	   Fig.	   2B).	   Similarly,	   infection	   of	   fetal	   liver	   cells	   with	   Suz12	   shRNA#3	  
resulted	  in	  an	  augmentation	  of	  T-­‐ALL	  onset	  (n=9,	  p=0.0002,	  mean	  latency	  =	  41	  days,	  Fig.	  2B)	  
	  	   90	  
confirming	  the	  previously	  established	   in	  vivo	  tumor	  suppressor	  role	  of	  the	  PRC2	  complex	  in	  
T-­‐ALL	  (9,	  11,	  12).	  	  
	  
In	  all	  murine	  tumors,	  histological	  analysis	  revealed	  aggressive	  leukemia	  phenotypes	  marked	  
by	   absence	   of	   apoptosis,	   high	   proliferation	   and	   infiltration	   of	   lymphoblasts	   in	   different	  
organs	   (Supplementary	   Fig.	   S3A).	   In	   addition,	   evaluation	   of	   Utx	   and	   Suz12	   knockdown	  
confirmed	  the	  validity	  of	  the	  shRNAs	   in	  vivo	   (Fig.	  2C	  and	  Supplementary	  Fig.	  S3B).	  Notably,	  
immunohistochemistry	   revealed	   a	   marked	   decrease	   in	   H3K27me3	   levels	   in	   lymphoblasts	  
from	  Suz12	  driven	  tumors	  as	  compared	  to	  NOTCH1	  driven	  control	   tumors,	   in	   line	  with	   the	  
role	   of	   the	   PRC2	   complex	   in	   H3K27	   methylation	   (Fig.	   2D).	   In	   contrast,	   H3K27me3	   levels	  
between	   Utx	   driven	   and	   control	   murine	   T-­‐cell	   tumors	   were	   largely	   comparable	   (Fig.	   2D).	  
Hence,	  our	  in	  vivo	  data	  surprisingly	  shows	  that	  loss	  of	  the	  H3K27	  demethylase	  Utx	  promotes	  
T-­‐ALL	   development	   in	   the	   same	  manner	   as	   loss	   of	   the	   H3K27	  methyltransferase	   complex	  
member	  Suz12.	  
	  
Finally,	   immunophenotypic	   characterization	  of	  mouse	   leukemias	   indicated	  an	  earlier	   T-­‐cell	  
maturation	  arrest	  for	  tumors	  driven	  by	  loss	  of	  Utx	  or	  Suz12	  as	  compared	  to	  NOTCH1	  control	  
tumors	   (Fig.	   2E,	   Supplementary	   Table	   S2-­‐5).	   The	   NOTCH1	   only	   controls	   were	   typically	  
Cd4+Cd8+	  double	  positive,	  whereas	   tumor	  cells	  driven	  by	   loss	  of	  Suz12	  expressed	  Cd8	  with	  
mixed	  levels	  of	  Cd4.	  In	  contrast,	  immunophenotypic	  marker	  expression	  in	  Utx	  driven	  tumors	  
was	  more	  heterogeneous	   including	   cell	   populations	   that	   lacked	  both	  Cd8	  and	  Cd4	   surface	  
expression	  (Fig.	  2E,	  Supplementary	  Table	  S2-­‐5).	  
	  
Transcriptional	  programs	  driven	  by	  loss	  of	  Utx	  in	  murine	  T-­‐ALL	  models	  
	  
To	   gain	   more	   insight	   in	   the	   oncogenic	   mechanisms	   mediated	   by	   loss	   of	   the	   H3K27me3	  
demethylase	   Utx,	   we	   performed	   gene	   expression	   profiling	   of	   NOTCH	   control	   tumors	   and	  
mouse	  leukemias	  driven	  by	  loss	  of	  Utx.	  Supervised	  gene	  expression	  analysis	  (FC>1.5,	  p<0.05;	  
Fig.	   3A)	   showed	   that	   Utx	   deficient	   mouse	   tumors	   are	   associated	   with	   a	   specific	   gene	  
expression	  signature	  that	  is	  characterized	  by	  down	  regulation	  of	  the	  T-­‐ALL	  tumor	  suppressor	  
genes	   Ect2l	   (11)	   and	   Nf1	   (21)	   and	   activation	   of	   the	   T-­‐ALL	   oncogene	   Tal1	   (22)	   (Fig.	   3A).	  
Furthermore,	  Gene	   Set	   Enrichment	  Analysis	   (GSEA)	   (23)	   in	   these	  mouse	   tumors	   driven	   by	  
loss	  of	  Utx	  showed	  enrichment	  of	  gene	  sets	  linked	  to	  early	  T-­‐cell	  lymphocytes	  (24)	  (p<0.01;	  
Fig.	   3B;	   Supplementary	   Fig.	   S4A)	   and	   LYL1	   neighbouring	   genes	   in	   T-­‐ALL	   (3)	   (p=0.02;	  
Supplementary	  Fig.	  S4B),	  in	  line	  with	  the	  early	  immunophenotypic	  arrest	  observed	  in	  these	  
murine	  leukemias	  (Fig.	  2E).	  	  
	  
Next,	  we	  performed	  H3K27me3	  chromatin	   immunoprecipitation	  (ChIP)	  sequencing	  analysis	  
on	   murine	   tumor	   material,	   to	   evaluate	   if	   genes	   down	   regulated	   in	   Utx	   driven	   mouse	  
leukemias	   show	   differential	   H3K27me3	   levels	   at	   their	   respective	   promoters.	   Notably,	   this	  
analysis	   revealed	   accumulation	   of	   H3K27me3	   at	   promoter	   regions	   of	   some	   of	   these	  
transcripts,	   including	   genes	   with	   putative	   tumor	   suppressor	   activity	   like	   Pcgf2	   (25),	   Lzts2	  
(26),	  Dock4	  (27),	  Pura	  (28),	  Col2a1	  (29),	  Slc26a4	  (30)	  (Fig.	  3C,	  Supplementary	  Fig.	  S5).	  
	  
To	  further	  explore	  the	  relationship	  between	  the	  genetic	  program	  mediated	  by	  Utx	  in	  the	  in	  
vivo	   transplant	  model	   and	   the	   in	   vitro	  MOHITO	  model,	   we	   performed	   GSEA	   (23)	   of	   gene	  
expression	   signatures	   associated	   with	  Utx	   knockdown	   in	  MOHITO	   cells.	   Interestingly,	   this	  
analysis	  revealed	  a	  significant	  enrichment	  of	  genes	  down	  regulated	  upon	  loss	  of	  Utx	   in	  the	  
mouse	   leukemias	   in	   Utx	   deficient	   MOHITO	   cells	   (p=0.007;	   82	   of	   252	   probes	   in	   core	  
enrichment,	  Fig.	  3D).	  Notably,	  the	  Ect2l	  (11)	  tumor	  suppressor	  was	  amongst	  the	  top-­‐ranking	  
genes	  in	  the	  leading	  edge	  of	  the	  GSEA	  plot	  (Fig.	  3D).	  Therefore,	  consistent	  down	  regulation	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in	  both	  in	  vitro	  and	  in	  vivo	  Utx	  knockdown	  model	  systems	  suggests	  that	  Ect2l	  (11)	  might	  act	  
as	  an	  important	  target	  downstream	  of	  UTX	  in	  the	  biology	  of	  T-­‐ALL.	  	  
	  
Loss	  of	  Utx	  provides	  a	  selective	  pressure	  towards	  DZNep	  treatment	  
	  
As	  loss	  of	  UTX	  will	  affect	  the	  genome-­‐wide	  distribution	  of	  H3K27me3,	  we	  hypothesized	  that	  
decreased	   UTX	   levels	   would	   render	   leukemia	   cells	   more	   vulnerable	   to	   treatment	   with	   3-­‐
Deazaneplanocin	   A	   (DZNep),	   an	   epigenetic	   compound	   that	   specifically	   targets	   H3K27me3	  
(31).	  Treatment	  of	   three	  T-­‐ALL	  cell	   lines	  with	  DZNep	  demonstrated	  enhanced	  sensitivity	  of	  
the	  UTX	  mutant	  cell	  line	  PF-­‐382	  as	  compared	  to	  the	  PEER	  cell	  line	  and	  the	  EZH2	  mutant	  cell	  
line	  TALL-­‐1	   (Fig.	  4A-­‐D).	  Moreover,	  TALL-­‐1	  cells	  were	  strongly	   resistant	   to	  DZNep	  treatment	  
even	  at	  100	  μM	  presumably	  because	  of	  very	  low	  H3K27me3	  levels	  (Fig.	  4C-­‐D).	  As	  expected,	  
DZNep	   treatment	   of	   PF-­‐382	   and	   PEER	   resulted	   in	   decreased	   levels	   of	   H3K27me3	   (31)	   as	  
determined	  by	  western	  blot	   (Fig.	  4E).	   In	  parallel,	  we	  confirmed	  that	  MOHITO	  cells	   showed	  
enhanced	  sensitivity	  towards	  DZNep	  treatment	  upon	  Utx	  knockdown	  as	  compared	  to	  control	  
cells	  (Fig.	  4F).	  Notably,	  although	  control	  and	  Utx	  knockdown	  MOHITO	  cells	  show	  comparable	  
baseline	   levels	  of	  H3K27me3,	  DZNep	  treatment	   induced	  a	  stronger	  decrease	   in	  H3K27me3	  
expression	   in	   the	  Utx	   knockdown	   samples	   as	   compared	   to	   the	  empty	   vector	   controls	   (Fig.	  
4G).	  Hence,	  UTX	  deficient	  T-­‐ALL	  shows	  collateral	  sensitivity	  to	  H3K27me3	  inhibition.	  
	  
	   	  
	  	   92	  
DISCUSSION	  
	  
A	   role	   for	   UTX	   as	   tumor	   suppressor	   was	   initially	   postulated	   in	   several	   human	   tumors	  
including	  multiple	  myeloma,	  esophageal	  and	  renal	  cancer	   (15).	  Notably,	  UTX	  deletions	  and	  
mutations	  have	  also	  been	  identified	  in	  patients	  with	  the	  Kabuki	  syndrome,	  a	  rare	  congenital	  
anomaly	   syndrome	   (32).	   Interestingly,	   a	   2-­‐year	   old	   Kabuki	   patient	   developed	   pre-­‐B-­‐ALL	  
suggesting	   an	   increased	   susceptibility	   to	   cancer	   for	   patients	   carrying	   abnormalities	   in	  UTX	  
(33).	   In	   this	   study,	   we	   identified	   gender-­‐restricted	   somatic	   loss-­‐of-­‐function	   mutations	  
targeting	   the	   histone	  demethylase	  UTX	   in	  male	   T-­‐ALL	   patients	   and	  demonstrate	   its	   tumor	  
suppressor	   function.	   In	   contrast	   to	   other	   X-­‐linked	   tumor	   suppressor	   genes	   in	   T-­‐ALL	   (PHF6	  
(34)	   and	   RPL10	   (35)),	   UTX	   escapes	   chromosome	   X-­‐inactivation	   in	   female	   T-­‐ALL	   blasts,	  
suggesting	  that	  females	  are	  protected	  against	  single	  copy	  loss	  of	  one	  UTX	  allele.	  Therefore,	  
UTX	   is	   the	   first	   X-­‐linked	   tumor	   suppressor	   gene	   that	   might	   partially	   explain	   the	   skewed	  
gender	  distribution	  in	  T-­‐ALL	  towards	  males	  on	  a	  genetic	  level.	  
	  
The	  PRC2	  complex	  mediates	  H3K27	  methylation	  and	  therefore	  counteracts	  UTX	  activity.	  Tri-­‐
methylation	   of	   lysine	   27	   on	   histone	   3	   is	   a	   chromatin	   state	   that	   is	   usually	   associated	  with	  
transcriptional	  gene	  repression.	  Depending	  on	  the	  tissue-­‐type	  and	  cellular	  context,	  the	  PRC2	  
complex	   can	   function	   as	   an	   oncogene	   (for	   example	   in	   B-­‐cell	   lymphoma	   (36))	   or	   tumor	  
suppressor	   gene	   (for	   example	   in	   T-­‐ALL	   (9,	   11,	   12)).	   In	   addition,	  Ezh2	   loss	  was	   sufficient	   to	  
induce	  murine	  T-­‐ALL	  development	  further	  supporting	  a	  tumor	  suppressive	  activity	  for	  EZH2	  
in	  the	  context	  of	  T-­‐ALL	  (12).	  In	  agreement	  with	  these	  findings,	  we	  identified	  mutations	  and	  
deletions	  targeting	  SUZ12	  and	  EED	  in	  our	  T-­‐ALL	  patient	  cohort.	  Notably,	  in	  our	  patient	  series,	  
mutations	  or	  deletions	  in	  EZH2	  were	  absent.	  
	  
Given	   that	   both	   opposite	   H3K27me3	   modulators	   PRC2	   and	   UTX	   are	   targeted	   by	   loss-­‐of-­‐
function	  alterations	   in	  primary	  T-­‐ALL,	  we	  explored	   their	   tumor	   suppressor	  activity	  using	   in	  
vitro	  and	   in	  vivo	  perturbation	  model	  systems.	  First,	  Utx	  or	  Suz12	  knockdown	  both	  provided	  
murine	  leukemia	  cells	  with	  an	  oncogenic	  advantage	  after	  interleukin	  depletion	  using	  the	  IL2-­‐
IL7	   dependent	   MOHITO	   culture	   system	   (19).	   Second,	   loss	   of	   Suz12	   or	   Utx	   resulted	   in	  
significant	  acceleration	  of	  leukemia	  onset	  in	  a	  NOTCH1-­‐induced	  T-­‐ALL	  mouse	  model	  (20).	  For	  
the	   first	   time,	   these	   functional	   in	   vitro	   and	   in	   vivo	  data	   firmly	  establish	  Utx	   as	  a	  bona	   fide	  
tumor	  suppressor	  involved	  in	  murine	  T-­‐cell	  transformation.	  
	  
The	  PRC2	  complex	  and	  UTX	  have	  opposing	  roles	  on	  cellular	  H3K27me3	  levels	  but	  both	  act	  as	  
bona	  fide	  tumor	  suppressors	  in	  T-­‐ALL.	  Therefore,	  these	  epigenetic	  regulators	  most	  probably	  
exert	   different	   biological	   roles	   in	   T-­‐cell	   transformation	   and	   do	   not	   simply	   represent	  
enzymatically	   opposing	   elements.	   In	   addition,	   differences	   in	   tumor	   immunophenotype	  
between	  mouse	  leukemias	  driven	  by	  loss	  of	  Utx	  or	  Suz12	  suggest	  that	  the	  tumor	  suppressor	  
activity	   of	   these	   H3K27me3	   regulators	   could	   depend	   on	   the	   maturation	   arrest	   or	   cell	   of	  
origin	  during	  murine	  T-­‐cell	  transformation.	  
	  
Transcriptional	   profiling	   of	   the	   in	   vivo	   transplant	  model	   revealed	   that	   loss	   of	  Utx	   drives	   a	  
unique	   gene	   expression	   signature	   in	   NOTCH1	   driven	   mouse	   leukemias.	   Notably,	   an	  
important	   part	   of	   this	   gene	   expression	   profile	  most	   likely	   reflects	   the	   immunophenotypic	  
differences	  observed	  between	  control	  and	  Utx	  deficient	  tumors.	  However,	  ChIP	  seq	  analysis	  
confirmed	  that	  some	  of	  the	  transcriptional	  differences	  are	  associated	  with	  accumulation	  of	  
H3K27me3	   at	   the	   promoter	   regions	   and	   therefore	   most	   probably	   reflect	   direct	  
consequences	  of	  loss	  of	  Utx	  during	  malignant	  T-­‐cell	  transformation.	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Epigenetic	  drugs	  are	  currently	  developed	  and	  evaluated	  in	  different	  cancer	  subtypes.	  Since	  
we	   identified	  UTX	  as	  a	  bona	   fide	   tumor	   suppressor	  gene	   in	   the	  pathogenesis	  of	  T-­‐ALL,	  we	  
hypothesized	   that	   loss	   of	   UTX	  would	   render	   leukemia	   cells	  more	   vulnerable	   to	   treatment	  
with	   particular	   chromatin	   modifying	   drugs.	   As	   loss	   of	   UTX	   is	   associated	   with	   enhanced	  
H3K27me3	   levels,	   we	   explored	   the	   effect	   of	   DZNep,	   an	   epigenetic	   compound	   that	  
specifically	  targets	  the	  H3K27me3	  mark.	  Previous	  studies	  reported	  a	  strong	  apoptotic	  effect	  
after	   DZNep	   administration	   in	   cancer	   cells	   whereas	   normal	   cells	   were	   not	   affected	   (31).	  
Importantly,	   in	   our	   study,	   we	   showed	   in	   both	   murine	   and	   human	   in	   vitro	   T-­‐ALL	   model	  
systems	   that	   loss	   of	   UTX/Utx	   renders	   the	   leukemic	   population	   more	   sensitive	   to	   DZNep	  
treatment.	   Importantly,	   such	   proof	   of	   principle	   data	   should	   be	   further	   validated	   in	   a	  
preclinical	   setting	   in	   which	   H3K27me3	   modifying	   agents	   are	   formally	   tested	   in	   well-­‐
characterized	  genetic	  animal	  models	  of	  T-­‐ALL.	  	  
	  
In	  conclusion,	  our	  results	  provide	  new	  insights	  into	  the	  pathogenesis	  and	  gender	  distribution	  
in	  T-­‐ALL.	  Furthermore,	  we	  identified	  UTX	  as	  an	  X-­‐linked	  tumor	  suppressor	  gene	  and	  showed	  
that	  Utx	  and	  Suz12	  both	  act	  as	  bona	  fide	  tumor	  suppressors	  in	  T-­‐ALL.	  All	  together,	  our	  study	  
reveals	   how	   maintaining	   and	   pharmacologically	   restoring	   the	   precise	   balance	   of	   H3K27	  
methylation	  can	  restrain	  T-­‐cell	  leukemia.	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METHODS	  
	  
Collection	  of	  T-­‐ALL	  patient	  samples	  
	  
A	   cohort	   of	   35	   bone	   marrow	   samples	   from	   primary	   T-­‐ALL	   patients	   was	   collected	   from	  
different	  medical	  institutes	  (UZ	  Ghent,	  Ghent,	  Belgium;	  UZ	  Leuven,	  Leuven,	  Belgium;	  Hôpital	  
Purpan,	  Toulouse,	  France).	  This	   study	  was	  approved	  by	   the	  Medical	  Ethical	  Commission	  of	  
Ghent	  University	   Hospital	   (Ghent,	   Belgium,	   B67020084745).	   DNA	   isolation	  was	   performed	  
using	  the	  QIAamp	  DNA	  Mini	  kit	  (Qiagen).	  	  
	  
Murine	  and	  human	  T-­‐ALL	  cell	  lines	  
	  
The	  MOHITO	  T-­‐ALL	  mouse	  cell	  line	  was	  cultured	  in	  RPMI-­‐1640	  supplemented	  with	  20%	  FCS,	  
glutamine	   (2	  mM),	  penicillin	   (100	  U/ml)-­‐streptomycin	   (100	  μg/ml),	   IL-­‐7	   (10	  ng/mL)	  and	   IL-­‐2	  
(5	  ng/ml)	  (Peprotech)(19).	  
Human	  T-­‐ALL	  cell	   lines	  PEER,	  TALL-­‐1	  and	  PF-­‐382	  were	  obtained	  from	  the	  DSMZ	  repository.	  
The	   cell	   lines	   were	   cultured	   in	   RPMI-­‐1640	   medium	   supplemented	   with	   10%	   or	   20%	   FCS,	  
glutamine	   (2	  mM),	   penicillin	   (100	  U/ml)	   and	   streptomycin	   (100	  μg/ml)	   under	   controlled	  
conditions	  (37°C,	  5%	  CO2).	  
	  
Sequencing	  analysis	  
	  
We	  sequenced	  all	   coding	  exons	  of	  PTEN,	  PHF6	   and	  UTX,	  and	  mutation	  hotspot	   regions	   for	  
NOTCH1	   and	  FBXW7	   in	  35	  T-­‐ALL	  patient	   samples	  by	  Sanger	   sequencing.	  Primer	   sequences	  
are	   noted	   in	   Table	   S6.	   The	   PCRx	   enhancer	   system	   (Invitrogen)	  was	   used	   for	  NOTCH1	   PCR	  
reactions.	   FBXW7,	   PTEN,	   PHF6	   and	  UTX	   amplification	  was	   performed	   using	   the	   KAPATaq	  
HotStart	  kit	   (KapaBiosystems).	  For	  all	   reactions,	   the	  following	  PCR	  protocol	  was	  used:	  95°C	  
for	  10	  min,	  (96°C	  for	  15	  sec,	  57°C	  for	  1	  min,	  then	  72°C	  for	  1	  min)	  for	  40	  cycles,	  then	  72°C	  for	  
10	  min.	  PCR	  products	  were	  purified	  and	  analyzed	  using	  the	  Applied	  Biosystems	  3730XL	  DNA	  
Analyzer.	  	  
MISEQ	  next-­‐generation	  sequencing	  of	  EZH2,	  SUZ12	  and	  EED	   in	  the	  35	  human	  T-­‐ALL	  patient	  
samples,	  Sanger	  sequencing	  of	  Utx,	  Ezh2,	  Suz12	  and	  Eed	  in	  the	  MOHITO	  cell	  line,	  and	  Sanger	  
sequencing	  of	  UTX,	  EZH2,	  SUZ12	  and	  EED	  on	  human	  T-­‐ALL	  cell	   lines	  was	  performed	  at	   the	  
Geoffrey	  Beene	  Translational	  Oncology	  Core	  Facility	  at	  MSKCC.	  
	  
Array	  Comparative	  Genomic	  Hybridization	  (array	  CGH)	  
	  
T-­‐ALL	   patient	   samples	   were	   profiled	   for	   copy	   number	   analysis	   on	   SurePrint	   G3	   Human	  
4x180K	  CGH	  Microarrays	  (Agilent	  Technologies).	  In	  brief,	  patient	  and	  control	  genomic	  DNAs	  
were	   labeled	   using	   random	   prime	   labeling	   with	   Cy3	   and	   Cy5	   dyes	   (Perkin	   Elmer),	  
respectively.	   Next,	   hybridization	   was	   performed	   according	   to	   the	   manufacturer’s	  
instructions	   (Agilent	  Technologies)	   followed	  by	  data-­‐analysis	  using	   the	   in-­‐house	  developed	  
analysis	  tool	  arrayCGHbase	  (37).	  
	  
SNP	  genotyping	  
	  
Genotyping	  and	  allelic	  expression	  analysis	  of	  SNPs	  rs181547731	  and	  rs20539	  located	  in	  the	  
3’	  UTR	  and	  exon	  20	  of	  UTX	   respectively	  was	  performed	   in	  both	  genomic	  DNA	   (gDNA)	  and	  
cDNA	  samples	  of	  3	  female	  T-­‐ALL	  patients.	  The	  standard	  PCR	  and	  sequencing	  protocols	  were	  
used	  as	  described	  above.	  Primer	  sequences	  are	  listed	  in	  Table	  S6.	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Real-­‐Time	  quantitative	  Polymerase	  Chain	  Reaction	  (qPCR)	  
	  
RNA	  isolation	  of	  human	  T-­‐ALL	  patient	  samples,	  normal	  T-­‐cell	  populations,	  MOHITO	  samples	  
and	   mouse	   leukemia	   samples	   were	   performed	   using	   the	   miRNeasy	   mini	   kit	   with	   DNA	  
digestion	   on-­‐column	   (Qiagen).	   Next,	   RNA	   concentration	   was	   measured	   on	   the	   NanoDrop	  
1000	   Spectrophotometer	   followed	   by	   RNA	   quality	   assessment	   using	   the	   Experion	  
Automated	   Electrophoresis	   System	   according	   to	   the	  manufacturer’s	   instructions	   (Bio-­‐rad).	  
After	   quality	   assessment,	   complementary	   DNA	   (cDNA)	   synthesis	  was	   performed	   using	   the	  
iScript	   cDNA	   Synthesis	   Kit	   (Bio-­‐rad)	   followed	   by	   qPCR	   analysis.	   The	   qPCR	   reaction	   was	  
performed	   using	   the	   LightCycler	   480	   (Roche)	   and	   qPCR	   data	   was	   analysed	   by	   the	   ΔΔCt	  
method	   using	   the	   in-­‐house	   developed	   qPCR	   analysis	   program	   qBasePlus	   (Biogazelle).	  
Primers	  used	   to	  measure	   the	  expression	  of	   the	   genes	  of	   interest	   and	   reference	   genes	   are	  
provided	  in	  Table	  S7.	  
	  
Interleukin	  depletion	  assay	  
	  
Short	   hairpin	   RNAs	   (shRNAs)	   were	   designed	   using	   the	   online	   program	   Designer	   of	   Small	  
Interfering	  RNA	   (DSIR)	   followed	  by	  cloning	   into	   the	   retroviral	  MLS	  vector	  backbone,	  which	  
also	  encodes	  for	  GFP	  co-­‐expression.	  Next,	  the	  interleukin	  (IL-­‐2/IL-­‐7)	  dependent	  MOHITO	  cell	  
line	  was	  transduced	  with	  shRNAs	  against	  Suz12	  and	  Utx,	  and	  GFP	  percentage	  was	  evaluated	  
using	  the	  GUAVA	  Flow	  Cytometer	  (Millipore).	  Subsequently,	  MOHITO	  cells	  were	  depleted	  of	  
IL-­‐2	   and	   IL-­‐7	  until	   less	   than	  10%	  of	   viable	   cells	  were	  detected	   followed	  by	   rescue	   through	  
supplementing	  IL-­‐2	  and	  IL-­‐7	  back	  in	  the	  media.	  After	  each	  round	  of	  interleukin	  depletion,	  the	  
GFP	  percentage	  was	  measured.	  The	  sequences	  of	  the	  shRNAs	  are	  listed	  in	  Table	  S8.	  
	  
T-­‐ALL	  mouse	  model	  
	  
Fetal	  liver	  cells	  were	  isolated	  at	  embryonic	  day	  13-­‐14	  followed	  by	  retroviral	  transduction	  of	  
shRNAs	   or	   empty	   control	   labeled	   with	   GFP	   (MLS	   backbone)	   and	   NOTCH1	   labeled	   with	  
mCherry	   (MIG	  backbone)	   (20).	  Next,	   the	   transduced	   fetal	   liver	   cells	  were	   tail	   vein	   injected	  
after	  lethal	  irradiation	  of	  mouse	  recipients.	  Subsequently,	  mouse	  recipients	  were	  monitored	  
for	   leukemia	   onset	   by	   analysis	   of	   lymphoblast	   counts	   in	   blood	   smears	   and	   by	   physical	  
appearance.	  By	  the	  time	  of	  leukemia	  formation,	  various	  tissues	  including	  spleen,	  lungs,	  liver,	  
kidney	   and	   lymph	   nodes	   were	   fixed	   for	   histological	   evaluation.	   Furthermore,	   the	  
lymphoblasts	  from	  spleen	  and	  thymus	  were	  mashed	  to	  single-­‐cell	  suspensions	  and	  frozen	  in	  
10%	   DMSO.	   Survival	   data	   was	   analyzed	   using	   the	   Kaplan-­‐Meier	   method	   and	   statistical	  
significance	  was	  calculated	  using	  the	  log-­‐rank	  (Mantel-­‐Cox)	  test.	  
	  
Immunophenotypic	  analysis	  
	  
Surface	   marker	   analysis	   of	   murine	   tumor	   cells	   was	   performed	   using	   a	   BD	   LSR	   II	   flow	  
cytometer	  with	  monoclonal	  antibodies	  CD3-­‐APC	  (BD	  Biosciences),	  CD8a-­‐PECY7	  (eBioscience)	  
and	   CD4-­‐biotin	   (Pharmingen).	   Data	   were	   analyzed	   with	   FACSDiva	   6.1.2	   software	   (BD	  
Biosciences)	  and	  compensations	  were	  set	  using	  OneComp	  eBeads	  (eBioscience).	  
	  
Histology	  
	  
Histological	  analysis	  including	  Hematoxylin	  &	  Eosin	  (H&E)	  staining,	  Ki67	  staining,	  H3K27me3	  
staining	  and	  Terminal	  deoxynucleotidyl	  transferase	  dUTP	  nick	  end	  labeling	  (TUNEL)	  assay	  of	  
the	  different	  mouse	  leukemias	  was	  performed	  at	  the	  Laboratory	  of	  Comparative	  Pathology	  
of	  MSKCC.	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Western	  Blotting	  
	  
Cells	  were	   lysed	  using	  a	   lysis	  buffer	  containing	  2%	  SDS,	  62.5	  mM	  Tris	  pH	  6.8,	  10%	  glycerol,	  
5%	   β-­‐mercaptoethanol,	   supplemented	  with	   EDTA	   free	   protease	   inhibitor	   cocktail	   (Roche).	  
Denaturated	   samples	   were	   loaded	   on	   10%	   or	   7.5%	   gels	   (1h15min,	   250V)	   (Bio-­‐rad)	   for	  
electrophoresis,	   followed	   by	   immunoblotting	   on	   PVDF	   membranes	   using	   a	   wet	   blotting	  
system	   (1h,	   250V)	   (Bio-­‐rad).	   Membranes	   were	   incubated	   with	   primary	   and	   secondary	  
antibody	   dilutions	   in	   5%	   milk/TBST	   solutions,	   developed	   using	   SuperSignal	   West	   Dura	  
Chemiluminescent	   Substrate	   (Pierce)	   and	   visualised	   on	   ChemiDoc-­‐It	   imaging	   system	   500	  
(UVP).	   Following	   antibodies	   were	   used:	   Utx	   (155	   kDa,	   A302-­‐374A,	   Bethyl	   Laboratories),	  
Suz12	  (83	  kDa,	  3737,	  Cell	  Signaling),	  H3K27me3	  (17	  kDa,	  9733,	  Cell	  Signaling),	  Ezh2	  (95-­‐100	  
kDA,	  612666,	  BD	  Biosciences),	  tubulin	  (50	  kDa,	  T5168,	  Sigma).	  
	  
Gene	  expression	  arrays	  
	  
From	  the	  mouse	  leukemia	  and	  MOHITO	  samples,	  RNA	  was	  isolated	  using	  the	  miRNeasy	  mini	  
kit	   with	   DNA	   digestion	   on-­‐column	   (Qiagen).	   RNA	   concentration	   was	   measured	   on	   the	  
NanoDrop	   1000	   Spectrophotometer	   followed	   by	   RNA	   quality	   assessment	   by	   use	   of	   the	  
Experion	   Automated	   Electrophoresis	   System	   according	   to	   the	   manufacturer’s	   instructions	  
(Bio-­‐rad).	   Next,	   RNA	   samples	   were	   profiled	   for	   gene	   expression	   analysis	   on	   SurePrint	   G3	  
Mouse	   8x60K	   Microarrays	   according	   to	   the	   manufacturer’s	   instructions	   (Agilent	  
Technologies).	  Normalisation	  of	   gene	   expression	  data	  was	   done	  by	   quantile	   normalisation	  
using	   R.	   Background	   correction	   was	   done	   based	   on	   the	   dark	   corner	   probe	   group	   of	   the	  
Agilent	   slides.	   Differential	   gene	   expression	   analysis	   was	   performed	   using	   fold	   change	  
analysis	   and	   p-­‐value	   calculation	   based	   on	   unpaired	   t-­‐test.	   Biased	   gene	   set	   enrichment	  
analysis	   (GSEA)	  was	   performed	  using	   a	   gene	   set	   consisting	   of	   differential	   probes	   between	  
the	  Utx	  sh#1	  and	  control	  murine	  leukemias,	  and	  evaluated	  against	  gene	  expression	  data	  of	  
the	  Utx	   deficient	  MOHITO	   samples.	  Unbiased	  GSEA	  was	   executed	   against	   annotated	   gene	  
sets	  of	  the	  Molecular	  Signatures	  Database	  (MSigDB).	  
	  
ChIP-­‐sequencing	  	  
	  
Lymphoblasts	   from	  murine	   leukemias	  were	  cross-­‐linked	   in	  1%	  formaldehyde	  for	  10	  min	  on	  
rotating	   platform	   in	   37°C	   oven.	   Next,	   2.5M	   of	   glycine	   (0.122M	   final	   concentration)	   was	  
added	   for	  5	  min	  at	  37°C	   to	  quench	   the	  cross-­‐linking	   reaction.	  The	  cells	  were	  subsequently	  
pelleted	  at	  4°C	  for	  5	  min	  at	  1750	  rpm	  followed	  by	  three	  washing	  steps	  in	  cold	  PBS.	  The	  final	  
pellet	   was	   stored	   at	   -­‐80°C.	   Following	   H3K27me3	   ChIP-­‐procedure	   was	   performed	   as	  
previously	   described	   (Beguelin	   et	   al.	   Cancer	   Cell	   2013)	   (38).	   H3K27me3	   ChIP-­‐seq	   libraries	  
were	  prepared	  using	  the	  Illumina	  ChIP-­‐Seq	  sample	  kits	  based	  on	  the	  manufacturer.	  Libraries	  
were	  validated	  using	  the	  Agilent	  Technologies	  2100	  Bioanalyzer	  and	  8-­‐10pM	  was	  sequenced	  
on	  HiSeq2000	  sequencer.	  The	  raw	  data	  were	  aligned	  to	  mm9	  genome	  using	  ELAND.	  Reads	  
were	   normalizing	   for	   total	   ChIP-­‐seq	   reads	   and	   quantified	   in	   1	   kb	   bins	   genome-­‐wide.	   The	  
enriched	   regions	   were	   identified	   as	   consecutive	   bins	   with	   read	   counts	   greater	   than	   1	  
standard	  deviation	  of	  the	  genome-­‐wide	  mean.	  
	  
Cell	  viability	  assay	  
	  
Murine	   and	   human	   T-­‐ALL	   cell	   lines	  were	   treated	  with	   3-­‐Deazaneplanocin	   A	   hydrochloride	  
(DZNep,	  Sigma)	  using	  a	  dilution	  series	   ranging	   from	  50	  nM	  to	  100	  μM.	  After	  24	  hours,	  cell	  
viability	  was	  measured	  using	  the	  luminescence	  detection	  kit	  CellTiter	  Glo	  Cell	  Viability	  Assay	  
(Promega).	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FIGURE	  LEGENDS	  
	  
Figure	  1.	  UTX	  mutations	  in	  human	  T-­‐ALL	  	  
A,	  DNA	  sequencing	  chromatogram	  showing	  a	  UTX	  mutation	  in	  the	  gDNA	  of	  a	  male	  primary	  T-­‐
ALL	   patient	   sample.	   The	  mutation	   is	   absent	   in	   remission	  material	   of	   the	   same	   patient.	  B,	  
graphical	   representation	  of	   the	   localization	  of	   genetic	   lesions	   in	   the	  UTX	  protein	   structure	  
(TPR	  =	  tetratricopeptide	  repeat,	  JmjC	  =	  Jumonji	  C).	  In-­‐frame	  deletion/insertion	  mutations	  are	  
depicted	   in	   orange	   circles,	   frameshift	   mutations	   in	   blue	   circles.	   C,	   genotyping	   and	   allelic	  
expression	   analysis	   of	   SNP	   rs181547731	   in	   gDNA	   and	   cDNA	   derived	   from	   female	   T-­‐ALL	  
lymphoblasts.	   D,	   graphical	   representation	   of	   the	   different	   mutations	   (depicted	   by	   dark	  
orange	  rectangles)	  and	  deletions	  (depicted	  by	  light	  orange	  rectangles)	  present	  in	  a	  set	  of	  T-­‐
ALL	   oncogenes	   and	   tumor	   suppressor	   genes	   in	   35	   primary	   T-­‐ALL	   patient	   samples.	   The	  
different	   T-­‐ALL	   subgroups	   include	   TAL-­‐LMO,	   TLX3,	   TLX1,	  HOXA	   and	   patients	   for	  which	   the	  
subgroup	  is	  unknown.	  The	  age	  subgroups	  include	  children	  (age	  ≤	  15	  years,	  depicted	  in	  dark	  
red	  rectangles)	  and	  adults	  (age	  >	  15	  years,	  depicted	  in	  light	  red	  rectangles).	  Male	  and	  female	  
T-­‐ALL	  patient	  samples	  are	  presented	  in	  dark	  blue	  and	  light	  blue	  rectangles,	  respectively.	  
	  
Figure	  2.	  Loss	  of	  Utx	  accelerates	  leukemia	  development	  in	  a	  NOTCH1-­‐induced	  T-­‐ALL	  mouse	  
model	  
A,	  graphical	  illustration	  of	  NOTCH1-­‐induced	  T-­‐ALL	  mouse	  model.	  Fetal	  liver	  cells	  are	  partially	  
transduced	  with	  vectors	  encoding	  NOTCH1	  (ICN)	  (co-­‐expressing	  mCherry)	  and	  the	  shRNA	  or	  
empty	  vector	  control	  (co-­‐expressing	  GFP)	  followed	  by	  tail	  vein	  injection	  in	  lethally	  irradiated	  
mouse	   recipients	   and	  monitoring	   of	   leukemia	   onset.	  B,	   Kaplan-­‐Meier	   curves	   and	   log-­‐rank	  
(mantel-­‐cox)	   analysis	   show	   accelerated	   leukemia	   onset	   in	  Utx	   sh#1	   (n=7,	   p<0.0001,	   blue),	  
Utx	   sh#3	   (n=4,	   p=0.02,	   green)	   and	   Suz12	   sh#3	   (n=9,	   p=0.0002,	   red)	  mice	   as	   compared	   to	  
empty	  vector	  (n=14,	  black)	  mouse	  recipients.	  C,	  western	  blot	  analysis	  of	  Utx	  and	  Suz12	  in	  a	  
representative	   Utx	   sh#1	   and	   Suz12	   sh#3	   mouse	   leukemia	   sample,	   respectively.	   Utx	   and	  
Suz12	  protein	   levels	  are	  quantified	  by	   Image	  J,	  normalized	  to	  tubulin	   levels,	  and	  compared	  
to	   expression	   levels	   in	   control	  mice.	  D,	   H3K27me3	   staining	   of	   the	   lymphoblasts	   on	   lymph	  
node	   tissue	   of	   a	   representative	   Utx	   sh#1,	   Suz12	   sh#3	   and	   empty	   vector	   control	   mouse	  
leukemia	  sample	  (20x	  magnification).	  E,	  immunophenotypical	  FACS	  analysis	  of	  Cd4	  and	  Cd8	  
T-­‐cell	   markers	   in	   the	   Utx,	   Suz12	   and	   empty	   vector	   control	   mouse	   leukemias.	   A	  
representative	  example	  of	  each	  subtype	  is	  depicted.	  	  
	  
Figure	  3.	  Gene	  networks	  regulated	  by	  Utx	  in	  T-­‐ALL	  
A,	   differentially	   expressed	   genes	   (FC>1.5;	   p<0.01)	   between	   Utx	   knockdown	   and	   control	  
murine	  leukemias	  are	  represented	  in	  a	  heat	  map.	  A	  selection	  of	  genes	  is	  shown	  in	  rows	  and	  
each	  column	  represents	  one	  individual	  mouse	  leukemia	  sample.	  The	  scale	  bar	  shows	  color-­‐
coded	  differential	  expression	  from	  the	  mean	  in	  standard	  deviation	  units	  with	  red	  indicating	  
higher	   levels	   and	   blue	   lower	   levels	   of	   expression.	   B,	   unbiased	   GSEA	   of	   gene	   expression	  
signatures	   associated	  with	  murine	   leukemias	  driven	  by	   loss	  of	  Utx	   or	  NOTCH1	  only	   vector	  
controls.	  Gene	  sets	   involving	  early	  T-­‐lymphocytes	   (p<0.01)	  are	  significantly	  enriched	   in	  Utx	  
driven	  leukemias.	  C,	  H3K27me3	  ChIP-­‐seq	  profiles	  at	  2	  specific	  gene	  loci	  (Lzts2	  and	  Pcgf2)	  in	  
murine	   leukemias	   driven	   by	   loss	   of	   Utx	   or	   NOTCH1	   only	   vector	   controls.	   D,	   GSEA	   of	  
transcripts	  significantly	  down	  regulated	  upon	  Utx	  knockdown	  in	  murine	   leukemias	  (FC>1.5,	  
p<0.05,	  252	  probes)	  in	  gene	  expression	  signatures	  obtained	  from	  MOHITO	  samples	  driven	  by	  
loss	  of	  Utx.	  Heatmap	  displays	  the	  TOP25	  leading	  edge	  of	  this	  gene	  set	  in	  Utx	  driven	  MOHITO	  
samples.	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Figure	  4.	  Human	  cell	  lines	  are	  more	  sensitive	  for	  H3K27me3	  inhibition	  	  
A,	  genomic	  DNA	  sequencing	  chromatograms	  representing	  2	  missense	  mutations	  in	  the	  EZH2	  
gene	  detected	  in	  the	  T-­‐ALL	  cell	  line	  TALL-­‐1.	  B,	  DNA	  sequencing	  chromatogram	  representing	  a	  
nonsense	  mutation	  in	  the	  UTX	  gene	  detected	  in	  the	  human	  T-­‐ALL	  cell	  line	  PF-­‐382.	  C,	  western	  
blot	  analysis	  of	  EZH2,	  H3K27me3	  and	   tubulin	   in	   the	  human	  T-­‐ALL	   cell	   lines	  PF-­‐382,	  TALL-­‐1	  
and	   PEER.	   Ezh2	   protein	   and	   H3K27me3	   levels	   are	   quantified	   by	   Image	   J,	   normalized	   to	  
tubulin	   levels.	   D,	   luminescence-­‐based	   viability	   assay	   after	   24	   hours	   (24h)	   of	   DZNep	  
administration	  in	  3	  different	  T-­‐ALL	  cell	  lines	  (TALL-­‐1:	  black,	  PEER:	  red,	  PF-­‐382:	  green)	  using	  a	  
range	   of	   DZNep	   concentrations	   from	   0	   to	   100μM.	   The	   experiment	   was	   done	   using	   6	  
replicates,	  and	  repeated	  two	  times	  independently.	  The	  viability	  score	  for	  each	  concentration	  
was	  significantly	  different	  between	  the	  3	  T-­‐ALL	  cell	  lines	  (*Kruskal-­‐Wallis	  test,	  p<0.0001).	  E,	  
western	  blot	  analysis	  of	  H3K27me3	  and	  tubulin	  24h	  after	  DZNep	  administration	  (1000nM	  &	  
500nM)	   in	   2	   different	   T-­‐ALL	   cell	   lines	   (PEER:	   red,	   PF-­‐382:	   green).	   H3K27me3	   levels	   are	  
quantified	  by	  Image	  J,	  normalized	  to	  tubulin	  levels.	  DZNep	  treated	  samples	  are	  compared	  to	  
expression	   levels	   in	   untreated	   samples.	   F,	   luminescence-­‐based	   viability	   assay	   after	   24h	   of	  
DZNep	   administration	   in	  Utx	   knockdown	   and	   control	  MOHITO	   samples	   (vector:	   black,	   Utx	  
sh#1:	  green).	  The	  experiment	  was	  done	  in	  fourfold	  (unpaired	  t-­‐test:	  *p<0.0001).	  G,	  western	  
blot	  analysis	  of	  H3K27me3	  and	  tubulin	  24h	  after	  DZNep	  administration	  (1000nM	  &	  500nM)	  
in	  Utx	  knockdown	  and	  control	  MOHITO	  samples	  (vector:	  black,	  Utx	  sh#1:	  green).	  H3K27me3	  
levels	   are	   quantified	   by	   Image	   J,	   normalized	   to	   tubulin	   levels.	   DZNep	   treated	   samples	   are	  
compared	  to	  expression	  levels	  in	  untreated	  samples.	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SUPPLEMENTARY	  FIGURE	  LEGENDS	  
	  
Figure	  S1.	  SUZ12	  mutation	  and	  deletion	  in	  primary	  T-­‐ALL	  patient	  samples	  
A,	  DNA	  sequencing	  chromatogram	  representing	  a	  SUZ12	  mutation	   in	  a	  male	  primary	  T-­‐ALL	  
patient.	   B,	   array	   CGH	   plot	   of	   leukemia	   DNA/control	   DNA	   ratios	   in	   a	   male	   primary	   T-­‐ALL	  
patient	   sample	   that	   harbors	   a	   deletion	   encompassing	   the	   SUZ12	   gene	   (deletion	   indicated	  
with	  red	  line).	  
	  
Figure	  S2.	  Knockdown	  of	  Utx	  augments	  the	  oncogenic	  activity	  in	  the	  murine	  T-­‐ALL	  cell	  line	  
MOHITO	  
A-­‐B,	  western	  blot	  analysis	  of	  GFP	  sorted	  MOHITO	  knockdown	  samples	  containing	  3	  different	  
hairpins	   against	   Utx	   (A)	   and	   Suz12	   (B)	   compared	   to	   empty	   vector	   control.	   Blots	   were	  
incubated	  with	  antibodies	  against	  Utx,	  Suz12	  and	  tubulin.	  Expression	  levels	  were	  normalized	  
to	   tubulin	   levels	   and	   compared	   to	   the	   vector	   control.	   C,	   graphical	   illustration	   of	   the	  
interleukin	   depletion	   assay	   in	   the	   IL2-­‐IL7	   dependent	  MOHITO	   cell	   line.	   MOHITO	   cells	   are	  
partially	   transduced	  with	   vectors	   encoding	   shRNA	   against	   Utx	   or	   Suz12	   and	   co-­‐expressing	  
GFP,	   after	   which	   the	   GFP	   percentage	   is	   measured	   by	   FACS	   analysis	   before	   and	   after	  
successive	  rounds	  of	  interleukin	  depletion.	  D,	  GFP	  percentage	  measured	  at	  Day	  0,	  and	  after	  
1st	   and	   2nd	   depletion	   rounds	   in	  Utx	   sh#1,	  Utx	   sh#2	   and	  Utx	   sh#3	   knockdown	   samples	   and	  
controls.	   The	   depletion	   assay	   was	   repeated	   twice.	   The	   GFP	   enrichment	   was	   statistically	  
significant	  after	  the	  1st	  depletion	  for	  Utx	  sh#1*	  and	  Utx	  sh#3**	  and	  after	  the	  2nd	  depletion	  
for	  Utx	  sh#1***	  compared	  to	  empty	  vector	  control	  respectively	  (unpaired	  t-­‐test:	  *p=0.005,	  
**p=0.049,	  ***p=0.008).	  E,	  GFP	  percentage	  measured	  at	  Day	  0,	  and	  upon	  the	  1st,	  2nd	  and	  3th	  
depletion	   round	   in	   Suz12	   sh#3	  knockdown	   samples	  and	   controls.	   The	  depletion	  assay	  was	  
repeated	   twice.	   The	   GFP	   enrichment	   was	   statistically	   significant	   after	   the	   2nd	   and	   3th	  
depletion	   for	   Suz12	   sh#3	   compared	   to	   empty	   vector	   control	   respectively	   (unpaired	   t-­‐test:	  
*p=0.0438,	  **p=0.029).	  
	  
Figure	  S3.	  Aggressive	  leukemia	  phenotype	  in	  NOTCH1-­‐induced	  T-­‐ALL	  mouse	  model	  
A,	  representative	  images	  of	  H&E,	  TUNEL	  and	  Ki67	  stainings	  of	  T-­‐ALL	  lymphoblasts	  in	  spleen,	  
kidney,	   lung	   and	   liver	   of	   an	  Utx	   sh#1	  mouse	   leukemia	   (20x	  magnification).	   The	  pathologic	  
appearance	  of	  Utx	   sh#1	  driven	   leukemias,	   Suz12	   sh#3	  driven	   leukemias	   and	  empty	   vector	  
controls	   is	   identical	   (not	   shown).	   B,	   gene	   expression	   analysis	   of	   Utx	   and	   Suz12	   in	   a	  
representative	   Utx	   sh#1	   and	   Suz12	   sh#3	   mouse	   leukemia	   sample,	   respectively.	   The	  
expression	  levels	  are	  compared	  to	  levels	  in	  control	  mice.	  Vector:	  black,	  shRNA:	  green.	  
	  
Figure	  S4.	  Gene	  sets	  enriched	  in	  Utx	  knockdown	  driven	  murine	  leukemias	  
A-­‐B,	  unbiased	  GSEA	  of	  gene	  expression	  signatures	  associated	  with	  murine	  leukemias	  driven	  
by	   loss	   of	   Utx	   or	   NOTCH1	   only	   vector	   controls.	   Gene	   sets	   involving	   early	   T-­‐lymphocytes	  
(p<0.01)	   and	   LYL1	   neighbouring	   genes	   (p=0.02)	   in	   T-­‐AL	   are	   significantly	   enriched	   in	   Utx	  
driven	  leukemias.	  
	  
Figure	   S5.	   ChIP-­‐seq	   profiles	   of	   H3K27me3	   in	   Utx	   knockdown	   and	   vector	   control	  murine	  
leukemias	  
H3K27me3	   ChIP-­‐seq	   profiles	   at	   4	   specific	   gene	   loci	   (Dock4,	   Pura,	   Col2a1	   and	   Slc26a4)	   in	  
murine	  leukemias	  driven	  by	  loss	  of	  Utx	  or	  NOTCH1	  only	  vector	  controls.	  
	  	  
  
	  	   104	  
	  
	  
Figure 1
A
D
UTX
NOTCH1
FBXW7
PTEN
PHF6
SUZ12
EZH2
sex
EED
UTX c.3337ins(CTACC)
p.Val1113Leufs*8
MUT: C G T G T C C T A C C G T A WT: C G T G T C G T A
R         V        VR        V        L        P     
male
female
mutation
deletion
B in-frame deletion/insertion
frameshift mutation
age
adult
child
rs181547731
3’UTR UTX
gDNA cDNA
C T G G A C G G G A G A G
A
C T G G A C G G G A G A G
A
C
UTX
TL
X3
un
kn
ow
n
un
kn
ow
n
TL
X3
TL
X3
HO
XA
TL
X3
un
kn
ow
n
un
kn
ow
n
un
kn
ow
n
un
kn
ow
n
TA
L-
LM
O
TL
X3
TA
L-
LM
O
TA
L-
LM
O
TA
L-
LM
O
TA
L-
LM
O
TA
L-
LM
O
TL
X3
TL
X1
TA
L-
LM
O
TA
L-
LM
O
TL
X1
HO
XA
TL
X1
TA
L-
LM
O
TA
L-
LM
O
un
kn
ow
n
TA
L-
LM
O
TA
L-
LM
O
TA
L-
LM
O
TL
X1
HO
XA
un
kn
ow
n
HO
XA
diagnostic remission
TPR repeats JmjC domain
	  	   105	  
	  
	   	  
Figure 2
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Figure 3
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Figure S1
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Figure S2
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Figure S3
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Figure S4
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Figure S5
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SUPPLEMENTARY	  TABLES	  
	  
Table	  S1.	  UTX	  mutations	  in	  primary	  T-­‐ALL	  patient	  samples	  
UTX	  mutation	  (DNA)	   UTX	  mutation	  (protein)	   Remission	  
c.3337G>TCC	   p.Val1113SerfsX7	   Yes,	  mutation	  absent	  
c.3337ins(CTACC)	   p.Val1113LeufsX8	   Yes,	  mutation	  absent	  
c.3338ins(TGTGGGCCCG)	   p.Val1113Val,	  Ser1114TrpfsX40	  	   NA	  
c.[3331delC;3331_3332insTGGG]	   p.[Arg1111Trp;	  Arg1111_Val1112insGly]	   NA	  
c.[3337_3342delGTATCA;	  
3337_3343insTTGCGGCATCTGTTTCAA]	  
p.[Val1113_Ser1114del;Val1112_Ala1115	  
insLeuArgHisLeuPheGln]	  
NA	  
	  
Table	  S2.	  Immunophenotyping	  of	  Utx	  sh#1	  mice	  
Utx	  sh#1	   CD8	   CD4	   CD3	  
Utx	  sh#1_1	   52.7	   1.6	   3.5	  
Utx	  sh#1_2	   36.6	   30.5	   1.1	  
Utx	  sh#1_3	   99.6	   49.3	   6.5	  
Utx	  sh#1_4	   88.2	   66.8	   8.5	  
Utx	  sh#1_5	   42.1	   80.2	   28.3	  
mean	   63.8	   45.7	   9.6	  
sd	   28.3	   30.9	   10.8	  
	  
Table	  S3.	  Immunophenotyping	  of	  Utx	  sh#3	  mice	  
Utx	  sh#3	   CD8	   CD4	   CD3	  
Utx	  sh#3_1	   18.2	   17.5	   27	  
Utx	  sh#3_2	   67.3	   55.6	   17.5	  
Utx	  sh#3_3	   67.1	   58.1	   6.8	  
Utx	  sh#3_4	   99.9	   87.7	   38.7	  
mean	   63.1	   54.7	   22.5	  
sd	   33.7	   28.8	   13.6	  
	  
Table	  S4.	  Immunophenotyping	  of	  Suz12	  sh#3	  mice	  
Suz12	  sh#3	   CD8	   CD4	   CD3	  
Suz12	  sh#3_1	   99.9	   55.6	   9.2	  
Suz12	  sh#3_2	   99.9	   21.5	   3.7	  
Suz12	  sh#3_3	   98.5	   77	   5.2	  
Suz12	  sh#3_4	   100	   38.9	   9.7	  
Suz12	  sh#3_5	   99.8	   80.8	   6	  
Suz12	  sh#3_6	   100	   86.5	   5.4	  
Suz12	  sh#3_7	   99.8	   57.4	   7.4	  
mean	   99.7	   59.7	   6.7	  
sd	   0.5	   23.7	   2.2	  
	  
Table	  S5.	  Immunophenotyping	  of	  empty	  vector	  control	  mice	  
Control	   CD8	   CD4	   CD3	  
Control_1	   99.8	   75.2	   7.5	  
Control_2	   74.9	   15.9	   41.6	  
Control_3	   63	   8.4	   16.7	  
Control_4	   99.7	   99.7	   5.4	  
Control_5	   93.4	   100	   27.9	  
Control_6	   99.4	   93.2	   44.4	  
Control_7	   99.4	   88.3	   0.6	  
	  	   114	  
Control_8	   99.6	   57.2	   3.3	  
Control_9	   98.6	   93.5	   4.6	  
mean	   92.0	   70.2	   16.9	  
sd	   13.5	   35.6	   17.0	  
	  
Table	  S6.	  Primers	  used	  for	  Sanger	  sequencing	  and	  SNP	  analysis	  
Primer	  name	   Forward	  primer	  sequence	   Reverse	  primer	  sequence	  
NOTCH1	  exon	  26	   AGGAAGGCGGCCTGAGCGTGT	   AGAGTTGCGGGGATTGACCGT	  
NOTCH1	  exon	  27	   GTGGCGTCATGGGCCTCA	   GCACAAACAGCCAGCGTGT	  
NOTCH1	  exon	  28	   GATCGGTGTCATGTGAAGT	   TCCCGGTGAGGATGCTCGG	  
NOTCH1	  exon	  34a	  	   CTTCCTCTGGTGATGGAACCT	   CATCCCAGGCAGGTGGTTGA	  
NOTCH1	  exon	  34b	  	   GCCCTCCCCGTTCCAGCAGTCT	   GCCTGGCTCGGCTCTCCACTCA	  
NOTCH1	  exon	  34c	  	   AGCCGCACCTTGGCGTGAGC	   TGGTCGGCCCTGGCATCCAC	  
FBXW7	  exon	  7	   TTTATGCCTTCATTTTTCTCTT	   GGGGAAAAAAGCTAAGTTATG	  
FBXW7	  exon	  8	   TTTTCCAGTGTCTGAGAACAT	   CCCAAATTCACCAATAATAGA	  
FBXW7	  exon	  9	   TAAACGTGGGTTTTTTTGTT	   TCAGCAATTTGACAGTGATT	  
FBXW7	  exon	  10	   CCTGGCATTACCTGTTTC	   AGGCTCCATATTTCTCTTGA	  
FBXW7	  exon	  11	   GGACATGGGTTTCTAAATATGTA	   CTGCACCACTGAGAACAAG	  
PTEN	  exon	  1	   AGCTTCTGCCATCTCTCTC	   TTTCGCATCCGTCTACTC	  
PTEN	  exon	  2	   ACATTGACCACCTTTTATTACTC	   GGTAAGCCAAAAAATGATTATAG	  
PTEN	  exon	  3	   ATGGTGGCTTTTTGTTTGT	   GCTCTTGGACTTCTTGACTTA	  
PTEN	  exon	  4	   TCAGGCAATGTTTGTTAGTATT	   ATCGGGTTTAAGTTATACAACATA	  
PTEN	  exon	  5	   TTGTATGCAACATTTCTAAAGTT	   ATCTGTTTTCCAATAAATTCTCA	  
PTEN	  exon	  6	   ACGACCCAGTTACCATAGC	   TAGCCCAATGAGTTGAACA	  
PTEN	  exon	  7	   AATCGTTTTTGACAGTTTGAC	   TCACCAATGCCAGAGTAAG	  
PTEN	  exon	  8	   GATTGCCTTATAATAGTCTTTGTG	   TTTTTGACGCTGTGTACATT	  
PTEN	  exon	  9	   GCCTCTTAAAGATCATGTTTG	   GGTCCATTTTCAGTTTATTCA	  
PHF6	  exon	  2	   TTTCTTGGGGCTTAGAGTG	   AAATGGCATAGCATTAGTGA	  
PHF6	  exon	  3	   GCTATGCCATTTTTACTAGAAA	   GCTGGCTCAGAGAAAAAAAA	  
PHF6	  exon	  4	   CCCCAGAAGAATTTTATTCC	   CAAAAGCCCAAAGAAAGTAT	  
PHF6	  exon	  5	   AAAGGGTGTTTTTGATAAGA	   AAACGTGGCTAAATGATGTA	  
PHF6	  exon	  6	   GGGTGGCTTTATTGAACAT	   GCTATCGGTATTTCAAGCTTA	  
PHF6	  exon	  7	   TTGGATTCTTACTTTTGTTGC	   GGGGAAATTTTTTGGTTAC	  
PHF6	  exon	  8	   TTTTCCTGCATTTTTCTTCT	   GCAAATGCCTTGAAATGTAT	  
PHF6	  exon	  9	   GAGGGCTTATCAAAGTATGG	   AGGAAAATGCCAATTGTAGT	  
PHF6	  exon	  10	   AGCCTCATCCACTAATGTTG	   GAGTTGGGCAGTAAAAAGTT	  
UTX	  exon	  1	   ATGTGACCCTACAGCCGAAA	   ATCTCACGAACCCAAAGAGG	  
UTX	  exon	  2	   CTCGGTTTGGCGCTCTTC	   GAAAAGAGCGATTTCGCAAG	  
UTX	  exon	  3	   AATATTGACTTCTTAGGTGATCGAA	  	   TCTATATCAAACTGGGTCACTTTCT	  
UTX	  exon	  4	   TATCTACTGGGAGGTGGGTGTG	  	   CAGCCTTCTTTTACTCCCAGG	  
UTX	  exon	  5	   GTTGATTGGAATCTGTGCCA	  	   CCAAAAAGCTTTCTAATCTAAGCC	  
UTX	  exon	  6	   CATATGCCCCTTTTCAATTTT	  	   TGTTACCATGGAAGTCTTAGCA	  
UTX	  exon	  7	   GGCTAGTGTATTTTATTTGCATAGCAT	  	   CCAGCAAAACCTGTTTTTAATCC	  
UTX	  exon	  8	   GACAGAAATTTCATTTGATAATGACC	  	   GGAATTAATTTGTACACAGCAAGC	  
UTX	  exon	  9	   CAACTGTCTGATGTTAAAGAAACATTC	  	   GGGTTAAATACTAGGGAGTAATTTTGA	  
UTX	  exon	  10	   ATGGCCAGAATTGGCAGT	  	   GTCCTGCTAGACCAGATTATGCT	  
UTX	  exon	  11	   CAGCATGCTTTTTAGCACCT	  	   GGCTGATTTTGCTGCTGATA	  
UTX	  exon	  12	   CAGATACATGGTGTTCAATAGGG	  	   GGAAACAGATTATAGACATCAAAACA	  
UTX	  exon	  13	   GGTTTATATTCCGGTTACCCTGT	  	   AGGTTCTAAGTTGGTACCCCAAA	  
UTX	  exon	  14	   AATGTTGGATCTAGTGGACAGTG	  	   TTAATACTTGTTTGCTACCTCTACTCC	  
UTX	  exon	  15	   TGACCAGATAGTGGTTCTGAGTTT	  	   AGCCCTAAAAACCTTGCCTC	  
UTX	  exon	  16a	   CACACATTCCCTAATTATACATCTTCA	  	   AGTTGGTTTTTCCACGGCT	  
UTX	  exon	  16b	   GGCCAATGGACCCTTTTC	  	   CCACTGTAAATTAATGGTGCATTTT	  
UTX	  exon	  17a	   AGGACTTGGGTCAAATTATCTTATACA	  	   TCAACAAGGCAGAGAGCTGA	  
UTX	  exon	  17b	   TACCTCAGGTGGACAACAAGG	  	   GCAGATCTGTTTTCATGGGG	  
UTX	  exon	  17c	   AACTCTGTTGCCTCTTCACCA	  	   GGGCAGTAACAGCACAATCA	  
	  	   115	  
UTX	  exon	  18	   TGGACTTGTGCAAATGCCT	  	   GCTGCTCAAAATTAGGGCAAT	  
UTX	  exon	  19	   TCACCCCATAAAATGCGTTA	  	   CACAATTATGTAAACGGACCAAA	  
UTX	  exon	  20	   ATAGCTCAGGTTGTGCAGAGG	  	   GAGACAACTGGAGAACACTTACAAA	  
UTX	  exon	  21	   TTTTTCAGTTGTATGGTGGAAAG	  	   AATGACAATAAATGAAACAGAAGAGG	  
UTX	  exon	  22	   CCAGTTGTAGAACACTAAACTAGACTG	  	   ATGACAATAAATGAAACAGAAGAGG	  
UTX	  exon	  23	   TTTTGTTGGGAAGTTTTCTTTGG	  	   ATGAAAAGGGGAAAAATCTTAATCTG	  
UTX	  exon	  24	   TGAGCATTTGTAAGGTTTTGTTT	  	   CTTTTCTATCTTCTTAATTCATGGGT	  
UTX	  exon	  25	   ATATACATACAGCAGATCTTTTTGCAC	  	   TACTACGAATTACAATTCTATGCAAGG	  
UTX	  exon	  26	   GTTTTGAGGTTTTCAGAATTGATG	  	   TGGGAAAGAAGCACAGGTCT	  
UTX	  exon	  27	   TCAGGCCTGCTGAGCATT	  	   AATGGCTAAGCAACAAAATTGAA	  
UTX	  exon	  28	   AACCAGAGATCACTGTCCACAA	  	   CTCACCCAGGAAAACTGAAAA	  
UTX	  exon	  29	   AGCAGGCTGTTGAACTTTTTG	   AAGGGGGAAAAGACAGATGAA	  
3’UTR	  UTX	  SNP	   TTCTGCACCACTGGTTTTTG	   AGATGTTGCCAGTTTTGTCAGA	  
UTX	  exon	  20	  cDNA	   GTGATGCTTTCTTTCCTCCA	   CGATGTAGATTCACTATCTGAGTGG	  
	  
Table	  S7.	  Primers	  used	  for	  qPCR	  
Primer	  name	   Forward	  primer	  sequence	   Reverse	  primer	  sequence	  
Utx	  mouse	   ATCCCAGCTCAGCAGAAGTT	   GGAGGAAAGAAAGCATCACG	  
Suz12	  mouse	   AGGCTGCCTCCATTTGAGA	   TGGTTTCTCCTGTCCATCG	  
Gapdh	  mouse	   CGGAGTCAACGGATTTGGTCGTAT	   AGCCTTCTCCATGGTGGTGAAGAC	  
Tbp	  mouse	   CCCCACAACTCTTCCATTCT	   GCAGGAGTGATAGGGGTCAT	  
Ppia	  mouse	   CAGACGCCACTGTCGCTTT	   TGTCTTTGGAACTTTGTCTGCAA	  
Ubc	  mouse	   GCAGATCTTTGTGAAGACCC	   GAAGGTACGTCTGTCTTCCT	  
	  
Table	  S8.	  shRNA	  sequences	  
Primer	  name	   Sequence	  
Utx	  sh1	  mouse	   TTAAACTAGACTCATAGTCTG	  
Utx	  sh2	  mouse	   TAGGACTGCAAACAGCATCTG	  
Utx	  sh3	  mouse	   ATAACGTTCCACTGCTAACTT	  
Suz12	  sh1	  mouse	   TTGATTGAAACATCTATCCTA	  
Suz12	  sh2	  mouse	   TATTGGACAACTTACATCCTT	  
Suz12	  sh3	  mouse	   TTGAACTTGTAACACAACTGA	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2.	  MicroRNAs	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  
	  
	  
PAPER	  3	  
A	  cooperative	  microRNA	  –	  tumor	  suppressor	  gene	  network	  in	  acute	  T-­‐cell	  
lymphoblastic	  leukemia	  (T-­‐ALL)	  
	  
	  
PAPER	  4	  
MicroRNA-­‐193b-­‐3p	  acts	  as	  a	  tumor	  suppressor	  by	  targeting	  the	  MYB	  oncogene	  in	  
T-­‐cell	  acute	  lymphoblastic	  leukemia	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   119	  
PAPER	  3	  
	  
A	  cooperative	  microRNA	  –	  tumor	  suppressor	  gene	  network	  in	  acute	  T-­‐cell	  
lymphoblastic	  leukemia	  (T-­‐ALL)	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The importance of individual microRNAs (miRNAs) has been 
established in specific cancers. However, a comprehensive 
analysis of the contribution of miRNAs to the pathogenesis 
of any specific cancer is lacking. Here we show that in T-cell 
acute lymphoblastic leukemia (T-ALL), a small set of miRNAs 
is responsible for the cooperative suppression of several tumor 
suppressor genes. Cross-comparison of miRNA expression 
profiles in human T-ALL with the results of an unbiased miRNA 
library screen allowed us to identify five miRNAs (miR-19b, 
miR-20a, miR-26a, miR-92 and miR-223) that are capable of 
promoting T-ALL development in a mouse model and which 
account for the majority of miRNA expression in human 
T-ALL. Moreover, these miRNAs produce overlapping and 
cooperative effects on tumor suppressor genes implicated 
in the pathogenesis of T-ALL, including IKAROS (also known 
as IKZF1), PTEN, BIM, PHF6, NF1 and FBXW7. Thus, a 
comprehensive and unbiased analysis of miRNA action in T-ALL 
reveals a striking pattern of miRNA-tumor suppressor gene 
interactions in this cancer.
T-ALL arises as a consequence of several cooperating genetic lesions1. For 
example, most affected individuals harbor activating lesions of NOTCH1 
(ref. 2), and tumor suppressor genes including PTEN (ref. 3), NF1  
(ref. 4), PHF6 (ref. 5), PTPN2 (ref. 6), IKAROS (refs. 7–11) and FBXW7 
(refs. 12,13) are targets of inactivating somatic mutations or deletions 
in T-ALL. Individual miRNAs have also been implicated in T-ALL. For 
example, miR-19b is a member of the oncogenic miR-17-92 cluster, 
which is targeted by the t(13;14)(q32;q11) translocation in T-ALL14,15. 
miRNA expression analyses in various cancers indicate that only a few 
miRNAs are highly expressed in cancer cells, and that a pattern reminis-
cent of the tissue of origin is maintained16,17. How a set of abundantly 
expressed miRNAs acts in leukemogenesis is currently unclear.
The regulation of gene expression by miRNAs is complex. Many 
mRNAs contain 3` untranslated region (UTR) binding sites for multiple 
miRNAs, and likewise, most miRNAs can potentially target a large 
number of genes18. Clearly, not all predicted miRNA targets contribute 
to a phenotype, and in some instances, a coordinate effect on a cellular 
pathway has been shown. For example, miR-19b controls multiple regu-
lators of phosphatidylinositol-3-OH kinase (PI3K) signaling15, and 
miR-181a can adjust the sensitivity of T-cell receptor activation19. It is 
unclear whether a group of miRNAs can produce cooperative effects 
on genes, pathways and processes involved in tumor suppression.
To comprehensively assess miRNA action in T-ALL, we compared 
miRNA expression data with an unbiased miRNA library screen 
and computational analyses and tested candidates in a T-ALL model 
(Fig. 1a). First, we measured the expression of 430 miRNAs in 50 
clinical T-ALL specimens representing distinct cytogenetic groups1 
(MLL (n = 4), Calm-Af10 (n = 3), Inv(7) (n = 5), LMO2 (n = 7), SIL-
TAL (n = 8), TLX3 (n = 10), TLX1 (n = 5) and unknown (n = 8)) 
and 18 T-ALL cell lines by quantitative RT-PCR (qRT-PCR)20. Ten 
miRNAs were highly expressed, whereas others were less abundant. 
The ‘top-ten’ miRNAs were (in descending order) miR-223, miR-19b, 
miR-20a, miR-92, miR-142-3p, miR-150, miR-93, miR-26a, miR-16 
and miR-342 (Fig. 1b and Supplementary Table 1). In our series, 
hierarchical clustering and principal component analysis did not 
distinguish between the major cytogenetic groups (HOXA, TAL or 
LMO and TLX1 or TLX3), which differed in a few miRNAs (Fig. 1c, 
Supplementary Fig. 1 and Supplementary Table 2). Sequence ana-
lysis confirmed mutations in NOTCH1 (21/37 clinical specimens) and 
FBXW7 (9/37) (Supplementary Fig. 2 and Supplementary Table 3). 
Hierarchical clustering of the miRNA expression data recovered 
NOTCH1 mutational status but not FBXW7. In a pairwise compari-
son, miR-200b segregated with NOTCH1, whereas miR-100, miR-484 
and miR-589 segregated with FBXW7 status (Supplementary Fig. 3 
and Supplementary Table 4). The pattern of miRNA expression was 
preserved in human T-ALL cell lines (Supplementary Fig. 4a and 
Supplementary Table 5). Pairwise comparisons by NOTCH1, FBXW7, 
PTEN and PHF6 mutation status or sensitivity to gamma secretase 
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inhibition revealed differentially expressed miRNAs12 (Supplementary 
Table 6). Comparisons with purified progenitors (CD34+ and 
CD4+CD8+CD3−) and differentiated T-cells (CD4+CD8+CD3+ and 
CD4+ or CD8+) revealed leukemia-specific increases in miR-223, but 
less of an increase in miR-376 and miR-662 (Supplementary Fig. 4b,c 
and Supplementary Tables 7,8). Hence, a small number of miRNAs 
are highly expressed in T-ALL, and among them, miR-223 is most 
strongly upregulated in leukemia.
Next, we analyzed the 3` UTRs of twelve tumor suppressor genes 
(FBXW7, PTEN, PHF6, PTPN2, IKAROS (IKZF1), NF1, BIM, CDK8, 
CYCLINC, NLK, RB and P53) implicated in T-ALL for miRNA bind-
ing sites21,22. As expected, many miRNAs are predicted to bind these 
genes, and we generated a rank order by calculating a cumulative 
context score (Table 1 and Supplementary Table 9a) or by adding the 
number of conserved 7- and 8-mer sites (Supplementary Table 9b), 
in both cases restricting the calculations to broadly conserved miRNA 
seed families. Notably, five of the ten most highly expressed miR-
NAs ranked highest in this analysis: miR-19b, miR-20a/93, miR-26a, 
miR-92 and miR-223. This enrichment was significant compared to 
random sets of 10,000 genes of the same size (P < 0.043, empirical 
P value). Hence, highly expressed miRNAs in T-ALL preferentially 
target tumor suppressor genes.
In parallel, we conducted an unbiased miRNA library screen for 
potentially oncogenic miRNAs (oncomirs). We used a two-step, sibling- 
selection protocol and first screened for bypass of c-MYC–induced 
apoptosis23 and second for cytokine independence in lymphocytes15 
(Fig. 2a). c-MYC is a key effector of NOTCH1 in T-ALL24–26. We 
collected the surviving cells from the primary screen and identi-
fied the miRNAs, which included the highly expressed miR-25/92, 
miR-19b and miR-223 (Fig. 2b and Supplementary Table 10). To 
generate a secondary library, we sub-cloned all miRNAs from the 
primary screen and partially transduced FL5-12 lymphocytes with 
the pooled vectors expressing individual miRNAs along with the GFP 
reporter. Upon enrichment of miRNA and GFP expressing cells, we 
identified the most abundant miRNAs by sequence analysis (Fig. 2c 
and Supplementary Table 11). Ultimately, retesting confirmed 
in vitro protection for miR-148a/152, miR-22, miR-19b, miR-101, 
miR-25/92 and miR-20a/106 (the pairs miR-148/152, miR-20/106 
and miR-25/92 have identical seed sequences) (Fig. 2d).
To summarize the interim results, we found ten miRNAs that 
account for most detectable miRNAs in human T-ALL cells, five of 
which are predicted to target tumor suppressor genes implicated in 
T-ALL and readily emerge from an unbiased screen for oncogenic 
activities (Fig. 2e). Hence, using complementary approaches, we iden-
tified several candidate oncomirs in T-ALL.
Next, we directly tested candidate oncomirs in a mouse model of 
NOTCH1-induced T-ALL. Briefly, we transduced hematopoietic pro-
genitors (HPCs) with NOTCH1 and either empty vector or miRNA, 
transplanted the HPCs into lethally irradiated recipients and moni-
tored the animals for leukemia15 (Fig. 3a). As expected, miR-19b 
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Figure 1 Comprehensive study of oncogenic miRNAs in T-ALL. (a) Schematic of the experimental strategy. (b) Average miRNA expression across 50  
T-ALL samples by quantitative RT-PCR and normalized to the mean expression value of all expressed miRNAs in a given sample (mean and s.d.); 
miRNAs are ordered by expression levels, and the ‘top-ten’ most abundantly expressed miRNAs are indicated. (c) miRNA expression in different 
cytogenetic subgroups of T-ALL (mean and s.d.; ordered numerically, and the most abundant miRNAs are indicated).
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accelerated leukemia development (n = 7, P < 0.01) compared to vector 
(n = 13)15. miR-20a (n = 4, P < 0.001), miR-26a (n = 5, P < 0.001), miR-92 
(n = 5, P = 0.02) and miR-223 (n = 7, P < 0.01) similarly produced 
leukemia within 75 days; at this time >80% of vector or miR-30 con-
trols (n = 5, P = 0.15) were disease free (Fig. 3b). Some less abundant 
miRNAs also enhanced leukemogenesis. Specifically, miR-148 (n = 7, 
P < 0.01) and miR-27 (n = 5, P = 0.05) were leukemogenic, whereas 
miR-23 (n = 5, P > 0.05) and miR-24 (n = 5, P > 0.05) showed no effect 
(Supplementary Fig. 5a). In all cases, pathology revealed CD4-CD8 
double positive T-ALL (Supplementary Fig. 5b and Supplementary 
Table 12), high proliferation (Ki67 stain), absence of apoptosis by 
TUNEL and widespread organ infiltration that included the lungs 
and brain (Fig. 3c). miRNAs were twofold and sixfold increased in 
miRNA-expressing leukemia compared to controls, and twofold and 
25-fold increased compared to normal thymocytes (Supplementary 
Fig. 5c,d). Thus, the abundantly expressed miR-19b, miR-20a, 
miR-26a, miR-92 and miR-223 act as oncomirs in vivo.
These experimentally validated oncomirs were significantly enriched 
among the highest-ranking miRNAs in our computational analysis of 
target genes (empirical P < 1 × 10−4 for number of seeds or context 
scores) (Table 1 and Supplementary Table 9). We used an unbiased 
machine learning approach based on lasso regression to identify the 
targets that discriminate between oncomirs and random miRNAs. 
Accounting for the small number of positive training examples, we 
performed a stability analysis by repeating the learning procedure 50 
times with different sets. Among the top 15 most frequently included 
target genes, we found FBXW7 (identified in 46/50 runs), BIM (in 
21/50 runs) and PTEN (in 11/50 runs) (Supplementary Table 13).
We experimentally tested these target predictions in mouse leuke-
mic cells using reporter assays (Fig. 4a and Supplementary Fig. 6), 
qRT-PCR (Fig. 4b) and immunoblots (Fig. 4c–g). Briefly, miR-19b 
regulates Pten expression15 (Supplementary Fig. 7a). miR-20a and 
miR-26a reduce levels of Pten and Phf6, and miR-20a has similar 
effects on Bim. Ikzf1, Nf1 and Fbxw7 are regulated by miR-27a, and 
miR-148a regulates Ikzf1, Pten and Bim. Similarly, miR-92 affects 
Ikzf1, Fbxw7 and, to a lesser extent, Bim and Pten, but not mouse Nf1. 
miR-223 is a strong regulator of Fbxw7. We confirmed these find-
ings in FL5-12 cells (Supplementary Fig. 7b–e). Hence, oncomirs 
produce partially overlapping effects on key tumor suppressor genes 
implicated in T-ALL.
Next, we directly examined the tumor suppressor function of these 
target genes in our mouse T-ALL model. Briefly, we used short-hairpin 
RNAs (shRNAs) directed against Pten15, Bim15, Nf1, Phf6 and 
Fbxw7 (Supplementary Fig. 8) and a dominant negative Ikzf1 allele 
(Dn-Ikzf1)27 in the same adoptive transfer model described above. 
NOTCH1-triggered leukemia was accelerated by shRNAs against 
Pten (n = 3, P < 0.05), Bim (n = 6, P < 0.01)15, Nf1 (n = 6, P < 0.01), 
Phf6 (n = 3, P < 0.05) and Dn-Ikzf1 (n = 10, P < 0.01); Fbxw7 showed 
a trend (n = 4, P = 0.1) (Fig. 5a). MCL1 is a target of the FBXW7 E3 
ligase28,29 and accordingly, we found that MCL1 levels are increased 
Table 1 Computational analysis and ranking of miRNA binding 
sites in candidate tumor suppressor genes implicated in T-ALL
miRNA/context 
scorea,b FBXW7 BIM NF1 PTEN IKZF1 PHF6 Sumc
miR-25/92d −0.9 −0.6 −0.2 −0.4 −0.2 0.0 −3.2
miR-27 −0.8 −0.2 −0.2 0.0 −0.4 0.0 −3.0
miR-203 0.0 −0.2 −0.2 0.0 −0.7 −0.6 −2.9
miR-148/152d 0.0 −0.8 0.0 −0.7 −0.3 0.0 −2.4
miR-101 −0.2 −0.3 −0.4 0.0 −0.1 −0.2 −2.3
miR-26 0.0 0.0 0.0 −0.9 0.0 −0.4 −2.3
miR-103 −0.3 0.0 −0.9 −0.6 0.0 0.0 −2.2
miR-200 −0.6 −0.2 −0.4 −0.2 0.0 −0.4 −2.2
miR-144 0.0 −0.2 −0.9 −0.3 0.0 −0.2 −2.0
miR-128 −0.3 0.0 −0.3 0.0 −0.4 −0.5 −1.9
miR-19 0.0 −0.3 −0.3 −0.6 −0.1 0.0 −1.8
miR-223 −1.4 0.0 0.0 0.0 0.0 0.0 −1.8
miR-137 −0.3 −0.1 −0.4 0.0 −0.2 0.0 −1.7
miR-217 0.0 −0.2 −0.6 −0.1 −0.2 −0.5 −1.6
miR-20/93/106d 0.0 −0.2 0.0 −0.3 0.0 −0.2 −1.5
aThe context score was calculated by correlating contextual features at a predicted site (local 
AU content, predicted binding at the 3` end of the miRNA and position in the 3` UTR) with 
extent of downregulation in miRNA transfection experiments and indicates the strength of 
the miRNA-mRNA interaction; larger negative values correspond to more effective sites; only 
values less than −0.1 are shown; scores are rounded to one decimal place. bWe tested the  
significance of this enrichment by randomly sampling 10,000 gene sets of the same size 
as the tumor suppressor gene set and computed how often the positive miRNAs showed the 
same enrichment. The enrichment of highly expressed miRNAs targeting tumor suppressor 
genes was significant (P < 0.043, empirical P value). cThe sum is calculated for all 12 genes 
included in the analysis; see Supplementary Table 9 for the full list of genes and miRNAs. 
dIndicates homologous miRNAs with identical seed sequences. See Supplementary Table 9  
for the full analysis.
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in mouse leukemias expressing miR-223 
and miR-92, both of which target Fbxw7 
(Supplementary Fig. 9a). Moreover, the 
homologous Bcl2 (n = 4; P < 0.001 for Bcl2 
versus vector) strongly accelerates leukemia 
development with Notch1 (Supplementary 
Fig. 9b). Similarly, Mcl1 and Bcl2 promote tumor development trig-
gered by c-Myc, a key effector of Notch1 (refs. 25,30,31). This indicates 
that FBXW7 acts, at least in part, through regulation of the anti-
apoptotic BCL2 family member MCL1. shRNAs and miRNAs may 
differ in their mechanism and efficiency of target knockdown, and 
our results indicate the tumor suppressive function of these genes in 
NOTCH1-triggered T-ALL.
Given the pleiotropic and overlapping pattern of tumor suppressor 
regulation by miRNAs, we wondered about the relevant contribution of 
each miRNA (Fig. 5). The human TALL-1 cell line expresses miR-19a, 
miR-19b, miR-26a and miR-92 but lacks miR-148a and miR-182 
(Fig. 5b inset and Supplementary Table 5). Antagomirs against miR-
19a/b, miR-26a and miR-92 reduce growth and viability (P < 0.05 for 
each antagomir versus vector) (Fig. 5b,c). These antagomirs cause 
derepression of PTEN and BIM (Fig. 5d,f). By contrast, antagomirs 
against miR-148a and miR-182 have no effect (P > 0.05). There are 
cell-line–specific differences, and in KOPTK1 cells, which express 
high levels of miR-148, an antagomir against miR-148 restores BIM 
and PTEN expression (Supplementary Fig. 10). This indicates that 
miR-148 maintains BIM and PTEN repression in KOPTK1 cells but 
not in TALL-1 cells. Hence, individual miRNAs make relevant con-
tributions that affect the viability of T-ALL cells.
Do miRNAs that bind common target genes produce cooperative 
effects? Co-expression of antagomirs against miR-19a/b, miR-26a 
and miR-92 had a stronger effect on the growth of TALL-1 cells than 
the individual antagomirs (P < 0.001 combined antagomirs versus 
vector) (Fig. 5b). The effect on cell viability was even more pro-
nounced, such that the three antagomirs together produced twice 
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as much apoptosis in a short-term assay than the individual anta-
gomirs (Fig. 5c). Accordingly, the combined treatment produced 
larger increases in BIM and PTEN expression compared to the indi-
vidual antagomirs (Fig. 5d,f). Similarly, co-expression of miR19b and 
miR-92 or miR-19b, miR-26a and miR-92 produced additive effects on 
the BIM and PTEN 3` UTR reporter activity, respectively (Fig. 5e,g). 
Thus, highly expressed miRNAs cooperate in regulating key tumor 
suppressor genes in human T-ALL cells.
Our study provides new insights into miRNA action in leukemia. 
We obtained a comprehensive view of oncomirs in T-ALL by compar-
ing miRNA expression data, computational analyses and an unbiased 
screen. A small number of abundantly expressed miRNAs target a set 
of key tumor suppressor genes and promote T-ALL in vivo (Fig. 5h). 
These oncomirs act in a miRNA-tumor suppressor gene network that 
is partially redundant and includes unique and cooperative miRNA 
effects. In this manner, miR-19b, miR-20a/93, miR-26a, miR-92 and 
miR-223 act as multi-targeted regulators of T-ALL tumor suppres-
sors including PTEN, BIM, NF1, FBXW7, IKZF1 and PHF6. mir-
223 is notable for its differential upregulation in T-ALL; it promotes 
NOTCH1-driven leukemia at least in part by controlling the E3 ligase 
FBXW7 (ref. 32), which directs degradation of the anti-apoptotic 
MCL1 protein28,29. Other miRNAs are also found in normal progeni-
tors and differentiated T-cells, and their oncogenic potential may only 
be realized in the context of additional mutations. Our study deline-
ates the key oncomirs in T-ALL and informs therapeutic strategies 
using antagomirs. The description of genetic networks by experimen-
tal means is limited by technology, and our study exemplifies how 
computational approaches can complement such analyses. Additional 
studies need to address potential tumor suppressive miRNAs. In 
 summary, we provide a conceptual framework for oncomir-tumor 
suppressor gene interactions that may also apply to other cancers.
METHODS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
T-ALL samples. Diagnostic bone marrow samples of 50 individuals with 
T-ALL were obtained from different European centers (Universitair Ziekenhuis 
(UZ) Ghent, Ghent, Belgium; UZ Leuven, Leuven, Belgium; Hôpital Purpan, 
Toulouse, France; Centre Hospitalier Universitaire (CHU) de Nancy-Brabois, 
Vandoeuvre-Les-Nancy, France). The resulting T-ALL cohort consisted of 15 
TAL or LMO (7 LMO2 and 8 SIL-TAL), 12 HOXA (4 MLL, 6 inv(7)(p15q35) 
and 2 CALM-AF10), 10 TLX3 and 5 TLX1 cases, and 8 cases could not be 
categorized. Total RNA was isolated using the miRNeasy mini kit (QIAGEN).
This study (2008/531) was approved by the Medical Ethical Commission of 
Ghent University Hospital (Belgium, registration B67020084745).
T-ALL cell lines. Eighteen T-ALL cell lines cultured in RPMI-1640 
(Invitrogen), 15% FCS, 1% penicillin and streptomycin and 1% kanamycin, 
1% glutamine. RNA isolation was performed as described above.
Subsets of normal T-cell populations. Normal T-cell populations from pedi-
atric thymuses (CD34+, CD4+CD8+CD3−, CD4+CD8+CD3+, CD3+CD4+CD8− 
and CD3+CD4−CD8+) were obtained by FACS and MACS33 using CD34 
microbeads (Miltenyi Biotec), double positive were isolated by staining with 
CD3−FITC, CD8−PE and CD4−APC, and single positive were depleted CD1+ 
thymocytes by Dynabeads (Dynal Biotech) and were subsequently labeled with 
CD3−FITC, CD8−PE and CD4−APC. The purity of the different subsets of normal 
T-cell populations was always at least 98%. RNA isolation was performed as 
described above.
MicroRNA profiling. miRNA profiling was performed using stem-loop 
reverse transcriptase primers for miRNA complementary DNA (cDNA) syn-
thesis followed by a pre-amplification step and TaqMan PCR analysis (Applied 
Biosystems)34. In brief, 20 ng of total RNA was reverse transcribed by use of 
the megaplex reverse transcriptase stem-loop primer pool for miRNA cDNA 
synthesis of 448 small RNAs, including 430 miRNAs and 18 small RNA con-
trols. Pre-amplification of cDNA was performed in a 14-cycle PCR reaction 
by use of TaqMan PreAmp Master Mix (2×) and PreAmp Primer Mix (5×) 
(Applied Biosystems) consisting of a miRNA-specific forward primer and a 
universal reverse primer35. Finally, the 448 small RNAs were profiled for each 
sample using a 40-cycle PCR protocol. SDS software version 2.1 was used to 
calculate the raw Cq values, using automatic base line settings and a threshold 
of 0.05. For normalization of the qPCR data of the miRNA expression profiles, 
we used the mean expression value of all expressed miRNAs in a given sample 
as the normalization factor; miRNAs with a Cq value >32 were considered 
unexpressed20.
Cell culture, viability, proliferation assays and vectors constructs. FL5-12 
mouse lymphocytes, cell cycle, apoptosis studies and viral transductions 
were as previously described36,37. Vectors are based on murine stem cell virus 
(MSCV)35,38,39. The pooled library35,38 has been expanded by PCR cloning 
to contain ~300 miRNAs. The antagomirs MZIP19a-PA-1, MZIP19b-PA-1, 
MZIP26a-PA-1, MZIP92a-PA-1, MZIP148a-PA-1 and MZIP182-PA1 and the 
scrambled control (MZIP000-PA-1) were from System Biosciences.
Library screens. The primary screen is based on c-MYC–induced apoptosis 
in mouse embryo fibroblasts (MEFs)23. MEFs were transduced with c-MYC 
and the miRNA library, puromycin was selected and apoptosis was triggered 
by reducing the serum to 0.1%. Surviving and adherent cells were collected for 
DNA isolation, and we performed PCR amplification of the integrated miRNA 
library constructs, sub-cloning into pGEM-T vector, bacterial transformation 
and sequence identification of ~100 colonies. A secondary library was con-
structed by sub-cloning all miRNAs from the primary screen into an MSCV 
construct. The secondary screen was for IL-3 independence15,37. FL5-12 cells 
were transduced with the library and were IL-3 depleted. miRNAs were identi-
fied as above and individually retested.
Generation of mice. The mouse T-ALL model has been previously 
reported39,40. Data were analyzed in Kaplan-Meier format using the log-rank 
(Mantel-Cox) test for statistical significance. The surface marker analysis was 
as described40.
Protein blot analysis. Immunoblots were performed from whole cell lysates as 
described40. Antibodies were against Bim (AAP-330, 1:1,000, Assay Designs), 
Nf1 (sc67, 1:100, Santa Cruz), Cdc4/Fbw7 (ab7405, 1:500, Abcam), Ikzf1 
(sc-13039, 1:500, Santa Cruz), Phf6 (NB100-79861, 1:1,000, Novus Biologicals), 
Pten (9559, 1:1,000, Cell Signaling), Tubulin (1:5,000, Sigma, B-5-1-2), Actin 
(1:5,000, Sigma, AC-15) and Mcl1 (1:1,000, Rockland 600-401-394).
Real time quantitative PCR for gene expression. Total RNA and miRNA-
enriched RNA was extracted using the AllPrep DNA/RNA/Protein and miRNeasy 
Mini. cDNA synthesis and qRT-PCR and analysis by the $$ Ct method was per-
formed as described36. TaqMan Gene Expression Assays: Bim (Mm00437796_m1), 
BIM (Hs00197982_m1), Pten (Mm01212532_m1), PTEN (Hs02621230_s1), Nf1 
(Mm00812430_m1), NF1 (Hs01035104_m1), Ikzf1 (Mm01187878_m1), IKZF1 
(Hs00172991_m1), Fbxw7 (Mm00504452_m1), FBXW7 (Hs00217794_m1), Phf6 
(Mm00804415_m1) and mouse GAPD (GAPDH) (4352932, Applied Biosystems), 
and expression was normalized to RNU6B (001093, Applied Biosystems). Primer 
sequences are available upon request.
Computational analyses of microRNA-target gene interaction. To generate 
training data, we carried out a supervised learning approach to identify, in 
an unbiased way, target genes that could discriminate between miRNAs that 
passed all screens (+1 class) and those that did not pass (−1 class). As positive 
training data (+1 class), we took the miRNAs that validated through the screen 
(miR-19, miR-20/93, miR-25/92, miR-148, miR-26a, miR-223 and miR-27ab). 
miR-20/93 and miR-25/92 were grouped together in the subsequent analysis 
because the respective seed sequence (pos 2:8) were identical. As negative 
training data (−1 class), we included three miRNAs that failed to validate at the 
final stage (miR-30a, miR-23a and miR-24), as well as five additional miRNAs 
that are highly expressed in T-ALL but which failed in the initial screen (miR-
142-3p, miR-150, miR-342-3p, miR-146 and miR-16).
Target prediction. Using the seed sequence (position 2:8) for each miRNA, we 
identified conserved mRNA targets by requiring the complementary sequence 
to occur in both mouse and human 3` UTRs of orthologous mRNAs. We used 
the minimum number of seed matches from both UTRs as the conserved 
7-mer count for each miRNA-mRNA pair. We used Biopython to extract 3` UTR 
sequences for mouse and human using RefSeq (Release 42). The longest 3` UTR 
was used when multiple RefSeq transcripts were present for a single gene.
Lasso regression. We used lasso regression to identify ‘discriminative’ gene 
sets between positive miRNAs and negative miRNAs. In this approach, each 
miRNA (positive or negative) is represented by its vector XmiR of conserved 
7-mer seed counts over all possible genes. The regression learns a weight vector 
W over genes such that the weighted sum of 7-mer seed counts for positive 
(or negative) miRNAs is close to +1 (or −1). The lasso constraint in the regres-
sion model encourages sparsity, meaning most of the genes will have a weight 
(regression coefficient) equal to 0. In this way, lasso regression identifies a 
smaller number of target genes that can discriminate between the two classes. 
Formally, we solve the optimization problem: 
min ( )w ggy w x wmiR miR
miR
 £ £< 2 M
where ymiR is +1 for validated miRNAs and −1 for non-validated miRNAs, 
XmiR is the vector of conserved 7-mer counts and L is the regularization 
parameter, which we chose to give ten nonzero weights. Lasso regression was 
performed using the glmnet package from Bioconductor.
Enrichment of miRNAs. The empirical P value for enrichment of miRNAs in 
Table 1 was determined by selecting 10,000 random samples of genes (of size 
equal to the set of tumor suppressor genes) from the full list of human genes 
for which we had 3` UTRs and target predictions. We computed the sum of 
TargetScan context scores for each broadly conserved miRNA seed family rela-
tive to each of these random gene sets and ranked the miRNA families accord-
ing to these scores. This procedure generates a randomized version of Table 1 
for each randomly selected gene set. We then calculated enrichment scores for 
these rankings using a Wilcoxon rank sum statistic comparing the ‘positive’ 
miRNAs (passed all screens) versus all other miRNAs. Finally, to compute the 
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empirical P value, we counted the number of times over the 10,000 randomly 
sampled gene sets we obtained a Wilcoxon rank sum score as good or better 
than the one we obtained with the tumor suppressor gene set. We found that 
428 random samplings performed as well or better than the tumor suppressor 
gene set, corresponding to a significant empirical P value (P < 0.043).
Comparison of cytogenetic and mutational subgroups. Differential miRNA 
expression analysis was performed using t-tests for groups of subject samples 
by cytogenetic criteria or presence and absence of NOTCH1 or FBXW7 muta-
tions. Cell lines were grouped by the indicated mutations and sensitivity to 
gamma secretase inhibitiors as reported12. A Benjamini-Hochberg correction 
was used for multiple hypotheses correction.
Analyses of miRNA-3` UTR interaction. By Targetscan 5.1 software21,22, a 
rank-order was based on a cumulative measure of site efficacy, by summing 
the context scores of predicted binding sites for a given miRNA across the set 
of tumor suppressor genes.
Luciferase assays. The mouse Fbxw7 (2,793–4,139 bp; NM_001177773), 
human NF1 (10,033–10,666 bp; NM_000267), human PHF6 (3,271–4,299 bp; 
NM_001015877) and Bim (3,155–4,773 bp; NM_009754) 3` UTR fragments 
were generated by PCR and cloned into the psi-CHECK-2 vector (Promega), 
with the exception of the IKZF1 UTR, which was purchased from Genecopoeia 
(HmiT000397b, 2,343–4,471 bp of the UTR). For the IKZF1 UTR luciferase 
assays, WT refers to the fragment containing the miR-92 binding site 
(from 2,343–4,470 bp), and MT refers to the fragment (containing positions 
1–2,343 bp of the UTR) in which the miR-92 binding site is absent. The 
Pten UTR has been previously described41. The assays were performed as 
described42. Details of the 3` UTR cloning and mutagenesis are shown in 
Supplementary Tables 14,15.
NOTCH1 and FBXW7 mutation analysis on 37 primary T-ALL samples. 
Primers used for amplification of exon 26, 27, 28 and 34 of NOTCH1 and 
exons 7, 8, 9, 10 and 11 of FBXW7 are reported in Supplementary Table 16 
(refs. 43,44). For NOTCH1 amplification, PCR was performed making use 
of the PCRx enhancer system (Invitrogen). A 50 Ml PCR reaction contained 
20 ng of DNA, 2.5U KapaTaq DNA Polymerase, 1× PCRx Amplification Buffer, 
2× PCRx Enhancer Solution, 0.2 mM dNTP, 1.5 mM MgSO4 and 0.2 mM of 
each primer. FBXW7 amplification used of 20 ng of DNA, 1× KapaTaq reaction 
buffer (KapaBiosystems), 1U KapaTaq DNA polymerase, 0.2 mM dNTP, 
2.5 MM MgCl2, 0.2 mM forward and reverse primer in a 25 Ml PCR reaction. 
PCR conditions were as follows: 10 min at 95 °C, 40 cycles (15 s at 96 °C, 
1 min at 57 °C and 1 min at 72 °C) and 10 at min 72 °C. Subsequently, PCR 
products were enzymatically purified followed by primer extension sequencing 
using dye terminator sequencing chemistry and electrophoresis by ABI3730xl 
(Applied Biosystems).
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Corrigendum: A cooperative microRNA-tumor suppressor gene network in 
acute T-cell lymphoblastic leukemia (T-ALL) 
Konstantinos J Mavrakis, Joni Van Der Meulen, Andrew L Wolfe, Xiaoping Liu, Evelien Mets, Tom Taghon, Aly A Khan, Manu Setti, 
Pieter Rondou, Peter Vandenberghe, Eric Delabesse, Yves Benoit, Nicholas B Socci, Christina S Leslie, Pieter Van Vlierberghe, 
Frank Speleman & Hans-Guido Wendel
Nat. Genet. 43, 673–678 (2011); published online 5 June; corrected after print 11 July 2011
In the version of this article initially published, the name of author Manu Setty was incorrectly spelled as Manu Setti. The error has been corrected 
in the HTML and PDF versions of the article.
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Suppl. Figure 1 Analysis of miRNA 
expression and its association with 
cytogenetic subgroups. a, Hierarchical 
clustering of miRNA expression analysis of 
HOXA, TAL and TNX1/3 subgroups. 
Unsupervised clustering does not recover the 
cytogenetic subgroups (Red-HOXA, Blue-
TAL, Green-TLX1/3); b, Principle 
component analysis (PCA) of miRNA 
expression in cytogenetic subgroups. PCA by 
the three main components separates normal 
from leukemia samples (not shown), but does 
not separate the cytogenetic subgroups (Red-
HOXA, Blue-TAL, Green-TLX1/3); c, 
Differentially expressed miRNA between 
cytogenetic subgroups. In a pair wise 
comparison miR-125b, miR-153, miR-196a 
and miR-196b show significantly different 
expression between subgroups (p < 0.05). 
(Red-HOXA, Blue-TAL, Green-TLX1/3). 
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Suppl. Figure 2 Sequence analysis of NOTCH1 and FBXW7 in 37 human T-ALL samples. 
a, Diagram of NOTCH1 and FBXW7 indicating domain structure and sites of mutations; b, 
Relative frequency of NOTCH1 and FBXW7 mutations. Note that in our series NOTCH1 
PEST domain and FBXW7 mutations are not mutually exclusive; c, Example of a new 
FBXW7 mutation in diagnosis and not a remission sample. 
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Suppl. Figure 3 Association of miRNA expression and Notch or Fbxw7 mutations. a, 
Hierarchical clustering of miRNA expression analysis of NOTCH1 wild type and mutant cases. 
Unsupervised clustering produces a grouping of cases by NOTCH1 status, although 7 wild type 
cases cluster with the mutant group. (Red-NOTCH MT, Blue-NOTCH WT). b, Principle 
component analysis (PCA) of miRNA expression by NOTCH1 mutation status. The three plots 
show the pair wise comparisons of the first three principal components. (Red-NOTCH MT, 
Blue-NOTCH WT); c, Differential expression of miR-200b between NOTCH1 wild type and 
mutant cases. Only miR-200b is significantly different (p < 0.05). (Red-NOTCH MT, Blue-
NOTCH WT); d, Hierarchical clustering of miRNA expression analysis by FBXW7 status. 
Unsupervised clustering does not recover the groups based on FBXW7 status. (Red-FBXW7 
MT, Blue-FBXW7 WT); e, Principle component analysis (PCA) of miRNA expression by 
FBXW7 status. PCA does not separate the subgroups. (Red-FBXW7 MT, Blue-FBXW7 WT); f,  
Differentially expressed miRNA by FBXW7 status. In a pair wise comparison miR-100, miR-
484, and miR-589 show significantly different expression between wild type and mutant cases 
(p < 0.05). (Red-FBXW7 MT, Blue-FBXW7 WT). 
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Suppl. Figure 4 MiRNA expression analyses. a, qRT-PCR measurement of miRNA expression in 18 human 
T-ALL cell lines (shown are mean and SD); b, qRT-PCR measurement of miRNA expression in FACS 
sorted normal cell populations (shown are mean and SD of two replicate profilings on one sample); c, 
Differential miRNA expression comparing the average value across all human T-ALL samples (L) to the 
indicated normal cell populations (N). Shown are only miRNAs with a fold change difference > 5 and 
detectable expression (relative value > 50) in either normal or leukemic sample; black numbers indicate 
higher expression in leukemic cells, red numbers indicate higher expression in normal cells.  
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Suppl. Figure 5 Candidate miRNAs act as oncogenes in a murine T-ALL model. a, Kaplan-
Meier analysis of leukemia free survival after transplantation of HPCs expressing NOTCH1-ICN 
and vector (black, n=13), or miR-27a (red, n=5; p < 0.05 compared to vector), miR-24 (magenta, 
n=5; p = 0.5), miR-23a (green, n=5; p < 0.05), miR-148a (blue, n=7; p < 0.05); b, Analysis of 
surface marker expression on murine T-ALLs, indicated is the percentage of cells staining 
positive for the indicated marker; c, qRT-PCR measurement of miRNA expression in murine 
leukemic cells expressing the indicated miRNA compared to leukemias arising in vector controls; 
d, qRT-PCR measurement of miRNA expression in murine leukemic cells expressing the 
indicated miRNA compared to murine thymocytes. 
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Suppl. Figure 6 Reporter assay for 3’UTR repression. Inhibition of the 3’UTR by the 
indicated miRNA compared to vector as mean +/- SD ratio of Renilla to Firefly luciferase 
activity (RLuc/Luc). Shown are effects of the indicated miRNAs on wild type (WT) and 
mutated (Mt) miRNA 3’UTR binding sites of Pten, Phf6, Ikzf, Nf1, Fbxw7. The Ikzf Mt 
3’UTR is truncated and missing the miR-92 site, and in the case of Fbxw7 we mutated single 
and combinations of all three binding sites for miR-223 (labelled Mt1-3).  
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Suppl. Fig. 7 MiRNAs affect the 
expression of several tumor 
suppressor genes in murine 
FL5-12 cells. a-e, Lysates of 
GFP-sorted FL5-12 cells 
expressing either empty vector or 
the indicated miRNA were probed 
for the indicated proteins. 
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Suppl. Figure 8 shRNA validation and control experiments; a-c, Protein knockdown 
by shRNAs in FL5-12 cells. Lysates of GFP-sorted FL5-12 cells expressing either empty 
vector or the indicated shRNAs were probed for the indicated proteins; d-f, Protein 
knockdown by shRNAs in murine leukemias expressing the shRNAs or vector. Lysates 
of murine leukemic cells expressing either empty vector or the indicated shRNAs were 
probed for the indicated proteins; g, I, k, Evaluation of mutiple shRNAs against Nf1, 
Phf6 and Fbxw7. Enrichment of shRNA and GFP expressing FL5-12 cells in subsequent 
rounds of IL3 depletion and rescue by addition of IL3; h, j l, corresponding immunoblots 
on lysates of shRNA expressing FL5-12 cells probed as indicated; m, Reversion of 
shRNA effect by cDNA expression. Expression of indicated cDNAs reverses the 
protective effect of shRNAs and causes a negative selection (loss of cDNA expressing 
cells) upon IL-3 depletion.  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Suppl. Figure 10 Antagomir studies in the human 
KOPTK1 T-ALL cell line. a, Cell number during in 
vitro culture of KOPTK1 cells expressing the 
indicated antagomirs (shown are mean and SD for 
each time point, *indicates significant (p < 0.05) 
growth delay; b, and c, qRT-PCR of Bim (b) and 
Pten (c) mRNA levels in KOPTK1 cells expressing 
the indicated antagomirs (mean and SD, * is p < 0.05 
compared to vector). 
 
Suppl. Fig. 9 Deregulation of Mcl1 in miR-223 
and miR-92 expressing murine leukemias. a) 
Immunoblot on lysates from Notch1-driven 
leukemias that express the indicated miRNAs or 
shRNA; b) Bcl2 (blue; n = 4) cooperates with 
Notch1-ICN in murine leukemogenesis compared to 
Notch1-ICN/ vector (black, n = 13; p < 0.001). 
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Suppl. Table 2) Comparison of miRNA expression between cytogentic 
subgroups (only significant differences are shown) 
 
 
 
 
 
 
 
 p-value HOXA mean Other mean TAL mean 
hsa-mir-125b 0.0124 -2.2938 2.1695 -1.819 
hsa-mir-153 0.0076 -5.4164 -5.5594 -9.1937 
hsa-mir-196a 0.0045 7.1794 3.3939 -0.7036 
hsa-mir-196b 0.0045 7.2014 3.3183 -0.7178 
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Suppl. Table 4) Differential microRNA expression by FBXW7 and NOTCH 
mutation status in T-ALL patient samples 
 
 
 
 
 
1. Fbxw7 wild type versus Fbxw7 mutant. 
microRNA p-value mutant mean exp wt mean exp 
miR-100 0.0143 -5.718 -2.6865 
miR-484 7.00E-04 -3.369 -1.307 
miR-589 0.0363 -7.3454 -5.467 
 
 
2. Notch1 wild type versus Notch1 mutant  
microRNA p-value mutant mean exp wt mean exp 
miR-200b 0.0143 -6.4442 -3.3669 
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Suppl. Table 6) Differential microRNA expression by mutation status in T-ALL cell 
lines  
 
1. Fbxw7 wild type versus Fbxw7 mutant: No significant differences. 
2. Notch1 wild type versus Notch1 mutant H: No significant differences. 
3. Notch1 wild type versus Notch1 mutant (any). 
microRNA p-value mutant mean exp wt mean exp 
miR-449b 0.0339 -8.1629 -4.7352 
4. NCID Status: No significant differences 
5. Pten wild type versus Pten mutant: No significant differences. 
6. GSI S/R: No significant differences. 
7. Phf6 wild type versus Phf6 mutant. 
microRNA p-value mutant mean exp wt mean exp 
miR-125b 0.0339 3.6653 -5.5518 
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Suppl. Table 10) Results of primary screen: Myc-induced apoptosis in MEFs
MicroRNA # sequences % of sequences
miR-30 10 9.803921569
let7 9 8.823529412
miR-34 9 8.823529412
miR-25 6 5.882352941
miR-148 5 4.901960784
miR-19b 4 3.921568627
miR-223 4 3.921568627
miR-125/351 4 3.921568627
miR-23 4 3.921568627
miR-21 2 1.960784314
miR-22 2 1.960784314
miR-106 2 1.960784314
miR-138 2 1.960784314
miR-146 2 1.960784314
miR-154 2 1.960784314
miR-217 2 1.960784314
miR-101 2 1.960784314
miR-221 2 1.960784314
miR-7 1 0.980392157
miR-9 1 0.980392157
miR-16 1 0.980392157
miR-99 1 0.980392157
miR-100 1 0.980392157
miR-103 1 0.980392157
miR-122 1 0.980392157
miR-124 1 0.980392157
miR-128 1 0.980392157
miR-135 1 0.980392157
miR-136 1 0.980392157
miR-140 1 0.980392157
miR-150 1 0.980392157
miR-181 1 0.980392157
miR-189 1 0.980392157
miR-196 1 0.980392157
miR-200 1 0.980392157
miR-201 1 0.980392157
miR-206 1 0.980392157
miR-211 1 0.980392157
miR-295 1 0.980392157
miR-302 1 0.980392157
miR-322 1 0.980392157
miR-325 1 0.980392157
miR-328 1 0.980392157
miR-339 1 0.980392157
miR-337 1 0.980392157
miR371 1 0.980392157
miR-27 1 0.980392157
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Suppl. Table 11) Result of secondary screen 
Sequences
miR-148/152 32
miR-34a 20
miR-19b 8
miR-223 8
mi-30 4
miR-320 4
miR-9 4
miR-96 4
miR-25/32/92 3
miR-20/106 2
miR-26 1
miR-23 1
miR-24 1
miR-27 1
miR-101 1
miR-128 1
miR-15 1
miR-16 1
miR-181c 1
miR-200 1
miR-221 1
miR-137 1
miR-217 1
miR-22 1
miR-182 1
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Suppl. Table 12) Surface marker analysis on murine leukemias
Marker
Tumor CD4 CD8 Thy-1 C-Kit B220
27a-1 64 83 83.6 77 34
27a-2 66 83 87 79 43
mean 65 83 85.3 78 38.5
sdev 1.414213562 0 2.404163056 1.414213562 6.363961031
92a-1 69 83.3 86 78 52
92a-2 36 44 38 19.2 23
mean 52.5 63.65 62 48.6 37.5
sdev 23.33452378 27.7892965 33.9411255 41.57787873 20.50609665
20a 57 53 66 10 15
20a-2 72 84 75 54 53
64.5 68.5 70.5 32 34
sdev 10.60660172 21.92031022 6.363961031 31.11269837 26.87005769
26a 81 86 87 7 30
26a-2 92 96 82 62.1 52
mean 86.5 91 84.5 34.55 41
sdev 7.778174593 7.071067812 3.535533906 38.96158364 15.55634919
148a 68 76 72 21 40
148a-2 79 85 83 35 20
mean 73.5 80.5 77.5 28 30
sdev 7.778174593 6.363961031 7.778174593 9.899494937 14.14213562
223-1 50.24 70.48 78.46 1.71 2.02
223-2 28.85 85.77 93.43 1.97 0.72
mean 39.545 78.125 85.945 1.84 1.37
sdev 15.12501405 10.81166268 10.58538851 0.183847763 0.919238816
19b-1 81.98 65 99.97 1.1 11.38
19b-2 97.46 80.7 99.32 1.83 13.16
mean 89.72 72.85 99.645 1.465 12.27
sdev 10.94601297 11.10157646 0.459619408 0.51618795 1.258650071
Vector-1 49.98 82.62 85.08 1.98 76.66
Vector-2 86.83 94.72 76.92 1.2 12.44
mean 68.405 88.67 81 1.59 44.55
sdev 26.05688489 8.555992052 5.769991334 0.551543289 45.41039749
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Suppl. Table 13) Results of an unbiased machine learning approach to identify target 
genes that discriminate oncogenic and non-oncogenic miRNAs.
Lasso regression was run 50 times comparing experimentally confirmed oncomirs to randomly selected groups of 30 miRNAs that did not pass the screen. 
The number of non-zero coefficients indicates how often (out of 50 runs) the gene was identified in this analysis.
The Mean coefficient is the actual coefficient for each gene; a coeeficient >0 implies positive association with the oncomir group.
Gene No. of non zero coefficients (out of 50)Mean coefficient
FBXW7 46 0.2919
CHIC1 36 0.1114
MAP3K2 31 0.0566
ABL2 30 0.0725
SNN 29 0.0815
BIM 21 0.0707
MED12L 20 0.0728
BBX 19 0.0733
ANKIB1 18 0.0422
PPARA 12 0.0274
PTEN 11 0.0587
SLC8A1 11 0.031
DMXL1 11 0.0271
PTPRD 10 0.0306
DCP2 8 0.0067
LPP 7 0.0152
CREB1 6 0.006
MKL2 5 0.0054
MFHAS1 5 0.0122
EIF2C1 5 0.0138
TNRC6B 5 0.006
FBXL17 4 -0.006
NFIC 3 -0.0022
STRBP 3 -0.004
TULP3 3 -4.00E-04
NUFIP2 3 0.0103
RAP2C 2 0.0041
ADCY1 2 3.00E-04
PPP1R9A 2 9.00E-04
CELF2 2 -0.0164
SLC24A2 2 2.00E-04
FAM53C 2 -9.00E-04
SCAI 2 -0.0012
PRX 2 -0.0014
FUT9 2 1.00E-04
STEAP2 2 -2.00E-04
TARDBP 2 -3.00E-04
MYLK4 2 -5.00E-04
PLXNA4 2 -0.0037
WASL 2 8.00E-04
DOCK5 1 0
HIF3A 1 -0.0012
ANKRD45 1 0
AAK1 1 9.00E-04
WNK3 1 0
TMEM170B 1 -9.00E-04
RFNG 1 -0.0032
TBL1XR1 1 0
ATXN1L 1 0.0021
MDGA2 1 -4.00E-04
YWHAZ 1 -4.00E-04
SP1 1 -0.0011
CBX5 1 -3.00E-04
CLMN 1 -0.0021
SPAG9 1 -0.0018
DENND5B 1 1.00E-04
GNAO1 1 -4.00E-04
CLOCK 1 0.0053
SYNJ2BP 1 -3.00E-04
ONECUT2 1 -4.00E-04
KRAS 1 -0.0038
TET3 1 -0.0012
MAN2A1 1 5.00E-04
SH3PXD2B 1 -2.00E-04
UNC5C 1 0
CYYR1 1 -2.00E-04
LAPTM5 1 -1.00E-04
OTUD7B 1 -0.0015
CDC14B 1 0
TBX22 1 -1.00E-04
QSER1 1 1.00E-04
FRS2 1 5.00E-04
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FZD5 1 -0.0017
PRTG 1 -0.0012
NEURL1B 1 0.006
TLN2 1 -1.00E-04
HOOK3 1 -4.00E-04
GPM6B 1 -6.00E-04
CACNB4 1 0
AKAP13 1 -2.00E-04
SYNPO 1 -3.00E-04
RUFY2 1 0
STXBP5L 1 -0.0011
XPO7 1 0
RASAL2 1 -9.00E-04
RGS17 1 0
SRF 1 -7.00E-04
PTPN2 1 0
TMF1 1 0
SHISA7 1 -6.00E-04
PGR 1 0
PHIP 1 6.00E-04
DENND1B 1 0.0074
ZYG11B 1 -2.00E-04
BTBD3 1 -6.00E-04
ZBTB41 1 0
SLC1A2 1 0.0012
ARIH1 1 -1.00E-04
INO80D 1 0.0036
SHISA6 1 0
PAPPA 1 -7.00E-04
RAP1GAP2 1 -5.00E-04
CDS1 1 1.00E-04
PACS1 1 0
DNM3 1 -6.00E-04
ARRB1 1 -4.00E-04
NUCKS1 1 -3.00E-04
NAV1 1 -0.0022
AMOTL1 1 -6.00E-04
PRKCA 1 -0.002
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Suppl. Table 15) Mutagenesis of 3’UTR miRNA binding sites 
 
PHF6 mir-20a binding site  
Position 2330-2336 of PHF6 3' UTR 
      
         T   GTG 
         X   XXX 
5'  ...CUAGCAACCAGAAUAGCACUUUA…-Phf6 3’UTR 
                                         | | | | | | |  
3'     GAUGGACGUGAUAUUCGUGAAAU -miR-20a 
 
PHF6 mir-26a binding site 
Position 3152-3158 of PHF6 3' UTR 
  
         G   TGG 
         X   XXX 
5'  ...GAAUCAGAAUCUGUGUACUUGAA...-Phf6 3’UTR 
                                         | | | | | | |  
3'      UCGGAUAGGACCUAAUGAACUU -miR-26a 
 
 
NF1 miR-92a binding site 
Position 1810-1816 of NF1 3' TTR 
  
        T  TAG 
        X  XXX 
5' ...AAATACTGAAGACAGGTGCAATT... -NF1 3’UTR 
                                        | | | | | | |  
3'     TGTCCGGCCCTGTTCACGTTAT -miR-92a 
 
FBXW7 miR-92a binding site 
Position 285-291 of FBXW7 3' UTR 
  
        T  TTG 
        X  XXX 
5' ...TCTAAATCAAACCAGGTGCAATT... -FBXW7 3’UTR 
                                        | | | | | | |  
3'     TGTCCGGCCCTGTTCACGTTAT -miR-92a 
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FBXW7 miR-92a binding site 
Position 1595-1601 of FBXW7 3' UTR 
  
 
       T  TTG 
       X  XXX 
5' ...TTTCTTATAACTTAAGTGCAATA... -FBXW7 3’UTR 
                                      | | | | | | | |  
3'     TGTCCGGCCCTGTTCACGTTAT -miR-92a 
 
 
FBXW7 miR-223 binding site 1 
Position 189-195 of FBXW7 3' UTR 
 
         C  GT   
         X  XX 
5' ...GAGAUGACAAACCAUAACUGACA... -FBXW7 3’UTR 
                                        | | | | | | |  
3'    ACCCCAUAAACUGUUUGACUGU  -miR-223 
 
 
 
FBXW7 miR-223 binding site 2 
Position 1144-1150 of FBXW7 3' UTR 
 
         C  GT 
         X  XX 
5' ...GAACGUACAUCGUAAAACUGACA... -FBXW7 3’UTR 
                           | | | | | | |  
3'    ACCCCAUAAACUGUUUGACUGU -miR-223 
 
 
FBXW7 miR-223 binding site 3 
Position 1260-1266 of FBXW7 3' UTR 
 
                  C  GT 
            X  XX 
5'    ...UUUAUUGCUCUGAGUAACUGACA...-FBXW7 3’UTR 
                                           | | | | | | |  
3'       ACCCCAUAAACUGUUUGACUGU   -miR-223 
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Suppl. Table 16 
 
 
Primer name  Primer sequence  Protein domain 
NOTCH1 exon26 F  AGGAAGGCGGCCTGAGCGTGT 
NOTCH1 exon26 R  AGAGTTGCGGGGATTGACCGT 
Heterodimerization domain 
(HD) N‐terminal 
NOTCH1 exon27 F  GTGGCGTCATGGGCCTCA 
NOTCH1 exon27 R  GCACAAACAGCCAGCGTGT 
HD C‐terminal 
NOTCH1 exon28 F  GATCGGTGTCATGTGAAGT 
NOTCH1 exon28 R  TCCCGGTGAGGATGCTCGG 
Juxtamembrane (JM) domain 
NOTCH1 exon34a F  CTTCCTCTGGTGATGGAACCT 
NOTCH1 exon34a R  CATCCCAGGCAGGTGGTTGA 
NOTCH1 exon34b F  GCCCTCCCCGTTCCAGCAGTCT 
NOTCH1 exon34b R  GCCTGGCTCGGCTCTCCACTCA 
NOTCH1 exon34c F  AGCCGCACCTTGGCGTGAGC 
NOTCH1 exon34c R  TGGTCGGCCCTGGCATCCAC 
Transactivation (TAD) domain 
and proline glutamate serine 
threonine (PEST) domain 
FBXW7 exon7 F  TTTATGCCTTCATTTTTCTCTT 
FBXW7 exon7 R  GGGGAAAAAAGCTAAGTTATG 
FBXW7 exon8 F  TTTTCCAGTGTCTGAGAACAT 
FBXW7 exon8 R  CCCAAATTCACCAATAATAGA 
FBXW7 exon9 F  TAAACGTGGGTTTTTTTGTT 
FBXW7 exon9 R  TCAGCAATTTGACAGTGATT 
FBXW7 exon10 F  CCTGGCATTACCTGTTTC 
FBXW7 exon10 R  AGGCTCCATATTTCTCTTGA 
FBXW7 exon11 F  GGACATGGGTTTCTAAATATGTA 
FBXW7 exon11 R  CTGCACCACTGAGAACAAG 
WD40‐repeats 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PAPER	  4	  
	  
MicroRNA-­‐193b-­‐3p	  acts	  as	  a	  tumor	  suppressor	  by	  targeting	  the	  MYB	  oncogene	  in	  
T-­‐cell	  acute	  lymphoblastic	  leukemia	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Abstract	  
	  
The	   MYB	   oncogene	   is	   a	   leucine	   zipper	   transcription	   factor	   essential	   for	   normal	   and	  
malignant	   hematopoiesis.	   In	   T-­‐cell	   acute	   lymphoblastic	   leukemia	   (T-­‐ALL),	   elevated	   MYB	  
levels	  can	  arise	  directly	  through	  T-­‐cell	  receptor	  mediated	  MYB	  translocations,	  genomic	  MYB	  
duplications	  or	  enhanced	  TAL1	  complex	  binding	  at	  the	  MYB	   locus,	  or	  indirectly	  through	  the	  
TAL1/miR-­‐223/FBXW7	   regulatory	   axis.	   In	   this	   study,	   we	   used	   an	   unbiased	  MYB	   3’UTR	   –	  
microRNA	  library	  screen	  and	  identified	  33	  putative	  MYB	  targeting	  microRNAs.	  Subsequently,	  
transcriptome	  data	  from	  two	  independent	  T-­‐ALL	  cohorts	  and	  different	  subsets	  of	  normal	  T-­‐
cells	  were	  used	  to	  select	  microRNAs	  with	  relevance	  in	  the	  context	  of	  normal	  and	  malignant	  
T-­‐cell	   transformation.	   Hereby,	   miR-­‐193b-­‐3p	   was	   identified	   as	   a	   novel	   bona	   fide	   tumor	  
suppressor	   microRNA	   that	   targets	   MYB	   during	   malignant	   T-­‐cell	   transformation	   thereby	  
offering	  an	  entry	  point	  for	  efficient	  MYB	  targeting	  oriented	  therapies	  for	  human	  T-­‐ALL.	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Introduction	  
	  
T-­‐cell	   acute	   lymphoblastic	   leukemia	   (T-­‐ALL)	   is	   an	   aggressive	   hematological	   malignancy	  
affecting	   children,	   adolescents	   and	   adults.	   In	   T-­‐ALL	   development,	   immature	   thymocytes	  
undergo	   oncogenic	   transformation	   caused	   by	   cooperative	   genetic	   lesions	   that	   affect	  
proliferation,	   survival	   and	   differentiation1.	   Constitutive	   activation	   of	   NOTCH1	   signaling,	  
provoked	  by	  activating	  NOTCH1	  mutations2	  or	  inactivating	  FBXW7	  aberrations3,	   is	  the	  most	  
prominent	   oncogenic	   pathway	   in	   T-­‐ALL	   pathogenesis.	   In	   addition,	   T-­‐ALL	   patients	   often	  
display	  recurrent	  translocations,	  duplications	  and	   interstitial	  deletions	  resulting	   in	  aberrant	  
expression	  of	  several	   transcription	  factor	  oncogenes	   including	  MYB.	   Illegitimate	  expression	  
of	   these	   transcriptional	   regulators	  drives	  specific	  gene	  expression	  programs	  that	  catalogue	  
T-­‐ALL	  patients	  in	  different	  molecular	  genetic	  subgroups4-­‐6.	  
	  
The	  MYB	  proto-­‐oncogene	  is	  a	  leucine	  zipper	  transcription	  factor	  that	  is	  aberrantly	  activated	  
in	   a	   subset	   of	   T-­‐ALL	   patients	   through	   a	   recurrent	   T-­‐cell	   receptor	   mediated	   translocation	  
t(6;7)(q23;q34)	   leading	   to	   TCRβ	  mediated	  MYB	   overexpression	   in	   of	   cases	   7%	   or	   somatic	  
duplications	   in	  10-­‐15%	  of	   cases7,	  8.	   Furthermore,	   additional	  mechanisms	  of	  MYB	  activation	  
include	  direct	  MYB	  up	  regulation	  by	  the	  oncogenic	  TAL1/GATA3/RUNX1	  complex9	  or	  indirect	  
through	   the	   TAL1/miR-­‐223/FBXW7	   regulatory	   axis10,	   11.	   In	   line	   with	   this	   notion,	   T-­‐ALL	  
patients	   that	   show	  aberrant	  expression	  of	   the	  TAL1	   oncogene	   (60%)4	   are	   characterized	  by	  
high	   levels	   of	  MYB	   expression9.	   During	   normal	   hematopoiesis,	   MYB	   plays	   a	   major	   role	   in	  
directing	   proliferation,	   lineage	   commitment	   and	   differentiation12,	   13.	   Interestingly,	   T-­‐cell	  
specific	  ectopic	  expression	  of	  v-­‐Myb,	  a	  truncated	  and	  rearranged	  form	  of	  MYB,	  in	  transgenic	  
mice	   gives	   rise	   to	   high	   grade	   T-­‐cell	   lymphomas	   underscoring	   the	   driver	   role	   of	   MYB	   in	  
normal	  and	  malignant	  T-­‐cell	  development14.	  Finally,	  MYB	   is	  an	  essential	  downstream	  target	  
of	   homeobox	   (HOX)	   genes,	   which	   serve	   as	   critical	   regulators	   of	   normal	   and	   malignant	  
hematopoiesis15.	  
	  
In	   the	   past	   decades,	  microRNAs	   (miRNAs)	  were	   identified	   as	   a	   group	   of	   small	   non-­‐coding	  
RNA	  molecules	  that	  negatively	  regulate	  gene	  expression.	  Sequence	  complementarity	  of	  the	  
seed	   of	   the	  miRNA	   and	   the	   3’UTR	  of	   the	   target	  mRNA	   initiates	   the	   formation	   of	   the	   RISC	  
complex	   leading	   to	   mRNA	   degradation	   or	   inhibition	   of	   translation16.	   Deregulated	   miRNA	  
expression	   is	   a	   common	   feature	   of	   human	   cancers	   and	   can	   be	   caused	   by	   specific	  
chromosomal	   abnormalities	   including	   somatic	   deletions	   (for	   example,	   miR-­‐15a/miR-­‐16-­‐1	  
deletions	   in	  chronic	   lymphoblastic	   leukemia17	  or	  translocations	  (for	  example,	  TCRβ-­‐miR-­‐17-­‐
92	  translocation	  in	  T-­‐ALL18).	  Importantly,	  some	  of	  these	  small	  RNA	  molecules	  have	  emerged	  
as	   important	   players	   in	   the	   control	   of	   driver	   genes	   implicated	   in	   T-­‐ALL10,	  11,	  18-­‐20	   and	  might	  
serve	  as	  excellent	  candidates	  for	  miRNA-­‐based	  therapies	  in	  the	  treatment	  of	  T-­‐ALL21.	  	  
	  
Thus	   far,	   the	   miRNA	   regulatory	   network	   controlling	   T-­‐ALL	   oncogenes	   has	   not	   been	  
extensively	  studied.	  Here,	  we	  selected	  the	  MYB	  proto-­‐oncogene	  as	  the	  first	  candidate	  for	  an	  
in-­‐depth	  exploration	  of	  this	  miRNA	  network	  through	  an	  unbiased,	  high	  throughput	  3’UTR	  -­‐
miRNA	   library	   screen	   and	   subsequent	   analyses	   of	   miRNA-­‐mRNA	   correlation	   data	   during	  
normal	   T-­‐cell	   differentiation	   and	   in	   primary	   T-­‐ALL	   patient	   samples.	   Using	   this	   unique	  
integrative	  approach	  and	  subsequent	  in	  vitro	  and	  in	  vivo	  validation,	  we	  identified	  miR-­‐193b-­‐
3p	  as	  a	  bona	  fide	  T-­‐ALL	  tumor	  suppressor	  miRNA,	  targeting	  MYB.	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Materials	  and	  methods	  
	  
MicroRNA	  profiling	  of	  T-­‐ALL	  patient	  samples	  and	  normal	  T-­‐cell	  subsets	  
	  
MicroRNA	  profiling	   (430	  miRNAs)	  was	   performed	  on	   a	   T-­‐ALL	   patient	   cohort	   of	   50	   primary	  
patient	  samples	  (15	  TAL/LMO,	  15	  TLX1/TLX3,	  12	  HOXA	  and	  8	  cases	  could	  not	  be	  categorized)	  
and	  on	  5	  normal	  thymocyte	  subsets	  (CD34+,	  CD4+CD8+CD3-­‐,	  CD4+CD8+CD3+,	  CD4+,	  CD8+).	  This	  
miRNA	   dataset	   was	   reported	   before,	   for	   a	   detailed	   description	   of	   the	   miRNA	   profiling	  
protocol,	  we	  refer	  to	  Mavrakis	  et	  al19.	  This	  study	  (2008/531)	  was	  approved	  by	  the	  Medical	  
Ethical	  Commission	  of	  Ghent	  University	  Hospital	  (Belgium,	  registration	  B67020084745)19.	  
	  
In	   addition,	   we	   performed	   microRNA	   profiling	   (755	   miRNAs)	   of	   a	   second	   T-­‐ALL	   patient	  
cohort	   of	   64	   primary	   patient	   samples	   (15	   immature,	   25	   TAL/LMO,	   17	   TLX1/TLX3	   and	   7	  
HOXA).	   These	   patient	   samples	  were	   previously	   investigated	   in	   a	   study	   of	   Clappier	   et	   al.22.	  
The	  samples	  were	  collected	  with	  informed	  consent	  according	  to	  the	  declaration	  of	  Helsinki	  
from	   Saint-­‐Louis	   Hospital	   (Paris,	   France)	   and	   the	   study	   was	   approved	   by	   the	   Institut	  
Universitaire	  d’Hematologie	  Institutional	  Review	  Board.	  
	  	  
Transcriptome	  profiling	  of	  T-­‐ALL	  patient	  samples	  
	  
On	  the	  cohort	  of	  64	  primary	  T-­‐ALL	  patient	  samples,	  gene	  expression	  analysis	  was	  performed.	  
Briefly,	   RNA	   quality	  was	   evaluated	   on	   the	   Agilent	   2100	   bioanalyzer	   (Agilent	   Technologies,	  
Santa	   Clara,	   CA,	   USA).	   Next,	   transcriptome	   profiling	   was	   performed	   on	   GeneChip	   Human	  
Genome	  U133	  2.0	  Plus	  arrays	   (Affymetrix,	  Santa	  Clara,	  CA,	  USA)	  according	  to	  standardized	  
procedures	   at	   the	   IGBMC	   (www.igbmc.fr,	   Strasbourg,	   France).	   Normalization	   of	   the	   gene	  
expression	   profiles	   was	   done	   using	   the	   variance	   stabilization	   and	   calibration	   (VSN)	   R	  
package23.	  Correlation	  analysis	  was	  performed	  using	  the	  Spearman	  rank	  correlation	  analysis	  
in	  R	  statistical	  programming	  environment	  (version	  3.0.1).	  Microarray	  data	  files	  are	  available	  
from	  ArrayExpress	  under	  accession	  no.	  E-­‐MTAB-­‐60422.	  
	  
MYB	  3’UTR-­‐miRNA	  library	  screen	  
	  
Twenty-­‐four	  hours	   after	   seeding,	  HEK-­‐293T	   cells	   (10	  000	   cells/well	   in	   96-­‐well	   plates)	  were	  
transfected	   with	   a	   pRL-­‐TK	   control	   vector	   (20	   ng)	   containing	   Renilla	   luciferase	   (Promega,	  
Madison,	   WI,	   USA)	   and	   a	   reporter	   vector	   (100	   ng)	   containing	   wild-­‐type	   3’UTR	   of	   MYB	  
downstream	  of	  Firefly	  luciferase	  (SwitchGear	  Genomics,	  Menlo	  Park,	  CA,	  USA)	  together	  with	  
a	   library	   of	   470	   miRNA	   mimics	   (2.5	   pmol)	   (Ambion's	   Pre-­‐miR	   miRNA	   Precursor	   Library	   -­‐	  
Human	   V3,	   design	   based	   on	   miRBase	   release	   9.2	   with	   exclusion	   of	   hsa-­‐miR-­‐122a,	   Life	  
Technologies,	   Carlsbad,	   CA,	   USA)	   by	   use	   of	   Dharmafect	   (Dharmacon,	   Thermo	   Fisher	  
Scientific,	  Waltham,	  MA,	  USA).	  After	  48h,	  luciferase	  activities	  were	  measured	  using	  the	  Dual-­‐
Luciferase	   Reporter	   assay	   (Promega)	   on	   a	   Fluostar	   Optima	   (BMG	   Labtech,	   Ortenberg,	  
Germany).	   For	   each	   miRNA	   a	   robust	   Z-­‐score	   was	   calculated,	   which	   represents	   the	   ratio	  
between	  Firefly/Renilla	   luciferase	  activities	  of	  a	  specific	  miRNA	  subtracted	  with	  the	  median	  
Firefly/Renilla	   value	   of	   the	   96-­‐well	   plate.	   An	   interaction	   score	   was	   then	   calculated	   which	  
represents	  the	  robust	  Z-­‐score	  of	  a	  miRNA	  subtracted	  with	  the	  median	  robust	  Z-­‐score	  of	  this	  
miRNA	   over	   all	   the	   screens	   that	  were	   performed.	   This	   screen	   is	   part	   of	   a	   large	   screening	  
effort	  of	  17	  known	  cancer	  genes	   (Van	  Peer	  et	  al.,	  manuscript	   in	  preparation).	  Notably,	   the	  
lower	  the	  interaction	  score,	  the	  more	  likely	  a	  miRNA	  will	  interact	  with	  the	  3’UTR	  of	  interest.	  
Two	   criteria	   were	   used	   to	   determine	   the	   cut-­‐off	   with	   the	   highest	   accuracy	   using	   a	   ROC–
curve	  analysis	   (cut-­‐off	  <	   -­‐1.93,	  specificity	  =	  99%,	  sensitivity	  =	  51%)	  to	  separate	   interactions	  
from	   non-­‐interactions.	   To	   perform	   this	   ROC-­‐curve	   analysis,	   interaction	   scores	   were	   taken	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into	  account	  of	  a	  set	  of	  selected	  miRNA	  interactions	  that	  were	  validated	  in	  literature	  as	  well	  
as	  interaction	  scores	  of	  miRNAs	  derived	  from	  an	  empty	  3’UTR	  vector	  miRNA	  library	  screen.	  
Our	   MYB	   3’UTR-­‐miRNA	   library	   screen	   was	   performed	   in	   duplicate	   to	   determine	   the	  
reproducibility	  of	  our	  screening	  method.	  
	  
Single	  3’UTR-­‐miRNA	  reporter	  gene	  assays	  and	  rescue	  experiments	  
	  
To	  produce	  a	  MYB	  3’UTR	  mutant	  vector	  in	  which	  the	  two	  6-­‐mer	  target	  sites	  for	  miR-­‐193b-­‐3p	  
were	   mutated,	   the	   Site-­‐Directed	   Mutagenesis	   Kit	   (Stratagene,	   Agilent	   Technologies)	   was	  
used	  according	  to	  manufacturer’s	  guidelines.	  
Primer	  sequences	  for	  mutagenesis:	  
6mer1	  F	   GGTAATGAATTGTATCACTTTGTTAATATCTTAATGCAG	  
6mer1	  R	   CTGCATTAAGATATTAACAAAGTGATACAATTCATTACC	  
6mer2	  F	   CTGTGGTTGATAGTCACTTCACTGCCTTAAG	  
6mer2	  R	   CTTAAGGCAGTGAAGTGACTATCAACCACAG	  
The	  wild-­‐type	  or	  mutant	  3’UTR	  vector	  of	  MYB	  (SwitchGear	  Genomics)	  and	  a	  pRL-­‐TK	  control	  
vector	  (Promega)	  were	  co-­‐transfected	  in	  HEK-­‐293T	  cells	  with	  either	  a	  miRNA	  mimic	  for	  miR-­‐
193b-­‐3p	   (PM12383,	   Ambion)	   or	   a	   scrambled,	   non-­‐targeting	   control	   (NTC)	   miRNA	   mimic	  
(AM17111,	  Ambion),	  followed	  by	  luciferase	  measurements	  as	  described	  above.	  
	  
Electroporation	  of	  miRNA	  mimics	  in	  T-­‐ALL	  cell	  lines	  
	  
First,	  64	  x106	  cells	  from	  T-­‐ALL	  cell	  lines	  were	  suspended	  in	  2	  ml	  RPMI-­‐1640	  medium	  together	  
with	   the	   miRNA	   mimic	   or	   NTC	   (final	   concentration:	   400	   nM).	   Next,	   500	   µl	   of	   each	   cell	  
suspension	  was	  transferred	  to	  electroporation	  tubes	  followed	  by	  electroporation	  (0.300	  kV	  
and	  1	  mF)	  with	  the	  Gene	  Pulser	  II	  (Bio-­‐Rad	  Laboratories,	  Hercules,	  CA,	  USA).	  The	  cells	  from	  1	  
electroporation	   were	   divided	   over	   4	   wells	   of	   a	   12-­‐well	   plate	   and	   diluted	   to	   a	   final	   cell	  
suspension	  of	  1.6	  x	  106/ml.	  Finally,	  cells	  were	  collected	  for	  RNA	  and	  protein	   isolation	  after	  
24,	  48	  and	  72	  hours.	  
	  
NOTCH1-­‐induced	  T-­‐ALL	  mouse	  model	  
	  
The	  institutional	  and	  national	  guide	  for	  the	  care	  and	  use	  of	  laboratory	  animals	  was	  followed.	  
At	   embryonic	   day	   13-­‐14,	   we	   isolated	   fetal	   liver	   cells	   with	   hematopoietic	   progenitor	   cells	  
(HPCs)	   from	  pregnant	  mice.	  Next,	  we	   transduced	   the	  HPCs	  with	   ICN1	   (active	  NOTCH1,	   co-­‐
expression	   of	   mCherry)	   and	   a	   vector	   encoding	   antagomiR	   (sequence	   =	  
AGCGGGACTTTGAGGGCCAGTT)	   against	   miR-­‐193b-­‐3p	   or	   an	   empty	   vector	   control	   (co-­‐
expressing	  GFP).	  After	   irradiation	  of	  mouse	   recipients,	   the	   transduced	  HPCs	  were	   injected	  
using	   tail	   vein	   injection	   followed	   by	   monitoring	   of	   leukemia	   onset.	   Various	   tissues	   were	  
collected	   at	   time	   of	   leukemia	   formation	   and	   fixed	   in	   formaldehyde	   for	  
immunohistochemistry.	  Spleen	  and	  thymus	  cells	  were	  mashed	  to	  single-­‐cell	  suspensions	  and	  
frozen	  in	  10%	  DMSO.	  RNA	  and	  protein	  lysates	  were	  generated	  from	  the	  mouse	  samples	  and	  
used	   for	   qPCR	   and	   western	   blot	   analysis.	   Leukemia	   onset	   data	   was	   analyzed	   using	   the	  
Kaplan-­‐Meier	  method	  and	  the	  log-­‐rank	  test	  for	  statistical	  significance.	  
	  
Immunohistochemistry	  of	  mouse	  leukemias	  
	  
Tissue-­‐specific	   samples	   (kidney,	   liver,	   lung	   and	   lymph	   node)	   of	   mouse	   leukemias	   were	  
washed,	  paraffin-­‐embedded	  and	  sectioned	  at	  5	  mm	  according	  to	  standard	  procedures.	  Next,	  
sections	   were	   stained	   with	   hematoxylin	   and	   eosin	   (H&E)	   or	   a	   rabbit	   polyclonal	   anti-­‐Ki67	  
primary	   antibody	   (dilution	   1/1000,	   Cell	   Signaling).	   Visualization	   was	   done	   using	   DAB	   kit	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(Dako),	  analyzed	  with	  a	  BX51	  Discussion	  microscope	  (Olympus,	  Shinjuku,	  Tokyo,	  Japan)	  and	  
pictures	  were	  taken	  with	  a	  cooled	  interline	  CCD	  camera.	  
	  
T-­‐test	  
	  
We	  identified	  all	  differential	  expressed	  miRNAs	  between	  T-­‐ALL	  patient	  samples	  and	  normal	  
thymocyte	   subsets	   by	   use	   of	   the	   standard	   t-­‐test	   combined	   with	   Benjamini-­‐Hochberg	  
multiple	  testing	  correction	  (p<0.05).	  We	  applied	  the	  same	  t-­‐test	  to	  identify	  all	  miRNAs	  that	  
are	  differential	  expressed	  between	  the	  TAL	  subgroup	  and	  other	  T-­‐ALL	  subgroups	  (p<0.05).	  
	  
miR-­‐193b-­‐3p	  nomenclature	  
	  
Official	  nomenclature	  and	  sequence	  annotation	   for	  miR-­‐193b-­‐3p	  by	   the	  miRBase	  database	  
(http://www.mirbase.org/)	  changed	  a	  few	  times	  during	  the	  course	  of	  this	  study.	  During	  the	  
time	  of	  the	  3’UTR	  high	  throughput	  screening	  effort	  and	  the	  miRNA	  profiling	  of	  cohort	  1,	  miR-­‐
193b	   was	   annotated	   in	   miRbase	   with	   the	   following	   mature	   sequence:	  
AACUGGCCCUCAAAGUCCCGCUUU.	  Before	  profiling	  of	  cohort	  2,	  the	  sequence	  of	  this	  miRNA	  
changed	  to	  AACUGGCCCUCAAAGUCCCGCU	  but	   the	  nomenclature	   remained	  unchanged.	  As	  
the	  sequence	  change	  occurred	  at	   the	  3’	  end	  of	   the	  miRNA’s	   sequence,	   the	  seed	  sequence	  
remained	  unchanged,	  which	  likely	  does	  not	  affect	  the	  function	  of	  miR-­‐193b.	  At	  the	  start	  of	  
our	  validation	  studies,	  a	  new	  miRbase	  release	  was	  published	  and	  the	  nomenclature	  for	  miR-­‐
193b	  changed	  to	  miR-­‐193b-­‐3p.	  In	  this	  manuscript,	  we	  therefore	  refer	  to	  this	  miRNA	  by	  miR-­‐
193b-­‐3p	  according	  to	  the	  latest	  miRBase	  release.	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Results	  
	  
Identification	   of	   miRNAs	   targeting	  MYB	   using	   an	   unbiased	  MYB	   3’UTR	   –	   miRNA	   library	  
screen	  
	  
Given	  the	  oncogenic	  role	  of	  MYB	  in	  T-­‐ALL	  and	  the	  relevance	  of	  perturbed	  miRNA	  signaling	  in	  
T-­‐cell	  transformation,	  we	  conducted	  a	  miRNAome-­‐wide	  screen	  to	  identify	  novel	  miRNAs	  that	  
target	   the	  MYB	   proto-­‐oncogene.	  More	   specifically,	   we	   performed	   a	   high-­‐throughput	   dual	  
luciferase-­‐based	  MYB	  3’UTR	  –	  miRNA	  library	  screen	  to	  explore	  possible	  interactions	  between	  
470	  miRNA	  mimics	   and	   the	   3’UTR	   of	  MYB	   in	   HEK-­‐293T	   cells.	   After	   co-­‐transfection	   of	   the	  
miRNA	  mimics	  together	  with	  the	  MYB	  3’UTR	  and	  control	  vector,	  we	  measured	  the	  luciferase	  
activities	  and	  calculated	  a	  miRNA	  interaction	  score	  for	  each	  miRNA	  mimic	  (see	  Materials	  and	  
methods)	  (Figure	  1a).	  We	  conducted	  2	   independent	  MYB	  3’UTR	  library	  screens	  to	  evaluate	  
the	  reproducibility	  of	  our	  screening	  method	  and	  ensure	  the	  reliable	  identification	  of	  positive	  
miRNA	   hits	   (Figure	   1b,	   Pearson	   correlation	   coefficient	   r	   =	   0.85).	   Next,	   we	   determined	  
positive	  hits	  based	  upon	  interaction	  scores	  <	  -­‐1.93,	  a	  cut-­‐off	  that	  was	  established	  based	  on	  
3’UTR	   library	  screens	   for	  17	  known	  cancer	  genes	   (see	  Materials	  and	  methods;	  Van	  Peer	  et	  
al.,	  manuscript	  in	  preparation).	  As	  such,	  this	  MYB	  3’UTR	  screening	  analysis	  yielded	  a	  total	  of	  
33	  miRNAs	  that	  could	  potentially	  target	  MYB	   (Figure	  1c	  and	  Supplemental	  Table	  1).	  Eleven	  
out	  of	  these	  33	  hits	  were	  not	  predicted	  by	  various	  target	  prediction	  programs	  (TargetScan,	  
PicTar,	   miRanda,	   MirTarget2,	   DianamicroT)	   emphasizing	   the	   strength	   of	   our	   screening	  
method	  as	  an	  unbiased	  tool	  for	  the	  identification	  of	  novel	  non-­‐predicted	  miRNA-­‐target	  gene	  
interactions.	  The	  fact	  that	  the	  number	  of	  experimentally	  identified	  33	  hits	  through	  the	  3’UTR	  
library	  screen	  is	  significantly	  lower	  as	  those	  generated	  by	  online	  target	  prediction	  databases	  
(e.g.	   74	   predicted	   miRNAs	   by	   TargetScan	   or	   159	   predicted	   miRNAs	   using,	   DianamicroT)	  
underscores	   the	   significant	   level	   of	   false	   negatives	   generated	  by	   computational	   prediction	  
programs.	   In	   addition,	   our	   analysis	   identified	   5	   out	   of	   8	   (63%)	   known	   miRNA-­‐MYB	  
interactions	   described	   in	   literature	   including	   miR-­‐15024,	   miR-­‐200b25,	   miR-­‐42426,	   miR-­‐42927	  
and	   miR-­‐12628.	   The	   3	   remaining	   miRNAs	   (miR-­‐15526,	   miR-­‐15a29	   and	   miR-­‐200c30)	   could	  
represent	  false	  negatives	  in	  our	  screen.	  	  
	  
MicroRNA-­‐193b-­‐3p	  potentially	   targets	  MYB	   in	  normal	   and	  malignant	   T-­‐cell	   development	  
and	  shows	  low	  expression	  in	  the	  TAL	  rearranged	  T-­‐ALLs	  
	  
Following	   the	   unbiased	   identification	   of	   33	   positive	  miRNA	   hits	   in	   our	  MYB	   3’UTR-­‐miRNA	  
library	   screen,	   we	   explored	   the	   miRNA	   expression	   profiles	   of	   normal	   T-­‐cell	   subsets	  
representing	  major	  stages	  of	  thymocyte	  maturation31	  and	  two	  genetically	  well–characterized	  
T-­‐ALL	  patient	  cohorts	  to	  identify	  relevant	  miRNAs	  in	  the	  context	  of	  normal	  and	  malignant	  T-­‐
cell	   development.	   First,	   we	   evaluated	   the	   expression	   of	   430	   miRNAs	   in	   a	   primary	   T-­‐ALL	  
cohort	   consisting	   of	   50	   T-­‐ALL	   patient	   cases	   as	   well	   as	   5	   normal	   T-­‐cell	   subsets	   (CD34+,	  
CD4+CD8+CD3−	   (DP3-­‐),	   CD4+CD8+CD3+	   (DP3+),	   CD4+	   (SP4+)	   and	   CD8+	   (SP8+))19.	   Next,	   we	  
explored	  both	  the	  miRNAome	  (755	  miRNAs)	  (Supplemental	  Table	  2)	  and	  transcriptome22	  of	  a	  
second	   independent	   T-­‐ALL	   patient	   cohort	   of	   64	   primary	   T-­‐ALL	   cases	   to	   identify	   putative	  
miRNA-­‐mRNA	  interactions	  based	  on	  integrative	  miRNA-­‐mRNA	  correlation	  analysis.	  
	  
By	  performing	  differential	  miRNA	  expression	  analysis,	  we	  first	   identified	  36	  putative	  tumor	  
suppressor	   miRNAs	   with	   significant	   reduced	   levels	   of	   expression	   in	   T-­‐ALL	   patients	   as	  
compared	  to	  normal	  T-­‐cell	  subsets	  (p<0.05;	  Supplemental	  Table	  3).	  Cross-­‐comparison	  of	  the	  
36	  putative	   tumor	  suppressor	  miRNAs	  with	   the	  33	  hits	   identified	   in	   the	  MYB	  3’UTR	  screen	  
retained	   5	  miRNAs	   shared	   in	   both	   analyses	   (Figure	   2a).	   Interestingly,	   two	  miRNAs	   out	   of	  
these	   5	   common	   miRNAs,	   namely	   miR-­‐195	   and	   miR-­‐193b-­‐3p,	   showed	   strong	   opposite	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expression	   patterns	   with	   MYB	   expression	   during	   normal	   T-­‐cell	   differentiation	   (Pearson	  
correlation	   coefficient	   r	   =	   -­‐0.75	   for	   miR-­‐193b-­‐3p	   and	   r	   =	   -­‐0.66	   for	   miR-­‐195,	   Figure	   2b-­‐c,	  
Supplemental	  Figure	  1a-­‐d).	  However,	  only	  miR-­‐193b-­‐3p	  was	  negatively	  correlated	  with	  MYB	  
expression	   in	   primary	   T-­‐ALLs	   (Spearman	   rank	   correlation	   with	   correlation	   factor	   <	   -­‐0.5;	  
Supplemental	  Table	  4),	  suggesting	  that	  MYB	  regulation	  by	  miR-­‐193b-­‐3p	  might	  be	  functional	  
in	  both	  normal	  and	  malignant	  T-­‐cell	   context	   (Figure	  2b-­‐f,	   Supplemental	   Figure	  1e).	   Finally,	  
we	   evaluated	   the	  miR-­‐193b-­‐3p	   expression	   in	  molecular	   genetic	   subtypes	   of	   human	   T-­‐ALL.	  
Significantly	   lower	   expression	   levels	   of	   miR-­‐193b-­‐3p	   were	   identified	   in	   TAL	   rearranged	   T-­‐
ALLs	  in	  both	  patient	  cohorts	  (Supplemental	  Table	  5-­‐6,	  Figure	  2d-­‐f),	  which	  corresponds	  to	  the	  
previously	  reported	  higher	  expression	  levels	  of	  MYB	  in	  TAL	  rearranged	  leukemias9.	  	  
	  
In	  vitro	  validation	  of	  the	  interaction	  between	  MYB	  and	  miR-­‐193b-­‐3p	  in	  T-­‐ALL	  cells	  
	  
Following	   the	   selection	   of	   miR-­‐193b-­‐3p	   as	   putatively	   functionally	   relevant	   miRNA	   in	   the	  
context	  of	  normal	  T-­‐cell	  maturation	  and	  T-­‐ALL	  oncogenesis,	  we	  decided	  to	  validate	  the	  direct	  
interaction	   between	   miR-­‐193b-­‐3p	   and	   the	   3’UTR	   of	   MYB	   using	   single	   luciferase-­‐based	  
reporter	   assays	   to	   confirm	   the	   3’UTR-­‐miRNA	   library	   screen	   results.	   This	   assay	   showed	   a	  
substantial	   down-­‐regulatory	   effect	   of	  miR-­‐193b-­‐3p	  on	   luciferase	   activity	   as	   compared	   to	   a	  
non-­‐targeting	  miRNA	   control	   (NTC)	   (Figure	   3a).	  We	   identified	   two	   potential	   6mer	   binding	  
sites	   for	   miR-­‐193b-­‐3p	   (Figure	   3b)	   and	  mutation	   of	   both	   target	   sites	   abolished	   the	   down-­‐
regulatory	   effect	   of	   miR-­‐193b-­‐3p	   on	   luciferase	   activity,	   demonstrating	   the	   seed-­‐specific	  
interaction	  between	  miR-­‐193b-­‐3p	  and	  the	  3’UTR	  of	  MYB	  (Figure	  3c).	  	  
	  
Next,	   we	   investigated	  whether	  miR-­‐193b-­‐3p	   regulates	  MYB	   expression	   levels	   in	   the	   T-­‐ALL	  
cell	   line	   RPMI-­‐8402,	  which	   contains	   a	   genomic	  MYB	   duplication,	   and	   in	   the	   T-­‐ALL	   cell	   line	  
LOUCY,	  which	  harbors	  high	  MYB	  protein	  expression	   levels	  as	  compared	   to	  other	  T-­‐ALL	  cell	  
lines	   (Supplemental	   Figure	   2)8.	   In	   both	   T-­‐ALL	   cell	   lines,	   overexpression	   of	   miR-­‐193b-­‐3p	  
induced	  down	  regulation	  of	  MYB	  protein	  levels	  compared	  to	  a	  non-­‐targeting	  miRNA	  control	  
at	   different	   time	   points	   (Figure	   3d-­‐e).	   Previous	   studies	   identified	  MCL1	   as	   a	  miR-­‐193b-­‐3p	  
target	   in	  other	  cancer	  types32,	  33.	   Importantly,	  MCL1	  was	  also	  shown	  to	  contribute	  to	  T-­‐ALL	  
formation19.	   Therefore	   we	   tested	   the	   effect	   of	   overexpression	   of	   miR-­‐193b-­‐3p	   on	   MCL1	  
levels	  and	  observed	  miR-­‐193b-­‐3p	  induced	  down	  regulation	  of	  MCL1	  protein	  levels	  in	  both	  T-­‐
ALL	   cell	   lines	   (Figure	   3d-­‐e).	   Hence,	   the	   putative	   tumor	   suppressor	   miR-­‐193b-­‐3p	   interacts	  
with	   both	   MYB	   and	   MCL1	   by	   site-­‐specific	   complementarity	   and	   affects	   MYB	   and	   MCL1	  
protein	  levels	  in	  T-­‐ALL	  thus	  further	  broadening	  the	  miR-­‐193b-­‐3p	  network	  in	  T-­‐ALL.	  	  
	  
In	  vivo	  down	  regulation	  of	  miR-­‐193b-­‐3p	  accelerates	  T-­‐ALL	  onset	  
	  
Next,	  we	  evaluated	  the	  oncogenic	  effect	  of	  loss	  of	  the	  putative	  T-­‐ALL	  tumor	  suppressor	  miR-­‐
193b-­‐3p	   in	   a	   NOTCH1-­‐induced	   T-­‐ALL	   mouse	   model34.	   In	   brief,	   fetal	   liver	   cells	   were	  
retrovirally	  transduced	  with	  an	  ICN1	  (NOTCH1)	  construct	  (co-­‐expressing	  mCherry)	  as	  well	  as	  
a	   construct	   encoding	   antagomiR	   against	   miR-­‐193b-­‐3p	   (co-­‐expressing	   GFP)	   or	   an	   empty	  
vector	   construct.	  Next,	   the	   transduced	  hematopoietic	  precursor	   cells	   (HPCs)	  were	   tail	   vein	  
injected	   into	   lethally	   irradiated	   recipient	  mice	   and	   T-­‐ALL	   onset	  monitored	   (Figure	   4a).	  We	  
observed	  accelerated	   leukemia	  onset	   in	  mice	   injected	  with	  HPCs	  containing	  the	  antagomiR	  
against	   miR-­‐193b-­‐3p	   (n=4,	   mean	   latency	   =	   43	   days,	   log-­‐rank	   test	   p=0.02)	   compared	   to	  
NOTCH1-­‐only	   controls	   (n=7,	   mean	   latency	   =	   56	   days)	   (Figure	   4b).	   Notably,	   the	   T-­‐cell	  
lymphoblasts	  derived	  from	  the	  murine	  leukemias	  displayed	  a	  clear	  GFP	  enrichment	  at	  time	  
of	   disease	   onset	   (data	   not	   shown).	   Furthermore,	   an	   increase	   in	   MYB	   protein	   levels	   was	  
observed	   in	   the	   leukemias	   with	   reduced	   miR-­‐193b-­‐3p	   compared	   to	   controls	   (Figure	   4c).	  
Finally,	   immunohistochemistry	   analysis	   of	   the	   murine	   leukemias	   showed	   an	   aggressive	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leukemia	   phenotype	   with	   infiltration	   of	   highly	   proliferative	   T-­‐cell	   lymphoblasts	   in	   liver,	  
kidney,	  spleen	  and	  lungs	  in	  both	  miR-­‐193b-­‐3p	  loss	  and	  NOTCH1-­‐only	  control	  samples	  (Figure	  
4d).	  No	  difference	   in	  H&E	  or	   Ki67	   levels	   between	   the	  miR-­‐193b-­‐3p	   loss	   and	  NOTCH1-­‐only	  
control	  samples	  was	  observed	  (Figure	  4d).	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Discussion	  
	  
The	  MYB	  oncogene	  was	  discovered	  more	  than	  30	  years	  ago	  as	  a	  viral-­‐transforming	  gene	  in	  
hematopoietic	   cells35.	   More	   recently,	   two	   independent	   research	   groups	   described	   MYB	  
duplications	   (10-­‐15%)	   and	   translocations	   (7%)	   in	   primary	   T-­‐ALL	   patient	   samples7,	  8,	   linking	  
oncogenic	  MYB	  activity	  to	  T-­‐ALL	  pathogenesis.	  Furthermore,	  T-­‐ALL	  patient	  samples	  marked	  
with	  aberrant	  TAL1	  expression	  display	  high	  MYB	  expression	  levels	  directly	  provoked	  by	  TAL1	  
complex	  binding9.	   Therapeutic	   approaches	   targeting	  MYB	   include	  direct	   strategies	   like	   the	  
antisense	  MYB	  oligodeoxynucleotides	   currently	   tested	   in	   clinical	   trials36	   as	  well	   as	   indirect	  
strategies	  like	  histone	  deacetylase	  inhibitors	  (HDACi)37,	  38.	  Therapeutic	  miRNA	  delivery	  might	  
represent	  an	  alternative	  approach	  for	  targeting	  MYB39.	  	  
	  
Hence,	  we	  designed	  and	  performed	  a	  miRNAome-­‐wide	  MYB	  3’UTR-­‐miRNA	  library	  screen	  in	  
HEK-­‐293T	  cells	  in	  which	  33	  miRNAs	  (positive	  hits)	  were	  identified	  that	  putatively	  target	  MYB.	  
In	   our	   screen,	   one	   third	   of	   the	   positive	   miRNA	   hits	   were	   not	   predicted	   by	   five	   different	  
miRNA	   target	   prediction	   programs	   underlining	   the	   power	   of	   this	   unbiased	   strategy	   in	   the	  
identification	  of	  non-­‐predicted	  miRNA-­‐target	  gene	  interactions.	  Alternatively,	  comparison	  of	  
the	   33	   hits	   from	   the	   screen	   to	   the	   extensive	   list	   of	   miRNAs	   predicted	   by	   computational	  
prediction	  programs	  suggests	  that	  online	  tools	  predict	  many	  false	  negatives.	  Literature	  data	  
on	   other	   genes	   that	   where	   tested	   in	   our	   library	   screens	   also	   show	   that	   many	   bona	   fide	  
targets	   remain	  undetected	  using	  prediction	   tools	   and	   likewise	  only	   a	   small	   fraction	  of	   the	  
predicted	  miRNAs	  were	  identified	  as	  hits	  in	  these	  library	  screens40,	  41.	  To	  our	  knowledge,	  this	  
is	   the	   first	  unbiased	  3’UTR	   library	   screen	  that	  was	  conducted	   for	   the	   identification	  of	  MYB	  
targeting	  miRNAs.	  	  
	  
Integration	   of	   these	   results	   with	   miRNA	   and	   mRNA	   expression	   profiles	   of	   primary	   T-­‐ALL	  
patient	  samples	  as	  well	  as	  normal	  thymocytes	  allowed	  us	  to	  identify	  miR-­‐193b-­‐3p	  as	  the	  top	  
candidate	  putative	  tumor	  suppressive	  miRNA	  targeting	  MYB	  in	  normal	  and	  malignant	  T-­‐cell	  
development.	   In	   our	   sorted	   normal	   T-­‐cell	   subsets,	   we	   observed	   and	   validated	   that	  MYB	  
expression	   levels	   drastically	   decrease	   during	   T-­‐cell	   differentiation42.	  MYB	   expression	   levels	  
are	  tightly	  regulated	  in	  this	  developmental	  process,	  whereby	  MYB	  essentially	  contributes	  to	  
three	  specific	  T-­‐cell	  developmental	   stages43,	  44.	   	  Next	   to	  MYB,	  microRNAs	  are	  also	  essential	  
contributors	   to	  correct	  T-­‐cell	  development	  as	  deletion	  of	  Dicer,	  an	  essential	   component	   in	  
the	   miRNA	   biogenesis	   pathway,	   in	   mice	   impedes	   the	   survival	   of	   αβ	   T-­‐cells	   in	   early	   T-­‐cell	  
stages	   45.	   In	   our	   data,	   miR-­‐193b-­‐3p	   was	   shown	   to	   be	   strongly	   anti-­‐correlated	   with	  MYB	  
expression	   during	   normal	   T-­‐cell	   differentiation	   and	   miR-­‐193b-­‐3p	   controlled	   regulation	   of	  
MYB	   levels	  through	  a	  seed-­‐specific	   interaction.	  Taken	  together,	  we	  can	  propose	  miR-­‐193b-­‐
3p	  as	  an	  important	  regulator	  of	  MYB	  expression	  during	  normal	  T-­‐cell	  development.	  	  
	  
Based	  on	  T-­‐ALL	  patient	  data	  and	  miR-­‐193b-­‐3p	  perturbation	  studies	  in	  T-­‐ALL	  cell	  lines	  and	  the	  
NOTCH1	   T-­‐ALL	   mouse	   model,	   we	   could	   demonstrate	   that	   miR-­‐193b-­‐3p	   acts	   as	   bona	   fide	  
tumor	   suppressor	   gene	   targeting	  MYB	   in	   T-­‐ALL.	   The	   oncogene	  MCL1	   has	   previously	   been	  
described	   as	   a	   miR-­‐193b-­‐3p	   target	   in	   liver	   cancer	   and	   melanoma32,	   33,	   which	   we	   could	  
confirm	   in	   our	   in	   vitro	  model	   system.	  Of	   interest,	   TAL1	   knockdown	   in	   T-­‐ALL	   cell	   lines10	   or	  
enforced	  expression	  of	  miR-­‐92a	  and	  miR-­‐223	  in	  NOTCH1-­‐driven	  T-­‐ALL	  mouse	  leukemias	  also	  
influences	  MCL1	  protein	  levels	  in	  T-­‐ALL.	  Mechanistically,	  MCL1	  is	  a	  downstream	  target	  of	  the	  
TAL1/miR-­‐223/FBXW710	   or	   miR-­‐92a/FBXW7	   regulatory	   axes19,	   46.	   Hence,	   in	   our	   study	   we	  
identified	  the	  novel	  tumor	  suppressor	  miR-­‐193b-­‐3p	  that	  can	  directly	  regulate	  MYB	  and	  MCL1	  
levels	  in	  T-­‐ALL.	  Importantly,	  this	  indicates	  that	  the	  in	  vivo	  tumor	  suppressor	  activity	  of	  miR-­‐
193b-­‐3p	   will	   be	   mediated	   by	   the	   cooperative	   and	   simultaneous	   activation	   of	   multiple	  
oncogenes,	  a	  notion	  that	  has	  been	  postulated	  for	  multiple	  other	  miRNAs19.	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In	  line	  with	  previous	  studies9,	  MYB	  expression	  levels	  were	  elevated	  in	  TAL	  positive	  T-­‐ALLs	  in	  
both	  leukemic	  patient	  cohorts	  that	  we	  analyzed.	  Furthermore,	  miR-­‐193b-­‐3p	  is	  low	  expressed	  
in	   TAL	   rearranged	   T-­‐ALLs,	   which	   corresponds	   with	   the	   unraveled	   miR-­‐193b-­‐3p	   –	   MYB	  
interaction	  shown	  in	  our	  study.	  In	  the	  paper	  of	  Correia	  et	  al.,	  miR-­‐193b-­‐3p	  is	  down	  regulated	  
after	  TAL1	  overexpression	  in	  the	  P12-­‐ICHI	  T-­‐ALL	  cell	   line11	  indicating	  that	  the	  TAL1	  complex	  
can	  putatively	  indirectly	  repress	  miR-­‐193b-­‐3p	  expression.	  	  
	  
Finally,	  using	  the	  NOTCH1	  T-­‐ALL	  induced	  mouse	  model,	  we	  could	  show	  for	  the	  first	  time	  that	  
elevated	   MYB	   levels,	   caused	   by	   introduction	   of	   an	   antagomiR	   against	   miR-­‐193b-­‐3p,	  
cooperate	   in	   vivo	   with	   ectopic	   expression	   of	   NOTCH1.	   Accordingly,	   a	   strong	   synergistic	  
inhibitory	   effect	   on	   proliferation	   and	   viability	   was	   already	   demonstrated	   in	   vitro	   after	  
combined	   knockdown	   of	   MYB	   and	   NOTCH1	   in	   GSI-­‐sensitive	   T-­‐ALL	   cell	   lines8.	   Hence,	   we	  
conclude	  that	  the	  novel	  tumor	  suppressor	  miR-­‐193b-­‐3p	  can	  cooperate	  with	  NOTCH1	  in	  T-­‐ALL	  
pathogenesis.	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Figure	  Legends	  
	  
Figure	   1.	   An	   unbiased	   high-­‐throughput	  MYB	   3’UTR-­‐miRNA	   library	   screen	   identifies	   33	  
candidate	  miRNAs	  targeting	  MYB	  
(a)	  HEK-­‐293T	  cells	  were	  transfected	  with	  a	  reporter	  vector	  containing	  the	  wild-­‐type	  3’UTR	  of	  
MYB	   downstream	   of	   a	   Firefly	   luciferase	   gene	   and	   a	   control	   vector	   containing	   a	   Renilla	  
luciferase	  gene	  together	  with	  a	  library	  of	  470	  miRNA	  mimics.	  Forty-­‐eight	  hours	  later,	  Firefly	  
and	  Renilla	   luciferase	  activities	  were	  measured.	  After	  normalization,	   inter-­‐plate	   calibration	  
and	  correction	  for	  systemic	  error,	  a	  miRNA	  interaction	  score	  was	  calculated	  for	  each	  miRNA	  
in	  the	  screen.	  The	  lower	  the	  interaction	  score,	  the	  more	  likely	  a	  miRNA	  will	  interact	  with	  the	  
3’UTR	  of	  MYB.	  (b)	  The	  plot	  of	  the	  interaction	  scores	  for	  each	  miRNA	  from	  two	  independent	  
MYB	   3’UTR	   library	   screens	   demonstrates	   the	   high	   reproducibility	   of	   our	   assay	   (Pearson	  
correlation	  coefficient	  r	  =	  0.85).	  (c)	  Our	  screens	  reveals	  33	  candidate	  miRNAs	  (Supplemental	  
Table	   1)	   targeting	   the	   3’UTR	   of	  MYB	   (interaction	   score	   <	   -­‐1.93).	   The	   average	   interaction	  
score	   of	   the	   2	   screens	   is	   plotted	   on	   the	   y-­‐axis	   for	   each	   miRNA	   that	   was	   included	   in	   the	  
screen	  (x-­‐axis).	  	  
	  
Figure	  2.	  Selection	  of	  miR-­‐193b-­‐3p	  as	  a	  top	  candidate	  MYB	  targeting	  miRNA	  in	  T-­‐ALL	  
(a)	   Selection	  criteria	   to	   identify	   top	  candidate	  miRNAs	   targeting	  MYB	   in	  T-­‐ALL:	   (1)	  positive	  
hits	   from	   the	   MYB	   3’UTR-­‐miRNA	   library	   screen,	   (2)	   miRNAs	   that	   are	   significantly	   lower	  
expressed	  in	  T-­‐ALL	  versus	  normal	  T-­‐cell	  subsets	  (t-­‐test,	  p<0.05),	  (3)	  miRNAs	  that	  display	  anti-­‐
correlation	  with	  MYB	   expression	   in	  primary	  human	  T-­‐ALL	  patient	   samples	   (Spearman	   rank	  
correlation	   factor	   <	   -­‐0.5).	   (b)	  MYB	   is	   highly	   expressed	   in	   the	   immature	   CD34+	   stage	   and	  
thereafter	   decreases	   during	   T-­‐cell	   development.	   (c)	   MicroRNA-­‐193b-­‐3p	   exhibit	   lower	  
expression	   in	   the	   immature	   CD34+	   stage	   followed	   by	   a	   strong	   up	   regulation	   in	   the	  more	  
mature	   stages.	   (d)	  MYB	   is	   highly	   expressed	   in	   the	   TAL	   positive	   T-­‐ALL	   subgroup.	   (e-­‐f)	  miR-­‐
193b-­‐3p	  is	  significantly	  lower	  expressed	  in	  the	  TAL	  rearranged	  patients	  samples	  compared	  to	  
other	  T-­‐ALL	  subgroups	  (t-­‐test,	  p<0.05)	  in	  both	  T-­‐ALL	  patient	  cohorts.	  
	  
Figure	  3.	  MicroRNA-­‐193b-­‐3p	  directly	   targets	   the	  3’UTR	  of	  MYB	   and	  down	  regulates	  MYB	  
expression	  in	  T-­‐ALL	  cell	  lines	  
(a)	  Transfection	  of	  miR-­‐193b-­‐3p	  reduces	  the	   luciferase	  activity	  of	  the	  wild-­‐type	  MYB	  3’UTR	  
reporter	   construct	   in	   HEK-­‐293T	   cells.	   Bar	   graphs	   represent	   the	   mean	   (+/-­‐	   SD)	   of	   4	  
independent	  experiments	  relative	  to	  the	  non-­‐targeting	  miRNA	  transfection	  control	  (NTC).	  (b)	  
The	   human	  MYB	   3’UTR	   contains	   two	   6mer	   sites	   for	   miR-­‐193b-­‐3p.	   The	   sequences	   for	   the	  
wild-­‐type	   (WT)	   vector,	   the	   mutated	   (MUT)	   vector	   and	   miR-­‐193b-­‐3p	   are	   depicted.	   (c)	  
Mutation	  of	  the	  two	  6mer	  target	  sites	  of	  miR-­‐193b-­‐3p	  in	  the	  3’UTR	  MYB	  vector	  completely	  
abolishes	   the	   down	   regulatory	   effect	   of	   miR-­‐193b-­‐3p	   on	   luciferase	   activity.	   Bar	   graphs	  
represent	  the	  mean	  (+/-­‐	  SD)	  of	  2	  independent	  experiments	  relative	  to	  NTC.	  (d-­‐e)	  MicroRNA-­‐
193b-­‐3p	  overexpression	  down	  regulates	  MYB	  and	  MCL1	  levels	  in	  LOUCY	  (d)	  and	  RPMI-­‐8402	  
(e)	   T-­‐ALL	   cell	   lines.	   The	   results	   shown	   from	   one	   experiment	   are	   representative	   for	   two	  
independent	  biological	  replicates.	  MYB	  and	  Tubulin	  protein	  levels	  were	  quantified	  by	  use	  of	  
Image	  J	  software.	  Subsequently	  MYB	  levels	  were	  normalized	  to	  Tubulin	  levels	  and	  compared	  
to	  the	  relative	  MYB	  levels	  of	  the	  NTC	  samples.	  
	  
Figure	  4.	  Down	  regulation	  of	  miR-­‐193b-­‐3p	  accelerates	  T-­‐ALL	  onset	  in	  vivo	  
(a)	   Schematic	   representation	   of	   the	  NOTCH1-­‐induced	   T-­‐ALL	  mouse	  model.	   Fetal	   liver	   cells	  
derived	   from	   pregnant	  mice	  were	   partially	   transduced	  with	   a	   vector	   encoding	   antagomiR	  
against	  miR-­‐193b-­‐3p	  or	  an	  empty	  vector	  control	  (labeled	  in	  GFP),together	  with	  the	  NOTCH1	  
(ICN1)	  construct	  (co-­‐expressing	  mCherry).	  Next,	  the	  transduced	  cells	  were	  tail	  vein	  injected	  
in	   irradiated	  mouse	   recipients	   followed	   by	  monitoring	   of	   leukemia	   formation.	   (b)	   Survival	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plot	   (Kaplan-­‐Meier)	   depicting	   accelerated	   leukemia	   onset	   in	   the	   mouse	   recipients	   with	  
reduced	   miR-­‐193b-­‐3p	   levels	   (n=4,	   p=0.02	   log-­‐rank	   test,	   red)	   compared	   to	   NOTCH1-­‐only	  
controls	   (n=7,	   black).	   (c)	   Western	   blot	   analysis	   of	   Myb	   protein	   levels	   in	   mouse	   tumor	  
samples	   from	   both	   groups.	   Myb	   protein	   levels	   are	   quantified	   by	   Image	   J,	   normalized	   to	  
Tubulin	   levels	  and	  compared	  to	  NOTCH1-­‐only	  vector	  controls.	   (d)	  H&E	  and	  Ki67	  staining	  of	  
lymphoblasts	   in	   kidney,	   liver,	   lung	   and	   spleen	   tissue	   of	   a	   representative	   antagomiR	   miR-­‐
193b-­‐3p	  and	  control	  mouse	  leukemia	  sample	  (10x	  magnification).	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Supplemental	  Figure	  Legends	  
	  
Supplemental	   Figure	   1.	   MiRNA-­‐429,	   miR-­‐503,	   miR-­‐200,	   miR-­‐195	   and	   miR-­‐193b-­‐3p	  
expression	   during	   normal	   T-­‐cell	   differentiation.	   MiRNA-­‐193b-­‐3p	   expression	   in	   T-­‐ALL	  
patient	  samples	  
(a-­‐c)	  The	  expression	  patterns	  of	  (a)	  miR-­‐429	  (a),	  miR-­‐503	  (b)	  miR-­‐200b	  (c)	  and	  miR-­‐195	  (d)	  in	  
5	  sorted	  T-­‐cell	  subsets	  during	  normal	  T-­‐cell	  development	  are	  depicted	  (all	  miRNAs:	  Pearson	  
correlation	   coefficient	   with	   MYB	   >	   -­‐0.5).	   (d)	   miR-­‐195	   exhibit	   lower	   expression	   in	   the	  
immature	  CD34+	   stage	   followed	  by	   a	   strong	  up	   regulation	   in	   the	  more	  mature	   stages.	   (e)	  
Expression	  levels	  of	  miR-­‐193b-­‐3p	  in	  T-­‐ALL	  patient	  samples	  and	  normal	  T-­‐cell	  subsets.	  
	  
Supplemental	  Figure	  2.	  MYB	  expression	  levels	  in	  T-­‐ALL	  cell	  lines	  
MYB	  protein	  levels	  in	  a	  set	  of	  T-­‐ALL	  cell	  lines	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Supplemental	  Materials	  and	  methods	  
	  
Cell	  lines	  
	  
All	  cell	  lines	  used	  were	  obtained	  from	  DSMZ	  (Braunschweig,	  Germany)	  and	  cultured	  in	  RPMI-­‐
1640	  (Gibco,	  Life	  Technologies,	  Carlsbad,	  CA,	  USA)	  supplemented	  with	  10%	  FCS,	  L-­‐glutamine	  
(10	  ml/L),	  penicillin	  (100	  µg/ml)	  and	  streptomycin	  (100	  µg/ml).	  
	  
Protein	  isolation	  and	  Western	  blot	  
	  
Cell	  pellets	  were	   lysed	   in	  RIPA	  buffer	   (32	  mM	  Sodium	  Deoxycholate,	  150	  mM	  NaCl,	  50mM	  
TrisHCl	   (pH	   7.5),	   0.1%	   SDS	   en	   1%	   NP-­‐40)	   with	   protease	   inhibitors	   (cOmplete	   Protease	  
Inhibitor	  Cocktail	  Tablets;	  Roche,	  Basel,	  Switzerland).	  For	  denaturation	  of	  the	  samples,	  20	  µl	  
cell	   lysate	   was	  mixed	  with	   5	   µl	   of	   denaturation	   buffer	   (5x	   laemli	   buffer	   (25	  ml	   10%	   SDS-­‐
solution,	  20	  ml	  100%	  glycerol,	  7.75	  ml	  1M	  TrisHCl	  pH	  6.8	  en	  1.25	  ml	  1%	  BromoPhenol	  Blue	  
solution),	  1:7	  40x	  β-­‐mercaptoethanol),	  and	  incubated	  at	  95°C	  for	  10min.	  Next,	  20	  µl	  of	  the	  
denatured	  fractions	  were	  loaded	  on	  precast	  gels	  (10%	  SDS;	  Bio-­‐Rad)	  and	  subjected	  to	  SDS-­‐
PAGE	   (100V	   and	   0.25A,	   1-­‐2	   hours).	   Additionally,	   a	   biotinylated	   protein	   ladder	   was	   used	  
(7727S;	   Cell	   Signaling,	   Danvers,	   MA,	   USA).	   Next,	   proteins	   were	   transferred	   onto	   a	  
nitrocellulose	   membrane	   (nitrocellulose/Filter	   Paper	   Sandwiches	   0.2µm;	   Bio-­‐Rad)	   (100V,	  
0.25A,	   1-­‐2	   hours).	   Primary	   antibodies	   used:	   anti-­‐MYB	   (mouse,	   05-­‐175,	   dilution	   1/1000;	  
Upstate,	   Millipore,	   Billerica,	   MA,	   USA),	   anti-­‐MCL1	   (rabbit,	   5453S,	   dilution	   1/1000;	   Cell	  
Signaling)	   and	   anti-­‐Tubulin	   (mouse,	   T5168,	   dilution	   1/5000;	   Sigma-­‐Aldrich,	   St.	   Louis,	   MI,	  
USA).	   Secondary	   antibodies	   used:	   HRP-­‐linked	   anti-­‐mouse	   or	   anti-­‐rabbit	   (7076S	   -­‐	   7074S,	  
dilution	   1/5000;	   Cell	   Signaling)	   and	   HRP-­‐linked	   anti-­‐biotin	   (7075S,	   dilution	   1/1000;	   Cell	  
Signaling).	   For	   chemiluminescent	   detection,	   membranes	   were	   incubated	   with	  
luminal/enhancer	   buffer	   (Super	   Signal	   West	   Dura	   Extended	   Duration	   Substrate;	   Thermo	  
Fisher	   Scientific)	   and	   developed	   using	   the	   UCP	   chemiDoc-­‐it®500	   Imaging	   System	   (UVP,	  
Upland,	   CA,	   USA).	   To	   remove	   antibodies,	   stripping	   buffer	   (Restore	   PLUS	   Western	   Blot	  
Stripping	  Buffer;	  Thermo	  Fisher	  Scientific)	  was	  used.	  
	  
RNA	  isolation,	  cDNA	  synthesis	  and	  qPCR	  
	  
RNA	  isolation	  and	  DNase-­‐treatment	  on	  column	  was	  performed	  using	  the	  miRNeasy	  Mini	  Kit	  
and	  the	  RNase-­‐Free	  DNase	  Set	  (Qiagen,	  Hilden,	  Germany).	  RNA	  concentration	  was	  measured	  
on	  Nanodrop	  (Thermo	  Fisher	  Scientific).	  For	  cDNA	  synthesis,	  500	  ng	   input	  RNA,	  4	  µl	   iScript	  
reaction	  mix	   and	   1	   µl	   of	   iScript	   reverse	   transcriptase	   (iScript;	   Bio-­‐Rad)	  was	   used	   in	   a	   final	  
volume	  of	  20	  µl	  and	  samples	  were	  incubated	  for	  5’	  at	  25°C,	  30ʹ′	  at	  42°C	  and	  5ʹ′	  at	  85°C	  using	  
the	  iCycler	  (Bio-­‐Rad).	  qPCR	  experiments	  were	  performed	  according	  to	  the	  MIQE	  guidelines.	  
The	  qPCR	  reactions	  were	  executed	  using	  5	  ng	  cDNA,	  250	  nM	  primers	  and	  2.5	  µl	  SsoAdvanced	  
master	  mix	   (Bio-­‐Rad)	   in	   a	   final	   volume	  of	   5	   µl	   and	   run	   on	   the	   LightCycler	   480	   instrument	  
(Roche).	  Normalization	  of	  expression	  values	  was	  done	  against	  a	  set	  of	  reference	  genes	  and	  
analyzed	  using	  the	  qBasePlus	  software	  (http://www.biogazelle.com).	  The	  qPCR	  primers	  were	  
developed	   using	   RTPrimerDB	   (http://www.rtprimerdb.org)	   and	   are	   listed	   in	   Supplemental	  
Table	  7.	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Supplemental	  Table	  1.	  3’UTR	  MYB	  library	  screen	  (only	  shown	  33	  hits)	  
Average	  interaction	  scores	  of	  the	  2	  3'UTR	  MYB-­‐microRNA	  library	  screens,	  33	  positive	  
microRNA	  hits	  (interaction	  score	  <	  -­‐1,93)	  are	  indicated	  in	  bold	  
*	  Accession	  number	  in	  miRBase	  
**	  Mature	  microRNA	  sequence	  of	  the	  microRNAs	  used	  in	  the	  library	  
***	  MicroRNAs	  that	  are	  predicted	  by	  at	  least	  one	  of	  the	  following	  in	  silico	  prediction	  
algorithms:	  TargetScan,	  PicTar,	  miRanda,	  MirTarget2,	  Diana,	  microT	  -­‐-­‐>	  indicated	  by	  "x"	  (only	  
indicated	  for	  the	  33	  positive	  hits)	  
	  
MicroRNA	  ID	   Accession	  
number*	  
Mature	  miRNA	  sequence**	   Interaction	  
score	  
Predicted	  
***	  	  
hsa-­‐miR-­‐150	   MIMAT0000451	   UCUCCCAACCCUUGUACCAGUG	   -­‐6.529	   x	  
hsa-­‐miR-­‐127	   MIMAT0000446	   UCGGAUCCGUCUGAGCUUGGCU	   -­‐4.973	   	  	  
hsa-­‐miR-­‐449b	   MIMAT0003327	   AGGCAGUGUAUUGUUAGCUGGC	   -­‐4.719	   x	  
hsa-­‐miR-­‐449	   MIMAT0001541	   UGGCAGUGUAUUGUUAGCUGGU	   -­‐4.527	   x	  
hsa-­‐miR-­‐221	   MIMAT0000278	   AGCUACAUUGUCUGCUGGGUUUC	   -­‐4.517	   	  	  
hsa-­‐miR-­‐629	   MIMAT0003298	   GUUCUCCCAACGUAAGCCCAGC	   -­‐4.371	   	  	  
hsa-­‐miR-­‐34c	   MIMAT0000686	   AGGCAGUGUAGUUAGCUGAUUGC	   -­‐4.267	   x	  
hsa-­‐miR-­‐193b	   MIMAT0002819	   AACUGGCCCUCAAAGUCCCGCUUU	   -­‐3.698	   x	  
hsa-­‐miR-­‐222	   MIMAT0000279	   AGCUACAUCUGGCUACUGGGUCUC	   -­‐3.445	   	  	  
hsa-­‐miR-­‐105	   MIMAT0000102	   UCAAAUGCUCAGACUCCUGU	   -­‐3.307	   x	  
hsa-­‐miR-­‐193a	   MIMAT0000459	   AACUGGCCUACAAAGUCCCAG	   -­‐3.248	   x	  
hsa-­‐miR-­‐624	   MIMAT0003293	   UAGUACCAGUACCUUGUGUUCA	   -­‐2.956	   	  	  
hsa-­‐miR-­‐34a	   MIMAT0000255	   UGGCAGUGUCUUAGCUGGUUGUU	   -­‐2.900	   x	  
hsa-­‐miR-­‐34b	   MIMAT0000685	   UAGGCAGUGUCAUUAGCUGAUUG	   -­‐2.785	   x	  
hsa-­‐miR-­‐126	   MIMAT0000445	   UCGUACCGUGAGUAAUAAUGC	   -­‐2.721	   	  	  
hsa-­‐miR-­‐195	   MIMAT0000461	   UAGCAGCACAGAAAUAUUGGC	   -­‐2.702	   x	  
hsa-­‐miR-­‐497	   MIMAT0002820	   CAGCAGCACACUGUGGUUUGU	   -­‐2.619	   x	  
hsa-­‐miR-­‐565	   MIMAT0003229	   GGCUGGCUCGCGAUGUCUGUUU	   -­‐2.479	   	  	  
hsa-­‐miR-­‐454-­‐3p	   MIMAT0003885	   UAGUGCAAUAUUGCUUAUAGGGUUU	   -­‐2.420	   x	  
hsa-­‐miR-­‐516-­‐5p	   MIMAT0002859	   CAUCUGGAGGUAAGAAGCACUUU	   -­‐2.313	   	  	  
hsa-­‐miR-­‐429	   MIMAT0001536	   UAAUACUGUCUGGUAAAACCGU	   -­‐2.291	   x	  
hsa-­‐miR-­‐503	   MIMAT0002874	   UAGCAGCGGGAACAGUUCUGCAG	   -­‐2.266	   x	  
hsa-­‐miR-­‐600	   MIMAT0003268	   ACUUACAGACAAGAGCCUUGCUC	   -­‐2.250	   x	  
hsa-­‐miR-­‐200b	   MIMAT0000318	   UAAUACUGCCUGGUAAUGAUGAC	   -­‐2.249	   x	  
hsa-­‐miR-­‐107	   MIMAT0000104	   AGCAGCAUUGUACAGGGCUAUCA	   -­‐2.183	   x	  
hsa-­‐miR-­‐124a	   MIMAT0000422	   UUAAGGCACGCGGUGAAUGCCA	   -­‐2.157	   x	  
hsa-­‐miR-­‐33b	   MIMAT0003301	   GUGCAUUGCUGUUGCAUUGCA	   -­‐2.094	   x	  
hsa-­‐miR-­‐451	   MIMAT0001631	   AAACCGUUACCAUUACUGAGUUU	   -­‐2.054	   	  	  
hsa-­‐miR-­‐424	   MIMAT0001341	   CAGCAGCAAUUCAUGUUUUGAA	   -­‐2.049	   x	  
hsa-­‐miR-­‐519c	   MIMAT0002832	   AAAGUGCAUCUUUUUAGAGGAU	   -­‐2.040	   x	  
hsa-­‐miR-­‐383	   MIMAT0000738	   AGAUCAGAAGGUGAUUGUGGCU	   -­‐2.016	   	  	  
hsa-­‐miR-­‐518c*	   MIMAT0002847	   UCUCUGGAGGGAAGCACUUUCUG	   -­‐1.994	   	  	  
hsa-­‐miR-­‐519b	   MIMAT0002837	   AAAGUGCAUCCUUUUAGAGGUUU	   -­‐1.967	   x	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Supplemental	  Table	  2.	  Normalized	  logarithmic	  microRNA	  expression	  values	  in	  64	  primary	  
T-­‐ALL	  patient	  samples	  (cohort	  2)	  
	  
Not	  shown	  in	  thesis	  
	  
	  
Supplemental	  Table	  3.	  MicroRNAs	  significantly	  (p-­‐value	  <0.05)	  higher	  expressed	  in	  normal	  
thymocyte	   subsets	   compared	   to	   T-­‐ALL	   samples	   (t-­‐test	   with	   Benjamini-­‐Hochberg	  
correction)	  
	  
MicroRNA	  ID	   t-­‐test	  (p-­‐value)	   Benjamini-­‐Hochberg	   Fold	  Change	  
hsa-­‐mir-­‐195	   6.713E-­‐71	   0.0001618	   -­‐9.7496195	  
hsa-­‐mir-­‐662	   1.924E-­‐35	   0.0003236	   11.1918201	  
hsa-­‐mir-­‐29a	   6.862E-­‐32	   0.0004854	   -­‐5.3857330	  
hsa-­‐mir-­‐376a	   2.317E-­‐22	   0.0006472	   13.5329875	  
hsa-­‐mir-­‐7	   2.460E-­‐21	   0.0008091	   -­‐2.6219184	  
hsa-­‐mir-­‐223	   5.219E-­‐13	   0.0009709	   5.6164570	  
hsa-­‐mir-­‐503	   1.287E-­‐11	   0.0011327	   -­‐2.1598713	  
hsa-­‐mir-­‐95	   1.671E-­‐10	   0.0012945	   -­‐4.5268055	  
hsa-­‐mir-­‐23b	   2.093E-­‐10	   0.0014563	   -­‐0.8762993	  
hsa-­‐mir-­‐205	   2.823E-­‐09	   0.0016181	   -­‐3.2165296	  
hsa-­‐mir-­‐296	   2.931E-­‐09	   0.0017799	   -­‐3.6639771	  
hsa-­‐mir-­‐520d	   1.357E-­‐08	   0.0019417	   3.3680172	  
hsa-­‐mir-­‐141	   2.710E-­‐08	   0.0021036	   -­‐4.1685127	  
hsa-­‐mir-­‐651	   3.849E-­‐08	   0.0022654	   -­‐2.6730653	  
hsa-­‐mir-­‐100	   0.0000001	   0.0024272	   -­‐5.6657351	  
hsa-­‐mir-­‐373	   0.0000001	   0.0025890	   -­‐3.0880892	  
hsa-­‐mir-­‐520c	   0.0000001	   0.0027508	   6.7330880	  
hsa-­‐mir-­‐200c	   0.0000004	   0.0029126	   -­‐2.4689724	  
hsa-­‐mir-­‐99a	   0.0000005	   0.0030744	   -­‐5.2848169	  
hsa-­‐mir-­‐210	   0.0000006	   0.0032362	   -­‐3.2328291	  
hsa-­‐miR-­‐645	   0.0000010	   0.0033981	   2.7928400	  
hsa-­‐mir-­‐365	   0.0000022	   0.0035599	   -­‐2.7198946	  
hsa-­‐mir-­‐200a*	   0.0000038	   0.0037217	   -­‐0.9497195	  
hsa-­‐miR-­‐589	   0.0000063	   0.0038835	   -­‐2.4041596	  
hsa-­‐miR-­‐606	   0.0000063	   0.0040453	   1.9699663	  
hsa-­‐mir-­‐627	   0.0000064	   0.0042071	   -­‐2.0415349	  
hsa-­‐miR-­‐363*	   0.0000073	   0.0043689	   -­‐2.2591361	  
hsa-­‐mir-­‐574	   0.0000108	   0.0045307	   2.8307624	  
hsa-­‐mir-­‐580	   0.0000163	   0.0046926	   -­‐1.3622854	  
hsa-­‐mir-­‐219	   0.0000200	   0.0048544	   -­‐1.4469472	  
hsa-­‐mir-­‐34b	   0.0000202	   0.0050162	   -­‐0.3656468	  
hsa-­‐mir-­‐145	   0.0000297	   0.0051780	   2.6493413	  
hsa-­‐mir-­‐526b*	   0.0000298	   0.0053398	   -­‐1.0748624	  
hsa-­‐miR-­‐599	   0.0000414	   0.0055016	   -­‐0.6880783	  
hsa-­‐mir-­‐132	   0.0000420	   0.0056634	   -­‐3.0212290	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hsa-­‐mir-­‐449	   0.0000527	   0.0058252	   -­‐1.2066026	  
hsa-­‐mir-­‐30e-­‐5p	   0.0000609	   0.0059871	   2.3165613	  
hsa-­‐mir-­‐338	   0.0000760	   0.0061489	   -­‐2.6201088	  
hsa-­‐mir-­‐192	   0.0000928	   0.0063107	   -­‐2.7723308	  
hsa-­‐mir-­‐363	   0.0001200	   0.0064725	   1.2885197	  
hsa-­‐mir-­‐218	   0.0001405	   0.0066343	   -­‐2.2704391	  
hsa-­‐mir-­‐137	   0.0001646	   0.0067961	   3.6809823	  
hsa-­‐mir-­‐200b	   0.0002030	   0.0069579	   -­‐2.8418783	  
hsa-­‐mir-­‐520b	   0.0002388	   0.0071197	   -­‐1.1285756	  
hsa-­‐mir-­‐193b	   0.0003037	   0.0072816	   -­‐3.2876925	  
hsa-­‐mir-­‐425	   0.0003123	   0.0074434	   -­‐2.0688926	  
hsa-­‐mir-­‐501	   0.0003996	   0.0076052	   -­‐1.0622761	  
hsa-­‐mir-­‐491	   0.0007698	   0.0077670	   -­‐3.6667433	  
hsa-­‐mir-­‐324-­‐5p	   0.0009583	   0.0079288	   -­‐1.5877612	  
hsa-­‐mir-­‐451	   0.0011086	   0.0080906	   4.3005311	  
hsa-­‐mir-­‐422a	   0.0011654	   0.0082524	   -­‐1.2449892	  
hsa-­‐mir-­‐542-­‐5p	   0.0012136	   0.0084142	   -­‐0.2999885	  
hsa-­‐mir-­‐650	   0.0012499	   0.0085761	   -­‐1.9485388	  
hsa-­‐mir-­‐28	   0.0013181	   0.0087379	   -­‐1.3525218	  
hsa-­‐mir-­‐496	   0.0013440	   0.0088997	   1.8356225	  
hsa-­‐mir-­‐586	   0.0014230	   0.0090615	   -­‐0.2110830	  
hsa-­‐mir-­‐148a	   0.0016438	   0.0092233	   -­‐2.3600147	  
hsa-­‐mir-­‐200a	   0.0017042	   0.0093851	   -­‐1.3636241	  
hsa-­‐mir-­‐186	   0.0018389	   0.0095469	   -­‐1.3769981	  
hsa-­‐mir-­‐26a	   0.0020069	   0.0097087	   -­‐1.4617675	  
hsa-­‐miR-­‐532	   0.0023106	   0.0098706	   -­‐2.3333986	  
hsa-­‐mir-­‐181b	   0.0025073	   0.0100324	   -­‐1.3934098	  
hsa-­‐mir-­‐429	   0.0025617	   0.0101942	   -­‐2.0352242	  
hsa-­‐mir-­‐584	   0.0029069	   0.0103560	   0.0000000	  
hsa-­‐miR-­‐567	   0.0029069	   0.0105178	   0.0000000	  
hsa-­‐mir-­‐331	   0.0029672	   0.0106796	   -­‐0.9358149	  
hsa-­‐mir-­‐140	   0.0030062	   0.0108414	   -­‐2.3069168	  
hsa-­‐miR-­‐126	   0.0032826	   0.0110032	   2.5332965	  
hsa-­‐mir-­‐616	   0.0038812	   0.0111650	   -­‐1.5885154	  
hsa-­‐mir-­‐381	   0.0042010	   0.0113269	   1.3888124	  
hsa-­‐mir-­‐342	   0.0048092	   0.0114887	   -­‐1.1844081	  
hsa-­‐mir-­‐135b	   0.0049608	   0.0116505	   -­‐2.7111468	  
hsa-­‐mir-­‐502	   0.0053141	   0.0118123	   -­‐1.0241894	  
hsa-­‐mir-­‐610	   0.0054653	   0.0119741	   -­‐1.4935623	  
hsa-­‐mir-­‐193a	   0.0058309	   0.0121359	   -­‐1.4646607	  
hsa-­‐mir-­‐383	   0.0062825	   0.0122977	   -­‐1.2746388	  
hsa-­‐mir-­‐375	   0.0064374	   0.0124595	   -­‐1.6612633	  
hsa-­‐miR-­‐596	   0.0064878	   0.0126214	   0.0000000	  
hsa-­‐mir-­‐30a-­‐5p	   0.0066291	   0.0127832	   -­‐1.0154704	  
hsa-­‐mir-­‐187	   0.0070678	   0.0129450	   -­‐0.9742990	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hsa-­‐mir-­‐30b	   0.0073376	   0.0131068	   -­‐1.0131250	  
hsa-­‐mir-­‐106a	   0.0075057	   0.0132686	   -­‐1.2576614	  
hsa-­‐mir-­‐18a	   0.0075492	   0.0134304	   -­‐1.6392437	  
hsa-­‐mir-­‐155	   0.0075906	   0.0135922	   -­‐1.6153726	  
hsa-­‐mir-­‐660	   0.0077540	   0.0137540	   -­‐2.1595295	  
hsa-­‐mir-­‐10a	   0.0084745	   0.0139159	   1.8086133	  
hsa-­‐miR-­‐579	   0.0085684	   0.0140777	   -­‐1.8828573	  
hsa-­‐mir-­‐24	   0.0090554	   0.0142395	   -­‐1.3748805	  
hsa-­‐mir-­‐106b	   0.0099932	   0.0144013	   -­‐1.6189324	  
hsa-­‐mir-­‐559	   0.0104168	   0.0145631	   -­‐0.5886012	  
hsa-­‐mir-­‐632	   0.0111769	   0.0147249	   -­‐1.4962236	  
hsa-­‐mir-­‐142-­‐3p	   0.0115358	   0.0148867	   -­‐3.1319298	  
hsa-­‐mir-­‐34c	   0.0116842	   0.0150485	   -­‐0.7266410	  
hsa-­‐mir-­‐30c	   0.0121314	   0.0152104	   -­‐0.8788309	  
hsa-­‐mir-­‐98	   0.0135380	   0.0153722	   -­‐2.2402383	  
hsa-­‐mir-­‐31	   0.0135954	   0.0155340	   -­‐2.4044068	  
hsa-­‐mir-­‐486	   0.0136460	   0.0156958	   3.5125262	  
hsa-­‐mir-­‐410	   0.0141069	   0.0158576	   1.7235875	  
hsa-­‐miR-­‐450	   0.0141620	   0.0160194	   -­‐0.6475819	  
hsa-­‐mir-­‐224	   0.0146627	   0.0161812	   1.7923700	  
hsa-­‐mir-­‐324-­‐3p	   0.0156962	   0.0163430	   -­‐1.3357590	  
	  
	  
Supplemental	  Table	  4.	  miRNAs	  -­‐	  MYB	  correlations	  in	  primary	  T-­‐ALL	  patient	  samples	  (only	  
shown	  miRNAs	  with	  a	  correlation	  score	  of	  <	  -­‐0,5)	  
	  
MicroRNAs	   Correlation	  score	  
hsa-­‐miR-­‐876-­‐3p	   -­‐0.797802198	  
hsa-­‐miR-­‐1285	   -­‐0.754545455	  
hsa-­‐miR-­‐100	   -­‐0.581203008	  
hsa-­‐miR-­‐155	   -­‐0.575412088	  
hsa-­‐miR-­‐1303	   -­‐0.560714286	  
hsa-­‐miR-­‐326	   -­‐0.554179567	  
hsa-­‐miR-­‐21*	   -­‐0.524904215	  
hsa-­‐miR-­‐125a-­‐3p	   -­‐0.517857143	  
hsa-­‐miR-­‐193b	   -­‐0.503479853	  
hsa-­‐miR-­‐548a-­‐5p	   -­‐0.5	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Supplemental	  Table	  5.	  MicroRNAs	  significantly	  (p	  <0.05)	  differentially	  expressed	  between	  
the	   TAL	   subtype	   and	   other	   T-­‐ALL	   subtypes	   in	   cohort	   1	   (t-­‐test	   with	   Benjamini-­‐Hochberg	  
correction)	  
	  
microRNA	  ID	   t-­‐test	  (p-­‐value)	   Benjamini-­‐Hochberg	   Fold	  Change	  
hsa-­‐miR-­‐200c	   0.000007	   0.000167	   1.561932	  
hsa-­‐miR-­‐592	   0.000032	   0.005255	   2.054280	  
hsa-­‐miR-­‐196b	   0.000041	   0.005405	   -­‐4.659506	  
hsa-­‐miR-­‐196a	   0.000048	   0.005556	   -­‐4.684535	  
hsa-­‐miR-­‐646	   0.000079	   0.005706	   0.000000	  
hsa-­‐miR-­‐589	   0.000128	   0.005856	   1.441916	  
hsa-­‐miR-­‐567	   0.000414	   0.006006	   0.000000	  
hsa-­‐miR-­‐135a	   0.000528	   0.006156	   -­‐4.352846	  
hsa-­‐miR-­‐484	   0.000722	   0.006306	   1.152414	  
hsa-­‐miR-­‐362	   0.000764	   0.006456	   1.877522	  
hsa-­‐miR-­‐153	   0.001060	   0.006607	   -­‐2.057982	  
hsa-­‐miR-­‐502	   0.002047	   0.006757	   0.914466	  
hsa-­‐miR-­‐422a	   0.002268	   0.006907	   0.981960	  
hsa-­‐miR-­‐193b	   0.003167	   0.007057	   -­‐2.126321	  
hsa-­‐miR-­‐532	   0.003345	   0.007207	   1.994637	  
hsa-­‐miR-­‐148a	   0.006293	   0.007357	   1.811322	  
hsa-­‐miR-­‐125b	   0.006434	   0.007508	   -­‐2.172430	  
hsa-­‐miR-­‐130b	   0.007325	   0.007658	   1.041703	  
	  
	  
Supplemental	  Table	  6.	  MicroRNAs	  significantly	   (p<0.05)	  differentially	  expressed	  between	  
the	   TAL	   subtype	   and	   other	   T-­‐ALL	   subtypes	   of	   cohort	   2	   (t-­‐test	   with	   Benjamini-­‐Hochberg	  
correction)	  
	  
microRNA	  ID	   t-­‐test	  (p-­‐value)	   Benjamini-­‐Hochberg	   Fold	  Change	  
hsa-­‐miR-­‐15b*	   0.0000001	   0.0001190	   2.1082243	  
hsa-­‐miR-­‐148a	   0.0000005	   0.0002381	   3.2249217	  
hsa-­‐miR-­‐140-­‐3p	   0.0000009	   0.0003571	   -­‐4.4621059	  
hsa-­‐miR-­‐200c	   0.0000012	   0.0004762	   1.5013635	  
hsa-­‐miR-­‐1275	   0.0000013	   0.0005952	   1.4690232	  
hsa-­‐miR-­‐450a	   0.0000035	   0.0007143	   2.3650028	  
hsa-­‐miR-­‐141	   0.0000036	   0.0008333	   1.7252399	  
hsa-­‐miR-­‐155*	   0.0000045	   0.0009524	   -­‐1.5357130	  
hsa-­‐miR-­‐135b	   0.0000052	   0.0010714	   -­‐2.8707393	  
hsa-­‐miR-­‐155	   0.0000059	   0.0011905	   -­‐1.1840741	  
hsa-­‐miR-­‐542-­‐3p	   0.0000095	   0.0013095	   2.0830691	  
hsa-­‐miR-­‐199a-­‐3p	   0.0000137	   0.0014286	   -­‐2.2132103	  
rno-­‐miR-­‐29c*	   0.0000233	   0.0015476	   1.3388016	  
hsa-­‐miR-­‐29c	   0.0000284	   0.0016667	   1.4381646	  
hsa-­‐miR-­‐130b	   0.0000743	   0.0017857	   1.2494804	  
hsa-­‐miR-­‐146b-­‐5p	   0.0000763	   0.0019048	   -­‐1.2458543	  
hsa-­‐miR-­‐424	   0.0000829	   0.0020238	   1.8914370	  
hsa-­‐miR-­‐625*	   0.0001027	   0.0021429	   0.9115379	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hsa-­‐miR-­‐454*	   0.0001038	   0.0022619	   1.1192530	  
hsa-­‐miR-­‐454	   0.0001228	   0.0023810	   0.8860373	  
hsa-­‐miR-­‐301b	   0.0001611	   0.0025000	   1.0638763	  
hsa-­‐miR-­‐133a	   0.0001796	   0.0026190	   -­‐2.4124848	  
hsa-­‐miR-­‐942	   0.0002136	   0.0027381	   0.8041648	  
hsa-­‐miR-­‐146b-­‐3p	   0.0002477	   0.0028571	   -­‐1.4372405	  
hsa-­‐miR-­‐222	   0.0003794	   0.0029762	   -­‐1.1558824	  
hsa-­‐miR-­‐221*	   0.0006076	   0.0030952	   -­‐1.3214459	  
hsa-­‐miR-­‐31	   0.0006614	   0.0032143	   1.8566747	  
hsa-­‐miR-­‐502-­‐3p	   0.0008211	   0.0033333	   1.3276797	  
hsa-­‐miR-­‐126*	   0.0010863	   0.0034524	   -­‐1.5275477	  
hsa-­‐miR-­‐301a	   0.0011211	   0.0035714	   0.7397356	  
hsa-­‐miR-­‐31*	   0.0011790	   0.0036905	   1.5421801	  
hsa-­‐miR-­‐15b	   0.0012758	   0.0038095	   0.6859589	  
hsa-­‐miR-­‐18a*	   0.0013089	   0.0039286	   0.7357702	  
hsa-­‐miR-­‐376a	   0.0014459	   0.0040476	   1.4921312	  
hsa-­‐miR-­‐15a*	   0.0019645	   0.0041667	   0.5371654	  
hsa-­‐miR-­‐1244	   0.0020943	   0.0042857	   1.9340694	  
hsa-­‐miR-­‐455-­‐5p	   0.0021894	   0.0044048	   -­‐1.8964802	  
hsa-­‐miR-­‐125a-­‐5p	   0.0023960	   0.0045238	   -­‐2.0778450	  
hsa-­‐miR-­‐126	   0.0025778	   0.0046429	   -­‐1.5131013	  
hsa-­‐miR-­‐193b	   0.0027420	   0.0047619	   -­‐1.9393058	  
hsa-­‐miR-­‐411	   0.0027428	   0.0048810	   1.2588644	  
hsa-­‐miR-­‐503	   0.0032276	   0.0050000	   1.1878642	  
hsa-­‐miR-­‐125a-­‐3p	   0.0034847	   0.0051190	   -­‐0.7306363	  
hsa-­‐miR-­‐96	   0.0048807	   0.0052381	   1.0792698	  
hsa-­‐miR-­‐450b-­‐5p	   0.0051980	   0.0053571	   0.8109941	  
hsa-­‐miR-­‐362-­‐5p	   0.0054464	   0.0054762	   1.2215247	  
	  
	  
Supplemental	  Table	  7.	  Primers	  for	  qPCR	  
	  
Gene	   Forward	   Reverse	  
MYB	   GCTGCTTCCCAAGTCTGGAA	   CCACCAGCTTCTTCAGTTTTTCA	  
B2M	   TGCTGTCTCCATGTTTGATGTATCT	   TCTCTGCTCCCCACCTCTAAGT	  
SDHA	   TGGGAACAAGAGGGCATCTG	   CCACCACTGCATCAAATTCATG	  
TBP	   CACGAACCACGGCACTGATT	   TTTTCTTGCTGCCAGTCTGGAC	  
HPRT1	   TGACACTGGCAAAACAATGCA	   GGTCCTTTTCACCAGCAAGCT	  
UBC	   ATTTGGGTCGCGGTTCTTG	   TGCCTTGACATTCTCGATGGT	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Discussion	  &	  Future	  perspectives	  
	  
The	   genetic	   landscape	   of	   T-­‐ALL	   has	   been	   a	   very	   active	   area	   of	   research	   during	   the	   past	  
decades.	   This	   delivered	   an	   overwhelming	   body	   of	   exciting	   novel	   findings	   providing	   insight	  
into	   (1)	   the	   genetic	   heterogeneity	   of	   the	   disease	   with	   marked	   genetic	   subsets,	   (2)	   the	  
mechanisms	   of	   disruption	   of	   normal	   T-­‐cell	   development	   during	   leukemogenesis	   and	   (3)	  
emerging	   opportunities	   for	   novel	   therapeutic	   interventions1-­‐4.	   Of	   further	   interest,	   recent	  
genome	   wide	   sequencing	   studies	   identified	   involvement	   of	   a	   novel	   class	   of	   proteins	   as	  
emerging	  oncogenes	  and	  tumor	  suppressor	  genes	  in	  T-­‐ALL5-­‐9	  that	  actively	  participate	  in	  the	  
regulation	  of	  the	  T-­‐cell	  epigenome5-­‐9.	  In	  my	  own	  work,	  I	  contributed	  to	  the	  unraveling	  of	  the	  
epigenomic	   landscape	  of	  T-­‐ALL	  by	  the	   identification	  of	  recurrent	   inactivating	  defects	   in	  the	  
putative	  chromatin	  reader	  PHF6	   (paper	  16)	  and	  the	  histone	  H3K27me2/3	  demethylase	  UTX	  
in	  pediatric	  and	  adult	  T-­‐ALL	  cases	  (paper	  2,	  reviewed	  chapter	  210).	  Next	  to	  the	  broadening	  of	  
the	  epigenetic	  landscape	  in	  T-­‐ALL,	  I	  contributed	  to	  the	  exploration	  of	  the	  role	  of	  miRNAs	  in	  
T-­‐ALL	  pathogenesis.	  Using	  primary	  T-­‐ALL	  patient	  data	  and	  in	  vivo	  modeling	  in	  the	  NOTCH1	  T-­‐
ALL	  mouse	  model,	   we	   could	   identify	   a	   set	   of	   oncomiRs	   that	   are	   capable	   of	   co-­‐regulating	  
several	  T-­‐ALL	  tumor	  suppressor	  genes	  (paper	  311).	  Furthermore,	  implementation	  of	  a	  3’UTR	  
MYB	   library	   screen	   followed	   by	   validation	   of	   candidate	   miRNAs	   in	   T-­‐ALL	   model	   systems	  
enabled	   us	   to	   identify	   a	   miR-­‐193b-­‐3p	   mediated	   deregulation	   of	   MYB	   in	   T-­‐cell	   leukemia	  
(paper	  4).	  
	  
	  
PART	   1.	   Identification	   of	   X-­‐linked	   epigenetic	   drivers	   in	   T-­‐ALL	   and	   their	   role	   in	  
sensitivity	  to	  epigenetic	  therapy	  
	  
Given	   the	  higher	   incidence	  of	  T-­‐ALL	   in	  males	   (~3:1),	  we	  hypothesized	   that	   the	  presence	  of	  
tumor	   suppressor	   genes	   on	   the	   X-­‐chromosome	   could	   be	   a	   possible	   explanation	   for	   this	  
skewed	  gender	  distribution.	  In	  the	  early	  days	  of	  exome	  sequencing,	  it	  was	  therefore	  decided	  
to	  perform	  sequencing	  of	  the	  entire	  X-­‐chromosome	  exome	  in	  an	  attempt	  to	  identify	  one	  or	  
more	   X-­‐linked	   tumor	   suppressor	   genes	   (paper	   1)6.	   This	   pioneering	   study,	   performed	   as	  
collaborative	  effort	  with	  the	  Ferrando	  lab	  (Columbia,	  NY,	  USA),	  revealed	  PHF6	  mutations	  in	  a	  
set	  of	  pediatric	  (16%)	  and	  adult	  (38%)	  T-­‐ALL	  patient	  samples6.	  	  
	  
Several	  genetic	  defects	  present	  in	  T-­‐ALL	  are	  marked	  by	  a	  discrepancy	  in	  occurrence	  between	  
childhood	  and	  adult	  T-­‐ALL.	  TLX3	  translocations	  are	  present	  in	  22.4%	  of	  childhood	  and	  13.1%	  
of	   adult	   T-­‐ALL12.	   In	   contrast,	   TLX1	   rearrangements	   are	   more	   frequently	   present	   in	   adult	  
(30%)	   compared	   to	   childhood	  T-­‐ALL	   (5-­‐10%)4.	   Furthermore,	   JAK1	  mutations	  are	  present	   in	  
only	   2%	   of	   pediatric	   T-­‐ALL	  whereas	   26.3%	   of	   adults	  with	   T-­‐ALL	   bear	   JAK1	  mutations13.	   As	  
PHF6	  mutations	  are	  significantly	  associated	  with	  JAK1,	  TLX1	  and	  TLX3	  aberrations,	  the	  higher	  
frequency	  of	  PHF6	  mutations	  in	  adults	  can	  be	  in	  line	  with	  the	  age-­‐dependent	  occurrence	  of	  
defects	  in	  these	  other	  3	  genes6,14.	  
	  
Somatic	  PHF6	  mutations	  were	  also	  identified,	  although	  less	  frequent,	   in	  other	  cancer	  types	  
including	  AML15-­‐17,	  CML	  in	  blast	  crisis18,	  bladder	  cancer19	  and	  hepatocellular	  carcinoma16.	  As	  
the	  PHF6	   gene	   is	  most	   commonly	   targeted	   in	   T-­‐cell	   leukemia	   by	  mutations6,	   deletions6	   or	  
hypermethylation20	   and	   hereby	   quite	   restricted	   to	   malignant	   T-­‐cell	   pathogenesis,	   we	  
hypothesize	  a	  particular	  vulnerability	  for	  PHF6	  loss	  in	  normal	  thymocytes	  towards	  malignant	  
transformation.	   The	  molecular	   basis	   for	   this	   is	   currently	   under	   investigation	   in	   our	   lab	   in	  
close	   collaboration	  with	   the	   Taghon	   lab	   (UGent,	  Ghent,	   Belgium)	   and	   yielding	   some	  novel	  
and	  exciting	  preliminary	  insights.	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As	  cancer	  is	  a	  multi	  step	  process	  driven	  by	  typically	  at	  least	  5	  or	  more	  (epi)genetic	  events,	  it	  
is	   interesting	   to	   investigate	   to	   what	   extent	   such	   mutations	   contribute	   to	   early	   steps	   of	  
transformation	  rather	  than	  late	  or	  cooperative	  events.	  In	  this	  context,	  much	  can	  be	  learned	  
from	  familial	  cancer	  syndromes.	  Many	  of	  the	  now	  known	  tumor	  suppressor	  genes	  following	  
the	   classical	   Knudson	   two-­‐hit	   hypothesis	   were	   identified	   as	   familial	   cancer	   predisposing	  
genes,	  thus	  implicating	  these	  tumor	  suppressors	  can	  act	  as	  early	  events	  in	  tumor	  formation	  
in	  certain	  tissues.	   In	  this	  context,	   it	   is	  of	   interest	  that	  PHF6	  mutations	  are	  also	  found	  to	  be	  
the	   causal	   event	   in	   the	   development	   of	   the	   mental	   retardation	   syndrome	   BFLS21.	   Being	  
extremely	   rare,	   a	   thorough	   study	   of	   series	   of	   patients	   for	   risk	   in	   cancer	   development	   is	  
precluded.	   But	   it	   is	   remarkably	   that	   of	   the	   few	   patients	   reported	   thus	   far,	   the	   only	   one	  
developing	  cancer	  was	  described	   to	  have	  T-­‐ALL22.	   In	  agreement,	   loss	  of	  PHF6	  resulted	   in	  a	  
strong	  acceleration	  of	   leukemia	  onset	   in	   the	  well-­‐established	  NOTCH1	  T-­‐ALL	  mouse	  model	  
(paper	   311).	   These	   findings	   further	   underscore	   the	   crucial	   role	   of	   PHF6	   in	   T-­‐ALL	   and	   its	  
possible	  function	  in	  the	  early	  process	  of	  tumor	  development.	  
	  
The	   PHF6	   protein	   contains	   two	   PHD-­‐like	   zinc	   finger	   domains.	   As	   similar	   domains	   are	  
commonly	   present	   in	   nuclear	   proteins	   and	   chromatin-­‐associated	   factors	   and	   given	   the	  
nuclear	   localization	   of	   PHF6,	   it	   has	   been	   postulated	   that	   PHF6	   acts	   as	   a	   modifier	   of	   the	  
chromatin	  structure	  and	  thus	  implicated	  in	  gene	  regulation23.	  PHF6	  was	  shown	  to	  cooperate	  
with	   the	  chromatin	   remodeler	   complex	  NuRD24.	  Many	  members	  of	   the	  NuRD	  complex	  are	  
linked	   to	   negative	   regulation	   of	   gene	   transcription25.	   The	   HDAC	  members	   of	   NuRD	   erase	  
acetyl	  groups	  on	  lysines,	  a	  histone	  modification	  mark	  linked	  to	  active	  transcription;	  whereas	  
the	   MBD	   proteins	   can	   recognize	   DNA	   methylation	   present	   in	   closed	   chromatin	  
conformations25.	  The	  NuRD	  complex	  also	  associates	  with	  LSD1,	  a	  histone	  demethylase	  that	  
can	  erase	  methyl	  groups	  on	  H3K4	  leading	  again	  to	  compaction	  of	  the	  chromatin26.	  Notably,	  
the	   NuRD	   complex	   plays	   an	   important	   role	   in	   hematopoietic	   differentiation	   and	   more	  
specifically	   in	   transcriptional	   regulation	   of	   crucial	   genes	   during	   T-­‐cell	   development25.	  
Herewith	  it	  is	  intriguing	  to	  explore	  if	  PHF6	  has	  a	  role	  in	  negative	  transcriptional	  regulation	  in	  
accordance	  with	   the	  NuRD	  complex	   in	  normal	  and	  malignant	  T-­‐cell	  development.	   For	   this,	  
our	   lab	   has	   generated	   functional	   in	   vitro	   and	   in	   vivo	   model	   systems	   to	   explore	   the	  
transcriptional	   network	   regulated	   by	   PHF6.	   Of	   further	   notice,	   PHF6	   mutations	   are	   most	  
frequently	  detected	  in	  the	  TLX1	  and	  TLX3	  T-­‐ALL	  subgroups.	  Exploration	  of	  the	  link	  between	  
the	  TLX1,	  TLX3	  and	  PHF6	  proteins	  is	  ongoing	  in	  our	  lab	  through	  in	  vitro	  modeling	  of	  TLX1-­‐	  or	  
TLX3-­‐rearranged	   human	   T-­‐ALL	   cell	   lines	   and	   in	   vivo	   crossing	   of	   zebrafish	   strains	   in	  
collaboration	  with	  the	  Langenau	  Lab	  (Massachusetts	  General	  Hospital,	  Boston,	  USA).	  
	  
Intriguingly,	  PHF6	  has	  also	  been	  linked	  to	  yet	  another	  protein	  complex	  broadly	  implicated	  in	  
epigenetic	   remodeling,	   i.e.	   the	   SWI/SNF	   complex.	   Indeed,	   PHF6	  was	   recently	   found	   to	   be	  
mutated	   in	   patients	  with	   the	   Coffin-­‐Siris	   developmental	   disorder27.	   The	   discovery	   of	  PHF6	  
aberrations	   in	   the	  Coffin-­‐Siris	   syndrome	  was	  quite	  surprising	  since	   this	  syndrome	   is	  mainly	  
provoked	  by	  mutations	  in	  known	  components	  of	  the	  SWI/SNF	  remodeling	  complex27.	  Hence	  
it	   might	   be	   of	   interest	   to	   further	   investigate	   if	   PHF6	   plays	   a	   role	   in	   cooperating	   or	  
antagonizing	   this	   ATPase-­‐dependent	   remodeling	   complex.	   This	   hypothesis	   is	   currently	  
investigated	  in-­‐depth	  in	  our	  lab.	  
	  
Finally,	  functional	  studies	  have	  unraveled	  that	  the	  PHD-­‐containing	  protein	  PHF6	  has	  a	  role	  in	  
DNA	  damage	  response6,28	  and	  PHF6	   loss	   induces	  an	   increase	   in	   the	  global	   levels	  of	  γH2A.X	  
present	   in	   the	   chromatin	   (paper	   1)6,28.	   The	   NuRD	   complex	   becomes	   likewise	   PHF6	  
phosphorylated	  after	  DNA	  damage	  by	  the	  ATM	  and	  ATR	  DNA	  damage	  checkpoint	  kinases28	  
and	  actively	  aids	  in	  the	  repair	  after	  DNA	  damage24,25.	  Hereby	  the	  NURD-­‐PHF6	  complex	  might	  
	  	   193	  
be	  involved	  in	  active	  DNA	  repair,	  a	  research	  question	  that	  is	  currently	  addressed	  in	  our	  lab	  as	  
well.	  
	  
The	  recent	  discovery	  of	   inactivating	  mutations	   in	  the	  four	  members	  EZH2,	  EED,	  SUZ12	  and	  
JARID2	   of	   the	   PRC2	   complex	   in	   primary	   T-­‐ALL	   patient	   samples5,7,29	   further	   stresses,	   like	   in	  
most	  other	  cancer	  types,	  the	  broad	  implication	  of	  epigenetic	  perturbations,	  in	  particular	  for	  
T-­‐ALL	  an	  imbalance	  in	  H3K27	  methylation.	  Another	  regulator	  of	  H3K27	  methylation	  levels	  is	  
the	  histone	  H3K27me2/3	  demethylase	  UTX,	  already	  described	  as	  tumor	  suppressor	  gene	  in	  
many	   cancer	   types	   and	   like	   the	   PHF6	   gene	   also	   located	   on	   the	   X-­‐chromosome30-­‐34.	  
Accordingly,	   we	   hypothesized	   that	   the	   X-­‐linked	   epigenetic	   regulator	   UTX	   might	   also	   be	  
implicated	   in	  T-­‐ALL	  possibly	  further	  contributing	  to	  the	   increased	  T-­‐ALL	   incidence	   in	  males.	  
Inactivating	   mutations	   in	   the	   UTX	   gene	   were	   detected	   in	   5	   of	   35	   primary	   T-­‐ALL	   patient	  
samples	   (paper	   2).	   Intriguingly,	   these	   loss-­‐of-­‐function	   mutations	   were	   all	   present	   in	   the	  
functional	   JmjC	   domain	   of	   UTX	   presumably	   affecting	   the	   H3K27me2/3	   demethylase	  
function.	  
	  
As	  we	  detected	  UTX	  mutations	  in	  T-­‐ALL	  patient	  samples	  solely	  in	  the	  functional	  Jmjc	  domain	  
and	  UTX	  mutant	   samples	   are	  more	   sensitive	   to	  DZNep	   treatment,	   the	  oncogenic	   effect	   of	  
loss	  of	  UTX	  in	  T-­‐ALL	  might	  be	  mainly	  provoked	  by	  disruption	  of	  its	  H3K27me2/3	  demethylase	  
activity.	   But	   we	   can’t	   rule	   out	   that	   this	   oncogenicity	   in	   T-­‐ALL	   is	   caused	   through	   other	  
mechanisms	   since	   a	   demethylase-­‐independent	   role	   for	   UTX	   was	   demonstrated	   in	   the	  
interaction	   with	   the	   BRG1-­‐containing	   SWI/SNF	   remodeling	   complex	   promoting	   general	  
chromatin	   remodeling35,36.	   To	   address	   this	   question,	   one	  experimental	   set-­‐up	  would	  be	   to	  
test	   if	   a	   catalytic	   inactive	  Utx	  protein	   could	   rescue	   the	  oncogenic	   effect	   of	  Utx	   loss	   in	   the	  
MOHITO	  cell	  line.	  
	  
Of	  particular	  interest,	  the	  identified	  UTX	  mutations	  were	  only	  detected	  in	  male	  T-­‐ALL	  patient	  
samples.	  Since	  previous	  studies	  have	  shown	  that	  UTX	  can	  escape	  chromosome	  X-­‐inactivation	  
in	   certain	   tissues37,	   we	   explored	   if	   UTX	   is	   expressed	   also	   from	   both	   X-­‐chromosomes	   in	  
lymphoblasts	  of	   female	  T-­‐ALL	  patients.	  By	   sequencing	  of	   two	  silent	  SNPs	  on	  genomic	  DNA	  
(gDNA)	   and	   on	   complementary	   DNA	   (cDNA),	   we	   could	   confirm	   that	   UTX	   is	   bi-­‐allelically	  
expressed	  in	  female	  T-­‐ALL	  lymphoblasts	  (paper	  2).	  This	  important	  observation	  is	  in	  contrast	  
to	  the	  other	  identified	  X-­‐linked	  tumor	  suppressor	  genes	  PHF6	  (paper	  16)	  and	  RPL108	  in	  T-­‐ALL,	  
which	   are	   not	   able	   to	   escape	   X-­‐inactivation	   in	   female	   T-­‐ALL	   lymphoblasts.	   Hence	   the	  
identification	  of	  mutations	  in	  the	  UTX	  gene	  in	  males	  provides	  a	  further	  possible	  explanation	  
for	  the	  skewed	  gender	  distribution	  observed	  in	  T-­‐ALL.	  
	  
UTX	   is	   a	   frequent	   mutational	   target	   in	   many	   solid	   tumors	   and	   leukemias30,	   whereas	   the	  
second	   family	   member	   and	   also	   bona	   fide	   H3K27me2/3	   demethylase	   JMJD3	   is	   rarely	  
mutated	   (COSMIC	   database:	   JMJD3	   mutations	   detected	   in	   about	   1%	   of	   tumors).	   This	  
discrepancy	  underscores	  the	  partially	  non-­‐overlapping	  roles	  of	  UTX	  and	  JMJD3.	  Namely,	  the	  
H3K27me2/3	  demethylases	  UTX	  and	   JMJD3	  share	  common	  functionalities	  but	  also	  possess	  
non-­‐redundant	   roles.	   For	  example,	   the	  RAS-­‐RAF	  signaling	  pathway	   induces	   JMJD3,	  but	  not	  
UTX,	  leading	  to	  transcriptional	  activation	  of	  CDKN2A38.	  Vice	  versa	  JMJD3,	  unlike	  UTX,	  is	  not	  
required	   for	   efficient	   induction	   and	   re-­‐establishment	   of	   pluripotency	   during	   iPSC	  
formation39.	  So	  the	  strong	  oncogenic	  effect	  of	  UTX	  loss	  observed	  in	  our	  T-­‐ALL	  mouse	  model	  
is	  presumably	  not	  compensated	  by	  the	  other	  H3K27me2/3	  demethylase	  JMJD3.	  
	  
Likewise	  UTX,	   the	   epigenetic	   players	  DNMT3A	   and	   EZH2	   are	  more	   frequently	   affected	   by	  
somatic	   mutations	   compared	   to	   their	   close	   family	   members	   DNMT1/DNMT3B	   and	   EZH1,	  
respectively40.	  A	  higher	  prevalence	  of	  DNMT3A	  mutations	  in	  myeloid	  malignancies	  and	  T-­‐ALL	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can	   relate	   to	   the	   presumed	   unique	   role	   for	   DNMT3A	   in	   hematopoiesis40.	   The	   H3K27	  
methyltransferases	  EZH1	  and	  EZH2	  are	  incorporated	  in	  the	  PRC2	  complex	  depending	  on	  the	  
cellular	   context.	   EZH2	   is	   expressed	   in	   actively	   dividing	   cells,	   whereas	   EZH1	   is	   present	   in	  
resting	  cells41,42.	   In	   conditional	  EZH2	  knockout	  mice	   that	   spontaneously	  develop	  T-­‐ALL,	   the	  
EZH1	  protein	  was	  detectable	  but	  could	  not	  rescue	  the	  decrease	  in	  global	  H3K27me2/3	  levels	  
caused	  by	  EZH2	  loss29.	  Furthermore,	  EZH1	  is	  unable	  to	  rescue	  embryonic	  lethality	  caused	  by	  
EZH2	   loss	   in	  germline	  EZH2	  knockouts41,42.	  So	  epigenetic	  players	  with	  redundant	  enzymatic	  
activities	   can	   contain	   unique	   roles	   in	   the	   regulation	   of	   specific	   biological	   processes	  
depending	  on	  the	  cell-­‐type	  and	  the	  cellular	  context.	  	  
	  
Our	  finding	  that	  both	  UTX	  and	  the	  PRC2	  complex	  act	  as	  tumor	  suppressors	  in	  T-­‐ALL	  is	  quite	  
surprising	  and	  intriguing	  given	  their	  opposing	  enzymatic	  activities	  (Table	  1).	  Similar	   loss-­‐of-­‐
function	  mutations	  in	  UTX	  and	  the	  four	  members	  EZH2,	  SUZ12,	  EED	  and	  JARID2	  of	  the	  PRC2	  
are	   detected	   in	   myeloid	   malignancies	   including	   AML	   and	   MDS30,43-­‐46.	   One	   possible	  
explanation	  for	  this	  apparent	  contradiction	  is	  that	  UTX	  and	  PRC2	  regulate	  a	  different	  set	  of	  
target	   genes35.	   Alternatively,	   the	   other	   H3K27me2/3	   demethylase	   JMJD3	   can	   act	   at	   some	  
PRC2	  target	  genes	  instead	  of	  UTX	  as	  both	  H3K27me2/3	  demethylases	  were	  shown	  to	  exert	  a	  
distinct	   biology34,35,47,48.	  Moreover,	   both	  UTX	   and	   JMJD3	   have	   a	   demethylase-­‐independent	  
role	   interacting	  with	  the	  BRG1-­‐containing	  SWI/SNF	  remodeling	  complex	  promoting	  general	  
chromatin	   remodeling35,36,	   hence	   UTX-­‐JMJD3	   and	   PRC2	  might	   regulate	   different	   biological	  
processes	  even	  independent	  of	  H3K27me3	  regulation.	  	  
	  
Table1.	  Comparison	  of	  UTX	  and	  PRC2	  characteristics	  
	  
Functions	   UTX	   PRC2	  
T-­‐ALL	   tumor	  suppressor	   tumor	  suppressor	  
Cancer	   tumor	  suppressor	   dual:	  oncogene	  or	  tumor	  
suppressor	  
Developmental	  
disease	  
Kabuki	  syndrome	   Weaver	  syndrome	  (EZH2)	  
H3K27	   H3K27me2/3	  eraser	   H3K27	  methyltransferase	  
Target	  genes	  	   HOX,	  RB	   HOX,	  developmental	  regulators,	  
10%	  of	  all	  genes	  in	  ESCs,	  …	  
Interaction	   MLL2,	  CBP,	  BRG1	  -­‐	  SWI/SNF	   JARID2,	  AEBP2,	  PCL,	  HDAC1,	  
DNMTs,	  XIST,	  HOTAIR,	  …	  
Family	  members	   JMJD3,	  UTY	   PRC1,	  PRC2	  
Knockout	  mice	   embryonic	  lethality	  at	  E10.5-­‐
12.5	  for	  Utx-­‐/-­‐	  
embryonic	  lethality	  before	  
E10.5	  for	  Ezh2-­‐/-­‐	  
Loss	  in	  ESCs	   differentiation	  defect	   differentiation	  defect,	  loss	  of	  
pluripotency	  delayed	  
Inhibitors	   GSKJ4	   GSK126,	  EPZ-­‐6438,	  …	  
	  
In	  our	   in	   vitro	   and	   in	   vivo	  murine	  T-­‐ALL	  models	  with	  UTX	  or	  SUZ12	   loss,	  we	  could	  provide	  
some	   clues	   that	   UTX	   and	   SUZ12	   exert	   different	   roles	   in	   T-­‐cell	   transformation	   as	   gene	  
expression	  profiling	  showed	  that	  non-­‐overlapping	  genetic	  pathways	  were	  affected	  between	  
the	   two	   loss-­‐of-­‐function	   models	   (paper	   2).	   Next	   to	   the	   gene	   expression	   profiles,	   RNA-­‐
sequencing	   and	   chromatin	   immunoprecipitation	   (ChIP)	   followed	   by	   high-­‐throughput	  
sequencing	   (seq)	   of	   UTX,	   SUZ12	   as	   well	   as	   H3K27me3	   in	   our	   in	   vitro	   and	   in	   vivo	   model	  
systems	  would	  enable	  a	  more	  detailed	  characterization	  of	  the	  direct	  UTX	  and	  SUZ12	  target	  
genes	  and	  non-­‐coding	  genes.	  Given	  that	  UTX	  can	  physically	  associate	  with	  MLL2,	  it	  would	  be	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interesting	  to	  investigate	  if	  this	  is	  also	  true	  in	  a	  T-­‐ALL	  context	  using	  mass-­‐spectrometry	  &	  co-­‐
immunoprecipitation	  studies.	  Also	  ChIP-­‐seq	  of	  H3K4me3	  levels	  after	  UTX	  loss	  might	  indicate	  
if	  UTX	  is	  essential	  in	  T-­‐ALL	  for	  the	  functional	  activity	  of	  MLL2	  in	  H3K4me3	  regulation.	  Similar	  
approaches	   using	   gene	   expression	   profiling	   and	   ChIP-­‐seq	   have	   been	   undertaken	   in	   cancer	  
models,	  for	  example	  to	  identify	  the	  HOXA	  cluster	  as	  target	  of	  the	  epigenetic	  regulator	  ASXL1	  
in	  myeloid	  malignancies49.	  
	  
Knockdown	   of	   UTX	   and	   SUZ12	   provided	   a	   clear	   acceleration	   in	   leukemia	   onset	   in	   the	  
commonly	  used	  NOTCH1	  T-­‐ALL	  mouse	  model50	  (paper	  2).	  Furthermore,	  mutations	  targeting	  
UTX	  or	  the	  PRC2	  complex	  both	  frequently	  co-­‐occur	  with	  NOTCH1	  mutations	  (paper	  2)5.	  This	  
implicates	  that	  both	  loss	  of	  UTX	  or	  PRC2	  can	  cooperate	  with	  NOTCH1	  in	  T-­‐ALL	  pathogenesis.	  
A	  previous	  study	  of	  the	  Aifantis	  lab	  (NYU,	  NY,	  USA)	  has	  demonstrated	  that	  NOTCH1	  signaling	  
in	  T-­‐ALL	  promotes	  the	  reduction	  in	  PRC2	  activity	  at	  NOTCH1	  target	  genes	  marked	  by	  loss	  of	  
H3K27me3,	   these	   NOTCH1	   target	   genes	   being	   enriched	   for	   known	   PRC2	   target	   genes5.	  
Moreover,	  several	  NOTCH1	  ligands	  and	  HES1	  family	  members	  have	  been	  shown	  to	  be	  direct	  
targets	   of	   the	   PRC2	   complex	   in	   human	   ESCs	   and	   embryonic	   fibroblasts51,52.	   This	   indicates	  
that	   the	  NOTCH1	   pathway	  might	   be	   under	   influence	   of	   PRC2	   activity	   in	  mammals	   (Figure	  
1)53.	  
	  
	  
	  
Figure	  1.	  The	  histone	  methyltransferase	  PRC2	  and	  the	  histone	  demethylase	  UTX	  control	  the	  
NOTCH1	  signaling	  pathway	  at	  different	  levels53	  (graphics	  from	  www.somersault1824.com)	  
	  
In	   addition,	   in	   flies	   dUTX	   loss-­‐of-­‐function	   mutants	   give	   rise	   to	   decreased	   mRNA	   levels	   of	  
negative	   regulators	   of	   Notch	   and	   elevated	   protein	   levels	   of	   Notch53,54	   (Figure	   1).	   So	   both	  
H3K27me3	  regulators	  seem	  to	  influence	  the	  NOTCH1	  signaling	  pathway	  through	  regulation	  
of	   negative	   NOTCH1	   regulators	   by	   UTX	   and	   regulation	   of	   NOTCH1	   ligands	   and	   NOTCH1	  
target	   genes	   by	   PRC253,55	   (Figure	   1).	   Thus	   this	   distinct	   regulation	   of	   the	  NOTCH1	   signaling	  
might	  be	  a	  possible	  explanation	   for	  why	  these	  epigenetic	  players	  with	  opposing	  enzymatic	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activities	   are	   both	   inactivated	   in	   T-­‐ALL,	   but	   more	   research	   is	   needed	   to	   validate	   this	  
hypothesis.	  
	  
Both	   H3K27me2/3	   regulators	   UTX	   and	   PRC2	   are	   essential	   during	   normal	   embryonic	  
development	   since	   loss	   of	  Utx	   (together	   with	  Uty	   in	   males),	   Ezh2,	   Suz12	   or	   Eed	   leads	   to	  
embryonic	  lethality56-­‐61.	  Furthermore,	  these	  chromatin	  regulators	  seem	  to	  play	  crucial	  roles	  
during	   hematopoiesis58,60,62-­‐64.	   Loss	   of	   Ezh2	   provokes	   an	   early	   arrest	   in	   B-­‐cell	   and	   T-­‐cell	  
development64,	  whereas	   loss	   of	  Utx	   gives	   rise	   to	   an	  enlarged	   spleen,	   reduced	  hemoglobin	  
levels,	   anemia,	   thrombocytopenia	   and	   mild	   leukocytopenia60.	   Moreover,	   loss	   of	   Ezh2	   in	  
mouse	   HSCs	   induced	   murine	   T-­‐ALL	   formation29,	   in	   accordance	   with	   the	   observation	   that	  
adult	   mice	   bearing	   a	   hypomorphic	   Eed	   allele	   develop	   severe	   lymphoid	   and	   myeloid	  
disorders65.	   In	   our	   study,	   we	   provide	   first	   evidence	   that	   the	   PRC2	   member	   Suz12	   also	  
contributes	  in	  vivo	  to	  lymphoid	  tumor	  formation	  (paper	  2).	  
	  
The	  identification	  of	  these	  epigenetic	  drivers	  in	  T-­‐ALL	  can	  provide	  novel	  therapeutic	  angles	  in	  
this	   aggressive	  disease,	   since	  epigenetic	   therapies	  are	  promising	  agents	   in	   cancer	   therapy.	  
Moreover,	  the	  first	  epigenetic	  therapies	  have	  already	  been	  approved	  by	  the	  FDA	  as	  effective	  
cancer	   treatments,	  which	  are	   the	  DNMTi	  vidaza	  and	  decitabine	  approved	   for	   treatment	  of	  
MDS66,67	   and	   the	   HDACi	   vorinostat	   and	   romidepsin	   approved	   for	   treatment	   of	   T-­‐cell	  
cutaneous	   lymphoma66,68.	   In	  our	  UTX	  study,	  we	  were	  able	   to	   show	  that	  UTX	  mutant	  T-­‐ALL	  
cells	  are	  more	   sensitive	   to	   the	  H3K27me3	   inhibitor	  DZNep	  suggesting	   that	   this	  drug	  might	  
serve	   as	   a	   new	   therapeutic	   strategy	   for	  UTX	  mutant	   T-­‐ALL	   patients	   (paper	   2).	   DZNep	   is	   a	  
competitive	   inhibitor	  of	  the	  S-­‐adenosylhomocysteine	  hydrolase	   leading	  to	  an	  accumulation	  
of	   S-­‐adenosylhomocysteine	   and	   blocking	   the	   production	   of	   the	   essential	   HMT	   co-­‐factor	  
SAM69.	   Subsequently,	  H3K27	  methylation	   levels	  decline	   leading	   to	  apoptosis	  of	   cancer	   cell	  
lines69	  and	  UTX	  mutant	  T-­‐ALL	   samples	   (paper	   2).	   In	  addition,	   specific	  EZH2	   inhibitors	  were	  
developed	  including	  GSK-­‐126	  that	  enable	  direct	  EZH2	  blockage	  followed	  by	  H3K27me3	  loss	  
and	   provoking	   reactivation	   of	   PRC2	   target	   genes70.	   Since	   PRC2	   and	  UTX	   presumably	   exert	  
differential	  roles	  in	  malignant	  T-­‐cells,	  the	  use	  of	  these	  specific	  EZH2	  inhibitors	  like	  GSK-­‐126	  in	  
UTX	   mutant	   T-­‐ALL	   samples	   seems	   dual	   as	   direct	   EZH2	   inhibition	   might	   cause	   unwanted	  
effects.	   To	   conclude,	   we	   could	   demonstrate	   that	   restoring	   the	   precise	   balance	   of	   H3K27	  
methylation	  by	  use	  of	  DZNep	  can	  restrain	  UTX	  mutant	  T-­‐cell	  leukemia	  (paper	  2).	  In	  addition,	  
precaution	   is	  warranted	   in	   selecting	   T-­‐ALL	   patients	   for	   specific	   epigenetic	   therapies,	   since	  
both	  UTX	  and	  PRC2	  are	  acting	  as	  tumor	  suppressors	  in	  this	  disease.	  
	  
To	  conclude,	  we	  identified	  the	  X-­‐linked	  PHF6	  and	  UTX	  genes	  as	  mutational	  targets	  and	  bona	  
fide	  tumor	  suppressor	  genes	  in	  T-­‐ALL	  (paper	  16	  &	  2).	  Until	  now,	  we	  and	  others	  were	  unable	  
to	  show	  any	  prognostic	  relevance	  to	  the	  occurrence	  of	  PHF6	  or	  UTX	  loss-­‐of-­‐function	  defects	  
in	  T-­‐ALL	  (paper	  16	  &	  2).	  For	  this,	  detailed	  mutational	  and	  clinical	  characterization	  of	  large	  T-­‐
ALL	  cohorts	  is	  needed	  to	  connect	  these	  genetic	  defects	  to	  specific	  prognostic	  or	  treatment-­‐
response	  values.	  Also,	  these	  large	  T-­‐ALL	  cohorts	  can	  be	  used	  to	  further	  explore	  which	  lesions	  
co-­‐occur	  together	  with	  UTX	  and	  PHF6	  mutations	  in	  primary	  T-­‐ALL	  patient	  samples.	  	  
	  
Furthermore,	  we	  could	  show	  an	  oncogenic	  role	  for	  loss	  of	  UTX	  (paper	  2)	  and	  PHF611	  in	  our	  T-­‐
ALL	  mouse	  model.	  Further	  exploration	  of	  PHF6	  and	  UTX	  loss	  to	  T-­‐ALL	  pathogenesis	  by	  gene	  
expression	   and	   ChIP-­‐seq	   profiling	   is	   essential	   to	   grasp	   how	   these	   epigenetic	   players	  
mechanistically	   contribute	   to	   this	   aggressive	   cancer	   type.	   Establishment	  of	  hematopoietic-­‐
specific	   conditional	   knockout	  mice	   for	  UTX,	   SUZ12	   or	   PHF6,	   likewise	   the	   conditional	   EZH2	  
knockout	  mice29,	  can	  further	  unravel	  how	  these	  different	  epigenetic	  players	  contribute	  to	  T-­‐
ALL	  formation.	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In	  paper	  2,	  we	  observed	  a	  co-­‐occurrence	  of	  UTX	  mutations	  and	  SUZ12	  deletions	  in	  primary	  
T-­‐ALL	   patient	   samples,	   a	   quite	   remarkable	   finding	   given	   their	   opposite	   roles	   on	   H3K27	  
regulation.	   Generation	   of	   double	   knockouts	   with	   concurrent	   loss	   of	   two	   epigenetic	  
regulators	  has	  been	  already	  explored	  in	  vivo,	  for	  example	  the	  TET2	  –	  EZH2	  double	  knockout	  
in	  myeloid	  malignancies71.	  Hereby	  the	  generation	  and	  genomic	  exploration	  of	  UTX	  –	  SUZ12	  
double	  knockouts	  can	  shed	  light	  on	  the	  cooperativity	  of	  these	  two	  epigenetic	  evens	  in	  T-­‐ALL.	  
	  
	  
PART	  2.	  Search	  for	  deregulated	  microRNA	  networks	  in	  T-­‐ALL	  
	  
Twenty	  years	  ago,	  the	  first	  miRNA	  lin-­‐4	  was	  discovered	  which	  was	  shown	  to	  have	  a	  negative	  
impact	   on	   the	   development	   of	   Caenorhabditis	   elegans72.	   A	   small	   decade	   later,	   the	   first	  
chromosomal	  defects	   leading	   to	  miRNA	  deregulation	  were	   found	   through	   the	  discovery	  of	  
recurrent	   translocations	   and	   deletions	   targeting	   the	   miR-­‐15a/miR-­‐16-­‐1	   locus	   in	   chronic	  
lymphocytic	  leukemia	  (CLL)	  leading	  to	  a	  decreased	  expression	  of	  both	  miRNAs73.	  One	  of	  the	  
first	  key	  observations	  for	  involvement	  of	  miRNAs	  in	  T-­‐ALL	  was	  the	  finding	  of	  a	  chromosomal	  
translocation	   juxtaposing	   the	   miR-­‐17-­‐92	   cluster	   under	   the	   control	   of	   the	   T-­‐cell	   specific	  
enhancer	  of	   the	  TCRβ	   leading	  to	  strong	   induction	  of	  miR-­‐17-­‐9274.	  This	  polycistronic	  miRNA	  
cluster	   was	   described	   as	   one	   of	   the	   first	   oncomiRs	   in	   cancer75.	   The	   miR-­‐17-­‐92	   cluster	  
encodes	   6	  miRNAs	   (miR-­‐17,	  miR-­‐18a,	  miR-­‐19a,	  miR-­‐20a,	  miR-­‐19b-­‐1	   and	  miR-­‐92a-­‐1)	   and	   is	  
located	   in	   the	   non-­‐protein-­‐coding	   gene	   C13orf25	   at	   chromosome	   13.	   Importantly,	   these	  
polycistronic	  miRNA	  members	  are	  co-­‐transcribed	  but	  are	  individually	  processed,	  so	  different	  
expression	   levels	   of	   the	   individual	   members	   can	   be	   present	   in	   a	   specific	   cell-­‐type.	  
Furthermore,	   the	   mature	   and	   seed	   sequences	   differ	   between	   the	   miR-­‐17-­‐92	   members	  
thereby	  a	  specific	  set	  of	  target	  genes	  can	  be	  regulated	  by	  each	  member76.	  
	  
Of	  interest,	  the	  miR-­‐17-­‐92	  cluster	  plays	  a	  role	  in	  animal	  development,	  since	  lack	  of	  miR-­‐17-­‐
92	  in	  mice	  leads	  to	  postnatal	  lethality77.	  More	  specifically,	  the	  miR-­‐17-­‐92	  cluster	  was	  shown	  
to	   play	   a	   role	   in	   B-­‐cell	   differentiation	   as	  miR-­‐17-­‐92	   ablation	   leads	   to	   enhanced	   pro-­‐B-­‐cell	  
apoptosis	   during	   the	   pro-­‐	   to	   pre-­‐B-­‐cell	   stage77.	   Also	   in	   T-­‐cell	   development	   the	  miR-­‐17-­‐92	  
cluster	  contributes	  by	  promoting	  CD4+	  T-­‐cell	  helper	  cell	  responses78	  and	  effector	  CD8+	  T-­‐cell	  
expansion79.	   This	   data	   supports	   the	   oncogenic	   effects	   observed	   after	   deregulation	   of	   the	  
miR-­‐17-­‐92	  cluster	  in	  normal	  T-­‐cells.	  	  
	  
The	  miR-­‐19	  member	  was	  shown	  by	  Mavrakis	  et	  al.	  and	  other	  groups	  to	  be	  the	  key	  oncogenic	  
determinant	  of	  the	  miR-­‐17-­‐92	  cluster	  contributing	  to	  lymphoma	  and	  T-­‐ALL	  formation59,66,67.	  
In	   contrast,	   the	   miR-­‐17/20a	   miRNA	   members	   were	   shown	   to	   be	   the	   main	   oncogenic	  
components	  in	  retinoblastoma	  working	  in	  concert	  with	  Rb	  loss80.	  So	  depending	  on	  the	  cell-­‐
type	  and	  context,	  a	  different	  miRNA	  cluster	  member	  can	  play	  a	  key	  role	  in	  cancer	  formation.	  
In	  our	  study,	  we	  could	  demonstrate	  that	  miR-­‐20a	  and	  miR-­‐92	  are	  also	  oncogenic	  in	  T-­‐ALL	  in	  
addition	  to	  miR-­‐19,	  both	   in	  vitro	   in	  human	  T-­‐ALL	  cell	   lines	  and	   in	  vivo	   in	  the	  NOTCH1	  T-­‐ALL	  
mouse	   model	   (paper	   3)11,74.	   Furthermore,	   our	   study	   showed	   that	   the	   different	   members	  
miR-­‐19b,	  miR-­‐20a	  and	  miR-­‐92	  are	  capable	  of	  targeting	  the	  common	  T-­‐ALL	  tumor	  suppressor	  
genes	  PTEN	   and	  BIM.	   These	   findings	   are	   in	   agreement	  with	   a	   study	   in	  which	   a	  miR-­‐17-­‐92	  
transgenic	  mouse	  model	  with	   specific	  enhanced	  miR-­‐17-­‐92	  expression	   in	   lymphocytes	  was	  
shown	   to	   develop	   a	   lymphoproliferative	   disease	   and	   suppress	   Bim	   and	   Pten	   expression81.	  
Moreover,	  miR-­‐20a	  is	  also	  capable	  of	  targeting	  the	  tumor	  suppressor	  PHF6	  and	  miR-­‐92	  can	  
additionally	   regulate	   IKZF1,	   NF1	   and	   FBXW7	   in	   T-­‐ALL	   (paper	   3)11.	   Thus	   the	   miR-­‐17-­‐92	  
members	   can	   cooperate	   in	   promoting	   T-­‐ALL	   formation	   presumably	   through	   silencing	   of	   a	  
larger	  group	  of	  T-­‐ALL	  tumor	  suppressor	  genes	  than	  is	  plausible	  by	  only	  one	  miR-­‐17-­‐92	  cluster	  
member11,76.	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Besides	  cooperation	  with	  NOTCH1	  as	  we	  have	  shown	  in	  our	  oncomiR	  story	  (paper	  3)10,60,	  the	  
miR-­‐17-­‐92	  cluster	  can	  also	  work	  in	  concert	  with	  the	  MYC	  oncogene11,74,82.	  Overexpression	  of	  
the	   miR-­‐17-­‐19b-­‐1	   cluster	   (vertebrate	   portion	   of	   the	   miR-­‐17-­‐92	   cluster)	   together	   with	   the	  
MYC	   oncogene	   showed	   an	   accelerated	   MYC-­‐induced	   B-­‐cell	   lymphomagenesis	   in	   mice82.	  
Furthermore,	  MYC	  was	   shown	   to	  directly	   control	   the	  expression	  of	  miR-­‐17-­‐92	  and	   the	  cell	  
cycle	  regulator	  E2F1	  promoting	  cell	  cycle	  progression.	  Surprisingly,	  both	  miR-­‐17	  and	  miR-­‐20a	  
can	  negatively	  regulate	  E2F1	  protein	  expression	   leading	  to	  a	  tightly	  controlled	  proliferative	  
signal	  through	  MYC	  and	  its	  regulated	  miRNA	  cluster83.	  In	  addition,	  several	  MLL-­‐fusions	  were	  
shown	  to	  directly	  drive	  miR-­‐17-­‐92	  expression	   leading	  to	  aberrant	  H3	  acetylation	  and	  H3K4	  
trimethylation84.	  
	  
In	  addition	  to	  the	  miR-­‐17-­‐92	  cluster,	  we	  also	  identified	  miR-­‐223,	  miR-­‐26a,	  miR-­‐27a	  and	  miR-­‐
148a/152	   as	   bona	   fide	   oncomiRs	   in	   T-­‐ALL.	   MiR-­‐26a	   targets	   the	   T-­‐ALL	   tumor	   suppressors	  
PHF6	   and	   PTEN11,	   miR-­‐223	   targets	   the	   negative	   NOTCH1	   regulator	   FBXW711,85,86,	   miR-­‐27a	  
regulates	   BIM,	   IKZF1,	   NF1	   and	   FBXW711	   whereas	   miR-­‐148a/152	   targets	   PTEN,	   BIM	   and	  
IKZF111.	  To	  conclude,	  we	  could	  show	  that	  miR-­‐19b,	  miR-­‐20a,	  miR-­‐92,	  miR-­‐223,	  miR-­‐26a,	  miR-­‐
27a	  and	  miR-­‐148a/152	  regulate	  a	  defined	  set	  of	  tumor	  suppressors	   in	  T-­‐ALL	   including	  BIM,	  
PTEN,	  PHF6,	  IKZF1,	  NF1	  and	  FBXW7	  (paper	  3)11.	  This	  is	  one	  of	  the	  first	  miRNA	  networks	  that	  
was	   described	   in	   cancer	   and	   illustrates	   how	   coordinated	   regulation	   of	   multiple	   tumor	  
suppressor	  genes	  in	  T-­‐ALL	  is	  controlled	  by	  different	  miRNAs87.	  Other	  miRNA	  –	  protein-­‐coding	  
networks	   encompass	   the	   miR-­‐17-­‐92	   cluster/MYC/E2F1	   described	   in	   lymphoma83	   and	   the	  
miR-­‐15a/miR-­‐16-­‐1/miR-­‐34abc/TP53/ZAP70/BCL2/MCL1	  network	  in	  CLL88.	  
	  
Subsequent	  to	  oncomiRs,	  we	  have	  explored	  the	  presence	  of	  tumor	  suppressor	  miRNAs	  in	  T-­‐
ALL.	   Therefore	   we	   selected	   the	   oncogene	  MYB	   as	   a	   first	   candidate	   for	   exploration	   of	   a	  
possible	  miRNA-­‐MYB	  network	  in	  T-­‐ALL	  by	  use	  of	  an	  in-­‐house	  designed	  3’UTR	  library	  screen.	  
This	   miRNAome-­‐wide	   3’UTR	  MYB	   library	   screen	   unraveled	   33	   miRNA	   candidates	   directly	  
regulating	   the	  MYB	  oncogene.	  Filtering	  of	   these	  candidates	  using	  normal	  and	  malignant	  T-­‐
cell	   data	   enabled	   the	   identification	   of	   miR-­‐193b-­‐3p	   as	   a	   top	   candidate	   tumor	   suppressor	  
miRNA	   targeting	   MYB	   in	   T-­‐ALL,	   which	   we	   validated	   using	   in	   vitro	   and	   in	   vivo	   functional	  
studies	   (paper	   4).	   This	   is	   the	   first	   time	   that	  a	  miR-­‐193b-­‐3p	  –	  MYB	  connection	   is	  described	  
both	  in	  normal	  or	  malignant	  development.	  Other	  MYB	  targeting	  miRNAs	  have	  already	  been	  
identified	   in	   other	   specific	   cellular	   contexts	   like	  miR-­‐150	   in	   normal	   B-­‐cell	   differentiation89	  
and	   in	  MLL-­‐fusion	   driven	   leukemia90.	   Of	   the	   8	   known	  miRNA-­‐MYB	   interactions,	   we	   could	  
confirm	  5	  in	  our	  MYB	  library	  screen	  (paper	  4).	  Vice	  versa	  miR-­‐193b-­‐3p	  is	  already	  described	  
to	   target	   other	   oncogenes	   like	   MCL1	   and	   stathmin	   1	   in	   melanoma91,92.	   Since	   MCL1	   was	  
already	  shown	  to	  play	  an	  oncogenic	  role	  in	  T-­‐ALL11,86,	  we	  investigated	  and	  confirmed	  a	  miR-­‐
193b-­‐3p	   interaction	   with	   MCL1	   in	   T-­‐ALL	   samples.	   In	   addition	   to	   the	   identification	   of	   the	  
tumor	   suppressor	   miR-­‐193b-­‐3p	   in	   T-­‐ALL,	   we	   are	   collaborating	   on	   a	   broader	   T-­‐ALL	   tumor	  
suppressor	  network	  study	  with	   the	  Wendel	   lab	   (MSKCC,	  NY,	  USA)	   (Sanghvi	  et	  al.,	  Genes	  &	  
Development,	  under	  review).	  
	  
As	   we	   have	   shown	   that	  miRNAs	   can	  work	   together	   with	   NOTCH1	   in	   T-­‐ALL,	   we	  were	   also	  
wondering	  if	  NOTCH1	  could	  regulate	  miRNAs	  that	  mediate	  human	  T-­‐cell	  development	  under	  
normal	  physiological	  circumstances	  in	  the	  thymus.	  Therefore,	  we	  investigated	  which	  miRNAs	  
are	   under	   the	   control	   of	   NOTCH1	   in	   normal	   T-­‐cell	   development	   using	   detailed	   miRNA	  
expression	   profiles	   of	   in-­‐depth	   sorted	   normal	   T-­‐cell	   subsets,	   the	   OP9-­‐DL1	   normal	   T-­‐cell	  
model	   system	   and	   publically	   available	   NOTCH1	   ChIP-­‐sequencing	   data93.	   We	   first	   selected	  
those	   miRNAs	   that	   are	   positively	   correlated	   to	   NOTCH1	   expression	   during	   normal	   T-­‐cell	  
development.	   These	   miRNAs	   were	   further	   evaluated	   for	   their	   sensitivity	   to	   NOTCH1	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stimulation	   in	   an	   in	   vitro	   model	   mimicking	   normal	   T-­‐cell	   development.	   Out	   of	   these	  
candidates,	   the	   miR-­‐17-­‐92	   cluster	   and	   miR-­‐484	   are	   directly	   regulated	   by	   NOTCH193.	  
Interestingly,	   miR-­‐484	   is	   strongly	   anti-­‐correlated	   and	   predicted	   to	   interact	   with	   the	   T-­‐cell	  
regulator	  RORC.	  The	  candidate	  NOTCH1	  driven	  miRNAs	  and	  their	  target	  genes	  are	  presently	  
functionally	  modeled	  in	  the	  OP9-­‐DL1	  system	  to	  clearly	  define	  their	  contribution	  in	  normal	  T-­‐
cell	  development	   	   (Van	  der	  Meulen	  et	  al.	   in	  preparation).	  We	  have	  demonstrated	   that	   for	  
miR-­‐17-­‐92	  contributes	  to	  T-­‐ALL	  pathogenesis11,74,	  but	  until	  now	  miR-­‐484	  was	  not	  described	  
yet	   in	   normal	   or	   malignant	   T-­‐cell	   development.	   As	   we	   have	   now	   identified	   miR-­‐484	   as	   a	  
NOTCH1-­‐driven	   miRNA	   in	   normal	   T-­‐cell	   differentiation,	   an	   oncogenic	   role	   for	   miR-­‐484	   in	  
malignant	   T-­‐cell	   transformation	   seems	   plausible	   and	   would	   be	   interesting	   to	   further	  
investigate.	  
	  
MiRNA	   therapeutics	   have	   the	   advantage	   that	   many	   target	   genes	   are	   hit	   simultaneously	  
through	  targeting	  of	  only	  one	  miRNA	  or	  miRNA	  cluster87.	  As	  miR-­‐17-­‐92,	  miR-­‐26a,	  miR-­‐223,	  
miR-­‐27a	   and	  miR-­‐148a/152	   seem	   to	   be	   the	   key	   oncomiRs	   in	   T-­‐ALL	   regulating	  many	   T-­‐ALL	  
tumor	   suppressor	  genes11,74,85,86,	   the	  use	  of	   antisense	  oligonucleotide	   (ASO)	  approaches	  or	  
miRNA	  sponges	  against	   these	  miRNAs	  are	  possible	  options.	   In	  our	  oncomiR	  story,	  we	  have	  
shown	   that	   antagomiRs	   against	   miR-­‐19a/b,	   miR-­‐26a	   and	   miR-­‐92	   are	   able	   to	   reduce	   cell	  
viability	   of	   T-­‐ALL	   cell	   lines11.	   Moreover,	   an	   even	   stronger	   effect	   was	   seen,	   both	   on	   cell	  
viability	  as	  on	  target	  gene	  expression,	  when	  these	  antagomiRs	  were	  introduced	  together11.	  
Furthermore,	   the	   combination	   of	   miRNA	   directed	   therapies	   together	   with	  
chemotherapeutics	   or	   molecular	   therapies,	   could	   be	   a	   powerful	   approach	   to	   tackle	  
resistance	  against	  the	  latter87.	  For	  example,	  PI3K/AKT/mTOR	  inhibitors	  were	  shown	  to	  work	  
in	   concert	   with	   GSIs	   or	   glucocorticoids	   hereby	   abrogating	   GSI/glucocorticoid	   acquired	  
resistance94,95.	   Targeting	   of	   miR-­‐17-­‐92,	   miR-­‐26a	   and/or	   miR-­‐148a/152	   might	   also	   be	  
beneficial	   to	   treatment	   with	   GSIs	   or	   glucocorticoids,	   since	   these	   miRNAs	   were	   shown	   to	  
decrease	  PTEN	  activity.	  
	  
Next	   to	  miRNAs,	   a	   novel	   class	   of	   non-­‐coding	   RNAs	  was	   identified	   coined	   long	   non-­‐coding	  
RNAs	  (lncRNAs).	  These	  lncRNAs	  have	  been	  shown	  to	  be	  implicated	  in	  many	  different	  cellular	  
processes	   acting	   as	   guides,	   scaffolds	   or	   decoys,	   and	   can	   be	   implicated	   in	   cancer96.	   These	  
non-­‐coding	  RNAs	  represent	   interesting	   therapeutic	   targets	  since	   they	  are	   to	  a	   large	  extent	  
expressed	   in	   specific	   tissue-­‐types97.	   Targeting	   or	   restoring	   of	   lncRNAs	   has	   been	   already	  
described	  by	  the	  use	  of	  siRNAs,	  ASOs,	  ribozymes	  and	  synthetic	  lncRNA	  mimics87.	  In	  our	  lab,	  a	  
new	   research	   pipeline	   regarding	   the	   role	   of	   lncRNAs	   in	   normal	   and	   malignant	   T-­‐cell	  
development	  has	  been	  successfully	   initiated	  and	  will	  be	  explored	   in	  detail	  with	  the	  goal	  of	  
identifying	  novel	  therapeutic	  targets	  in	  T-­‐ALL.	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Summary	  
	  
T-­‐ALL	   is	   an	   aggressive	   hematological	  malignancy,	   in	   which	   undifferentiated	   normal	   T-­‐cells	  
acquire	  a	  set	  of	  (epi)genetic	  defects	  giving	  rise	  to	  a	  strong	  accumulation	  of	  malignant	  T-­‐cell	  
lymphoblasts.	   Cure	   rates	   in	   T-­‐ALL	   range	   from	   50-­‐75%	   depending	   on	   the	   age,	   but	  
unfortunately	   still	   a	   significant	  number	  of	  T-­‐ALL	  patients	   relapse	  early	  during	   therapy	  with	  
little	   chances	   for	   survival.	   Current	   treatment	   regimes	   encompass	   risk-­‐adapted	  
chemotherapy,	   hematopoietic	   stem	   cell	   transplantation	   and	   supportive	   care.	   I	   anticipate	  
that	  a	  detailed	  characterization	  of	   the	   (epi)genetic	   landscape	   in	  T-­‐ALL	  patient	   samples	  will	  
provide	  a	  basis	  for	  novel	  molecular	  therapies	  with	  higher	  efficiencies	  and	  less	  toxicity.	  In	  this	  
doctoral	   thesis,	   I	   have	   investigated	   the	   epigenetic	   landscape	   and	   the	  miRNAome	   of	   T-­‐ALL	  
patient	   samples	   and	   identified	   different	   novel	   players	   in	   T-­‐ALL.	   Subsequently,	   I	   have	  
explored	  the	  feasibility	  of	  targeted	  therapies	  against	  these	  players	  in	  different	  T-­‐ALL	  model	  
systems.	  
	  
One	  of	  the	  remarkable	  aspects	  of	  T-­‐ALL	  is	  the	  presence	  of	  a	  skewed	  gender	  distribution,	  with	  
a	  threefold	  higher	  T-­‐ALL	  occurrence	   in	  males.	  We	  hypothesized	  that	  the	  possible	  existence	  
of	   X-­‐linked	   tumor	   suppressors	   might	   be	   able	   to	   explain	   this	   gender	   bias.	   Therefore	   we	  
explored	  the	  X-­‐linked	  exome	  of	  primary	  T-­‐ALL	  patient	  samples	  for	  possible	  genetic	  defects.	  
The	   first	   novel	   epigenetic	   regulator	   found	   to	   be	   implicated	   in	   a	   large	   proportion	   of	   T-­‐ALL	  
cases	   in	   this	   study	  was	   the	  putative	   chromatin	   reader	  PHF6.	  We	  observed	   recurrent	  PHF6	  
loss-­‐of-­‐function	   mutations	   and	   deletions	   in	   primary	   T-­‐ALL	   patient	   samples,	   and	   these	  
inactivating	  defects	  are	  most	  frequently	  detected	  in	  the	  TLX1	  and	  TLX3	  T-­‐ALL	  subgroups.	  In	  
recent	   literature,	   PHF6	   was	   shown	   to	   interact	   with	   the	   ATPase	   chromatin	   remodeling	  
complex	  NuRD	  and	  to	  be	  involved	  in	  DNA	  damage	  repair.	  The	  contribution	  of	  PHF6	  to	  DNA	  
damage	  repair	  was	  illustrated	  in	  T-­‐ALL,	  as	  PHF6	  loss	  in	  T-­‐ALL	  cell	  lines	  induced	  an	  increase	  in	  
the	   global	   levels	   of	   γH2A.X.	   The	   further	   unraveling	   of	   the	   role	   of	   PHF6	   in	   normal	   and	  
malignant	  T-­‐cells	  is	  currently	  under	  investigation	  in	  our	  lab	  and	  yielding	  exiting	  new	  insights	  
into	  the	  role	  of	  PHF6	  during	  normal	  T-­‐cell	  differentiation	  and	  T-­‐ALL	  oncogenesis.	  
	  
In	  view	  of	  the	  success	  of	  identifying	  PHF6	  as	  a	  bona	  fide	  tumor	  suppressor	  gene	  in	  T-­‐ALL	  and	  
assuming	   that	  possible	  additional	  X-­‐linked	  epigenetic	   suppressors	   could	  also	  be	   involved,	   I	  
investigated	   the	   histone	   H3K27me2/3	   demethylase	   UTX	   and	   indeed	   observed	   recurrent	  
genetic	  inactivation	  in	  male	  T-­‐ALL	  patient	  samples.	  Furthermore,	  we	  could	  show	  that	  UTX	  is	  
able	   to	   escape	   X-­‐inactivation	   in	   female	   T-­‐ALL	   patient	   samples,	   in	   contrast	   to	   PHF6,	   and	  
provide	   hereby	   further	   explanation	   for	   the	   skewed	   gender	   distribution	   in	   T-­‐ALL.	   UTX	   loss	  
provided	  a	  strong	  oncogenic	  advantage	  in	  accelerating	  T-­‐ALL	  onset	  in	  a	  NOTCH1	  driven	  T-­‐ALL	  
mouse	  model,	  underscoring	  a	  bona	  fide	  tumor	  suppressor	  role	  for	  UTX	  in	  T-­‐ALL.	  Finally,	  as	  an	  
important	  translational	  component	  of	  this	  investigation,	  I	  could	  show	  that	  UTX	  mutant	  T-­‐cell	  
leukemias	   have	   a	   stronger	   sensitivity	   towards	   treatment	   with	   the	   H3K27me3	   inhibitor	  
DZNep,	   thus	   opening	   a	   possibility	   for	   therapeutic	   restoration	   of	   the	   precise	   balance	   of	  
H3K27	  methylation.	  
	  
Exploration	  of	  the	  T-­‐ALL	  miRNAome	  in	  primary	  T-­‐ALL	  patient	  samples	  and	   in	  vivo	  modeling	  
enabled	  the	  identification	  of	  a	  set	  of	  oncogenic	  miRNAs	  (miR-­‐17-­‐92,	  miR-­‐223,	  miR-­‐26a,	  miR-­‐
27a	  and	  miR-­‐148a/152)	  that	  can	  co-­‐regulate	  several	  T-­‐ALL	  tumor	  suppressors	  (FBXW7,	  PHF6,	  
NF1,	  PTEN,	  IKZF1	  and	  BIM).	  Next,	  we	  have	  undertaken	  a	  miRNA-­‐based	  therapeutic	  approach	  
through	  introducing	  antagomiRs	  against	  the	  identified	  oncomiRs	  in	  T-­‐ALL	  cell	  lines,	  resulting	  
in	   a	   clear	   reduction	   in	   cell	   viability.	   Importantly,	   an	   additive	   effect	   was	   observed	   when	  
antagomiRs	  directed	  against	  several	  oncomiRs	  were	  introduced	  simultaneously.	  Hence,	  the	  
blockage	  of	  multiple	  miRNAs	  in	  T-­‐ALL	  might	  collectively	  contribute	  to	  effective	  reactivation	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of	  a	   larger	  set	  of	  tumor	  suppressors	  and	  underscores	  the	   importance	  of	  this	  miRNA-­‐tumor	  
suppressor	  network	  identified	  in	  T-­‐ALL.	  
	  
In	  the	  last	  part	  of	  my	  thesis,	  I	  identified	  one	  of	  the	  first	  tumor	  suppressor	  miRNAs	  in	  T-­‐ALL,	  
miR-­‐193b-­‐3p,	  through	  the	  exploration	  of	  miRNAs	  capable	  of	  regulating	  the	  MYB	  oncoprotein	  
in	   T-­‐ALL.	   To	   this	   end,	   an	   in-­‐house	   designed	   3’UTR	   MYB	   library	   screen	   was	   performed,	  
identifying	  33	  miRNAs	  putatively	   targeting	  MYB.	  Next,	  we	   filtered	  these	  miRNA	  candidates	  
for	  their	  involvement	  in	  T-­‐ALL	  pathogenesis	  by	  using	  miRNA	  profiles	  of	  normal	  T-­‐cell	  subsets	  
and	  primary	  T-­‐ALL	  patient	  samples.	  Finally,	  functional	  modeling	  enabled	  and	  confirmed	  the	  
identification	  of	  miR-­‐193b-­‐3p	  as	  a	  novel	  tumor	  suppressor	  miRNA	  targeting	  MYB	  and	  MCL1	  
in	  T-­‐ALL.	  
	  
To	  conclude,	  the	  exploration	  of	  the	  epigenetic	  make-­‐up	  and	  miRNAome	  in	  T-­‐ALL	  enabled	  us	  
to	   identify	   novel	   epigenetic	   drivers	   and	   miRNAs	   in	   T-­‐ALL.	   The	   identification	   of	   these	  
perturbed	  molecular	  events	  in	  T-­‐ALL	  pathogenesis	  can	  contribute	  to	  the	  further	  exploration	  
of	  novel	  therapies	  in	  this	  cancer	  type.	  As	  the	  first	  epigenetic	  therapies	  are	  already	  approved	  
by	  the	  FDA	  and	  the	  first	  clinical	  trials	  with	  miRNA-­‐based	  therapeutics	  are	  currently	  ongoing,	  
we	  can	  be	  assured	  that	  targeted	  therapies	  against	  novel	  epigenetic	  and	  miRNA	  players	  offer	  
good	  prospects	  for	  T-­‐ALL	  treatment.	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Samenvatting	  
	  
T-­‐ALL	   is	   een	   agressieve	   hematologische	   maligniteit.	   In	   deze	   ziekte	   verwerven	  
ongedifferentieerde	  normale	  T-­‐cellen	  een	   reeks	   (epi)genetische	  defecten	  wat	   leidt	   tot	  een	  
sterke	  accumulatie	  van	  maligne	  T-­‐cel	  lymfoblasten.	  Afhankelijk	  van	  de	  leeftijd	  van	  de	  patiënt	  
schommelen	  de	  genezingskansen	  bij	   T-­‐ALL	   tussen	  50-­‐75%.	  Helaas	  hervallen	  een	  significant	  
aantal	   T-­‐ALL	   patiënten	   in	   een	   vroeg	   stadium	   van	   de	   behandeling.	   De	   behandelings-­‐
protocollen	   die	   vandaag	   toegepast	   worden,	   omvatten	   risico-­‐aangepaste	   chemotherapie,	  
hematopoëtische	   stamceltransplantatie	   en	   ondersteunende	   zorg.	   Ik	   anticipeer	   dat	   de	  
gedetailleerde	   ontrafeling	   van	   het	   (epi)genetisch	   landschap	   in	   T-­‐ALL	   een	   aangrijpingspunt	  
kan	  vormen	  voor	  nieuwe	  moleculaire	  therapieën	  met	  betere	  efficiëntie	  en	  lagere	  toxiciteit.	  
In	  deze	  doctorale	  thesis	  onderzocht	  ik	  het	  epigenetische	  landschap	  en	  het	  miRNAoom	  van	  T-­‐
ALL	  patiënten	  en	  identificeerde	  ik	  verschillende	  nieuwe	  spelers	  in	  T-­‐ALL.	  Vervolgens	  testte	  ik	  
mogelijke	  doelgerichte	  behandelingen	  uit	  tegen	  deze	  nieuwe	  spelers	   in	  verschillende	  T-­‐ALL	  
modelsystemen.	  
	  
Eén	   van	   de	   opmerkelijke	   aspecten/vaststellingen	   bij	   T-­‐ALL	   is	   de	   aanwezigheid	   van	   een	  
verstoorde	   gender	   distributie:	   T-­‐ALL	   komt	   namelijk	   3	   keer	   meer	   voor	   bij	   mannen	   dan	   bij	  
vrouwen.	  We	   hypothiseerden	   dat	   dit	  mogelijks	   zou	   kunnen	  wijzen	   op	   het	   bestaan	   van	   X-­‐
gebonden	   tumor	   suppressor	   genen	   in	   deze	   ziekte.	   In	   dit	   doctoraatsonderzoek	   hebben	  we	  
daarom	  onderzocht	  of	  genetische	  defecten	  aanwezig	  zijn	   in	  het	  X-­‐chromosoom	  exoom	  van	  
primaire	   T-­‐ALL	   patiëntenstalen.	   De	   eerste	   X-­‐gebonden	   epigenetische	   regulator	  
geïdentificeerd	   in	   deze	   studie	   is	   de	   veronderstelde	   chromatine	   lezer	   PHF6,	   mutationeel	  
geïnactiveerd	   in	  een	  hoog	  percentage	  van	  T-­‐ALL	  patiënten.	  Dit	  gen	   is	   frequent	  het	  doelwit	  
van	  inactiverende	  mutaties	  en	  deleties	  in	  primaire	  T-­‐ALL	  patiënten	  stalen,	  welke	  het	  vaakst	  
vastgesteld	   worden	   bij	   patiënten	   van	   de	   TLX1	   en	   TLX3	   T-­‐ALL	   subgroepen.	   In	   de	   recente	  
literatuur	  werd	   reeds	  beschreven	  dat	  PHF6	  kan	  samenwerken	  met	  het	  ATPase	  chromatine	  
remodeling	  complex	  NuRD	  en	  dat	  PHF6	  betrokken	  is	  bij	  herstel	  van	  DNA-­‐schade.	  Dit	  laatste	  
werd	   in	  onze	  studie	  ook	  geïllustreerd	   in	  T-­‐ALL,	  daar	  verlies	  van	  PHF6	   in	  T-­‐ALL	  cellijnen	  een	  
toename	  in	  globale	  niveaus	  van	  γH2A.X	  kan	  induceren.	  De	  verdere	  ontrafeling	  van	  de	  rol	  van	  
PHF6	   in	  normale	  en	  maligne	  T-­‐cellen	  wordt	  momenteel	  onderzocht	   in	  ons	   labo	  en	   leverde	  
reeds	  nieuwe	  interessante	  inzichten	  op	  naar	  de	  rol	  van	  PHF6	  in	  normale	  T-­‐cel	  differentiatie	  
en	  T-­‐ALL	  oncogenese.	  
	  
Gezien	  het	  succes	  van	  de	  identificatie	  van	  PHF6	  als	  bona	  fide	  tumor	  suppressor	  gen	  in	  T-­‐ALL	  
en	   veronderstellende	   dat	   additionele	   X-­‐gebonden	   epigenetische	   suppressors	   betrokken	  
zouden	  kunnen	  zijn	  in	  T-­‐ALL,	  onderzocht	  ik	  de	  X-­‐gebonden	  histon	  H3K27me2/3	  demethylase	  
UTX.	  We	  vonden	  in	  deze	  tweede	  epigenetische	  regulator	  eveneens	  recurrente	  inactiverende	  
genetische	  defecten,	  en	  dit	  in	  bijzonder	  enkel	  bij	  mannelijke	  T-­‐ALL	  patiënten.	  Verder	  konden	  
we	  aantonen	  dat	  UTX	   in	  vrouwelijke	  T-­‐ALL	  patiënten	   stalen	  aan	  chromosoom	  X-­‐inactivatie	  
kan	  ontsnappen,	  wat	  niet	  het	  geval	  was	  voor	  het	  X-­‐gebonden	  PHF6	  gen.	  Deze	  bevindingen	  
kunnen	  verder	  bijdragen	  tot	  een	  mogelijke	  verklaring	  voor	  de	  verstoorde	  gender	  distributie	  
in	   T-­‐ALL.	   Verder	   demonstreerden	   we	   dat	   verlies	   van	   UTX	   een	   sterk	   oncogeen	   voordeel	  
oplevert	  in	  T-­‐ALL.	  Met	  name,	  UTX	  verlies	  leidde	  tot	  een	  versnelde	  ontwikkeling	  van	  leukemie	  
in	  het	  NOTCH1	  T-­‐ALL	  muismodel,	  wat	  aantoont	  dat	  UTX	  een	  bona	  fide	  tumor	  suppressor	  is	  in	  
T-­‐ALL.	   Finaal	   konden	  we	  aantonen	  dat	  UTX	  mutante	  T-­‐cel	   leukemieën	  gevoeliger	   zijn	   voor	  
behandeling	  met	  de	  H3K27me3	   inhibitor	  DZNep,	  waarbij	  we	  een	  mogelijke	   therapeutische	  
restoratie	  van	  de	  balans	  in	  H3K27	  methylatie	  konden	  aantonen.	  
	  
Onderzoek	  van	  het	  miRNAoom	  in	  primaire	  T-­‐ALL	  patiëntenstalen	  en	   in	  vivo	  modelering	   liet	  
ons	  toe	  een	  reeks	  oncogene	  miRNAs	  te	  identificeren	  (miR-­‐17-­‐92,	  miR-­‐223,	  miR-­‐26a,	  miR-­‐27a	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en	   miR-­‐148a/152)	   die	   gezamenlijk	   verschillende	   T-­‐ALL	   tumor	   suppressors	   (FBXW7,	   PHF6,	  
NF1,	   PTEN,	   IKZF1	   en	   BIM)	   kunnen	   reguleren.	   Daarna	   onderzochten	   we	   een	   miRNA-­‐
gebaseerde	  behandelingsstrategie	  in	  T-­‐ALL,	  waarbij	  we	  antagomiRs	  introduceerden	  tegen	  de	  
geïdentificeerde	  oncomiRs	  in	  T-­‐ALL	  cellijnen.	  Deze	  behandeling	  resulteerde	  in	  een	  duidelijke	  
afname	  van	  celviabiliteit.	  Daarenboven	  konden	  we	  een	  additief	  effect	  waarnemen	  wanneer	  
antagomiRs	  tegen	  verschillende	  oncomiRs	  gezamenlijk	  werden	  toegediend.	  We	  kunnen	  dus	  
besluiten	  dat	   het	   tegelijkertijd	   blokkeren	   van	   verschillende	  miRNAs	   in	   T-­‐ALL	   kan	  bijdragen	  
tot	  een	  effectieve	  reactivatie	  van	  een	  grotere	  groep	  tumor	  suppressors	  en	  onderstreept	  het	  
belang	  van	  het	  door	  ons	  geïdentificeerde	  miRNA-­‐tumorsuppressor	  netwerk	  in	  T-­‐ALL.	  
	  
In	   het	   laatste	   deel	   van	   de	   thesis	   identificeerden	  we	   één	   van	   de	   eerste	   tumor	   suppressor	  
miRNAs	   in	   T-­‐ALL,	   met	   name	   miR-­‐193b-­‐3p.	   Dit	   miRNA	   werd	   ontdekt	   bij	   onderzoek	   naar	  
mogelijke	   miRNAs	   die	   in	   staat	   zouden	   zijn	   MYB	   negatief	   te	   reguleren	   in	   T-­‐ALL.	   Hiervoor	  
hebben	   we	   een	   uitgebreide	   screening	   uitgevoerd	   met	   een	   specifieke	   in-­‐huis	   ontworpen	  
3’UTR	  MYB	  library	  screen,	  waarbij	  we	  33	  miRNAs	  identificeerden	  die	  mogelijks	  MYB	  kunnen	  
reguleren.	  Vervolgens	  onderzochten	  we	   in	  hoeverre	  deze	  33	  miRNA	  kandidaten	  betrokken	  
zijn	   in	  T-­‐ALL	  pathogenese.	  Hiervoor	  maakten	  we	  gebruik	  van	  miRNA	  profielen	  van	  normale	  
T-­‐cel	   subsets	   en	   primaire	   T-­‐ALL	   patiënten	   stalen.	   Via	   functionele	   modelering	   konden	   we	  
finaal	   het	  miRNA	  miR-­‐193b-­‐3p	   identificeren	   als	   een	   nieuwe	   tumor	   suppressor	  miRNA	   dat	  
MYB	  en	  MCL1	  reguleert	  in	  T-­‐ALL.	  
	  
Als	   besluit	   kunnen	  we	   stellen	   dat	   ons	   onderzoek	   van	   het	   epigenetische	   landschap	   en	   het	  
miRNAoom	   in	   T-­‐ALL	   leidde	   tot	   de	   identificatie	   van	   verschillende	   nieuwe	   epigenetische	  
drijvers	   en	  miRNAs	   in	   T-­‐ALL.	   Via	   het	   achterhalen	   van	   deze	  moleculaire	   defecten	   in	   T-­‐ALL	  
pathogenese	   hebben	   we	   bijgedragen	   tot	   de	   verdere	   exploratie	   van	   nieuwe	   mogelijke	  
therapieën	   in	  dit	  kankertype.	  De	  eerste	  epigenetische	  therapieën	  zijn	  reeds	  aanvaard	  door	  
het	   FDA	   en	   de	   eerste	   klinische	   trials	   met	   miRNA-­‐gebaseerde	   therapieën	   zijn	   momenteel	  
reeds	   lopende.	  Hierdoor	  kunnen	  we	  er	  zeker	  van	  zijn	  dat	  gerichte	   therapieën	  tegen	  nieuw	  
geïdentificeerde	   epigenetische	   en	   miRNA	   spelers	   mooie	   vooruitzichten	   bieden	   voor	   de	  
behandeling	  van	  T-­‐ALL.	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  de	  tussenliggende	  Atlantische	  
Oceaan,	   was	   zeer	   tof,	   leerrijk	   en	   daarenboven	   succesvol.	   Ik	   heb	   veel	   geleerd	   van	   je	  
vastberadenheid,	   doorzetting,	   inzicht	   en	   enthousiasme	   voor	   het	   T-­‐ALL	   onderzoek.	   De	  
goesting	  om	  ‘GO	  WEST’	  te	  gaan	  heb	  ik	  ook	  zeker	  mede	  te	  danken	  aan	  jou	  en	  zal	  tot	  nu	  toe	  1	  
van	  de	   ‘beste’	  beslissingen	  van	  mijn	  doctoraatsperiode	  zijn	   (aka	  FNII).	  Bedankt	  Pieter	  voor	  
de	   mooie	   opportuniteiten	   die	   je	   me	   gaf	   waaronder	   mee	   deel	   te	   kunnen	   nemen	   aan	  
verschillende	   toponderzoeksprojecten,	   en	   ik	   wens	   je	   ook	   nog	   heel	   veel	   succes	   met	   je	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verdere	   carrière!	   Daarnaast	   wil	   ik	   ook	   graag	   ons	   diensthoofd	   prof.	   dr.	   Anne	   De	   Paepe	  
bedanken	  dat	  ik	  deel	  mocht	  uitmaken	  van	  deze	  mooie	  onderzoeksgroep	  en	  onderzoek	  heb	  
kunnen	   verrichten	   in	   deze	   bijzondere	   onderzoeksomgeving.	   I	  would	   also	   like	   to	   thank	   the	  
members	  of	  the	  examination	  committee	  to	  spend	  valuable	  time	  in	  the	  critical	  reading	  of	  my	  
thesis	  and	  making	  suggestions	  and	  comments	  on	  this	  work.	  	  
	  
Ik	   kijk	   ook	   zeer	   blij	   en	   tevreden	   terug	  naar	   de	   leuke	   tijd	   die	   ik	   beleefd	  heb	  met	  mijn	   vele	  
bureaugenootjes	   en	   het	   (steeds	   groter	   wordende)	   leukemieteam:	   Nadine,	   Bruce,	   Evelien,	  
Aline,	  Pieter,	  Kaat,	  Suzanne,	  Annelynn,	  Filip,	  Sofie,	  Els,	  Hetty,	  Fary,	  Gloria,	  An,	  Tim,	  Barbara,	  
Bea	  en	  Evelien.	  Allen	  een	  dikke	  merci	  voor	  de	  leuke	  momenten	  op	  het	  werk,	  op	  congres	  en	  
naast	   het	   werk,	   de	   leute,	   ontspanning,	   gelach,	   af	   en	   toe	   eens	   een	   sappige	   roddel,	   het	  
gezamenlijk	  DJ	  moment	  (Nadine	  blijft	  menig	  man,	  inclusief	  mezelf,	  altijd	  verrassen!),	  en	  het	  
leren	   kennen	   van	   enkele	   Gentse	   uitspraken	   zoals	   ‘Ja	   santé	   mijn	   ratse!’	   (aka	   Bruce).	  
Daarnaast	  wil	  ik	  ook	  graag	  het	  GKC	  team	  en	  alle	  collega’s	  van	  het	  CMGG	  bedanken,	  jullie	  zijn	  
een	   heel	   leuke	   enthousiaste	   bende,	   nogmaals	   gemerkt	   op	   FNII,	   en	   dat	   zal	  
hoogstwaarschijnlijk	   opnieuw	   in	  de	   verf	   gezet	  worden	  met	  ons	  nakend	   fietsavontuur	  naar	  
Keulen.	  Ben	  zeer	  trots	  hiervan	  deel	  uit	  te	  (mogen)	  maken	  en	  hoop	  dat	  ik	  velen	  van	  jullie	  nog	  
vaak	   zal	   terugzien	   in	   de	   nabije	   toekomst!!	   Heel	   erg	   bedankt	   allemaal	   voor	   de	   leuke	  
doctoraatsperiode	  en	  toffe	  samenwerking!	  
	  
In	  2012,	  I	  have	  got	  the	  nice	  opportunity	  to	  go	  to	  New	  York	  City,	  and	  be	  part	  of	  the	  Wendel	  
lab.	  This	  experience	  was,	  like	  a	  true	  American	  would	  say,	  AMAZING	  in	  all	  aspects!	  I	  learned	  
new	  techniques,	  new	  skills,	  broadened	  my	  view	  of	  the	  (scientific)	  world	  and	  learned	  to	  work	  
in	  a	  very	  international	  environment.	  I	  was	  spoiled	  with	  a	  great	  research	  team	  and	  PI,	  made	  
many	  new	  friends	  including	  the	  special	  NY	  ‘James’	  group,	  viewed	  the	  fireworks	  of	  the	  4th	  of	  
July	  in	  a	  50th	  floor	  apartment,	  went	  skiing	  in	  the	  first	  weekend	  in	  the	  USA,	  played	  golf	  for	  the	  
first	   time	  and	  enjoyed	  Halloween	  and	  Thanksgiving.	   Especially,	   I	  would	   like	   to	   thank	  Dino,	  
Viraj,	   Nanna	   and	   Silvi	   for	   the	   time	   we	   had	   together	   in	   NY.	   Thanks	   all	   for	   this	   great	  
experience!!	  
	  
Last	  but	  not	  least,	  mijn	  familie	  en	  vrienden	  wil	  ik	  heel	  graag	  bedanken	  voor	  er	  steeds	  te	  zijn	  
voor	   mij,	   hun	   eindeloze	   belangstelling	   in	   mijn	   doen	   en	   laten	   in-­‐	   en	   buiten	   het	   werk,	   de	  
ontelbare	  genietmomenten,	  de	  feestjes	  en	  vertier,	  de	  dozijnen	  ‘clubs’,	  de	  leutige	  avonturen,	  
en	   de	   steun	   bij	   het	   komende	   fietsavontuur.	   New	   York,	   inclusief	   mezelf,	   heeft	   bijna	   elk	  
familielid	   alsook	  menig	   vriend(in)	  mogen	   verwelkomen	   en	   verrassen	  met	   zijn	   culturele	   en	  
culinaire	   specialiteiten.	  Heel	   tof	   dat	   jullie	   er	  waren!	   In	   het	   bijzonder	  wil	   ik	   ook	   graag	  mijn	  
ouders	  en	  zus	  bedanken,	  zij	  betekenen	  heel	  veel	  voor	  me	  en	  samen	  staan	  we	  super	  sterk,	  
dat	   hebben	  we	  meermaals	  mogen	   ondervinden	   de	   laatste	   jaren.	   Daarenboven	  wil	   ik	  mijn	  
moeder	  ook	  graag	  extra	  bedanken	  voor	  de	  heel	  mooie	  design	  van	  mijn	  cover	  en	  uitnodiging!	  
Ik	   ben	   een	   heel	   trotse	   dochter	   en	   zus!	   Tenslotte,	   terugkijkend	   naar	   het	   hele	   traject	   van	  
enthousiast	   thesisstudentje	   tot	   contente	   ‘senior’	   doctoraatstudent,	   ben	   ik	   heel	   blij	   de	  
uitdaging	  te	  zijn	  aangegaan	  en	  kijk	  ik	  uit	  naar	  nieuwe	  avonturen	  in	  het	  verschiet!	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Scientific	  Achievements	  
	  
Publications,	  awards,	  oral	  presentations,	  posters,	  conferences	  and	  supervision	  of	  students	  
	  
Publications:	  
	  
! PHF6	   mutations	   in	   T-­‐cell	   acute	   lymphoblastic	   leukemia.	   Van	   Vlierberghe	   P*,	  
Palomero	  T*,	  Khiabanian	  H,	  Van	  der	  Meulen	  J,	  Castillo	  M,	  Van	  Roy	  N,	  De	  Moerloose	  
B,	   Philippé	   J,	   González-­‐García	   S,	   Toribio	   ML,	   Taghon	   T,	   Zuurbier	   L,	   Cauwelier	   B,	  
Harrison	   CJ,	   Schwab	   C,	   Pisecker	   M,	   Strehl	   S,	   Langerak	   AW,	   Gecz	   J,	   Sonneveld	   E,	  
Pieters	   R,	   Paietta	   E,	   Rowe	   JM,	   Wiernik	   PH,	   Benoit	   Y,	   Soulier	   J,	   Poppe	   B,	   Yao	   X,	  
Cordon-­‐Cardo	  C,	  Meijerink	  J,	  Rabadan	  R,	  Speleman	  F*	  &	  Ferrando	  AA*.	  Nat	  Genet.	  
2010	  Apr;42(4):338-­‐42.	  Impact	  factor	  35.5;	  Citations	  56.	  	  
	  
! The	   TLX1	   oncogene	   drives	   aneuploidy	   in	   T	   cell	   transformation.	  De	  Keersmaecker	  
K*,	  Real	  PJ*,	  Gatta	  GD*,	  Palomero	  T,	  Sulis	  ML,	  Tosello	  V,	  Van	  Vlierberghe	  P,	  Barnes	  
K,	   Castillo	  M,	   Sole	   X,	   Hadler	  M,	   Lenz	   J,	   Aplan	   PD,	   Kelliher	  M,	   Kee	   BL,	   Pandolfi	   PP,	  
Kappes	  D,	  Gounari	  F,	  Petrie	  H,	  Van	  der	  Meulen	  J,	  Speleman	  F,	  Paietta	  E,	  Racevskis	  J,	  
Wiernik	  PH,	  Rowe	  JM,	  Soulier	  J,	  Avran	  D,	  Cavé	  H,	  Dastugue	  N,	  Raimondi	  S,	  Meijerink	  
JP,	  Cordon-­‐Cardo	  C,	  Califano	  A	  &	  Ferrando	  AA.	  Nat	  Med.	  2010	  Nov;16(11):1321-­‐7.	  
Impact	  factor	  22.4;	  Citations	  30.	  
	  
! A	   cooperative	   microRNA	   –	   tumor	   suppressor	   gene	   network	   in	   acute	   T-­‐cell	  
lymphoblastic	   leukemia	   (T-­‐ALL).	  Mavrakis	  KJ*,	  Van	  der	  Meulen	  J*,	  Wolfe	  AL,	  Liu	  X,	  
Mets	   E,	   Taghon	   T,	   Khan	   AA,	   Setty	   M,	   Rondou	   P,	   Vandenberghe	   P,	   Delabesse	   E,	  
Benoit	   Y,	   Socci	  NB,	   Leslie	  CS,	  Van	  Vlierberghe	  P,	   Speleman	  F*	  &	  Wendel	  HG*.	  Nat	  
Genet.	  2011	  Jun	  5;43(7):673-­‐8.	  Impact	  factor	  35.5;	  Citations	  47.	  
	  
! EVI1	  mediated	   down	   regulation	   of	  miR-­‐449a	   is	   essential	   for	   the	   survival	   of	   EVI1	  
positive	  leukemic	  cells.	  De	  Weer	  A,	  Van	  der	  Meulen	  J,	  Rondou	  P,	  Taghon	  T,	  Konrad	  
TA,	   De	   Preter	   K,	   Mestdagh	   P,	   Van	   Maerken	   T,	   Van	   Roy	   N,	   Jeison	   M,	   Yaniv	   I,	  
Cauwelier	  B,	  Noens	  L,	  Poirel	  HA,	  Vandenberghe	  P,	  Lambert	  F,	  De	  Paepe	  A,	  Sánchez	  
MG,	  Odero	  M,	  Verhasselt	  B,	  Philippé	  J,	  Vandesompele	  J,	  Wieser	  R,	  Dastugue	  N,	  Van	  
Vlierberghe	   P,	   Poppe	   B	   &	   Speleman	   F.	   Br	   J	   Haematol.	   2011	   Aug;154(3):337-­‐48.	  
Impact	  factor	  4.941;	  Citations	  5.	  
	  
! Effective	   Alu	   Repeat	   Based	   RT-­‐Qpcr	   Normalization	   in	   Cancer	   Cell	   Perturbation	  
Experiments.	  
Rihani	  A,	  Van	  Maerken	  T,	  Pattyn	  F,	  Van	  Peer	  G,	  Beckers	  A,	  De	  Brouwer	  S,	  Kumps	  C,	  
Mets	   E,	   Van	   der	   Meulen	   J,	   Rondou	   P,	   Leonelli	   C,	   Mestdagh	   P,	   Speleman	   F	   &	  
Vandesompele	  J.	  PLoS	  One.	  2013	  Aug	  14;8(8):e71776.	  Impact	  factor	  3.7;	  Citations	  0.	  
	  
! The	   need	   for	   transparency	   and	   good	   practices	   in	   the	   qPCR	   literature.	  Bustin	   SA,	  
Benes	  V,	  Garson	  J,	  Hellemans	  J,	  Huggett	  J,	  Kubista	  M,	  Mueller	  R,	  Nolan	  T,	  Pfaffl	  MW,	  
Shipley	  G,	  Wittwer	  CT,	  Schjerling	  P,	  Day	  PJ,	  Abreu	  M,	  Aguado	  B,	  Beaulieu	  JF,	  Beckers	  
A,	   Bogaert	   S,	   Browne	   J,	   Carrasco-­‐Ramiro	   F,	   Ceelen	   L,	   Ciborowski	   K,	   Cornillie	   P,	  
Coulon	  S,	  Cuypers	  A,	  De	  Brouwer	  S,	  De	  Ceuninck	   L,	  De	  Craene	   J,	  De	  Naeyer	  H,	  De	  
Spiegelaere	   W,	   Deckers	   K,	   Dheedene	   A,	   Durinck	   K,	   Ferreira-­‐Teixeira	   M,	   Fieuw	   A,	  
Gallup	  J,	  Gonzalo-­‐Flores	  S,	  Goossens	  K,	  Heindryckx	  F,	  Herring	  E,	  Hoenicka	  H,	  Icardi	  L,	  
Jaggi	   R,	   Javad	   F,	   Karampelias	   M,	   Kibenge	   F,	   Kibenge	   M,	   Kumps	   C,	   Lambertz	   I,	  
Lammens	  T,	  Markey	  A,	  Messiaen	  P,	  Mets	  E,	  Morais	  S,	  Mudarra-­‐Rubio	  A,	  Nakiwala	  J,	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Nelis	  H,	  Olsvik	  PA,	  Pérez-­‐Novo	  C,	  Plusquin	  M,	  Remans	  T,	  Rihani	  A,	  Rodrigues-­‐Santos	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  IL-­‐7	  
receptor	  signalling	  and	  enhanced	  tumor-­‐initiating	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   E,	   Peirs	   S,	   Ghahremani	  MF,	   De	  
Medts	   J,	   Bartunkova	   S,	   Haigh	   K,	   Pieters	   T,	   Best	   JA,	   Deswarte	   K,	   Bogaert	   P,	   Canté-­‐
Barrett	  K,	  Haenebalcke	  L,	  Clappier	  E,	  Rondou	  P,	  Slowicka	  K,	  Berx	  G,	  Huylebroeck	  D,	  
Goldrath	  AW,	   Janzen	  V,	   Speleman	   F,	  Meijerink	   JPP,	   Soulier	   J,	   Van	  Vlierberghe	  P	  &	  
Haigh	  JJ.	  Under	  review	  in	  Nature	  Medicine.	  
	  
! MiR-­‐128-­‐3p	   is	   a	  novel	  oncomiR	   targeting	  PHF6	   in	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   B,	  
Vandesompele	  J,	  Benoit	  Y,	  Poppe	  B	  &	  Speleman	  F.	  7th	  Bi-­‐annual	  Childhood	  Leukemia	  
Symposium,	  April	  25-­‐27,	  2010,	  Antalya,	  Turkey	  
	  
! MicroRNA	  Signatures	  in	  Genetic	  Subtypes	  of	  T-­‐Cell	  Acute	  Lymphoblastic	  Leukemia.	  
Van	  der	  Meulen	  J*,	  Van	  Vlierberghe	  P*,	  Mestdagh	  P,	  Fieuw	  A,	  Van	  Roy	  N,	  De	  Preter	  
K,	   Taghon	   T,	   Plum	   J,	   Cauwelier	   B,	   Selleslag	   DLD,	   Heimann	   P,	   Vandenberghe	   P,	  
Dastugue	   N,	   Delabesse	   E,	   Gervais	   C,	   Gregoire	   MJ,	   Mozziconacci	   MJ,	   Lefebvre	   C,	  
Meijerink	   J,	   Buijs-­‐Gladdines	   J,	   Lammens	   T,	   De	   Paepe	   A,	   De	   Moerloose	   B,	  
Vandesompele	  J,	  Benoit	  Y,	  Poppe	  B	  &	  Speleman	  F.	  ESH-­‐EHA	  Scientific	  Workshop	  on	  
T-­‐cell	   acute	   lymphoblastic	   leukemia	   meets	   normal	   T-­‐cell	   development,	   May	   7-­‐9,	  
2010,	  Mandelieu,	  France	  
	  
! Cooperative	   miRNA	   mediated	   FBXW7	   suppression	   contributes	   to	   T-­‐cell	  
lymphoblastic	   leukemogenesis.	  Mets	   E,	  Van	  der	  Meulen	   J,	  Mavrakis	   KJ,	  Wolfe	  AL,	  
Taghon	  T,	  Khan	  AA,	  Setty	  M,	  Liu	  X,	  Vandenberghe	  P,	  Delabesse	  E,	  Benoit	  Y,	  Socci	  ND,	  
Leslie	   CS,	   Van	   Vlierberghe	   P,	   Wendel	   HG,	   Rondou	   P	   &	   Speleman	   F.	   Keystone	  
Symposia:	   MicroRNAs	   and	   Human	   Disease,	   February	   11-­‐16,	   2011,	   Banff,	   Alberta,	  
Canada	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! Regulatory	  networks	  governed	  by	  microRNAs	  in	  T-­‐ALL	  oncogenesis	  and	  normal	  T-­‐
cell	   development.	   Van	   der	   Meulen	   J,	   Mets	   E,	   Mestdagh	   P,	   Pipelers	   P,	   Taghon	   T,	  
Camacho-­‐Trujillo	   D,	   Avran	   D,	   Van	   Peer	   G,	   Van	   Roy	   N,	   Thas	   O,	   Benoit	   Y,	  
Vandesompele	   J,	   Poppe	   B,	   Van	   Vlierberghe	   P,	   Rondou	   P,	   Soulier	   J	   &	   Speleman	   F.	  
53rd	  ASH	  meeting,	  December	  10-­‐13,	  2011,	  San	  Diego,	  California,	  USA	  
	  
! Improved	   risk-­‐stratification	  and	  outcome	  prediction	   in	   children	  with	  average	   risk	  
precursor-­‐B	   acute	   lymphoblastic	   leukemia	   using	   a	   nineteen-­‐microRNA	   signature.	  
Ghazavi	  F,	  Lammens	  T,	  Suciu	  S,	  Laureys	  G,	  Bakkus	  M,	  Ferster	  A,	  Uyttebroeck	  A,	  Lutz	  
P,	   Cavé	   H,	   Plat	   G,	   Dastugue	   N,	   Dresse	   MF,	   Van	   der	   Meulen	   J,	   Mestdagh	   P,	  
Vandesompele	  J,	  Speleman	  F,	  De	  Moerloose	  B	  &	  Benoit	  Y.	  27th	  BHS	  meeting,	  January	  
27-­‐28,	  2012,	  Liege,	  Belgium	  
	  
! Regulatory	  networks	  governed	  by	  microRNAs	  in	  T-­‐ALL	  oncogenesis	  and	  normal	  T-­‐
cell	   development.	  Van	  der	  Meulen	   J,	  Mets	  E,	  Mestdagh	  P,	  Pipelers	  P,	  Van	  Peer	  G,	  
Taghon	  T,	  Camacho-­‐Trujillo	  D,	  Avran	  D,	  Van	  Roy	  N,	  Thas	  O,	  Benoit	  Y,	  Vandesompele	  
J,	   Poppe	   B,	   Van	   Vlierberghe	   P,	   Rondou	   P,	   Soulier	   J	   &	   Speleman	   F.	   12th	   BeSHG	  
meeting,	  March	  2,	  2012,	  Liege,	  Belgium	  
	  
! Unraveling	   a	   NOTCH1-­‐lncRNA-­‐miRNA	   regulatory	   network	   in	   acute	   T-­‐cell	  
lymphoblastic	   leukemia	   and	   normal	   T-­‐cell	   development.	  Durinck	   K,	  Mestdagh	   P,	  
Taghon	  T,	  Van	  der	  Meulen	  J,	  Van	  de	  Walle	  I,	  Volders	  PJ,	  Pattyn	  F,	  Van	  Roy	  N,	  Benoit	  
Y,	  Poppe	  B,	  Van	  Vlierberghe	  P,	  Menten	  B,	  Vandesompele	  J,	  Rondou	  P	  &	  Speleman	  F.	  
Keystone	   meeting	   Non-­‐Coding	   RNAs,	   March	   31	   -­‐	   April	   5,	   2012,	   Snowbird,	   Utah,	  
Belgium	  
	  
! Improved	   risk-­‐stratification	  and	  outcome	  prediction	   in	   children	  with	  average	   risk	  
precursor-­‐B	   acute	   lymphoblastic	   leukemia	   using	   a	   nineteen-­‐microRNA	   signature.	  
Ghazavi	  F,	  Lammens	  T,	  Suciu	  S,	  Laureys	  G,	  Bakkus	  M,	  Ferster	  A,	  Uyttebroeck	  A,	  Lutz	  
P,	   Cavé	   H,	   Plat	   G,	   Dastugue	   N,	   Dresse	   MF,	   Van	   der	   Meulen	   J,	   Mestdagh	   P,	  
Vandesompele	  J,	  Speleman	  F,	  De	  Moerloose	  B	  &	  Benoit	  Y.	  17th	  EHA	  meeting,	  June	  
14-­‐17,	  2012,	  Amsterdam,	  The	  Netherlands.	  
	  
! NOTCH1	   signaling	   induces	   global	   transcriptional	   changes	   in	   long	  non-­‐coding	  RNA	  
expression	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  and	  normal	  T-­‐cell	  development.	  
Durinck	  K,	  Mestdagh	  P,	  Volders	  PJ,	  Taghon	  T,	  Van	  de	  Walle	  I,	  Ongenaert	  M,	  Van	  der	  
Meulen	   J,	   Vanhauwaert	   S,	   Wallaert	   A,	   Soulier	   J,	   Van	   Roy	   N,	   Benoit	   Y,	   Poppe	   B,	  
Menten	  B,	  Vandesompele	   J,	  Van	  Vlierberghe	  P,	  Rondou	  P	  &	  Speleman	  F.	  Keystone	  
Symposia,	   Noncoding	   RNAs	   in	   development	   and	   cancer,	   January	   20-­‐25,	   2013,	  
Vancouver,	  Canada.	  
	  
! H3K27me3	  erasers,	  novel	   targets	   in	  T-­‐cell	   acute	   lymphoblastic	   leukemia.	  Van	  der	  
Meulen	   J,	  Mavrakis	   KJ,	   Sanghvi	   VR,	   Poppe	  B,	   Van	  Roy	  N,	   Rondou	  P,	   Benoit	   Y,	   Van	  
Vlierberghe	   P,	  Wendel	   HG	  &	   Speleman	   F.	   28th	   BHS	  meeting,	   January	   25-­‐26,	   2013,	  
Ghent,	  Belgium	  
	  
! Extending	   the	   functional	   redundant	   cooperative	   miRNA	   tumor	   suppressor	   and	  
oncogene	   network	   in	   T-­‐ALL.	  Mets	   E,	   Van	  Peer	  G,	   Van	  der	  Meulen	   J,	  Mestdagh	  P,	  
Taghon	   T,	   Avran	   D,	   Benoit	   Y,	   Poppe	   B,	   Soulier	   J,	   Van	   Vlierberghe	   P,	   Rondou	   P,	  
Vandesompele	   J*	   &	   Speleman	   F*.	   28th	   BHS	  meeting,	   January	   25-­‐26,	   2013,	   Ghent,	  
Belgium	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! H3K27me3	  erasers,	  novel	   targets	   in	  T-­‐cell	   acute	   lymphoblastic	   leukemia.	  Van	  der	  
Meulen	   J,	  Mavrakis	   KJ,	   Sanghvi	   VR,	   Poppe	  B,	   Van	  Roy	  N,	   Rondou	  P,	   Benoit	   Y,	   Van	  
Vlierberghe	   P,	   Wendel	   HG	   &	   Speleman	   F.	   13th	   BeSHG	   meeting,	   March	   15,	   2013,	  
Ghent,	  Belgium	  
	  
! NOTCH1	   signaling	   induces	   global	   transcriptional	   changes	   in	   long	  non-­‐coding	  RNA	  
expression	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  and	  normal	  T-­‐cell	  development.	  
Durinck	  K,	  Mestdagh	  P,	  Volders	  PJ,	  Taghon	  T,	  Van	  de	  Walle	  I,	  Ongenaert	  M,	  Van	  der	  
Meulen	   J,	   Vanhauwaert	   S,	   Wallaert	   A,	   Soulier	   J,	   Van	   Roy	   N,	   Benoit	   Y,	   Poppe	   B,	  
Menten	  B,	  Vandesompele	  J,	  Van	  Vlierberghe	  P,	  Rondou	  P	  &	  Speleman	  F.	  13th	  BeSHG	  
meeting,	  March	  15,	  2013,	  Ghent,	  Belgium	  
	  
! Extending	   the	   functional	   redundant	   cooperative	   miRNA	   tumor	   suppressor	   and	  
oncogene	   network	   in	   T-­‐ALL.	  Mets	   E,	   Van	  Peer	  G,	   Van	  der	  Meulen	   J,	  Mestdagh	  P,	  
Taghon	   T,	   Avran	   D,	   Benoit	   Y,	   Poppe	   B,	   Soulier	   J,	   Van	   Vlierberghe	   P,	   Rondou	   P,	  
Vandesompele	   J*	   &	   Speleman	   F*.	   13th	   BeSHG	   meeting,	   March	   15,	   2013,	   Ghent,	  
Belgium	  
	  
! NOTCH1	   signaling	   induces	   global	   transcriptional	   changes	   in	   long	  non-­‐coding	  RNA	  
expression	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  and	  normal	  T-­‐cell	  development.	  
Durinck	  K,	  Mestdagh	  P,	  Volders	  PJ,	  Taghon	  T,	  Van	  de	  Walle	  I,	  Ongenaert	  M,	  Van	  der	  
Meulen	   J,	   Vanhauwaert	   S,	   Wallaert	   A,	   Soulier	   J,	   Van	   Roy	   N,	   Benoit	   Y,	   Poppe	   B,	  
Menten	  B,	   Vandesompele	   J,	   Van	  Vlierberghe	   P,	   Rondou	   P	  &	   Speleman	   F.	   2nd	   ESH-­‐
EHA	  Scientific	  Workshop	  on	  T-­‐cell	  acute	  lymphoblastic	  leukemia,	  March	  22-­‐24,	  2013,	  
Lisbon,	  Portugal	  
	  
! Notch	   driven	   miRNAs	   implicated	   in	   normal	   and	   malignant	   T-­‐cell	   development.	  
Durinck	  K,	  Van	  der	  Meulen	  J,	  Van	  de	  Walle	  I,	  Pipelers	  P,	  Mestdagh	  P,	  Ongenaert	  M,	  
Van	  Roy	  N,	  Benoit	  Y,	  Poppe	  B,	  Vandesompele	  J,	  De	  Preter	  K,	  Thas	  O,	  Van	  Vlierberghe	  
P,	  Rondou	  P,	  Soulier	  J,	  Speleman	  F*	  &	  Taghon	  T*.	  2nd	  ESH-­‐EHA	  Scientific	  Workshop	  
on	  T-­‐cell	  acute	  lymphoblastic	  leukemia,	  March	  22-­‐24,	  2013,	  Lisbon,	  Portugal	  
	  
! A	   miRNAome	   wide	   3'UTR	   screen	   based	   mapping	   of	   convergent	   multi-­‐miRNA	  
targeting	   of	   tumor	   suppressor-­‐oncogene	   networks	   in	   T-­‐ALL.	  Mets	   E,	   Van	  Peer	  G,	  
Van	  der	  Meulen	  J,	  Mestdagh	  P,	  Taghon	  T,	  Avran	  D,	  Benoit	  Y,	  Poppe	  B,	  Soulier	  J,	  Van	  
Vlierberghe	  P,	  Rondou	  P,	  Vandesompele	  J*	  &	  Speleman	  F*.	  2nd	  ESH-­‐EHA	  Scientific	  
Workshop	   on	   T-­‐cell	   acute	   lymphoblastic	   leukemia,	   March	   22-­‐24,	   2013,	   Lisbon,	  
Portugal	  
	  
! MiR-­‐128	   is	   a	   novel	   PHF6	   targeting	   regulatory	   non-­‐coding	   RNA	   acting	   as	   a	   T-­‐ALL	  
oncogene.	  Mets	  E,	  Van	  der	  Meulen	  J,	  Van	  Peer	  G,	  Boice	  M,	  Mestdagh	  P,	  Taghon	  T,	  
Avran	   D,	   De	   Moerloose	   B,	   Benoit	   Y,	   Poppe	   B,	   Soulier	   J,	   Vandesompele	   J,	   Van	  
Vlierberghe	  P,	  Rondou	  P,	  Wendel	  G	  &	  Speleman	  F.	  2nd	  ESH-­‐EHA	  Scientific	  Workshop	  
on	  T-­‐cell	  acute	  lymphoblastic	  leukemia,	  March	  22-­‐24,	  2013,	  Lisbon,	  Portugal	  
	  
! H3K27me3	   erasers	   are	   novel	   targets	   in	   T-­‐cell	   acute	   lymphoblastic	   leukemia.	  Van	  
der	   Meulen	   J,	   Mavrakis	   KJ,	   Sanghvi	   VR,	   Van	   Roy	   N,	   Poppe	   B,	   Vandenberghe	   P,	  
Delabesse	  E,	  De	  Moerloose	  B,	  Benoit	  Y,	  Rondou	  P,	  Van	  Vlierberghe	  P,	  Ferrando	  AA,	  
Wendel	  HG*	  &	  Speleman	  F*.	  EMBO	  Conference	  Series	  -­‐	  Chromatin	  and	  Epigenetics,	  
May	  8-­‐12,	  2013,	  Heidelberg,	  Germany	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! The	   H3K27me3	   demethylase	   UTX	   is	   a	   tumor	   suppressor	   in	   T-­‐cell	   acute	  
lymphoblastic	   leukemia.	  Van	  der	  Meulen	  J,	  Mavrakis	  KJ,	  Sanghvi	  VR,	  Eggermont	  A,	  
Van	  Roy	  N,	  Poppe	  B,	  Baeyens	  A,	  Vandenberghe	  P,	  Delabesse	  E,	  Verhasselt	  B,	  Taghon	  
T,	  De	  Moerloose	  B,	  Benoit	  Y,	  Rondou	  P,	   Ferrando	  AA,	  Melnick	  A,	   Speleman	  F,	  Van	  
Vlierberghe	   P*	  &	  Wendel	   HG*.	   Cell	   Symposia	   –	   Cancer	   Epigenomics,	   October	   6-­‐8,	  
2013,	  Sitges,	  Spain	  
	  
! The	  plant	  homeodomain	  (PHD)-­‐like	  finger	  protein	  PHF6	  chromatin	  binding	  pattern	  
and	   transcriptional	   regulation	   indicates	   a	   functional	   link	   with	   NOTCH1	   in	   T	   cell	  
acute	   lymphoblastic	   leukemia.	   Durinck	   K,	   Van	   der	   Meulen	   J,	   Ongenaert	   M,	  
Verhasselt	  B,	  Taghon	  T,	  Van	  de	  Walle	  I,	  Van	  Roy	  N,	  Poppe	  B,	  Benoit	  Y,	  Gevaert	  K,	  Van	  
Vlierberghe	   P,	   Rondou	   P	   &	   Speleman	   F.	   Cell	   Symposia	   –	   Cancer	   Epigenomics,	  
October	  6-­‐8,	  2013,	  Sitges,	  Spain	  
	  
! Expanding	   The	   TLX1-­‐Regulome	   in	   T	   Cell	   Acute	   Lymphoblastic	   Leukemia	   Towards	  
Long	   Non-­‐Coding	   RNAs.	   Durinck	   K,	   Van	   der	   Meulen	   J,	   Ongenaert	   M,	   Volders	   PJ,	  
Wallaert	  A,	  Van	  Roy	  N,	  Benoit	  Y,	  Poppe	  B,	  Mestdagh	  P,	  Vandesompele	  J,	  Rondou	  P,	  
Soulier	  J,	  Van	  Vlierberghe	  P,	  Speleman	  F.	  EMBO	  Conference	  Series	  –	  The	  non-­‐coding	  
genome,	  October	  9-­‐12,	  2013,	  Heidelberg,	  Germany	  
	  
! Characterization	   of	   the	   NOTCH1-­‐driven	   miRNA	   network	   that	   controls	   normal	  
human	  T-­‐cell	  development.	  Van	  der	  Meulen	  J,	  Durinck	  K,	  Van	  de	  Walle	  I,	  Mestdagh	  
P,	   Pipelers	   P,	   De	   Preter	   K,	   Van	   Peer	   G,	   Van	   Roy	   N,	   Poppe	   B,	   Ongenaert	   M,	  
Vandesompele	  J,	  Thas	  O,	  Rondou	  P,	  Van	  Vlierberghe	  P,	  Speleman	  F	  &	  Taghon	  T.	  14th	  
BeSHG	  meeting,	  February	  7,	  2014,	  Antwerp,	  Belgium	  
	  
! The	   H3K27me3	   demethylase	   UTX	   is	   a	   gender-­‐specific	   tumor	   suppressor	   in	   T-­‐cell	  
acute	   lymphoblastic	   leukemia.	  Van	  der	  Meulen	  J,	  Sanghvi	  VR,	  Mavrakis	  KJ,	  Durinck	  
K,	  Rondou	  P,	  Vandenberghe	  P,	  Delabesse	  E,	  Lammens	  T,	  De	  Moerloose	  B,	  Menten	  B,	  
Van	  Roy	  N,	  Verhasselt	  B,	  Poppe	  B,	  Benoit	   Y,	   Taghon	  T,	   Speleman	  F,	  Wendel	  HG	  &	  
Van	  Vlierberghe	  P.	  14th	  BeSHG	  meeting,	  February	  7,	  2014,	  Antwerp,	  Belgium	  
	  
! Expanding	   The	   TLX1-­‐Regulome	   in	   T	   Cell	   Acute	   Lymphoblastic	   Leukemia	   Towards	  
Long	   Non-­‐Coding	   RNAs.	   Durinck	   K,	   Van	   der	   Meulen	   J,	   Ongenaert	   M,	   Volders	   PJ,	  
Wallaert	  A,	  Van	  Roy	  N,	  Benoit	  Y,	  Poppe	  B,	  Mestdagh	  P,	  Vandesompele	  J,	  Rondou	  P,	  
Soulier	   J,	   Van	   Vlierberghe	   P,	   Speleman	   F.	   14th	   BeSHG	  meeting,	   February	   7,	   2014,	  
Antwerp,	  Belgium	  
	  
! MicroRNA-­‐128-­‐3p	  is	  a	  novel	  oncomiR	  targeting	  PHF6	  in	  T-­‐cell	  acute	  lymphoblastic	  
leukemia.	  Mets	  E,	  Van	  Peer	  G,	  Van	  der	  Meulen	   J,	  Boice	  M,	  Taghon	  T,	  Goossens	  S,	  
Mestdagh	   P,	   Benoit	   Y,	   De	   Moerloose	   B,	   Van	   Roy	   N,	   Poppe	   B,	   Vandesompele	   J,	  
Wendel	   HG,	   Van	   Vlierberghe	   P,	   Speleman	   F*	   &	   Rondou	   P*.	   14th	   BeSHG	  meeting,	  
February	  7,	  2014,	  Antwerp,	  Belgium	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Conferences:	  
	  
! 8th	  BeSHG	  meeting,	  April	  25,	  2008,	  Leuven,	  Belgium	  
! Benelux	  qPCR	  symposium,	  October	  6,	  2008,	  Ghent,	  Belgium	  
! 11th	  Post-­‐ASH	  meeting,	  January	  9,	  2009,	  Brussels,	  Belgium	  
! 24th	  BHS	  meeting,	  January	  30,	  2009,	  Ostend,	  Belgium	  
! BACR	  meeting,	  January	  31,	  2009,	  ULB	  Brussels,	  Belgium	  
! 9th	  BeSHG	  meeting,	  February	  13,	  2009,	  ULB	  Brussels,	  Belgium	  
! 5de	  wintersymposium,	  March	  7,	  2009,	  Ghent,	  Belgium	  
! Journee	  d’honneur	  de	  Roland	  Berger,	  April	  2,	  2009,	  Paris,	  France	  
! 14th	  EHA	  meeting,	  June	  4-­‐7,	  2009,	  Berlin,	  Germany	  
! Summer	  conferences	  FASEB,	  August	  2-­‐7,	  2009,	  Vermont,	  USA	  
! EORTC	  CLG	  meeting,	  November	  20-­‐21,	  2009,	  Strasbourg,	  France	  
! 51st	   ASH	   Annual	   Meeting	   and	   Exposition,	   December	   5-­‐8,	   2009,	   New	   Orleans,	  
Louisiana,	  USA	  
! Keystone	   Symposia,	   Molecular	   Basis	   for	   Chromatin	   Structure	   and	   Regulation,	  
January	  17-­‐21,	  2010,	  Taos,	  New	  Mexico,	  USA	  
! Advances	  in	  Genomics,	  January	  28-­‐29,	  2010,	  Ghent,	  Belgium	  
! 10th	  BeSHG	  meeting,	  February	  26,	  2010,	  Ghent,	  Belgium	  
! 1st	   ESH-­‐EHA	   Scientific	   Workshop	   on	   T-­‐cell	   acute	   lymphoblastic	   leukemia	   meets	  
normal	  T-­‐cell	  development,	  May	  7-­‐9,	  2010,	  Mandelieu,	  France	  
! 52nd	  ASH	  Annual	  Meeting	  and	  Exposition,	  December	  4-­‐7,	  2010,	  Orlando,	  Florida,	  USA	  
! EORTC	  CLG	  meeting,	  March	  1,	  2011,	  Brussels,	  Belgium	  
! 11th	  BeSHG	  meeting,	  March	  4,	  2011,	  Louvain-­‐la-­‐Neuve,	  Belgium	  
! 16th	  EHA	  meeting,	  June	  9-­‐12,	  2011,	  London,	  UK	  
! EMBO-­‐EMBL	   Symposium:	   Cancer	   Genomics,	   September	   17-­‐19,	   2011,	   Heidelberg,	  
Germany	  
! 28th	  BHS	  meeting,	  January	  25,	  2013,	  Ghent,	  Belgium	  
! 13th	  BeSHG	  meeting,	  March	  15,	  2013,	  Brussels,	  Belgium	  
! 2nd	  ESH-­‐EHA	  Scientific	  Workshop	  on	  T-­‐cell	  acute	  lymphoblastic	  leukemia,	  March	  22-­‐
24,	  2013,	  Lisbon,	  Portugal	  
! EMBO	  Conference	  Series	  -­‐	  Chromatin	  and	  Epigenetics,	  May	  8-­‐12,	  2013,	  Heidelberg,	  
Germany	  
! Cell	  Symposia	  –	  Cancer	  Epigenomics,	  October	  6-­‐8,	  2013,	  Sitges,	  Spain	  
! Oncopoint	  II,	  February	  6,	  2014,	  Ghent,	  Belgium	  
! 14th	  BeSHG	  meeting,	  February	  7,	  2014,	  Antwerp,	  Belgium	  
	  
Supervision	  of	  students:	  
	  
! Z-­‐lijn	   paper,	   2nd	   Bachelor	   of	   Medicine	   2008-­‐2009:	   Sara	   David,	   Gamma	   secretase	  
inhibitor	  behandeling	  in	  T-­‐cel	  acute	  lymfoblastische	  leukemie.	  Supervision:	  Joni	  Van	  
der	  Meulen,	  promotor:	  Frank	  Speleman.	  
! Z-­‐lijn	  paper,	  2nd	  bachelor	  Geneeskunde	  2009-­‐2010:	  Johannes	  Libeer,	  Prognostische	  
relevantie	   van	   genetische	   defecten	   in	   TALL.	   Supervision:	   Joni	   Van	   der	   Meulen,	  
promotor:	  Frank	  Speleman.	  	  
! Master	   Thesis,	   2nd	   Master	   of	   Biochemistry	   and	   Biotechnology	   2009-­‐2010:	   Kaat	  
Durinck,	   Evaluation	  of	  PHF6	   as	   a	   tumor	   suppressor	   in	   hematological	  malignancies.	  
Supervision:	  Joni	  Van	  der	  Meulen	  and	  Pieter	  Rondou,	  promotors:	  Bruce	  Poppe	  and	  
Geert	  Berx.	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! Master	   Thesis,	   2nd	   Master	   of	   Biomedical	   Sciences	   2010-­‐2011:	   Lies	   Bosman,	  
Evaluation	   of	   PHF6	   as	   a	   tumor	   suppressor	   in	   hematological	   malignancies.	  
Supervision:	  Joni	  Van	  der	  Meulen	  and	  Pieter	  Rondou,	  promotor:	  Frank	  Speleman.	  
! Z-­‐lijn	  paper,	  2nd	  Bachelor	  of	  Medicine	  2012-­‐2013:	  Stijn	  Bogaert,	  De	  dubbele	  rol	  van	  
EZH2	  in	  leukemie	  en	  lymphoma.	  Supervision:	  Joni	  Van	  der	  Meulen,	  promotor:	  Frank	  
Speleman.	  
! Z-­‐lijn	  paper,	  2nd	  Bachelor	  of	  Medicine	  2012-­‐2013:	  Brecht	  Devriendt,	  De	  dubbele	  rol	  
van	  EZH2	   in	   leukemie	  en	   lymphoma.	   Supervision:	   Joni	  Van	  der	  Meulen,	  promotor:	  
Frank	  Speleman.	  
! Z-­‐lijn	  Master	  Thesis,	  1st	  -­‐2nd	  Master	  of	  Medicine	  2011-­‐2013:	  Laura	  Anrijs,	  De	  rol	  van	  
genetische	  defecten	   in	   pediatrische	  B-­‐cel	   acute	   lymfatische	   leukemie	   in	   relatie	   tot	  
prognose	   en	   behandeling.	   Supervision:	   Joni	   Van	   der	   Meulen,	   promotor:	   Frank	  
Speleman.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
